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Summary 
Amphibian skin secretions are a rich source of biomolecules (peptides, alkaloids and 
biogenic amines) which play a significant role in protecting the host from predators and 
microbial attack. Peptides from frog skin secretions have shown antimicrobial activity 
against a wide range of microorganisms. Also, these peptides have been shown to 
possess anticancer, immunomodulatory and insulinotropic activities. In this thesis, 
peptides from skin secretions of frogs belonging to the family of Alytidae, Hylidae, 
Pipidae, and Ranidae were examined for insulinotropic and antidiabetic activities. 
Frenatin 2D and its synthetic analogues from Discoglossus sardus, [A14K] and [S4K] 
analogues of PGLa-AM1 and CPF-AM1 respectively from Xenopus amieti, temporin 
peptides from Rana temporaria and esculentin-1 from Rana esculenta demonstrated 
concentration-dependent insulinotropic activities in rat clonal pancreatic beta cells 
(BRIN-BD11) and human-derived pancreatic beta cells (1.1B4). Insulinotropic 
activities of the esculentin-1 peptides were associated with an increase in membrane 
potential and intracellular calcium, whereas frenatin 2D and temporin peptides had no 
effect on these parameters. In BRIN-BD11 cells, frenatin 2D peptides produced a 
significant increase in cAMP production and its insulin-releasing activity was abolished 
in PKA downregulated cells. In addition to their insulinotropic activities, these peptides 
protected BRIN-BD11 cells against cytokine-induced apoptosis as well as stimulated 
proliferation of beta-cell.  Frenatin 2D and its synthetic analogues [D1W] and [G7W], 
temporin G and esculentin (1-21)1c improved blood glucose and increased insulin 
concentration in lean mice.  
In genetically obese-diabetic mice (db/db), frenatin 2D, [A14K] PGLa-AM1 and [S4K] 
CPF-AM1 improved blood glucose, insulin sensitivity, insulin secretory responses of 
islets to glucose and established insulin secretagogues, lipid profile and both kidney and 
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liver function. The gradual demise of beta cells and a decrease of circulating insulin in 
db/db mice was delayed significantly by these peptides. Also, genes involved in both 
insulin signalling and secretion were improved.  
In conclusion, this thesis highlights the potential of frog skin peptides belonging to the 
family of Alytidae, Hylidae, Pipidae and Ranidae for further development into 
therapeutic agents for type 2 diabetes. 
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1.1 Diabetes mellitus 
 
Diabetes mellitus is a group of metabolic diseases characterised by high blood glucose 
level (hyperglycaemia). In diabetes, blood glucose level escalates either due to 
pancreatic beta cell dysfunction or inability of the body to respond to available insulin 
or both. Diabetes and its related complications can be managed and delayed by making 
lifestyle changes (such as healthy diet, regular exercise) and using appropriate 
pharmacological interventions. 
As a result of the global rise in the rate of prevalence, mortality and morbidity together 
with increasing costs of treatment, diabetes has become one of the most significant 
healthcare problems. Rapid urbanisation, excessive calorie intake and increasingly 
sedentary lifestyle have resulted in a diabetes epidemic (Basu et al., 2013). According 
to the International Diabetes Federation (IDF) report, in 2017 more than 425 million 
people were affected by diabetes globally. This figure could rise to 629 million in 2045 
if no urgent actions are taken to improve diabetes outcome. In the UK alone, the 
diabetes population has increased from 1.8 million to 3.7 million in last two decade, 
according to a recent analysis by Diabetes UK. Due to the exponential rise in the 
prevalence of diabetes, healthcare expenditure globally has reached USD 727 billion 
per/annum. Despite spending such a considerable amount, there is still a large 
proportion of the worldwide diabetes population with no access to antidiabetic drugs, 
particularly in developing nations (IDF, 2017).  
 
 
1.1.1 History of diabetes 
 
The following scheme summarizes the history of diabetes and the manufacturing of 
first human insulin.  
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1500 BC 
 
Characteristic similar to diabetes mellitus were described by ancient 
Hindu and Egyptians scholar. 
 
250 BC  
 
Apollonius of Memphis coined term Diabetes. 
450-500AD 
 
 
 
Ancient Indian Scholar Sushruta called it Madhumeha (honey urine).   
Sushruta (Physician) and Charaka (Surgeon), the early pioneers of 
treating diabetes, identified two types of diabetes (now known by 
type1 and type 2 diabetes). 
980-1037  
 
Persian physician Avicenna, not only observed abnormal appetite and 
diabetic gangrene but also used plants seeds (lupin, fenugreek, 
zedoary) for treatment. 
 
1776 
 
Matthew Dobson confirmed that diabetes patient has excess sugar in 
urine and blood. 
 
1798 British Surgeon-General John Rollo coined the term mellitus (Latin, 
‘sweet like honey’ or sweet urine). 
 
1857 
 
 
Claude Bernard established the role of the liver in diabetes 
 
1869 
 
Paul Langerhans, observed clusters of cells scattered all over 
pancreas 
 
1889 
 
Joseph von Mering and Oskar Minkowski discovered the role of the 
pancreas in diabetes. 
 
1916 
 
Sir Edward Albert Sharpey-Schafer coined the word “insulin”. 
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1919 
 
Dr Frederick Allen, introduced starvation treatment to manage 
diabetes 
 
1923 
 
Dr Fredrick Banting and Prof John James Rickard Macleod received 
Nobel Prize for the discovery of insulin. 
 
1936 
 
British Scientist Sir Harold Percival (Harry) Himsworth, in his work, 
distinguished two main types of diabetes. 
 
1959 British biochemist Frederick Sanger received Nobel Prize for his 
work on the structure of human insulin. 
 
1978 David Goeddel produced synthetic “human” insulin using 
recombinant DNA technology 
 
The data in the above scheme is adapted from Ahmed, 2003, Das & Shah et al., 2011, 
Lakhtakia, 2013, Vecchio et al., 2018. 
 
1.1.2 Classification of Diabetes Mellitus  
 
Diabetes is classified mainly into two main types:  
A) Type1 diabetes mellitus (T1DM).  
B) Type 2 diabetes mellitus (T2DM). 
 
1.1.2.1 Type 1 diabetes mellitus (T1DM) 
In T1DM, insulin-producing pancreatic beta cells are challenged by the body’s 
immune system resulting in insulin deficiency (Maahs et al., 2012). Such individuals 
depend on external insulin source to maintain healthy blood sugar levels. It is a severe 
and permanent condition that can be developed at any stage of life, but more frequently 
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occurs in children (Frese & Sandholzer, 2013).  For these reasons, T1DM was also 
called “insulin-dependent diabetes” or “juvenile-onset diabetes. T1DM can be 
managed by proper insulin treatment, regular monitoring of blood sugar and 
maintaining a healthy lifestyle. According to the International Diabetes Federation, in 
2017 about 1 million children and adolescent (below age 20) were projected to have 
T1DM. In some parts of the world such as Europe, North America and Caribbean was 
recorded with the highest number of T1DM patient (below age 20). In high-income 
countries, the prevalence of T1DM was estimated between 7-12% of the total diabetes 
population (WHO, 2016). 
The cause of T1DM is not entirely understood, but it has been suggested that the 
genetic and environmental factors may activate an immune system that destroys beta 
cells population (Atkinson & Eisenbarth, 2001, Patterson et al., 2014). The 
polymorphism in Human leukocyte antigen (HLA) genes located on chromosome 
6p21 that encodes major histocompatibility complex, is considered as one of the main 
inherited factors that may contribute to T1DM. Mainly, the HLA alleles DR4-DQ8 & 
DR3-DQ2 account for 40-50% of heritable risk (Hirschhorn, 2003). It has also been 
proposed that environmental factors including toxins and virus may trigger this gene 
to produce antibodies that attack beta cells (You & Henneberg, 2016). Auto-antibodies 
to islet cells, insulin, glutamate decarboxylase, tyrosine phosphatase (IA-2a and IA-
2b) and zinc transporter 8 (ZnT8) have been reported that facilitate the destruction of 
pancreatic beta cells (Daneman, 2006, American Diabetes Association, 2015). 
 
1.1.2.2 Type 2 diabetes mellitus (T2DM) 
In T2DM, pancreatic beta cells fail to meet body requirement for insulin or the body 
loses its efficiency to utilise available insulin or both, resulting in hyperglycaemia. 
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This type is most prevalent among adults and accounts for 90% of the total diabetes 
population. T2DM is also seen occurring in children and young adults. This is mainly 
due to rapid urbanisation, the rising level of obesity, high energy intake and physical 
inactivity (Basu et al., 2013). According to the International Diabetes Federation 
(IDF), in 2015, more than 400 million people were affected by T2DM, and this figure 
will rise to 629 million by 2045. The incidence of T2DM population has been high, 
particularly in developing nations, which account for 80% of global diabetes 
population. T2DM can be managed by adopting a healthy lifestyle (healthy diet and 
physical exercise) and by taking appropriate medical treatment such as (metformin, 
sulphonylureas, thiazolidinediones, acarbose, GLP-1 agonists, DPP-4 inhibitors, 
SGLT2 inhibitors or insulin). If affected individuals did not receive appropriate 
treatment, they are at high risk of developing complications associated with diabetes 
such as microvascular (nephropathy, neuropathy, and retinopathy) and macrovascular 
complications (cardiovascular diseases) (Van Dieren & Beulens, 2010). 
T2DM is a complex disease and has multiple factors contributing to its development. 
Among these, genetic predisposition and environmental factors are the important ones, 
which interacts to cause T2DM. Genetic factors have a major influence on 
susceptibility to develop T2DM, which is supported by studies in monozygotic twins 
and certain ethnic groups (Rimoin, 1969, Poulsen et al., 1999). Further studies 
identified multiple genetic variants that increase the risk of T2DM (McCarthy, 2010). 
A study conducted by Grant et al., 2006, identified variants in transcription factor 7-
like 2 (TCF7L2) gene in Iceland individuals with T2DM. A similar finding was 
replicated in T2DM individuals from various ethnic groups (Cauchi et al., 2007). 
Some examples of genes associated with T2DM risk are: INS (insulin), IRS1 (insulin 
receptor substrate 1), PPARγ (peroxisome proliferator-activated receptor gamma), 
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KCNJ11 (potassium inwardly rectifying channel, subfamily J, member 11), ABCC8 
(ATP-binding cassette transporter sub-family C member 8),  SLC30A8 (solute carrier 
family 30 member 8), PCSK1 (proprotein convertase subtilisin/kexin type 1), KCNQ1 
(potassium voltage-gated channel subfamily Q member 1) (McCarthy, 2010, Wen et 
al., 2012, Grarup et al., 2014). Environmental factors such as excess body fat, 
overweight, obesity, high energy intake and physical inactivity, increase the risk of 
T2DM (Forouzanfar et al., 2015). Beyond these factors, differences in the gut flora 
and also socioeconomic status could play a role in the development of T2DM 
(Moreno-Indias et al., 2014). 
 
1.2 Pancreas 
The pancreas is an elongated organ, about 14-20 cm long, that lies horizontally in the 
upper abdomen behind the peritoneum. It is divided into four main parts head, neck, 
body and tail. The pancreas has two main components, exocrine pancreas and 
endocrine pancreas. Exocrine pancreas accounts for 98% of the pancreatic mass and 
is composed of acinar and ductal epithelial cells which produce digestive enzymes 
such as amylase, lipases and protease. These digestive enzymes travel through 
pancreatic duct into the duodenum where they digest macromolecules. Endocrine 
pancreas (2% of pancreatic mass) is composed of alpha (α) beta (β), delta (δ), epsilon 
(ε) and pancreatic polypeptide (PP) cells which produce important hormones 
glucagon, insulin, somatostatin, ghrelin and pancreatic polypeptide respectively 
(Longnecker, 2014). These hormones are released into the bloodstream to regulate 
metabolic function. The endocrine cells are present in the form of clusters surrounded 
by acinar cells, and these clusters are called islets of Langerhans. 
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1.2.1 Islets of Langerhans 
In 1869, Paul Langerhans was first to observe clusters of cells scattered all over 
pancreas. The French pathologist and histologist Laguesse proposed that secretion 
from these cluster of cells could play a key role in digestion and decided to name these 
cells after the name of Langerhans in 1893. The function of the pancreas in diabetes 
first was established by Von Mering and Minkowski in 1889. They observed a rise in 
blood glucose level in dogs after surgical removal of the pancreas (Xavier et al., 2018). 
In 1921, Frederick Banting and Charles Best discovered insulin and showed that 
insulin produced by pancreas reduces blood glucose level. Frederick Banting further 
collaborated with John Macleod for the clinical development of insulin.  In 1923, 
Frederick Banting along with John Macleod were awarded Nobel Prize in the field of 
Medicine. Since then, the focus has been directed towards islet biology (Xavier et al., 
2018).  
In humans, it is estimated that pancreas has about 1million islets (Ionescu-Tirgoviste 
et al., 2015). The average size of islets varies between 50-250 μM in diameter. Alpha 
(α), beta (β), delta (δ) and pancreatic polypeptide (PP) cells are the four major cells 
that constitute the islets of Langerhans (Figure 1). ε-cells are also present in islets but 
present in few numbers. The composition of these cells, as well as the structure of 
islet, vary between and within species (Kim et al., 2009). Human islets are composed 
of 52-74% insulin producing β-cells, ~20% glucagon-producing α-cells, ~5% 
somatostatin-producing δ-cells, 1-2% pancreatic polypeptide-producing PP cells and 
very few ghrelin-producing ε-cells (Powers and Stein, 2012). In humans, these cells 
are populated randomly throughout the islet, whereas in rodents insulin-producing 
beta cells occupy the core of the islet surrounded by other endocrine cells (Kim et al., 
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2009, Steiner et al., 2010, Xavier et al., 2018). In addition to these cells, islet also 
contains other cells such as immune cells, vascular cells and neural elements.  
Insulin and glucagon produced by beta and alpha cells respectively have opposite 
effects on blood glucose. These hormones are released in response to a change in blood 
glucose. Insulin not only mediates glucose uptake but also promote synthesis of 
glycogen, fats and proteins and inhibit hepatic glucose production. Glucagon, on the 
other hand, increases blood glucose by increasing hepatic glucose production and 
regulating the breakdown of glycogen and fats. Somatostatin expressed by delta cells 
inhibits the release of insulin, glucagon and pancreatic polypeptide (Kailey et al., 
2012). Ghrelin acts directly on the delta cell and promotes the release of somatostatin 
(Adriaenssens et al., 2016). Pancreatic polypeptide cells (also called F cells), majorly 
found in the head region of a pancreas release pancreatic polypeptide that reduces 
appetite and has also shown to inhibit glucagon release at low glucose (Tan & Bloom, 
2013). Ghrelin produced by epsilon cells has been identified to inhibit insulin secretion 
during fasting (Broglio et al., 2013). Moreover, ghrelin has been proposed for its role 
in beta cell function and survival (Andralojc et al. 2009). In both T1DM and T2DM, 
not only islet architecture is disrupted but also communication between islet cells type 
(Brereton et al., 2015). 
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Figure 1: Schematic representation of islet (Adapted from Efrat and Russ, 2012) 
 
1.2.2 Insulin synthesis 
Insulin hormone, which regulates carbohydrates, protein and fats metabolism, is 
synthesised in a significant quantity by beta cells of islets of Langerhans. The 
synthesised insulin contains 51 amino acids in two polypeptide chains [Chain A (21 
amino acids) and chain B (30 amino acids)] (Figure 2) and has a molecular weight of 
5.8KDa. The two polypeptide chains (A chain and B chain) are linked by two 
disulphide bonds at position A7-B7 and A20-B19, and an additional disulphide bond 
is found at position A6-A11 within A the chain (Chang et al., 2003, van Lierop et al., 
2017).  
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Figure 2: Primary structure of insulin (Adapted from Belgi et al., 2011) 
 
The insulin gene present on chromosome 11 in beta cells of the pancreas encodes 
insulin precursor known as preproinsulin. Preproinsulin contains 110 amino acids in 
four polypeptide chain (A chain, B chain, signal peptide and C-peptide). The signal 
recognition particles (SRP), a cytosolic ribonucleoprotein facilitate transportation of 
synthesised preproinsulin by interacting with hydrophobic N-terminal signal peptide 
into the endoplasmic reticulum lumen (Wolin & Walter, 1993). On translocation, the 
signal peptide is cleaved from preproinsulin by a signal peptidase to produce 
proinsulin. In the endoplasmic reticulum lumen, chaperone proteins assist rapid 
folding of proinsulin and formation of three disulphide bonds. The three-dimensional 
structure of proinsulin is further translocated to the Golgi complex, where proinsulin 
is believed to form hexamers around Zn+2 ions (Haataja et al., 2013, Liu et al., 2014). 
Proinsulin is further processed by prohormone convertase (PC1 and PC2) and 
carboxypeptidase E in secretory granules to yield insulin and C-peptide (Davidson, 
2004). The schematic representation of insulin biosynthesis is shown in Figure 3. 
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Figure 3: Insulin biosynthesis (Adapted from Skelin et al., 2010) 
 
1.2.3 Biology of insulin secretion 
Insulin secretion from beta cells is initiated by the sequential activation of multiple 
metabolic pathways. The macronutrients like glucose, proteins and fatty acids play a 
vital role in the release of insulin from pancreatic beta cells. A study conducted by 
Chang et al., 1978 has shown that the amount of insulin release by beta cells in 
response to oral glucose is more significant than protein and fatty acids when taken in 
the same amount. Glucose is taken up by beta cell by facilitated diffusion through 
GLUT2 transporter protein (GLUT1 in humans) and metabolised to pyruvate in the 
cytoplasm by glycolytic enzymes.  Pyruvate is further transported to mitochondria and 
oxidised to acetyl CoA by pyruvate dehydrogenase enzyme. Acetyl CoA enters the 
kerbs cycle and produces a reduced electron carrier (NADH & FADH2), which further 
undergoes oxidative phosphorylation to generate ATP. The depolarization of the cell 
membrane occurs when the generated ATP block the potassium channel followed by 
the opening of voltage-dependent calcium channel. This event leads to the elevation 
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of intracellular Ca2+, which subsequently triggers insulin release from secretory 
granules by exocytosis (Rorsman & Aschcroft, 2018). The intermediate of Krebs cycle 
like NADPH, malonyl-CoA, and glutamate have been reported to further amplify the 
insulin secretion from beta cells (Maechler & Wollheim, 2009). The schematic 
representation of insulin secretion is shown in Figure 4. 
Previous studies have confirmed that some amino acids also stimulate insulin release 
from beta cells. Amino acids including alanine, asparagine, tryptophan and glycine 
stimulate insulin release in the presence of glucose by membrane depolarization 
(Newsholme et al., 2006, Newsholme & Krause, 2012). Glutamine demonstrated 
insulinotropic effects only in combination with leucine (Dixon et al., 2003). Amino 
acids like alanine and glutamine elevate blood glucose level by stimulating the release 
of glucagon. This elevated glucose, in turn, triggers insulin secretion.  
GLP-1 (glucagon-like peptide) and GIP (glucose-dependent insulinotropic 
polypeptide) are incretin hormones produced by intestinal tract in response to food 
intake. These hormones act directly on pancreatic beta cells by binding to their 
receptors and subsequently activating adenylate cyclase enzyme that elevates the 
concentration of cAMP generated from ATP. In turn, cAMP activates protein kinase 
A (PKA) and type 2 ryanodine receptor (RY2) protein, which promotes insulin release 
via increasing intracellular Ca2+ concentration. Activated protein kinase A also 
influences insulin synthesis by preventing degradation of insulin mRNA gene by 
transporting phosphorylated polypyrimidine tract binding protein (PTBP-1) to the 
nucleus (Knoch et al., 2006). 
Previous studies have demonstrated that free fatty acids also promote insulin secretion 
from beta cells (Haber et al., 2003).  At low glucose concentrations, free fatty acids 
are used as a source of energy by pancreatic islets. Free fatty acids are converted to 
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long-chain acyl CoA by acyl CoA synthase. Long-chain acyl CoA is further oxidised 
by the mitochondrial enzyme carnitine palmitoyl transferase 1 (CPT-1) to generate 
energy and to release insulin. However, high glucose concentrations, due to 
inactivation of CPT-1 activity, long chain acyl CoA accumulate which induce insulin 
release by increasing intracellular Ca2+ concentration (Newsholme & Krause, 2012).    
Hormones like acetylcholine and cholecystokinin stimulate insulin release by 
activation of phospholipase C. Phospholipase C is ubiquitous, membrane-associated 
enzyme, which on activation cleaves phospholipid phosphatidylinositol 4,5-
bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG).  
IP3 promotes insulin release by mobilising intracellular Ca
2+ and DAG by activating 
protein kinase C (PKC) (Berridge et al., 2003). Other hormones like estrogen 
potentiate insulin release by KATP channel-dependent pathway (Nadal et al., 1998). 
 
Figure 4: Schematic representation of insulin secretion (Adapted from Seino 2012) 
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1.2.4 Insulin action 
Insulin hormone, synthesised and released by pancreatic beta cells, initiate its action 
by binding to its transmembrane receptor present on target cells (Kido et al., 2001, De 
Meyts et al., 2013). Insulin receptor belongs to the receptor tyrosine kinase family, 
consisting of two α subunit (insulin binding domains) and two β subunits (signal 
transduction domains) (Menting et al., 2013).  The extracellular alpha subunit 
undergoes conformational changes on interaction with insulin. These conformational 
changes in alpha subunit allow binding of ATP to intracellular beta subunit which 
activates tyrosine kinase. On activation of tyrosine kinase, beta subunit undergoes 
autophosphorylation, which further propagates phosphorylation of other endogenous 
substrate or other insulin signalling molecules such as insulin receptor substrate (IRS), 
phosphatidylinositol 3 kinase (PI(3)K), protein kinase A (PKA), Protein kinase B 
(PKB) and mitogen-activated protein (MAP) kinase. These activated signalling 
molecules in turn directly or indirectly regulate metabolic functions (Saltiel & Kahn 
et al., 2001). The schematic representation of insulin action is shown in Figure 5. 
Insulin mediates glucose uptake in skeletal muscles, liver and adipose tissue by 
recruiting GLUT4 transporter protein from cytoplasm to the cell surface, which 
regulate the entry of glucose inside cells (Huang & Michael, 2007, Bogan et al., 2012, 
Atkinson et al., 2013). At an elevated concentration of glucose, insulin promotes 
storage of glucose in the form of glycogen in liver and muscles cells by upregulating 
key enzyme involved in glycogenesis pathway such as glycogen synthase (Samuel & 
Shulman, 2012).  Activated PI(3)K and Akt increase the activity of glycogen synthase 
by restricting the activity of glycogen synthase kinase by phosphorylation. After 
entering the cells, glucose is converted to glucose 6 phosphate by cytosolic hexokinase 
enzyme. Glucose 6 phosphate is further metabolised to UDP glucose by 
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phosphoglucomutase and glucose 1-phosphate uridylyltransferase. By the action of 
glycogen synthase, UDP glucose is converted to glycogen (Bouskila et al., 2008). 
Insulin also limits the production and release of glucose from the liver by inhibiting 
the expression of enzymes of gluconeogenesis and glycogenolysis pathways 
(Ramnanan et al., 2010). Transcription of the genes encoding for 
phosphoenolpyruvate carboxylase, fructose 1,6 bisphosphates and glucose 6 
phosphatases gene transcription is reduced, while transcription of glycolytic and 
lipogenic enzymes is increased by insulin (Hall et al., 2007). 
In adipocytes, insulin promotes the synthesis of lipids from glucose by activation of 
fatty acid synthase and acetyl-CoA carboxylase enzymes (Saltiel & Kahn et al., 2001, 
Samuel & Shulman, 2012). Insulin also inhibits the degradation of lipid by limiting 
the activity of lipase enzyme by dephosphorylation (Zimmermann et al., 2009, Lass 
et al., 2011). These effects of insulin decrease the flow of free fatty acids to the liver, 
thus reducing gluconeogenesis, ketogenesis, as well as the production of very low-
density lipoproteins (VLDL) (Keller et al., 1988, Fukao et al., 2004). Insulin also 
stimulates protein synthesis by facilitating the transport of amino acids and regulating 
the translation of mRNA (Hyde et al., 2002, Proud, 2006, Drummond et al., 2010). In 
addition, insulin has paracrine effects on other hormone-producing cells of pancreatic 
islets. Insulin decreases the release of glucagon by directly acting on alpha cells, which 
in turn augments the metabolic effects of insulin (Briant et al., 2016).   
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Figure 5: Schematic representation of insulin action (Adapted from Saltiel & Kahn 
2001) 
 
1.3 Beta-cell dysfunction 
Insulin hormone, produced by the beta cells of the pancreas, perform an important 
function in maintaining the blood glucose level within a normal physiological range. 
In healthy individuals, when the insulin resistance occurs, the beta cell population is 
increased to compensate for the insulin demand and maintain normal glycemia. 
However, when the beta cells fail to compensate for increased insulin demand, it 
results in a rise of blood glucose and free fatty acids which further induces structural 
and functional changes contributing to beta cell dysfunction, followed by beta cell 
death (Tan et al., 2013). The schematic representation of islet beta cell dysfunction is 
shown in Figure 6. 
Several studies have highlighted the detrimental effects of high blood glucose on 
pancreatic beta cells function, and the process is termed as glucotoxicity. This includes 
18 
 
impaired insulin release in response to intravenous glucose and non-glucose 
secretagogues, a decrease in intracellular storage of insulin due to beta cell exhaustion 
and a decrease in insulin production due to damage of cellular components by 
increased ROS level (Robertson & Harmon, 2003, Cernea & Dobreanu, 2013). 
Hyperglycaemia is also believed to be an important factor that contributes to beta cell 
dedifferentiation by altering important transcription factor FOXO1, where beta cells 
lose their identity and functions and get converted to other endocrine cells.  (Talchai 
et al., 2012, Taylor et al., 2013, Puri et al., 2013, Guo et al., 2013, Wang et al., 2014).  
Studies have also reported adverse effects of elevated free fatty acids on beta-cell 
function, and the process is termed as lipotoxicity. Impaired glucose-stimulated insulin 
release and decreased insulin production was observed in pancreatic beta cells after 
chronic exposure to free fatty acids. It promotes beta cell loss by increasing expression 
of cytokines (such as TNFα and IL-2) and by activating ER stress by diminishing ER 
calcium store (DeFronzo, 2004, Cernea & Dobreanu, 2013, Sharma & Alonso, 2014) 
Islet amyloid polypeptide (IAPP, or amylin) secreted together with insulin by 
pancreatic beta cells, maintain glucose homeostasis by delaying gastric emptying and 
promoting satiety. Recent studies have reported that deposited islet amyloid 
polypeptide (IAPP) has cytotoxic properties which contribute to β-cell dysfunction 
and death (Akter et al., 2016).   
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Figure 6: Schematic representation of islet beta cell dysfunction (Adapted from 
Prentki et al., 2006) 
 
1.4 Insulin resistance 
Insulin resistance is when the body fails to use insulin effectively or respond weakly 
to available insulin, resulting in hyperglycaemia (American Diabetes Association, 
2010). As the insulin resistance progresses, pancreatic beta cells increase the 
production of insulin to compensate insulin demand, further contributing to 
hyperinsulinemia. The prevalence of insulin resistance among obese individuals is 
well documented, and these individuals are at high risk of developing T2DM. In 
addition, insulin resistance also occurs in old age, pregnant women and sometimes 
individuals at puberty (Buchanan et al., 1990, Sonagra et al., 2014). In obese 
individuals, it is believed that the accumulation of fat in the abdominal area influences 
the early development of insulin resistance. These fats are less sensitive to the 
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antilipolytic effects of insulin and results in an increase in the level of non-esterified 
fatty acids (NEFA) in the blood. Studies conducted by Roden et al., 1997, observed 
the development of insulin resistance and impaired glucose tolerance with rising 
plasma NEFA levels in humans. In obese and diabetic individuals, a decrease in insulin 
sensitivity was observed with rising NEFA level (Zeirath et al., 1998). NEFA enters 
the cells and undergoes oxidation to produce diacylglycerol, fatty acyl CoA and 
ceramides metabolites. These metabolites further activate serine/threonine kinase 
cascade, which phosphorylates serine/threonine residue of insulin receptor substrate-
1 (IRS1) and insulin receptor substrate-2 (IRS-2). In their phosphorylated form, IRS1 
and IRS2 fail to activate other molecules of insulin signalling and this results in loss 
of glucose entry in the cells. An alternative mechanism involves an increase in acetyl 
CoA/CoA and NADH/NAD+ ratio after fatty acid oxidation that leads to inactivation 
of pyruvate dehydrogenase enzyme and accumulation of citrate which subsequently 
inactivate glycolytic enzymes including phosphofructokinase and hexokinase enzyme. 
Inactivation of glycolytic enzymes results in the accumulation of glucose inside cells 
thereby affecting glucose uptake (Randle et al., 1963, Shulman, 2000). 
Proinflammatory cytokines such as tumour necrosis factor-α (TNF-α), interleukin-6 
(IL-6) release from adipose tissue also play a vital role in the development of insulin 
resistance by diminishing insulin signalling events (Kahn et al., 2006, 
Tangvarasittichai et al., 2016). 
 
1.5 Current Therapies for Diabetes 
1.5.1 Lifestyle modification 
The progression of T2DM can be prevented or delayed by following a healthy lifestyle 
(Miller et al., 2014).  Studies have demonstrated that following a healthy diet, regular 
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exercise and weight management can help to keep blood glucose under control (Chong 
et al., 2017).  A study conducted by Tuomileho et al., 2001, has shown that regular 
physical exercise helps to maintain a healthy blood glucose level and reduces the risk 
of secondary complications in people with T2DM.  The risk of onset of T2DM in 
patients with impaired glucose tolerance was significantly reduced by following a 
strict diet which is low in saturated and total fat and rich in carbohydrate and dietary 
fibre (Liu et al., 2015). Knowler et al., 2002, reported that lifestyle intervention is 
more effective than metformin in treating T2DM. 
 
1.5.2 Metformin 
The oral glucose-lowering agent Metformin, derived from plant Galega officinalis, 
was first reported by Dr Jean Sterne and his colleagues in 1950 (Rojas et al., 2013). 
After the UK Prospective Diabetes Study (UKPDS) in 1998, metformin was used as 
first-line treatment for T2DM. Also, according to clinical practice guidelines by the 
American Diabetes Association (2015), metformin was recommended as an initial 
treatment for managing T2DM. Traditionally, metformin is believed to control blood 
glucose level by suppressing gluconeogenesis and glycogenolysis pathways in the 
liver (Rena et al., 2017). Recent studies have also shown that metformin treatment 
also controls blood sugar level by improving 1) insulin sensitivity, 2) lipid metabolism 
and 3) islet insulin secretory responses (Kashi et al., 2016, Kocer et al., 2014). Further 
studies have also shown that metformin could also lower the risk of cardiovascular 
diseases associated with diabetes (Holman et al., 2008). At the molecular level, 
metformin has shown to demonstrate its effects via both AMP-activated protein kinase 
(AMPK)-dependent and an independent mechanism (Rena et al., 2017). Metformin 
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treatment can cause side effects such as abdominal pain, lactic acidosis and diarrhoea 
(Kalantar-Zadeh et al., 2013, DeFronzo et al., 2016). 
 
1.5.3 Insulin 
The discovery of Insulin by Dr Fredrick Bathing and his colleagues in 1921, was one 
of the important breakthroughs in the history of medicine. In T1DM patients, the 
pancreas does not produce insulin due to the destruction of beta cells. Such patients 
have to take insulin from external source multiple times a day to maintain near-normal 
blood sugar levels. Also, in T2DM as the diseases progress, the pancreas does not 
produce enough insulin due to loss of beta cell mass and function. In such 
circumstances, oral antidiabetic agents become therapeutically ineffective for the 
treatment. Eventually, many patients with T2DM will depend on external insulin to 
improve hyperglycaemia and complications associated with diabetes (Home et al., 
2014). Insulin demonstrates its glucose-lowering effects a) by recruiting GLUT4 
transporter protein to the plasma membrane, b) stimulating synthesis of glycogen, fatty 
acid and triacylglycerol c) inhibiting gluconeogenesis and glycogenolysis (Dimitriadis 
et al., 2011). Currently, several types of insulin are available such as rapid-acting, 
short-acting, mixed, intermediate-acting and long-acting insulin. Hypoglycaemia and 
weight gain are the main side effects associated with insulin treatment (Nansel et al., 
2013, Boucher-Berry1 et al., 2016). 
 
1.5.4 Amylin  
Amylin is a 37-amino acid peptide that is synthesised by pancreatic beta cells and co-
secreted with insulin. Amylin controls blood glucose by several mechanisms including 
suppressing postprandial glucagon secretion, reducing hepatic glucose production and 
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food intake and by slowing down gastric emptying. Pramlintide, a synthetic version 
of amylin, controls blood glucose by a similar mechanism. Additionally, pramlintide 
has been shown to improve lipid metabolism in both T1DM and T2DM (Hoogwerf et 
al., 2008).  Nausea is commonly observed in pramlintide treated patient. Other side 
effects such as anorexia and hypoglycaemia were also reported (Nogid and Pam, 
2006). 
 
1.5.5 Thiazolidinedione (glitazones) 
Thiazolidinediones (TZD) are oral hypoglycemic agents and were first approved for 
the treatment of T2DM in 1966 by the Food and Drug Administration (FDA) (Kendall, 
2006).  TZDs control blood glucose by improving insulin action in the muscle, liver 
and adipose tissue, thus, allowing insulin produced pancreas to work effectively 
(Davidson et al., 2017). TZDs demonstrate its efficacy by targeting peroxisome 
proliferator-activated receptor γ (PPARγ), which in turn activates genes involved in 
glucose and lipid metabolism. The expression of proinflammatory cytokines which 
contribute to insulin resistance was significantly downregulated by TZD treatment. 
Pioglitazone is the only thiazolidinedione, currently available for the treatment. 
Troglitazone followed by rosiglitazone, were withdrawn from the market because of 
its toxic effects (Jaeschke, 2007, Hemmeryckx et al., 2013). TZD is prescribed for the 
treatment of T2DM patient if other oral antidiabetic agents (e.g. metformin and 
sulfonylureas) fail to lower blood glucose level. Side effects of TZD may include 
weight gain, liver failure, heart problems and bone fractures (Rizos et al., 2009) 
 
1.5.6 Sulfonylureas 
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Sulfonylureas and their hypoglycemic effects were first reported in 1942 by Janbon 
and his colleagues. Sulfonylureas class of drugs (e.g., tolbutamide, gliclazide, 
glibenclamide) increase plasma insulin concentration by stimulating the release of 
insulin from beta cells of the pancreas by KATP channel-dependent pathway (Sola et 
al., 2013). Sulfonylureas act directly on beta cells by binding to the sulfonylurea 
receptor (SUR-1) present on the cell membrane. In treated patients, a decrease in blood 
HbA1C level and improvement of secondary complications were observed (Nathan et 
al., 2009). These drugs demonstrate insulinotropic effects in a glucose-independent 
manner. As a result, treated patients run a high risk of hypoglycaemia, and which is 
augmented in patients with kidney diseases (Dalem et al., 2013). The potency of 
sulfonylureas depends on beta cell function. Hence this drug is only effective or should 
be recommended only at an early stage of T2DM (Kalra et al., 2016). Side effects 
including cardiovascular diseases, weight gain and beta-cell dysfunction were noticed 
in sulfonylureas treatment (Thulé & Umpierrez, 2014, Maedler et al., 2015, Kalra et 
al., 2016). 
 
1.5.7 Meglitinides 
Meglitinides are short-acting insulin secretagogues, which control blood glucose by 
increasing plasma insulin levels. This class of drug induces its effects by blocking 
KATP channels in beta cells resulting in an increase in Ca
2+ influx and insulin secretion.  
Meglitinides such as repaglinide and nateglinide were approved by the FDA in 1997 
and 2000 respectively for the treatment of T2DM (Stein et al., 2013). In several 
clinical studies, a decrease in blood HbA1C was observed in repaglinide-treated 
patients. However, this class of drugs is, like sulfonylureas, associated with the risk of 
hypoglycaemia (Wu et al., 2018).  
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1.5.8 Alpha-glucosidase inhibitors (AGIs) 
Alpha-glucosidase inhibitors like acarbose, miglitol and voglibose are oral antidiabetic 
agents. This class of drugs demonstrates glucose lowering effects by suppressing the 
activity of the alpha-glucosidase enzyme, which subsequently delays the digestion of 
carbohydrate to glucose (He et al., 2014). Moreover, AGI treatment has shown to 
improve body weight, lipid metabolism and blood pressure (Hanefeld & Schaper, 
2008). Beneficial effects of AGIs were observed on cardiovascular events in treated 
diabetes patients. However, this class of drugs demonstrated poor glycaemic control 
compared to metformin and sulfonylureas and caused gastrointestinal complaints 
(Standl and Schnell, 2012). 
 
1.5.9 GLP-1 analogues and DPP-4 inhibitors 
Glucagon-like peptide-1 (GLP-1) and GIP are incretin hormones, synthesised by 
enteroendocrine cells in the intestine and released following food intake. Studies have 
shown that GLP-1 maintains glucose homeostasis through several mechanisms: 1) 
stimulated release of insulin from beta cells in a glucose-dependent manner, 2) delayed 
gastric emptying, 3) decreased energy intake and 4) reduced postprandial glucagon 
level (Tasyurek et al., 2014). Furthermore, GLP-1 has been shown to improve beta 
cell proliferation, survival, and beta cell mass by inhibiting apoptosis (Lee et al., 
2016). GLP-1 has a short half-life (less than 2 min) and is degraded by dipeptidyl 
peptidase-IV (DPP-IV). Because of this, the clinical efficacy of native GLP-1 is 
limited (Manandhar & Ahn, 2014). Research overcame this limitation by developing 
two pharmacological approaches: 1) synthesising GLP-1 analogues with improved 
half-life and 2) suppressing activity of DPP4 enzyme to improve endogenous GLP-1 
level (Chon & Gauiter, 2016).  
26 
 
To date, six GLP-1 analogues including exenatide, liraglutide, albiglutide, dulaglutide, 
lixisenatide and semaglutide are in used for the treatment of T2DM. According to 
guidelines of the National Institute for Health and Care Excellence, this class of drugs 
is considered for the treatment in combination with metformin and sulfonylureas. The 
risk of hypoglycaemia associated with this class of drugs is limited, as their insulin-
releasing effects are glucose dependent. Moreover, improvement in glycaemic 
response, a decrease in glucagon release, reduction in energy intake and weight loss 
were observed with GLP-1 analogues treatment (Lepsen et al., 2015). Nausea, 
vomiting and gastrointestinal problems were the main side effects associated with this 
class of drugs (Bettge et al., 2017). 
DPP-4 inhibitors (gliptins) are oral antidiabetic agents that increase the level of the 
endogenous GLP-1 level (2-3 fold) by suppressing the activity of DPP-4 enzyme. To 
date, five DPP4 inhibitors including sitagliptin, vildagliptin, saxagliptin, alogliptin, 
linagliptin are in clinical use. DPP4 inhibitors can be used as monotherapy in patients 
who may not be able to take metformin due to renal dysfunction or in combination 
with other oral antidiabetic agents such as metformin and sulfonylureas for the 
management of T2DM (Dicker, 2011). Unlike some of the other oral antidiabetic 
drugs, DDP-4 inhibitors have low hypoglycaemia risk profile and are weight neutral 
(Aschner et al., 2006, Malmgren & Ahrén, 2015). A headache, nasopharyngitis, upper 
respiratory tract infection, urinary tract infection was most common adverse reaction 
observed in a treated patient (Amori et al., 2007, Yazbeck et al., 2007, Richter et al., 
2008). 
 
1.5.10 SGLT2 Inhibitors 
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SGLT2 inhibitors are a new class of oral glucose-lowering agents for the treatment of 
T2DM (Karla, 2014). SGLT2 inhibitors target sodium-dependent glucose co-
transporter 2 (SGLT-2) proteins, which are exclusively expressed on proximal tubule 
of the nephron in the kidney. SGLT2 inhibitors, lower blood glucose through 
suppressing glucose reabsorption by blocking SGLT-2 transporter proteins (Lee et al., 
2007, Hummel et al., 2011). Dapagliflozin and canagliflozin are two popular SGLT2 
inhibitor drugs that have been approved by the regulatory agency for the treatment of 
T2DM. In SGLT-2 inhibitor treatment, reduction in glycated haemoglobin, body 
weight and blood pressure were observed in patients.  Recent studies have issued 
warning that SGLT2 inhibitors treatment could increase the risk of diabetic 
ketoacidosis, pancreatitis and bone fracture (FDA, 2015, Chowdhary et al., 2015, 
Fadini et al., 2017, Hsia et al., 2017). Other side effects associated with SGLT-2 
inhibitor are urinary tract infection and polyurea (Geerlings et al., 2014). 
 
1.5.11 Bariatric surgery for the treatment of diabetes 
Research studies have confirmed the beneficial effects of weight loss surgery (bariatric 
surgeries) in patients with gross obesity and T2DM (Kassem et al., 2017). Bariatric 
surgery has been shown to improve glucose homeostasis through several mechanisms 
including increasing insulin secretion, insulin sensitivity, satiation and weight loss 
(Cummings and Cohen, 2016, Rubino et al., 2016). Additionally, bariatric surgery has 
resulted in a dramatic reduction in cardiovascular diseases risk. According to NICE 
guidelines, a patient is considered for bariatric surgery assessment if BMI ranges 
between 30.0-34.9. For BMI above 50, bariatric surgery is recommended as a 
treatment option. The four main bariatric procedures are: 1) Vertical sleeve 
gastrectomy (VSG), 2) Laparoscopic adjustable gastric banding (LAGB), 3) 
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Laparoscopic Roux-en-Y gastric bypass surgery (RYGB), 4) Biliopancreatic 
Diversion (BPD). These procedures are mainly classified into restrictive (decrease 
gastric capacity) or malabsorptive (decrease absorptive capacity). RYGB is the most 
popular restrictive and malabsorptive procedure, which had shown an 88% diabetes 
remission rate and 50-84% reduction in CV risk. However, despite these beneficial 
effects, bariatric surgeries are associated with high cost and complications such as 
abdominal pain and nutritional deficiencies (Abdeen and le Roux, 2016)  
 
1.5.12 New medications for diabetes 
In the last 12 years, several new drugs, including oral and injectables, were approved 
by the European Medicines agency for the treatment of diabetes (Figure: 7).  
Oral drugs include: 
• Xigduo: Xigduo from AstraZeneca contains metformin (biguanides) and 
dapagliflozin (SGLT2 inhibitors).  
• Qtern: Qtern form AstraZeneca is a combination of dapagliflozin and 
saxagliptin. 
• Segluromet: Steglujan from Merck Sharp & Dohme B.V is a combination of 
ertugliflozin and metformin hydrochloride 
• Steglujan: Steglujan from Merck Sharp & Dohme B.V, combined 
ertugliflozin with sitagliptin. 
 
Injectable drugs include: 
• Soliqua: Soliqua from Sanofi contain long-acting insulin glargine and 
lixisenatide. 
• Ozempic: Ozempic from Novo Nordisk is a GLP-1 receptor agonist 
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Figure 7: Antidiabetic drugs approved by European Medicines Agencies since 2006, 
(Adapted from Blind et al., 2018). 
 
1.6 New treatments 
According to the IDF, diabetes is one of the leading health problems affecting 8.8% 
of the global population, of whom about 80% live in low and middle-income nations. 
The cost for the treatment has reached USD 727 billion per annum and is expected to 
rise dramatically due to the growing diabetes population particularly in developing 
nations (IDF, 2017). Although many classes of glucose-lowering drugs are available, 
none of them has shown the ability to achieve long-term glycaemic control, prevent 
secondary complications and restore pancreatic beta cell function. Moreover, these 
drugs are often given in combination to bring down blood glucose, which makes the 
treated patient susceptible to more side effects associated with drugs.  Further, the 
increasing cost of the treatment is imposing a heavy financial burden on the world 
30 
 
economy. Therefore, the search for new alternative therapies that are cost-effective 
and can overcome the limitations of existing drugs are required. 
 
1.7 Amphibian Skin secretions 
The name Amphibian was first coined by Linnaeus, to introduce to that class of 
vertebrates which is in-between fish and reptiles. In 1931, Nobel referred to 
amphibians as cold-blooded vertebrates that live in the aquatic and terrestrial 
environment. Amphibians are grouped in 3 classes Anura, Urodeles and 
Gymnophions. 
The skin of amphibians is a complex organ rich in glands which play an essential role 
in the amphibian survival under different environmental conditions. The primary roles 
of amphibian skin include respiration, water regulation, defence, temperature control, 
reproduction and excretion.  It consists of two main glands, mucus and granular 
glands, which are connected to the skin surface by secretory ductus (Wells, 2007). 
Mucus glands produce mucopolysaccharides that keep the skin moist, smooth, prevent 
loss of water, protect skin from mechanical damage and trap the pathogens. Granular 
glands (also known as poison glands) are present below the skin surface across the 
body, secrete chemical compounds that play a crucial role in host defence against 
microbial and fungal infection, as well as against predators. The secretions of granular 
glands, which are controlled by sympathetic nerves, are rich in peptides, bufotoxins 
(steroids), alkaloids, amines and bufogenines, and released during stress/injuries 
(Clark et al., 1997). 
In many ancient cultures, skin secretions of amphibians were used in the preparation 
of medicine for the treatment of diseases. Secretions of dried toad skin were used in 
Chinese traditional medicine for the treatment of arthritis. Chan Su, prepared from 
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skin glands of Chinese toad, is Chinese traditional medicine, was used for the 
treatment of heart diseases, leukaemia, rhinosinusitis and other diseases (Gomes et al., 
2007). 
In early 1970, research work by scientist Vittorio Erspamer and his colleagues 
identified several peptides in the skin secretions of amphibians (listed below). 
Sr no Peptide Amphibian Year 
1 Bradykinin Phyllomedusae and 
Ranae species 
1962 
2 Caerulein Hyla caerulea 1966 
3 Bombesin Bombina bombina 
Bombina variegata 
1971 
 
These peptides were found to be identical to mammalian peptides and hormones found 
in the gastrointestinal and central nervous system. For example, Caerulein isolated 
from frog Litoria caerulea, which has been shown to stimulate secretion of insulin, 
glucagon and calcitonin, was homologues of cholecystokinin and gastrin, and 
bombesin from genus bombina was found similar to gastrin-releasing peptides (GRP), 
which act on smooth muscles of gut (Pukala et al., 2006, Ohki-Hamazaki et al., 2005). 
After these discoveries, the search for amphibian skin peptides has gained momentum 
(Wang et al., 2009). The isolation and characterization of magainins from South 
African clawed frog Xenopus levis, is considered as a significant finding, which has 
resulted in the isolation of several other bioactive peptides from skin secretions of 
frogs/amphibian (Clarke 1997, Rinaldi, 2002). Isolated magainins demonstrated low 
or moderate potency against both gram-positive (Streptococcus, Staphylococcus) and 
gram-negative (Escherichia, Pseudomonas, Acinetobacter and Helicobacter) bacteria. 
As well they displayed low haemolytic activity against human erythrocytes (Zasloff, 
1987). Several recent studies have also revealed that magainin-2 peptides exhibit 
bactericidal activities by forming pores in lipid membranes (Imura et al., 2008, Tamba 
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et al., 2010).  The biological activity of amphibian skin peptides is not only confined 
to antimicrobial activity. Research has confirmed the presence of bufalin, and other 
antineoplastic and immunostimulatory agents in Chan Su medicine (Bhuiyan et al., 
2003, Shimizu & Inoue, 2004, Ko et al., 2005). Recent studies have also reported a 
wide range of biological activities of amphibian/frog skin peptides (Gomes et al., 
2007, Conlon et al., 2012a, Conlon & Mechkarska, 2014). 
Earlier, methanolic extraction method was used to separate peptides from sun-dried 
amphibian skins (Tyler et al., 1992). This method involves the killing of frogs, sun 
drying of skin and grinding of dried skin. Due to these multiple steps, the methanolic 
extraction method is more prone to contamination with foreign substances and peptide 
degradation. Hence using this method to isolate pure peptide is not considered 
desirable. In another method of extraction, frog skin is homogenised in sodium acetate 
containing protease inhibitors. However, this method is time-consuming and not 
feasible economically. The use of mild electric stimulation and injection of 
norepinephrine are considered as a most effective and non-harmful method for the 
isolation of pure compounds from skin secretions (Conlon et al., 2007a, Zahid et al., 
2011). 
 
1.7.1 Biological properties of amphibian skin peptides 
Peptides found in skin secretions of frogs vary in size from 8 to 63 amino acid residues. 
Sequence analysis revealed that these peptides do not have a conserved domain 
connected with their biological properties. However, these peptides are rich in 
positively charged amino acids including lysine, arginine and histidine and contain 
nearly 40-70% of hydrophobic amino acids. Due to the presence of multiple positive 
amino acids, these peptides carry positive charge between +2 and +6 at pH 7. In 
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aqueous solution, these peptides do not have any stable secondary structure, but in the 
vicinity of a phospholipid, bilayer peptides tend to form amphipathic alpha helix 
structure (Conlon & Mechkarska, 2014).   
Zasloff and his colleagues were first to report the antibacterial activity of peptides 
found in skin secretions of frogs (Andrade, 2015). Magainins peptides isolated from 
Xenopus levis demonstrated antimicrobial activity against both gram-positive and 
gram-negative bacteria. Subsequently, other antimicrobial peptides were isolated from 
X.levis and termed peptide glycine-leucine amide (PGLa), caerulein precursor 
fragment (CPF) and xenopsin precursor fragment (XPF) (Gibson et al., 1986, Soravia 
et al., 1988, Conlon & Mechkarska, 2014). Orthologues of these peptides were found 
in several species of frogs belonging to genus Xenopus. Both PGLa-AM1 and CPF-
AM1 from X. amieti, demonstrated broad-spectrum bactericidal activity against 
Escherichia coli and Staphylococcus aureus. Also, frog skin peptides showed activity 
against microorganisms that are resistance to currently available antibiotics. PGLa has 
an inhibitory effect against amphotericin B-resistant Candida albicans, and 
fluconazole-resistant Candida glabrata isolate (Helmerhorst et al., 1999). CPF-AM1 
displayed an inhibitory effect against the colistin-resistant strain of (clinical isolates 
of multidrug-resistant) Acinetobacter baumannii (Conlon Mechkarska, 2014). 
Temporin-Dra from Rana draytonii, and Frenatin 2.1S and Frenatin 2.2S from 
Sphaenorhynchus lacteus were effective against methicillin-resistant strains of 
Staphylococcus aureus (MRSA) (Conlon et al., 2011, 2014b).  
In addition to antimicrobial activity, frog skin peptides also showed cytotoxic potency 
against a variety of tumour cell lines. Ascaphin-8 from Ascaphus truei, Peptide XT7 
from Silurana tropicalis and Dermaseptin L1 and Phylloseptin L1 from Agalychnis 
lemur, showed cytotoxicity against hepatocarcinoma HepG2 cells (Conlon et al., 
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2007b, Conlon et al., 2008). Esculentin-2CHa from Lithobates chiricahuensis and 
Hymenochirin 1B from Hymenochirus boettgeri were active against lung 
adenocarcinoma (Attoub et al., 2013a, b). Magainin-2 from Xenopus laevis 
demonstrated tumoricidal activity against lung cancer cell line, bladder cancer cell line 
and hematopoietic cell line (Cruciani et al., 1991, Ohsaki et al., 1992, Lehmann et al., 
2006). Temporin-1CEa from Chinese brown frog Rana chensinensis and 
Hymenochirin 1B from Hymenochirus boettgeri, displayed cytotoxic activity against 
a human breast cancer cell line (Wang et al., 2013, Attoub et al., 2013a). Dermaptin 
B2 & B3 from Phyllomedusa bicolor demonstrated both cytotoxic and angiostatic 
properties against prostatic adenocarcinoma PC3 cells (Van Zoggel et al., 2012). 
Recent studies have shown antiviral activities of several frog skin peptide. Magainin-
1 and -2 from Xenopus levis, Dermaseptins S1–S5 from Phyllomedusa sauvagei and 
Brevinin-1 from Pelophylax porosus were effective inhibitors against herpes simplex 
virus type 1 (HSV-1) and herpes simplex virus type 2 (HSV-2) (Matanic et al., 2004, 
Belaid et al.,2002, Bergaoui et al., 2013). PGLa-AM1 and CPF-AM1 from Xenopus 
amieti showed antiviral properties against HSV-1, Caerin 1.1, 1.9, and maculatin 1.1 
from Australian tree frogs demonstrated antiviral activity against HIV infection 
(VanCompernolle et al., 2005). 
Frog skin peptides have also been shown to possess immunomodulatory activities. The 
synthetic analogues of ascaphin-8, temporin-Dra, XT-7 and hymenochirin-1B 
peptides enhanced the release proinflammatory cytokines while demonstrating 
antimicrobial activity, suggesting a possible role in protection from inflammation 
(Pantic et al., 2017b). Frenatin 2.1S from Sphaenorhynchus lacteus displayed 
antimicrobial activity by promoting immune cells including NK (Natural Killer cells), 
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NKT (Natural Killer T cells) and macrophages (Waldhauer & Steinle, 2008, Vivier et 
al., 2008).   
 
1.7.2 Insulin-releasing peptides from skin secretion of frogs 
The search for antidiabetic peptides from animal sources has gained momentum after 
the approval of exenatide, isolated from the venom of Heloderma suspectum, for the 
treatment of T2DM. The peptides found in skin secretions of frogs, which were 
initially characterised based on antimicrobial activity showed the ability to 
demonstrate insulin-releasing activity. Studies conducted in our laboratory have 
identified insulin releasing peptides derived from skin secretion of frogs belonging to 
Ranidae, Hylidae, Dicroglossidae, Leptodactylidae, Bombinatoridae & Pipidae 
families (Table 1.1). The isolated frog skin peptides demonstrated insulin release in 
vitro using rat clonal pancreatic beta cells (BRIN-BD11 cells), human-derived 
pancreatic beta cells (1.1B4), primary islet cells and in vivo in lean and high fat fed 
mice. 
Marenah et al., 2004b, demonstrated insulin-releasing activity of skin secretion of frog 
Rana palustri.  The isolated active compound, which demonstrated concentration-
dependent insulin release, exhibited 48% identity with brevinin-1, an antimicrobial 
peptide found in the skin secretion of various Rana species. Hence the peptide was 
named as brevinin-1. Subsequently, novel insulin releasing peptide (24 amino acid) 
was isolated from skin secretion of Rana pipiens. This peptide showed 100% 
homology to pipinin-1, which was initially characterised as an antimicrobial peptide 
(Marenah et al., 2005). Similarly, four insulinotropic peptides were isolated from skin 
secretions of Rana saharica that were identical to antimicrobial esculentin-1, 
esculentin-1B brevinin-1E and brevinin-2EC (Marenah et al., 2006).  
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Antimicrobial peptides belonging to the temporin family have also demonstrated 
insulin-releasing activity. Temporin-Oe, Temporin -Vb, Temporin -DRb, and 
Temporin -TGb isolated from Rana ornativentris, Lithobates virgatipes, Rana 
draytonii and Rana tagoi respectively, stimulated dose-dependent insulin release from 
BRIN-BD11 cells without affecting cell viability. Temporin-Oe was potent and 
displayed a 2.6-fold increase in insulin release compared to control (Abdel-Wahab et 
al., 2007). Seven peptides isolated from norepinephrine stimulated skin secretions of 
the Lithobates catesbeianus, potentiated insulin release from BRIN-BD11 cells with 
no release of LDH enzyme (Mechkarska et al., 2011). 
Peptides belonging to the Phylloseptin family also produced significant insulinotropic 
effects. Phylloseptin-L2 (a 15 amino acid peptide) from H. lemur stimulated insulin 
release from BRIN-BD11 cells by KATP channel-independent pathway (Abdel-Wahab 
et al., 2008b). Furthermore, this peptide also improved glucose tolerance in healthy 
mice by increasing insulin concentrations. Peptides with insulin releasing properties 
were also identified in the skin secretions of frogs belong to the subfamily 
Phyllomedusinae. RK-13 peptide from skin secretions of A. calcarifer stimulated 
insulin release in a dose-dependent manner from BRIN-BD11 cells without affecting 
cell viability. Early mechanistic studies revealed that peptide might stimulate insulin 
release cells by activation of protein kinase A (PKA) pathway (Abdel-Wahab et al., 
2005). 
 A recent study has described insulinotropic effects of Tigerinin-1R peptide 
(RVCSAIPLPICH.NH2) found in the skin secretions of frog Hoplobatrachus 
rugulosus (formerly known by Rana rugulosa).  The insulinotropic effects of the 
peptide were not associated with the release of LDH enzyme, suggesting the integrity 
of the plasma membrane. The maximum response produced by tigerinin-1R was 
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greater than that produced by GLP-1 and GIP under the same experimental condition. 
Like KCl and alanine, tigerinin-1R depolarised BRIN-BD11 beta cells and increased 
intracellular Ca2+. This study also revealed that C- terminal amidation is essential for 
good insulinotropic potency. Acute administration of Tigernin-1R significantly 
enhanced insulin release and improved glycaemic response in high-fat-fed mice (Ojo 
et al., 2015b). 
More recently, Owolabi et al., 2015 reported the dose-dependent insulin-releasing 
effects of Hymenochirin-1B, isolated from Hymenochirus boettgeri, in BRIN-BD11 
and isolated mouse islets. Preliminary mechanistic studies revealed that peptide might 
stimulate insulin release by PKA pathway. In high-fat-fed mice Hymenochirin-1B, 
significantly improved glycaemic control with a concomitant increase in insulin 
release after acute administration.  
 
1.7.3 Frog species studied in this thesis 
1.7.3.1 Discoglossus sardus 
Discoglossus sardus, also known as Tyrrhenian painted frog, is a medium-sized frog 
(up to 75 mm in length) that belong to the family Alytiade. Their population is 
scattered on Mediterranean islands but predominantly found on the island of Sardinia 
and Corsica. They are naturally found in a wide range of aquatic and terrestrial 
habitats. Unlike other frog skin peptides, the peptides found in the norepinephrine-
stimulated skin secretions of D. sardus did not exhibit antimicrobial or haemolytic 
activity. The peptidomic analysis of the norepinephrine-stimulated skin secretions 
revealed the presence of peptides that showed structural similarity to frenatin 2 
peptides found in the skin secretions of Australian frog Litoria infrafrenata. 
Henceforth, isolated peptides were termed as frenatin 2D, and frenatin 2D.1 Frenatin 
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2D predominately displayed immunostimulatory activities as demonstrated by 
enhancing the production of proinflammatory cytokines (TNF-α, IL-1β) by 
stimulating macrophages. Also, frenatin 2D has been shown to increase the production 
of IL-12 in LPS-stimulated and unstimulated macrophages (Lin & Karin, 2008, 
Conlon et al., 2013). 
 
1.7.3.2 Sphaenorhynchus lacteus 
Sphaenorhynchus lacteus (also referred as Orinoco Lime Treefrog), belonging to the 
family Hylidae, is found in the Amazon basin of South America and on the islands of 
Trinidad and Tobago (Frost, 2014). In norepinephrine-stimulated granular glands 
secretions of this frog species, three host defence peptides were found identical to 
frenatin 2. Hence these peptides were named as frenatin 2.1S, frenatin 2.2S and 
frenatin 2.3S. The former two are rich in glycine/leucine amino acids and α-amidation 
at C-terminal, while later lacks a α-amidation at C-terminus. Unlike frenatin 2D, 
frenatin 2.1S and frenatin 2.2S exhibited antimicrobial activity against gram-positive 
bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and 
Staphylococcus epidermidis. Also, both of these peptides demonstrated 
immunostimulatory activity (Conlon et al., 2014b, Pantic et al., 2017a).  
 
1.7.3.3 Xenopus amieti 
Xenopus amieti (also known by Volcano clawed frog), belongs to family Pipidae is 
majorly populated in volcanic highland areas of western Cameroon. Their skin 
secretions are an abundant source of peptides with antimicrobial and cytotoxicity 
properties. Nine peptides identified in norepinephrine-stimulated skin secretions of X. 
amieti, demonstrated differential antimicrobial activity against Staphylococcus aureus 
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and Escherichia coli. These peptides shared a high degree of structural similarity with 
peptides (magainin, PGLa, CPF, XPF) isolated from X. laevis and Silurana (formerly 
Xenopus) tropicalis (Conlona et al., 2010).  
A PGLa-AM1 peptide isolated from X. amieti, demonstrated broad-spectrum 
bactericidal activity against Escherichia coli and Staphylococcus aureus, and potent 
growth-inhibitory activity against colistin resistant Acinetobacter baumannii, with low 
haemolytic activity (Conlon & Mechkarska 2014). Also, PGLa-AM1 stimulated the 
release of GLP-1 from GLUTag cells (Ojo et al., 2013a). In a recent study, PGLa-
AM1 produced a dose-dependent stimulation of insulin release from rat clonal 
pancreatic beta cells (BRIN-BD11 cells) without the release of lactate dehydrogenase 
enzyme (LDH) indicating lack of cytotoxicity at concentrations up to 3μM.  Its 
cationic analogues [A14K] & [A20K], containing L-lysine substitution at 14th and 20th 
position respectively, demonstrated superior insulinotropic potency than parent 
peptide in BRIN-BD11 cells, and primary mouse islets. Acute administration of 
[A14K] & [A20K] improved glucose tolerance and increased plasma insulin level both 
in healthy lean and high fat-fed mice (Owolabi et al., 2017).   
Like PGLa-AM1, CPF-AM1 (isolated from Xenopus amieti) exhibited antimicrobial 
activity against Escherichia coli, Staphylococcus aureus and clinical isolates of 
Acinetobacter baumannii combined with moderate haemolytic activity. It also 
significantly stimulated release GLP-1 from GLUTag cells (Conlon Mechkarska, 
2014, Ojo et al., 2013a). In recent studies, CPF-AM1 showed concentration-dependent 
insulinotropic effects in BRIN-BD11 cells (Ojo et al., 2012). Its four cationic 
analogues produced by substitution of amino acids at the 4th and 14th position with 
either L lysine or L arginine demonstrated significant insulinotropic effects without 
causing beta cell cytotoxicity. The [S4K] analogue was the most potent, producing 
40 
 
greater stimulatory response both in BRIN-BD11 and isolate mouse islets than the 
parent peptide. Also, in acute in vivo studies, the [S4K] analogue appeared to be more 
potent than the native peptide at improving glucose tolerance and increasing plasma 
insulin level in high fat fed mice (unpublished data). 
 
1.7.3.4 Rana temporaria 
Rana temporaria also referred to as the European common frog, belongs to the family 
Ranidae. Their population is scattered in Great Britain, Europe and north-west Asia. 
They are naturally found near mountain lakes.  Rana temporaria is one of the two 
amphibian species that inhabit regions north of the Arctic Circle (Ludwiga et al., 
2015). Temporin peptides were first isolated from skin secretions of R.temporaria 
(Slmmaco et al., 1996). Subsequently, peptides showing structural similarity to 
temporins were identified in other frogs’ species of both American and Eurasian origin 
(Rinaldi et al., 2013). The members of temporin family have demonstrated activity 
against both gram-positive and gram-negative bacteria (Wade et al., 2000, Mangoni 
et al., 2013. Temporin A and Temporin B have shown potent growth-inhibitory 
activity against multidrug-resistant clinical isolates of Staphylococcus aureus, without 
affecting infected cells (Grazia et al., 2014). In addition, a few members of temporin 
family including Temporin-1Vb, -1Oe, -1DRb, and -1TGb demonstrated insulin-
releasing activity without cell cytotoxicity (Abdel Wahab et al., 2007).  
 
1.7.3.5 Rana esculenta 
Rana esculenta is a hybrid of Pelophylax lessonae (Pool frog) & Pelophylax 
ridibundus (marsh frog) (Conlon, 2008). Peptides from the skin secretions of these 
hybrid frogs mainly belong to brevinine 1, brevinine 2, esculentin 1 & esculentin 2 
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peptide family.  Esculentin 1 was first isolated from the skin secretions of this frog 
and subsequently identified in other frog species.  Esculentin 1 is one of the largest 
antimicrobial peptides comprised of 46 amino acids. It has demonstrated potent 
inhibitory activity against Pseudomonas aeruginosa, Candida albicans and 
Saccharomyces cerevisiae (Simmaco et al., 1994, Islas-Rodrìguez et al., 2009, Kang 
et al., 2010). The antibacterial activity of the N-terminal 1–18 amino acids of 
esculentin-1 was found similar to that of the intact peptide, suggesting that N terminal 
region is important for antimicrobial activity (Mangoni et al., 2003). 
 
1.7.4 Peptide Analogues 
The therapeutic potential of bioactive peptides isolated from natural sources (plants, 
animals or humans) is often challenged by poor oral availability, short/reduced 
metabolic stability, rapid degradation by digestive enzymes, lack of selective binding 
(interaction with nonspecific receptors), rapid renal clearance, risk of immunogenic 
effects and cytotoxicity (Lau and Dunn, 2018). The progress in peptide synthesis 
technology made it possible for the researchers to minimise these shortcomings by 
design and synthesising the analogues of the peptide with enhanced pharmaceutical 
properties. Several structure-activity relationship studies of host defence peptides 
helped to understand the importance of cationicity, hydrophobicity, amphipathicity, 
helicity and angle subtended by charged residue on biological activities of peptides. 
Based on this knowledge, several cytotoxic peptides with lower antimicrobial potency 
from skin secretion of frogs were modified to produce promising antimicrobial agents 
through the design and synthesis of their analogues (Conlon and Mechkarska, 2014). 
Analogues of frog skin peptides magainins, CPF peptides and hymenochirin-1B 
peptide have shown strong antimicrobial potency against multidrug-resistant 
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microorganism, with reduced haemolytic activity (Zasloff et al., 1998, Cuervo et al., 
1988, Conlon et al., 2008, Mechkarska et al., 2013). For example, a synthetic analogue 
of Hymenochirin-1B, [E6k, D9k] hymenochirin-1B, was designed to exhibit increased 
cationicity while maintaining amphipathicity, by substituting Glu6 and Asp9 by D-
Lysine, which produced high potency against multidrug resistant clinical isolate and 
low haemolytic activity (Mechkarska et al., 2013).  
Using a similar approach, insulin-releasing peptides were transformed into analogues 
which displayed potent insulinotropic activities both in vitro and in vivo. The insulin 
releasing potency of Pseudin-2 from paradoxical frog Pseudis paradoxa was enhanced 
by designing an analogue with increased cationicity. The analogue designed by 
substituting Leu18 → Lys, produced a 215% increase in insulin release at 10-6 M 
concentration in BRIN-BD11 cells, with no adverse effect on the integrity of plasma 
membrane (Abdel-Wahab et al., 2008a). Structure-activity study of alyteserin-2a 
(ILGKLLSTAAGLLSNLa), by Ojo et al., 2013b, demonstrated that cationic 
analogues containing L-lysine and D-lysine substitution show greater insulinotropic 
potency than the native peptide at 3 µM concentration. Acute administration of [G11k] 
alyteserin-2a (75 nmol/ kg body weight), resulted in a significant increase in insulin 
release and improved blood glucose in high fat fed mice. Structure-activity studies of 
Hymenochirin-1B (isolated from Hymenochryus begiottri) demonstrated that [P5K] 
and [D9k] analogues, nontoxic up to 3 µM concentration, produced maximum rate of 
insulin release than native from isolated mouse islets, and also improved glycaemic 
response with a concomitant increase in insulin secretion in high fat fed mice. 
Treatment of high fat fed mice for 28 days with [P5K] hymenochirin–1B, (75 nmol/kg 
body weight) significantly decreased blood glucose which was associated with 
enhanced insulin secretion. Molecular studies confirmed that genes involved in insulin 
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signalling (muscles) and secretion (isolated islets) were improved significantly in 
treated mice (Owolabi et al., 2015). 
The improvement in the insulinotropic activity of peptide analogue containing 
tryptophan substitution was also observed (Srinivasan et al., 2015). The recent study 
demonstrated that Trp10 substituted analogue of tigerinin-1R, produced greater 
insulinotropic potency both in BRIN-BD11 cells and primary isolated islet, in 
comparison with native peptide. Furthermore, twice daily intraperitoneal 
administration of Trp10 Tigerinin-1R (75 nmol/kg bw) in high-fat-diet-induced 
diabetic mice for 28 days, improved insulin sensitivity, islet insulin secretory 
responses, and glycaemic control (Srinivasan et al., 2015).  In another study, the 
insulinotropic activity of the frog skin peptide was enhanced by designing analogues 
containing fatty acid moiety. Vasu et al., 2017 designed stable analogues of esculentin-
2CHa(1–30) peptide by covalently attaching fatty acid (l-octanoate) to Lys at 15th 
position. In comparison with native peptide, [Lys15-octanoate]-esculentin-2Cha (1–
30) exhibited resistance to degradation by plasma peptidases and demonstrated potent 
insulin-releasing effects in BRIN-BD11, 1.1B4 and primary mouse islets. Treatment 
of high fat fed mice with [Lys15-octanoate]-esculentin-2Cha (1–30) for 28 days, 
produced significant improvements in glucose tolerance, insulin sensitivity and 
decreased HbA1C level similar to exendin-4 treated mice. 
 
1.8 Objectives and Aims 
1.8.1 General Objectives 
The primary objectives of this thesis were to characterise the bioactive peptides with 
insulinotropic and antidiabetic properties from skin secretions of selected frog species 
(listed in Table 1.2) and to assess the metabolic effects and potential role in 
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transdifferentiation of glucagon producing alpha cells to insulin producing beta cells 
of substituted analogue of PGLa-AM1 and CPF-AM1, from skin secretions of 
Xenopus amieti (Family: Pipidae), in different mice models of diabetes. 
 
1.8.2 Aims 
 1.8.2.1 In vitro studies 
• Synthesis of frog skin bioactive peptides and designing synthetic analogues of 
these peptides with enhanced insulinotropic activity. 
• Confirmation of purity & identity of peptides using reverse-phase high-
performance liquid chromatography (HPLC) & Matrix Assisted Laser 
Desorption Ionisation-Time of Flight (MALDI-TOF) respectively.  
• Assessment of acute concentration-dependent insulin-releasing effects of 
peptides in rat clonal beta cells (BRIN-BD11), human clonal beta cells (1.1B4) 
and isolated mouse islets, and cell cytotoxicity studies by lactate 
dehydrogenase assay. 
• Preliminary studies to delineate mechanism of insulinotropic action of peptides 
by assessing their effects on membrane potential and intracellular calcium, 
cAMP production, insulin release in the presence of known insulin 
secretagogues and calcium-free buffer, as well as in PKA/PKC downregulated 
cells.  
• Assessing the effects of active peptides on apoptosis and cell proliferation in 
BRIN‑BD11 cells, and glucose uptake using C2C12 muscle cells. 
• Investigation of metabolic stability of active peptide in mouse plasma. 
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1.8.2.2 In vivo studies 
• Investigation of acute in vivo effects of the active peptide on glucose tolerance, 
plasma insulin and food intake in lean mice to identify most promising peptide 
that can be used as templet for further modifications. 
• Evaluating the metabolic effects of long-term (28 days) administration of 
active peptides on energy intake, body weight, water intake, blood glucose, 
plasma insulin, blood HbA1C, glucose tolerance, insulin sensitivity, fat 
composition, liver and kidney functions, plasma lipid profile, islet morphology 
and genes involved in glucose homeostasis in diabetic mice model (db/db 
mice).  
• Investigating the effects of [A14K] PGLa-AM1 and [S4K] CPF-AM1 peptides 
on the regeneration of insulin-producing beta cells through and 
transdifferentiation of glucagon-producing alpha cells using GluCre-
ROSA26EYFP mice. 
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Table 1.1 List of amphibian skin peptides with insulinotropic activities from families Pipidae, Leptodactylidae, Hylidae, Ranidae, 
Bombinatoridae and Dicroglossidae 
Species Family Peptide Primary structure 
Xenopus borealis  Pipida Caerulein-B1  <EQDY(SO3)GTGWMDFa  
Xenopus amieti  Pipidae  Xenopsin  <EGKRPWIL  
Xenopus amieti  Pipidae   Xenopsin-AM2  <EGRRPWIL 
Xenopus amieti  Pipidae   CPF-AM1 GLGSVLGKALKIGANLLa 
Xenopus amieti  Pipidae   PGLa-AM1 GMASKAGSVLGKVAKVALKAALa 
Leptodactylus laticeps  Leptodactylidae  Ocellatin-L2  GVVDILKGAAKDLAGHLATKVMDKLa  
Agalychnis lemur Hylidae Phylloseptin L2   FLSLIPHVISALSSLa  
Agalychnis litodryas Hylidae  Dermaseptin-L11 AVWKDFLKNIGKAAGKAVLNSVTDMVNE 
Pseudis paradoxa Hylidae Pseudin-2  GLNALKKVFQGIHEAIKLINNHVQ  
Rana ornativentris  Ranidae Temporin-Oe   ILPLLGNLLNGLLa  
Lithobates catesbeianus Ranidae Ranatuerin-2CBd GFLDIIKNLGKTFAGHMLDKIRCTIGTCPPSP  
Lithobates catesbeianus Ranidae Brevinin-1CBb    FLPFIARLAAKVFPSIICSVTKKC  
Lithobates septentrionalis  Ranidae  Brevinin-2-related peptide GIWDTIKSMGKVFAGKILQNLa  
Rana pipiens Ranidae Brevinin-1Pa    FLPIIAGVAAKVFPKIFCAISKKC  
Rana palustris Ranidae Palustrin-1C    ALSILRGLEKLAKMGIALTNCKATKKC  
Bombina variegata Bombinatoridae   Bombesin   <EQRLGNQWAVGHLMa  
Bombina variegata Bombinatoridae Bombesin-related peptide    <EQRLGHQWAVGHLMa  
Bombina variegata  IN-21  Bombesin-related peptide  IYNAICPCKHCNKCKPGLLAN    
Hoplobatrachus rugulosus  Dicroglossidae Tigerinin-1R   RVCSAIPLPICHa  
Adapted from Ojo (2013). a = C-terminal α amidation. 
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Table 1.2: List of selected frog species and peptide studied in this thesis 
 
 
 
  
 
 
 
 
 
 
 
Sr no Frog species   Family Peptide 
1 Discoglossus sardus Alytidae ▪ Frenatin 2D 
2 Sphaenorhynchus lacteus Hylidae ▪ Frenatin 2.1S 
▪ Frenatin 2.2S 
▪ Frenatin 2.3S 
3 Rana temporaria Ranidae ▪ Temporin A 
▪ Temporin B 
▪ Temporin C 
▪ Temporin E 
▪ Temporin F 
▪ Temporin G 
▪ Temporin H 
▪ Temporin K 
4 Rana esculenta Ranidae • Esculentin-1a(1-21) 
• Esculentin-1a(1-14) 
• Esculentin-1a(9-21) 
• Esculentin-1b(1-18) 
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2.1 Materials 
The chemical reagents, assay kits and peptides used in experiments and their supplier 
are listed in the appendices. 
 
2.2 Peptides from skin secretions of frogs 
Peptides from skin secretions of frog Discoglossus sardus, Sphaenorhynchus lacteus, 
Rana temporaria and Rana esculenta were kindly provided in pure form by Professor 
J.M. Conlon. Synthetic peptides were supplied in crude as well as in >95% pure form 
by SynPeptide Co Ltd. (China). The procedure from the collection of skin secretions 
to structural characterisation of peptides is as follows:  
Collection of skin secretion from Norepinephrine (injected/immersed) stimulated 
frogs 
 
Partial purification of secretions using Sep-Pak C18 cartridges 
 
Investigating insulinotropic activity of each fraction in BRIN-BD11 cells 
 
Separation of peptide components from desired fractions using reversed-phase 
HPLC on C18 columns 
 
Investigating insulinotropic activity of each purified peptide components in BRIN-
BD11 cells 
 
Structural characterisation of the purified peptide by sequencing and mass 
spectrometry 
 
Synthesis of peptide and analogues 
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Insulin-releasing studies In vivo and In vitro 
 
2.2.1 Reverse-phase high-performance liquid chromatography (RP-HPLC) 
2.2.1.1 Purification of peptides 
Synthetic peptides supplied in crude form by SynPeptide Co Ltd. (China), were 
purified using Reverse phase-HPLC (Thermo Fisher Scientific Inc. Waltham, 
Massachusetts, USA). The representative image of Reversed-phase HPLC is shown in 
Figure 2.5. The crude peptide (5 mg) was dissolved in 1 ml of 0.1% (v/v) TFA/water 
and injected into Vydac 218TP1022 (C-18) reversed-phase HPLC column at the flow 
rate of 6 ml/min. Acetonitrile/water/TFA (70:29.9:0.1 v/v/v) concentration in the 
eluting solvent was increased to 30% over 10 min and to 70% over a period of 60 min. 
The absorbance was set at 214 nm to detect peptide.  The selected peaks were collected 
in 15 ml centrifuge tubes and subjected to vacuum concentrator SPD2010 (Integrated 
SpeedVac Systems, MA, USA) to remove acetonitrile. The purity of purified peptide 
and also those peptides that received in >95% pure form, was determined by Luna 5u 
C8 250x4.6mm column using a gradient from 0 to 100% acetonitrile over 28 min, and 
MALDI-TOF MS. 
 
2.2.2 Determination of molecular mass of peptides by matrix-assisted laser 
desorption ionisation time of flight mass spectrometry (MALDI-TOF MS) 
The molecular mass of purified peptide was determined using an analytical device 
Voyager-DE Bio spectrometry Workstation (PerSeptive Biosystems, Framingham, MA, 
USA). First, the instrument was calibrated with a peptide of known molecular mass in the 
range of 2000-4000 Da. After calibration, peptide sample (1.5 µl) was mixed with equal 
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volume of matrix solution [prepared by dissolving 10 mg of α-Cyano-4-hydroxycinnamic 
acid in 1 ml of acetonitrile/ethanol (1/1 ratio)] and placed on 100-well stainless-steel plate. 
After complete drying of the samples, the MALDI plate was injected into a Voyager DE-
PRO instrument, which calculates the molecular mass of peptide as a mass-to-charge 
(m/z) ratio. The experimental molecular mass of peptide obtained was compared with the 
theoretical mass of the peptide.  
 
2.3 Cell Culture 
2.3.1 Culturing of insulin-secreting cell lines (BRIN-BD11 and 1.1 B4 cells) 
BRIN-BD11 and 1.1B4 cells are insulin-secreting cell lines, the former was produced 
by electrofusion of RINm5f cells with New England Deaconess Hospital rat pancreatic 
islet cells (McClenaghan et al., 1996). The latter was generated by electrofusion of 
primary culture of human beta cells with PANC-1, a human pancreatic ductal 
carcinoma cell line (McCluskey 2011). These cell lines were stored in liquid nitrogen, 
in the cryogenic vials (1x106 cells/vial) containing freezing medium (10% DMSO, 
10% RPMI-1640 medium and 80% foetal bovine serum). For culturing of cells, 
cryovial was taken out from liquid nitrogen and immediately kept in the icebox. After 
thawing, the cell suspension was transferred to 15 ml of centrifuge tube and pre-
warmed warm media RPMI-1640 media (10 ml) containing foetal bovine serum 10% 
(v/v) (FBS) and 1% (v/v) antibiotics – penicillin (100 U/ml) and streptomycin (0.1 
mg/l), was slowly added to avoid osmotic shock to cells. The tube was then 
centrifugation at 900 rpm for 5 min; the supernatant was discarded and fresh 10 ml 
pre-warmed RPMI-1640 (supplemented like previously described) media was added. 
Cells were homogenously distributed by pipetting and transferred to a sterile tissue 
culture flask (75 cm2, Nunc, Roskilde, Denmark). Additional 15 ml of pre-warmed 
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RPMI-1640 media was added. The flask was then kept in a CO2 incubator at 37°C, 
5% CO2 and 95% air (LEEC secure CO2 incubator, LEEC, Nottingham) until 80% 
confluent with cells. These cells attach to the surface of the flask and grow as a 
monolayer with epithelioid characteristics. For subculturing, media was discarded 
from the flask and cells were washed with HBSS solution (1X concentration). 
Monolayer formed cells were detached by incubating with 3 ml of trypsin (0.25% 
(w/v) containing 1 mM EDTA) at 37°C for 3 min. After 3 min incubation, pre-warmed 
RPMI-1640 medium (10 ml) was added (FBS in media inhibit the action of trypsin), 
and the cell suspension was centrifuged at 900 rpm for 5 min. The supernatant was 
discarded, and 30 ml of RPMI-1640 medium was added to cell pellets. Cell population 
in 100 µl of cell suspension was determined by mixing with an equal volume of trypan 
blue dye (0.4%).  The viable cells (unstained and bright) were counted using Neubauer 
haemocytometer under a microscope (magnification 10X). Cells were maintained by 
transferring 1 ml of cell suspension back to the flask with an additional 25 ml of pre-
warmed RPMI-1640 medium and incubated in a CO2 incubator at 37°C for further 
experiments. The image of BRIN-BD11 cells growing in culture media is shown in 
Figure 2.4 (A).  
 
2.3.2 Culturing and differentiation of a skeletal muscle cell line (C2C12 cells) 
The skeletal muscle cell line (C2C12 cells) obtained from the Sigma-Aldrich 
(Catalogue number: 91031101-1VL) were maintained in growth media [D-MEM 
(Dulbecco’s modified Eagle’s medium: high glucose (4500 mg/L) + glutamine, no 
sodium pyruvate) supplemented with 20% FBS and 1% Pen/Strip] at 37°C with 95% 
air and 5% CO2 incubator until they reached 50–60% confluence. Differentiation was 
induced by replacing growth media with diﬀerentiation medium [D-MEM 
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(Dulbecco’s modified Eagle’s medium: high glucose + glutamine, no sodium 
pyruvate) supplemented with 2% donor equine serum and 1% Pen/Strip] 
(Balasubramanian et al., 2014). Differentiation media was changed every 24 hrs up to 
3 days. Before experiments, differentiated cells were serum starved for 12 hrs.  
 
2.4 In vitro insulin-release studies 
2.4.1 Insulin release studies using BRIN-BD11 and 1.1B4 cells 
2.4.1.1 Acute in vitro insulin releasing studies in BRIN-BD11 and 1.1B4 cells 
Acute insulin-releasing effects of frog skin peptides were assessed according to the 
method described by Owolabi et al., 2017. After harvesting and counting (as described 
in Section 2.3.1), cells were seeded at a density of 150,000 cells/well in 24 well plates 
(Nunc, Roskilde, Denmark) and incubated for 18 hr in a CO2 incubator at 37°C to form 
a monolayer. Following 18 hr incubation, culture media was replaced by 1 ml of 
preincubation buffer i.e. Krebs–Ringer bicarbonate buffer (KRBB- 115 mmol/l NaCl, 
4.7 mmol/l KCl, 1.2 mmol/l MgSO4 7H2O,, 1.28 mmol/l CaCl2 2H2O, 1.2 mmol/l 
KH2PO4, 20 mmol/l HEPES and 25 mmol/l NaHCO3, containing 0.5% (w/v) BSA, pH 
7.4) supplemented with 1.1 mM glucose. After 40 min, preincubation buffer was 
replaced by 1 ml of test peptides (ranging concentration from 3x10-6 to 10-12 M) insulin 
secretagogues prepared in KRBB buffer [supplemented with glucose (5.6 mmol/l or 
16.7 mmol/l)], and plates were incubated at 37°C for 20 min. After incubation, a test 
solution (950 µl) was transferred to LP4 tubes and stored at -20°C to measure insulin 
concentration using radioimmunoassay (RIA) (described in Section 2.4.3). 
 
2.4.1.2 Acute insulin release studies in the presence of modulators of insulin 
release 
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The mechanism of insulinotropic action of frog skin peptides was determined by using 
known modulators of insulin release (Srinivasan et al., 2013). In the presence or 
absence of frog skin peptides, BRIN-BD11 cells were incubated with either insulin 
modulators such as verapamil (50 µM, block calcium channel), diazoxide (300 µM, 
open ATP sensitive potassium channel), IBMX (200 µM, increase activity of 
adenylate cyclase), tolbutamide (200 µM, block ATP sensitive potassium channel) or 
DIDS (0.66 Mm, block chloride channel) prepared in KRB buffer supplemented with 
5.6 mM glucose. In another set of experiments, BRIN-BD11 cells were incubated with 
KCl (30 mM) prepared in KRB buffer supplemented with 16.7 mM glucose in the 
presence or absence of frog skin peptides. The procedure to perform the acute test is 
detailed in Section 2.4.1.1.  
 
2.4.1.3 Acute insulin release studies in the absence of extracellular calcium  
Effects of extracellular calcium on the insulinotropic activity of the peptide was 
investigated by incubating BRIN-BD11 cells with calcium-free KRB buffer [115 mM 
NaCl, 4.7 mM KCl, 1.28 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 20 mM 
HEPES, 25 mM NaHCO3, 0.1 mM EGTA and 0.1% BSA (pH 7.4)] (Srinivasan et al., 
2013). First, cells were preincubated for 40 min at 37°C with calcium-free KRB buffer 
supplemented with 1.1 mM glucose. After 40 min, the preincubation buffer was 
replaced by 1 ml of calcium-free KRB buffer supplement with 5.6 mM glucose in the 
presence or absence of frog skin peptides and incubated for 20 min at 37°C. The 
experimental protocol is detailed in Section 2.4.1.1. 
 
2.4.2 Insulin-release studies in primary islet cells isolated from the mouse 
2.4.2.1 Isolation of pancreatic islets 
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Islets were isolated from mice (NIH Swiss or C57 or db/db mice) pancreatic tissue by 
collagenase digestion method adapted from Lacy and Kostianovsky (1967). Hank’s 
Balanced Salt Solution (HBSS) was freshly prepared by dissolving 8 g/l NaCl, 0.4 g/l 
KCl, 0.14 g/l CaCl2, 0.1 g/l MgSO4.7H2O, 0.1 g/l MgCl2.6H2O, 0.06 g/l 
Na2HPO4.H2O, 0.006 g/l, KH2PO4, 1 g/l glucose, 0.02 g/l phenol red, 0.35 g/l NaHCO3 
in distilled water. Wash buffer and collagenase solution were prepared by dissolving 
BSA (0.1%) and collagenase (1.4 mg/ml) in stock HBSS buffer, respectively, and kept 
in the icebox for further use. After the above preparations, mice were sacrificed by 
cervical dislocation methods by following procedure approved by the U.K. Animals 
(Scientific Procedures) Act 1986. The abdominal cavity of mice was opened with 
scissors, and pancreatic tissue was dissected from the spleen and bile duct. The 
dissected pancreas was kept in a collagenase solution (5 ml/pancreas) and chopped 
with scissors. To accelerate tissue digestion process tubes were placed in a water bath 
for 8-9 min at 37°C followed by intermediate shaking. After incubation, cold wash 
buffer was added to slow down the activity of collagenase, this prevents tissue from 
over digestion, and preserved viability of islet cells. Further, tubes were centrifuged at 
1200 rpm for 2 min; the supernatant was discarded, and a fresh wash buffer was added. 
This washing process was repeated twice, at the third washing step solution was 
filtered using a strainer to separate undigested tissue. Wash buffer was added to the 
filtrate and centrifuged again for 2 min at 1200 rpm. The supernatant was discarded, 
and pre-warmed RPMI-1640 media supplemented with 10% BSA, 1% 
penicillin/streptomycin was added to the cell pellet. By pipetting, the cell pellet was 
homogenously distributed in media and transferred to a petri dish, which was further 
kept in 5% CO2 incubator (Laboratory technical engineering, Nottingham, UK) at 
37°C. The islets obtained were used to study the acute effects of peptides/insulin 
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secretagogues on insulin release within 72 hr of their isolation. The image of islet cells 
growing in culture media is shown in Figure 2.4 (B). 
 
2.4.2.2 Acute insulin release studies from isolated mouse islets 
Islets isolated from mice pancreatic tissue (described in Section 2.4.2.1) were used to 
investigate the acute effects of frog skin peptides and insulin secretagogues on insulin 
release. After 48 hr culturing of cells in RPMI-1640 media, fifteen islets were picked 
from Petri dish and transferred to a 1.5 ml Eppendorf tube. After the transfer of cells, 
tubes were centrifuged (1200 rpm for 5 min) to remove excess of media, followed by 
1 hr preincubation of cells with 500 µl of KRBB buffer containing 1.4 Mm glucose at 
37°C. After preincubation, tubes were centrifuged (1200 rpm for 5 min) and cells were 
test incubated for 1 h at 37°C with peptides (10- 6 M and 10- 8 M) and insulin 
secretagogues prepared in KRBB buffer supplemented with 16.7 mM glucose. After 
1 hr of incubation, the tubes were centrifuged, the supernatant was aliquoted in LP3 
tubes and stored at -20°C to measure insulin by dextran-coated charcoal 
radioimmunoassay as described in Section 2.4.4. 
 
2.4.2.3 Terminal islet studies 
The long-term effects of peptide administration on beta cell function were investigated 
in an animal model of diabetes (db/db). Following 28 days of treatment with peptide, 
pancreases were excised from sacrificed db/db mice and islets were isolated as 
described in Section 2.4.2.1. The isolated islets were incubated with insulin 
secretagogues such as alanine (10 mM), arginine (10 mM), KCl (10 mM), GLP-1 
(1µM) and GIP (1µM), to test insulin secretory response (experimental procedure 
described in Section 2.4.2.2). 
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2.4.2.4 Measurement of total insulin content of islets 
Total insulin content of islet was measured using the acid ethanol method as described 
by Otani et al., 2003. After performing islet acute insulin release studies, test solutions 
were retrieved, and islet cells were incubated with 500 µl of acid-ethanol solution 
(1.5% HCl, 75% ethanol and 23.5% H2O), overnight at 4°C. On the following day, 
samples/tubes were centrifuged at 1200 rpm for 2 min at 4°C, and the supernatant was 
aliquoted in LP3 tubes. Tubes were stored at -20°C for measuring insulin 
concentration by radioimmunoassay (described in Section 2.4.4). 
 
2.4.3 Iodination of insulin 
The method of iodination was first developed by Fraker and Speck in 1978. Iodination 
of bovine insulin was performed in RIA (radioimmunoassay) suite at Ulster 
University, as per the procedure established by Diabetes Research Group (DRG). In 
this experiment, iodogen (1,3,4,6-tetrachloro-3α,6α-diphenyl glycoluril) was used to 
catalyse iodination of bovine insulin. The iodogen solution was prepared fresh, by 
dissolving 2 mg of iodogen in 10 ml of dichloromethane. After preparation, 200 μl 
aliquot of iodogen solution was dispensed in a series of clear bottom 1.5 ml Eppendorf 
tubes.  Tubes were kept in a water bath for 5 min at 37°C to allow the solvent to 
evaporate and to form a uniform coating of iodogen. Insulin solution which was 
prepared by dissolving 1 mg of bovine insulin in 1 ml of 10 mM HCl, was further 
diluted to 125 µg/ml (1:8) in 500 mM phosphate buffer (pH 7). The reaction mixture 
was prepared by adding 20 μl of bovine insulin (125 μg/ml) and 5 μl of sodium iodide 
(Na125I 100 mCi/ml stock, Perkin Elmer, Cambridge, UK) to iodogen tubes. All 
additions were performed inside the standard laboratory chemical fume hood in RIA 
suite. After additions, iodogen tubes were kept in the icebox for 15 min with gentle 
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agitation by tapping with fingers every 3-4 min. The reaction mixture was transferred 
to clean 1.5 ml Eppendorf tubes, and 500 μl of 50 mM sodium phosphate buffer was 
added to stop the reaction. From the reaction mixture, iodinated 125I - bovine insulin 
was separated from unbound Sodium iodide (Na125I) by Vydac C-8 (4.6 x 250 mm) 
analytical reverse phase HPLC column (LKB Bromma, Sweden), operated at a flow 
rate of 1 ml/min. In the elution solvent, the concentration of organic modifier 
(acetonitrile) was increased from 0 to 56% over a period of 50 min and from 56% to 
70% over a period of 10 min. During 67 min HPLC run, fractions were collected into 
LP5 tubes by fraction collector (Frac-100, LKB) which was set at 1-min intervals. 
HPLC profile of iodinated bovine insulin is shown in Figure 2.1. The radioactivity of 
each fraction was measured by running 5 µl sample from each on Wizard™ 1470 
automatic gamma counter (Perkin Elmer, USA). Selected fractions were diluted with 
equal volume working RIA buffer and proceed for the binding test using different 
antibody dilutions (1:25,000, 1:35,000,1:45,000). Desired fractions were pooled 
together and stored at 4°C. 
 
2.4.4 Insulin radioimmunoassay (RIA) 
Dextran-coated charcoal radioimmunoassay (RIA) developed by Flatt and Bailey 
(1981), was used to measure insulin concentration in acute test and plasma samples. 
This assay was performed using a stock buffer for RIA contain disodium hydrogen 
orthophosphate (40 mM), thimerosal (0.2 g/l) and NaCl (0.3% (w/v). The pH of the 
stock RIA buffer was adjusted to 7.4 by adding sodium dihydrogen orthophosphate 
(40 mM). Working RIA buffer was prepared by dissolving bovine serum albumin 
(BSA) 0.5% (w/v) to stock RIA buffer. After preparation of buffer, insulin standards, 
ranging concentration from 20 ng/ml to 0.039 ng/ml were made by serial diluting rat 
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insulin (stock: 40 ng/ml) in working RIA buffer. Guinea pig anti-porcine antibody 
dilution was prepared from 1:25000 to 1:45000 in working RIA buffer to obtain 40% 
binding. Radiolabelled insulin (125I-insulin) was made up in assay buffer to achieve 
~10,000 counts per minute (CPM) /100 µl of assay buffer. Insulin standards and 
unknown samples (200 µl) were aliquoted in triplicates and duplicates respectively in 
LP3 tubes. 100 µl each of guinea pig anti-porcine antibody and 125I-insulin was added 
to standard (triplicates), unknown samples (duplicates) tubes and control tube (200 µl 
of assay buffer). The tube for total count contains the only 100 µl of the label, while 
the nonspecific binding tube, contains 300 µl of assay buffer and 100 µl of the 125I-
insulin. After all additions, tubes were incubated at 4°C for 48 hr.  Stock dextran-
coated charcoal (DCC) was made up by suspending 5 gm of dextran T 70 and 50 gm 
charcoal in 40 mM sodium phosphate buffer (1 litre). Stock DCC was further diluted 
with assay buffer (1:5) to make working DCC and stirrer for 30 min before use. After 
48 hr incubation, 1 ml of working DCC was added to the reaction mixture tubes 
(except tube for the total count) and incubated for 20 min at 4°C. The tubes were then 
centrifuged (Model J-6B centrifuge, Beckman Instruments Inc., UK) at 2500 rpm for 
20 min, the supernatant was discarded, and radioactivity of the pellet (which contain 
free radiolabelled insulin) was recorded by gamma counter (Perkin Elmer Wallac 
Wizard 1470 Automatic Gamma Counter). The gamma counter used a spline-curve 
fitting algorithm to determine insulin concentration against the known values of 
standard insulin. 
 
2.5 Cytotoxicity studies  
Lactate dehydrogenase (LDH) assay was performed to determine the cytotoxic effects 
of frog skin peptides. LDH is a cytosolic enzyme when the cell membrane is 
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compromised or damaged, this enzyme is released into extracellular space. LDH 
enzyme was measured using the CytoTox 96® non-radioactive cytotoxicity kit 
(Promega, UK), following the protocol provided in the kit. The test was performed in 
96 well plates. Acute test samples (50 µl) were mixed with an equal volume of light-
sensitive substrate mixture. The plate was covered with foil and incubated at room 
temperature for 30 min followed by addition of 50 µl of stop solution to stop the 
reaction. The chemical compound tetrazolium salt present in substrate mixture, get 
converted to red coloured formazan product in the presence of LDH. The change is 
colour was analysed by measuring absorbance at 490 nm, using VersaMax™ 
Microplate Reader (Molecular Device). 
 
2.6 Effects of peptides on beta cell membrane potential 
Change in membrane potential in peptide-treated BRIN-BD11 cells was determined 
using FLIPR membrane potential assay kit and Flex Station scanning fluorimeter 
(Molecular assay devices, USA), as previously described by Mathews et al., 2006. 
The assay kit was provided with a fluorescent dye (anionic and lipophilic by nature), 
which can move across the cell membrane, and emit a fluorescent signal on the 
increase in membrane potential. BRIN-BD11 cells were seeded at a density of 10000 
cells/well in 96 well microplates (Costar, Roskilde, Denmark) and incubated overnight 
at 37°C in 5% CO2 incubator. After overnight incubation, FLIPR membrane potential 
dye and test peptides (5X concentration) were prepared in fresh KRB buffer 
(supplemented with 5.6 mM glucose). Culture media was discarded and cells were 
incubated with 100 μl of KRB buffer (supplemented with 5.6 mM glucose) for 10 min 
at 37°C and subsequently with 100 μl of FLIPR membrane potential dye (prepared in 
KRB buffer) for 60 min. Following settings were made in flex station to measure the 
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change in membrane potential: 1) Excitation and the emission wavelength was set to 
530 nm and 565 nm respectively. 2) The interval between each reading: 1.52 seconds. 
3) Transfer of test solution to the reading plate was set to 50 μl. The test solution was 
added 20 sec after the start of data acquisition at a rate of ~62 μl/sec. After incubation 
with dye, the plate was subjected to flex station, and fluorescent signals were recorded. 
Membrane depolarising agent KCl (30 mM) was used as positive control. 
 
2.7 Effects of peptides on intracellular Ca2+ 
The assay protocol for measuring intracellular calcium in peptide treated BRIN-BD11 
cells is very similar to that used for measuring the change in membrane potential 
(described in Section 2.6). The experiment was performed using intracellular Ca2+ 
assay kit and KRBB buffer supplemented with 500 µmol/l probenecid, 1.28 mM CaCl2 
and 10nM NaHCO3. The assay kit consists of calcium indicators dye which emits a 
fluorescent signal on binding to intracellular Ca2+ only. The probenecid in assay buffer 
improves intracellular retention of the dye. Alanine (10 mM) was used as positive 
control and peptide concentration used is mentioned in corresponding chapters. Also, 
the settings in flux station for measuring intracellular Ca2+ is the same as that set for 
measuring membrane potential except excitation and the emission wavelength, which 
is set to 485 nm and 525 nm respectively 
 
2.8 Effects of peptide on adenosine 3’5’-cyclic monophosphate (cAMP) level 
The cAMP level in peptide treated BRIN-BD11 cells was determined as previously 
described by Owolabi et al., 2015. BRIN-BD11 cells were seeded in 24-well plate at 
a density of 200000 cells per well and cultured for 18 hr at 37°C. After preincubation 
with KRB buffer as described in Section 2.4.1.1, cells were treated with test solutions 
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for 20 min, which was prepared in KRB buffer supplemented with glucose (5.6 mM) 
and 3-isobutyl-1-methylxanthine (200 µM). After 20 min incubation, the supernatant 
was aliquoted in LP4 tubes for measuring insulin concentration by radioimmunoassay 
(described in Section 2.4.4). Cells were lysed by adding 200 µl of lysis buffer 
(provided in the cAMP assay kit) and stored at -70°C in 1.5 ml Eppendorf tubes. The 
cAMP was measured in cell lysate by following the instruction provided in the cAMP 
assay kit (R&D system parameter, Abingdon, UK). The standard curve for the cAMP 
assay is shown in Figure 2.3. 
 
2.9 Effects of downregulation of protein kinase A (PKA) or protein kinase C 
(PKC) pathway on the insulinotropic activity of frog skin peptides 
Forskolin (25 µM, Sigma-Aldrich, UK) and phorbol 12-myristate 13-acetate (PMA 10 
nM, Sigma-Aldrich, UK) stimulate insulin release by activation of PKA and PKC 
pathway respectively. However, after the overnight incubation of BRIN-BD11 cells 
with forskolin or PMA or both, downregulation of PKA or PKC or both were observed 
respectively (Owolabi et al., 2015). Either or both of these pathways were down-
regulated to investigate the mechanism of insulinotropic actions of peptides. To 
perform this experiment BRIN-BD11 cells were seeded in 24 well plates at a density 
of 15000 cells/well and incubated with either forskolin or PMA or both for 18 hr at 
37°C in an atmosphere of 5% CO2 and 95% air. After incubation media was discarded 
and cell were treated with preincubation buffer for 40 min followed by 20 min 
incubation with test solutions as described in Section 2.4.1.1. GLP-1 (10 nM), CCK8 
(10 nM), Forskolin (25 µM), PMA (10 nM) and forskolin (25 µM) + PMA (10 nM) 
were used as controls in experiments.  
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2.10 Effects of peptides on cytokine-induced apoptosis and proliferation in 
BRIN-BD11 cells  
The ability of frog skin peptides to protect cells against cytokine-induced DNA 
damage was analysed by using In situ Cell Death Detection Kit (Roche Diagnostics, 
Burgess Hill, UK) following the manufacturer’s instructions. BRIN-BD11 cells were 
harvested from the flask and counted using hemocytometer as described in Section 
2.3.1. BRIN-BD11 cells were seeded at a density of 4 x 104 cells on sterilised glass 
coverslips in 12 well plates for 18 h at 37°C with or without cytokine mixture, in the 
presence or absence of peptide/GLP-1 (1 µM). Cytokine mixture contained 200 U/ml 
tumour-necrosis factor-α, 20 U/ml interferon-γ and 100 U/ml interleukin-1β. All the 
treatment conditions were prepared in RPMI-1640 media. Following incubation, 
media was decanted, and the cells were washed with 0.9% phosphate-buffered saline 
(PBS) and fixed using 4% paraformaldehyde (Sigma Aldrich). After fixing, the 
permeability of cells was improved by treatment with 0.1 M sodium citrate buffer (pH 
6.0) at 94°C for 20 min in a water bath. The plates were removed from the water bath 
and allowed to cool for 20 min at room temperature. Sodium citrate buffer was 
decanted and cells were incubated with TUNEL reaction mixture (50 µl/well) for 1 hr 
at 37°C. Following incubation, the TUNEL reaction mixture was decanted, and the 
cells were washed with phosphate buffer solution (PBS) thrice for 5 min. A small drop 
of mounting media (prepared by mixing equal volume glycerol and PBS) was put on 
the slide. With the help of forceps, the coverslip was removed carefully from the well 
and placed cell-side down onto mountant. Two coverslips were mounted on a single 
glass slide. Slides were viewed using a fluorescent microscope with 488 nm filter 
(Olympus System Microscope, model BX51; Southend-on-Sea, UK) and 
photographed by a DP70 camera adapter system.  
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The positive effect of the peptide on β-cell proliferation was investigated by using Ki-
67 primary antibody (Abcam, Cambridge, UK). BRIN-BD11 cells were seeded as 
outlined above in 12 well plates containing sterilised coverslip and incubated with 
either peptide (1 µM) or GLP-1 (1 µM) for 18 hr at 37°C. As mentioned above after 
incubation, cells were fixed and permeabilised by using 4% paraformaldehyde and 0.1 
M sodium citrate buffer (pH 6.0), respectively. To avoid nonspecific antibody binding 
cells were treated with 300 µl of 1.1% BSA for 30 min, followed by treatment with 
rabbit anti-Ki-67 primary antibody for 2 hr at 37°C. After treatment with primary 
antibody, cells were washed thrice with PBS for 5 min and subsequently treated with 
Alexa Fluor 594 secondary antibody, which stains proliferating cells in red (Abcam. 
Cambridge, UK). As described above, two coverslips were mounted on a single glass 
slide. Approximately 150 cells per replicate were analysed, and proliferation 
frequency was expressed as % of total cells analysed. 
 
2.11 Effects of peptides on glucose uptake in C2C12 
Acute effects of frog skin peptides on glucose uptake in C2C12 cells were examined 
using Cell-Based assay kit (Cayman Chemicals), which is supplied with fluorescent 
glucose (2-NDBG) that emit a fluorescent signal at 485 nm. After attaining 50-60% 
confluent, C2C12 cells were harvested from the flask and counted as described in 
Section 2.3.1. C2C12 cells were then seeded into 96-well clear bottom plates at a 
density of 5 × 104 cells/well and maintained in growth media followed by 
differentiation media and serum-free media as described in Section 2.3.2. Peptides (1 
µM) were tested both in the presence and absence of insulin (10-6 M).  Test solutions 
were prepared in DMEM-No glucose media supplemented with 2-NDBG (150 µg/ml). 
Serum-starved media was replaced by 100 μl of test solutions, and the plates were 
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incubated for 30 min at 37°C with 95% air and 5% CO2 incubator.  After incubation 
plate was centrifuged for 5 min at 400 rpm at RT and supernatant was discarded. The 
assay buffer (200 μl) was added to each well and plates were again centrifuged. After 
centrifugation supernatant was discarded and 100 μl of assay buffer was added to each 
well and plates were subjected to flex station to record fluorescent signals. In the 
experiment, apigenin (50 µM) was used as negative control and insulin (10-6 M) as a 
positive control. 
 
2.12 Assessment of plasma degradation of the peptide 
The stability of peptide in plasma was investigated by following the procedure 
described by Ojo et al., 2015. Briefly, 100 µg of test peptide was incubated with 10 µl 
of mouse plasma and 395 µl of 50 mM triethanolamine-HCl (pH 7.8) and kept on a 
shaker at 37°C. The reaction was stopped by adding 10% trifluoroacetic acid (TFA) at 
0 min and 4 hr. The samples stopped at time point 0 and 4 hr were run separately on 
reverse phase HPLC column equilibrated with 0.1% TFA at the flow rate of 1 ml/min, 
to separated degraded and intact peptide. The collected peaks were subjected to the 
bioanalytical device MALDI-TOF, to determine molecular weight as described in 
Section 2.2.2. 
 
2.13 In vivo studies 
In vivo insulin-releasing activity of frog skin peptides were studied using normal mice 
(NIH swiss TO mice) and diabetic mice (db/db mice). All the animals were handled 
by following the guidelines according to the U.K. Animals (Scientific Procedures) Act 
1986. 
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2.13.1 Animal models 
2.13.1.1 NIH Swiss mice   
Male NIH Swiss mice (6-8 weeks) were purchased from Envigo, Huntingdon, UK. 
After arrival of mice to Ulster University’s Behavioural and Biomedical Research Unit 
(BBRU), they were housed individually with access to water and standard laboratory 
chow (10% fat, 30% protein, 60% carbohydrate; percentage of total energy 12.99 
KJ/g; Trouw Nutrition, Cheshire, UK) in air-conditioned room (22 ± 2°C) and with a 
12:12-h light-dark cycle. Mice were kept for 1-week acclimation period before the 
start of the experiment. For acute feeding studies, mice were trained to have a time-
restricted 3-hour feeding at a specific time (10 am to 1 pm) every day. 
 
2.13.1.2 Diabetic (db/db) mice 
Diabetic mice (db/db, BKS.Cg-+Leprdb/+Leprdb/OlaHsd) and normal littermates 
(BKS.Cg-(Lean)/OlaHsd) were purchased from Envigo, Huntingdon, UK. As the 
name suggests, db/db mice show symptoms of diabetes like polyurea, hyperglycaemia, 
hyperinsulinemia and obesity, and hence were used to investigate the antidiabetic 
potential of peptides. This mouse model which was first described in 1966 by Hummel 
et al., were derived from an autosomal recessive mutation in the leptin receptor gene 
located on chromosome 4. Gly to Thr mutation in the leptin receptor gene results in 
the production of a non-functional Ob-R protein (an isoform of the leptin receptor), 
which lead to severe metabolic changes as mentioned above. The db/db mice exhibit 
hyperglycemia within 4-8 week after birth (Yang et al., 2015). 
The procedure described in Section 2.13.1.1 were followed after the arrival of animals 
at Ulster University’s Behavioural and Biomedical Research Unit (BBRU). Prior to 
initiation of the treatment, blood glucose and body weight of mice were measured and 
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grouped accordingly to ensure that no statistical difference is observed in these 
parameters between the groups.  
 
2.13.1.3 GluCre-ROSA26EYFP mouse model 
Glu-CreROSA26EYFP is a transgenic mouse model developed by crossing ROSA26-
EYFP and glucagon-Cre mice (Quoix et al., 2007). These mice express the yellow 
fluorescent protein (EYFP) in pancreatic islet alpha cells. Before commencement of 
studies, male animals were housed individually with access to water and standard 
laboratory chow (10% fat, 30% protein, 60% carbohydrate; percentage of total energy 
12.99 KJ/g; Trouw Nutrition, Cheshire, UK). Tamoxifen (~32 mg/kg bw) was given 
to all non-fasted mice intraperitoneally to induce the expression of the yellow 
fluorescent protein.  After tamoxifen dose, animals were monitored five days for any 
adverse effects. On 5th day onwards, animals were given a low dose of streptozotocin 
(50 mg/kg bw) injection for the five consecutive days. Before injecting streptozotocin 
(STZ), animals were fasted overnight for 12 hr, and STZ was prepared fresh in citrate 
buffer, pH 4.5 on each occasion. Animals were monitored for 10 consecative days for 
hyperglycemia and body weight. Once diabetes was established, animals were 
grouped with matching average body weights and blood glucose prior to initiation of 
treatment. 
 
2.13.2 Glucose tolerance test (intraperitoneal and oral) 
Acute in vivo effects of the peptides on blood glucose and plasma insulin concentration 
was investigated by intraperitoneal administration of glucose alone (18 mmol/kg bw) 
or in combination with test peptides (25/50/75 nmol/kg bw) or GLP-1 (25 nmol/kg 
bw) to overnight fasted lean mice. Blood glucose was collected into heparinised 
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microcentrifuge tubes (Sarstedt, Germany) by tail bleeding at time points 0, 15, 30, 60 
and 90 min.  
Following 28 days of treatment with peptides, IPGTT and OGTT were performed in 
db/db mice. Glucose alone (18 mmol/kg bw) was administered intraperitoneally or 
orally to overnight fasted db/db mice and blood was collected by tail bleeding at time 
points 0, 15, 30 and 60 min. The collected blood was further analysed for glucose and 
insulin concentration (Section 2.13.5).  
 
2.13.3 Insulin sensitivity test 
Insulin sensitivity test was performed at the end of the treatment period. The body 
weight of db/db mice was measured and the insulin dose (50 U/kg bw) was 
administered accordingly. Blood glucose was measured prior to (t=0) and after 
intraperitoneal administration of bovine insulin at time points 15, 30 and 60 min. The 
improvement in insulin resistance was also determined by the homeostatic model 
assessment (HOMA). Blood was collected from 18 hr fasted db/db mice and analysed 
for glucose (Section 2.13.5) and insulin concentration (Section 2.13.6). The measured 
glucose and insulin concentration were used in the homeostatic model assessment 
(HOMA) formula to calculate insulin resistance: 
HOMA-IR = fasting plasma glucose x fasting plasma insulin/22.5 
 
2.13.4 Acute feeding studies (trained animals) 
Anti-obesity effects of the peptides were investigated by performing feeding studies 
in fasted (21 hours) NIH Swiss male mice that were housed individually. These mice 
had been trained to feed at 10 am to 1 pm for 3 hr each day. After intraperitoneal 
administration with either saline or test peptide (75 nmol/kg bw), mice were given the 
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known amount of food (i.e. pre-weighed), and food weight was measured at timepoint 
0, 30, 60, 90, 120, 150 and 180 min. 
 
2.13.5 Measurement of blood and plasma glucose, and plasma insulin 
concentrations 
The glucose concentration in blood (collected by tail bleeding) was measured in whole 
blood using Ascenacia Counter Blood Glucose Meter (Bayer, Newbury, UK). Blood 
was also collected in fluoride micro-centrifuge tubes (Sarstedt, Numbrecht, Germany) 
and centrifuged at 13000 rpm for 3 min at 4°C to separate plasma. Plasma was 
transferred to 0.5 ml fresh eppendorf tubes and stored at -20°C to perform biochemical 
tests. Plasma glucose was also sometimes measured by the GOD-PAP method (GL 
364, Randox Laboratories Ltd., UK). First, the working reagent was prepared by 
mixing buffer with GOD-PAP reagent (provided in the kit). The test was performed 
in 96 well plates. Blood sample (2.5 µl) was mixed with freshly prepared working 
reagent (250 µl) and incubated for 10 min at RT. After incubation, the plate was 
subjected to VersaMax™ Microplate Reader (Molecular Devices, US) and absorbance 
was measured at 505 nm. A standard curve for glucose by GOD-PAP reagent is shown 
in Figure 2.2. Briefly, glucose oxidase enzyme converts glucose in plasma to gluconic 
acid and hydrogen peroxide (H2O2). In the presence of peroxidase, hydrogen peroxide 
(H2O2) react with 4-aminophenazone and phenol to form a red-violet quinonimine dye. 
The amount of dye produced is directly proportional to glucose concentration in the 
sample. The intensity of colour was measured at 505 nm. For measuring plasma 
insulin, plasma samples were diluted with working RIA buffer (1:10 dilution) and 
measured for insulin concentration by radioimmunoassay as described in Section 
2.4.4.  
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2.13.6 Assessment of long-term (28 days) in vivo effects of the peptide in db/db 
mice 
Grouped male db/db mice received twice daily intraperitoneal injection of saline or 
peptide (75 nmol/kg bw) for 28 consecutive days. The dose of peptide was selected 
based on preliminary studies. Before commencement of treatment, mice were 
acclimatised to handling and injection by injecting twice daily with saline for 3 days. 
After the initiation of the treatment, body weight, food intake, water intake and blood 
glucose (once every 3 days) were monitored, and blood was collected by tail bleeding 
and analysed for insulin concentration by RIA (Section 2.13.6). After the end of the 
treatment period, terminal blood was collected, and animals were sacrificed by 
cervical dislocation and tissues were excised for further studies.  
 
2.13.7 Assessment of long-term (11 days) in vivo effects of the peptide in GluCre-
ROSA26EYFP mice 
For 11 consecutive days, GluCre mice received twice daily intraperitoneal injections 
of saline or test peptide (75 nmol/kg bw). During the treatment period every 3 days 
interval, non-fasting blood glucose, body weight, food intake and water intake were 
recorded. Blood samples collected at the start and end of the experiment were analysed 
for insulin concentration using RIA, as described previously in section 2.13.6. After 
the treatment, animals were sacrificed by cervical dislocation, and pancreatic tissues 
were excised and processed for histological staining as described in Sections 2.14 and 
2.14.1.  
 
2.13.8 Assessment of body fat composition by DXA scanning  
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Effects of chronic treatment of peptide on bone mineral density (BMD), bone mineral 
composition (BMC), bone area and body fat composition (lean body mass and % of 
body fat) in db/db mice were assessed using Dual-energy X-ray absorptiometry 
(DXA) PIXImus densitometer (Lunar Corp, Madison, Wisconsin). DXA measure 
these parameters by producing two different energy levels, 40 and 70 keV photons, 
which passes through only soft tissue (Rothney et al., 2009). DXA instrument was 
calibrated using a phantom mouse supplied by the manufacturer, and mice were 
sacrificed and positioned on a specimen tray for scanning. The data generated by 
densitometer for tissue and bone were analysed separately by Lunar Software version 
2.0. The representative image of DXA PIXImus densitometer is shown in Figure 2.6. 
 
2.13.9 HbA1c measurement 
After long-term treatment of peptides for 28 days, the HbA1c levels were measured in 
db/db mice using A1cNow+ kits (PTS diagnostics, IN, USA) by following the 
manufacturer’s instructions. 
 
2.13.10 Tissue excision 
After chronic treatment with peptides, terminal blood was collected, and mice were 
sacrificed by cervical dislocation. The abdominal cavity of mice was opened with 
scissors to dissect tissues (pancreas, adipose tissue, skeletal muscle, intestine and 
liver). Dissected tissues were covered in aluminium foil, labelled and snapped frozen 
in liquid nitrogen. Samples were then stored at -70°C to measure hormone content and 
to study the expression of key genes involved in glucose homeostasis. In addition, 
pancreatic tissue was processed for histological staining as described in Sections 2.14 
and 2.14.1.  
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2.13.11 Pancreatic insulin content 
Insulin content in the pancreas of saline and peptide-treated mice was measured by 
acid ethanol method. The pancreas was weighed and homogenised in 5 ml of freshly 
made acid ethanol using a VWR VDI 12 handheld homogenizer (VWR, UK). Tubes 
then centrifuged for 20 min at 5000 rpm, and the supernatant was transferred to a 15 
ml tube. 10 ml of tris base (pH 7) was added to supernatant and tubes were kept in 
speed wax overnight until the solution evaporates. The powder obtained was dissolved 
in 2 ml Tris base (pH 7) and stored at -20°C. 5 µl of the pancreatic extract was 
aliquoted in LP3 tubes and diluted to 200 µl using working RIA buffer and measured 
for insulin by radioimmunoassay (described in Section 2.4.4).  
 
2.13.12 Effects of the peptide on lipid profile, liver and kidney function, and 
amylase activity 
Plasma retrieved from terminal blood as described in the Section 2.13.5, was measured 
for total cholesterol, HDL cholesterol, and plasma triglycerides, creatinine, alanine 
transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP) level 
and amylase activity by following the procedure described in assay kits from suppliers. 
LDL cholesterol was determined by the de Cordova equation: 3/4 (total cholesterol - 
HDL-c). 
 
2.14 Immunohistochemistry 
Pancreatic tissues were excised from treated and untreated animals and fixed in 4% 
paraformaldehyde at 4°C for 48 h. Pancreatic tissues were processed using an 
automated tissue processor (Leica TP1020, Leica Microsystems, Nussloch, Germany). 
Tissues were embedded in paraffin wax and sectioned with a microtome (Shandon 
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finesse 325, Thermo Scientific, UK) to produce 7 μm thick sections. The section at an 
interval of 10 sections was placed on the same Polysine slide (Thermo Scientific, UK) 
and allowed to dry overnight on a hotplate (Thermo Scientific). 
 
2.14.1 Immunohistochemical staining for analysis of islet morphology 
The sections of processed pancreatic tissue were stained for insulin and glucagon as 
described previously by Vasu et al., 2014. First, sections were dewaxed and rehydrated 
using xylene (Sigma Aldrich, Dorset, UK) and an ethanol solution (100% for 5 min, 
95% for 5 min and 80% for 5 min), respectively. The sections were then incubated in 
sodium citrate buffer (10mM sodium citrate, 0.05% Tween 20, pH 6.0) at 94°C for 20 
min for the retrieval of antigen. To prevent nonspecific binding, sections were blocked 
using 2% BSA for 30 min. Three different types of double staining were performed 
depending on experiments: A) insulin-glucagon staining, B) insulin-GFP staining, C) 
glucagon-GFP staining. Slides were incubated with primary antibody [mouse anti-
insulin antibody (1:400; Abcam, ab6995) for insulin, guinea-pig anti-glucagon 
antibody (PCA2/4, 1:50; raised in-house) for glucagon and rabbit anti-GFP (1/400) for 
GFP] overnight at 4 °C. After overnight incubation with primary antibody, sections 
were washed twice with phosphate buffer solution (PBS) and incubated with 
secondary antibody (Alexa Fluor 488 goat anti-mouse-1/400, 594 goat anti-guinea 
pig-1/400 and 594 rabbit anti-GFP-1/400) for 45 min at 37°C. After treatment with 
secondary antibody, slides were washed with PBS, and nuclear staining was 
performed by incubating slides with 4',6-diamidino-2-phenylindole (DAPI) stain for 
15 min at 37°C. Following nuclear staining, the slide was washed with PBS and 
mounted using the anti-fade mounting medium. The slides were then viewed using a 
fluorescent microscope (Olympus System Microscope BX51, Olympus instruments, 
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UK), using a FITC filter (488 nm) and TRITC filter (594 nm). The images were 
captured using a DP70 camera adapter system as described by Vasu et al., 2013. Using 
Cell^F imaging software (Olympus System Microscope BX51, Olympus instruments, 
UK) islet number, islet area, beta cell area, alpha cell area and islet size distribution 
were measured. The representative image of the fluorescent microscope is shown in 
Figure 2.7. 
 
2.15 Gene expression studies 
2.15.1 RNA extraction 
RNA was isolated from the skeletal muscle tissue and islet cells of the treated and 
untreated animal using TriPure Isolation reagent (Roche, UK). 50-100 gm of tissue 
was added to 1 ml of tripure reagent in Biju tubes and homogenised using VWR VDI 
12 handheld homogeniser (VWR, UK). The homogenate was kept at room 
temperature for 5 min to dissolve the nucleoprotein complex. Chloroform (0.2 ml) was 
added to the homogenate, shaken vigorously for 15 sec and incubated for 10 min at 
20°C. The homogenate was transferred to the 1.5 ml centrifuge tubes, and tubes were 
centrifuged at 12000 rpm for 15 min at 4°C. Chloroform separates RNA, DNA and 
protein into aqueous, interphase and organic phase respectively. The aqueous phase 
(containing RNA) was transferred to RNase free tubes. After the addition of 
isopropanol (0.5 ml), tubes were mixed by inversion and incubated for 10 min at 20°C 
followed by centrifugation at 12000 rpm for 15 min at 4°C. Isopropanol precipitates 
RNA, hence after centrifugation supernatant was discarded. The pellet obtained was 
washed with 75% ethanol (1 ml) made in diethylpyrocarbonate (DEPC) treated water 
followed by centrifugation at 7500 rpm for 5 min. After centrifugation supernatant 
was discarded and pellets were air dried and resuspended in DEPC treated water (30 
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µl). RNA concentration in the samples was measured by Nanodrop (absorbance at 260 
nm) and stored at -20°C for cDNA synthesis.  
 
2.15.2 cDNA synthesis 
 RNA isolated from skeletal muscle tissue and islet cells was converted to cDNA using 
SuperScript II reverse transcriptase (Invitrogen, Life Technologies, UK) following the 
manufacturer’s instruction. Using Nanodrop, the concentration of RNA in the sample 
was calculated, and 3 µg of RNA was converted to cDNA using a three-step reaction 
in a thermocycler (G-STORM, UK). For the first step, reaction volume was prepared 
in RNase free tube by adding 1 µl of the Oligodt (Invitrogen, Life Technologies), a 
sample containing 3 µg of RNA and the volume was adjusted to 12 µl by adding the 
appropriate volume of RNase free water. In thermocycler tubes were heated at 70°C 
for 10 min.  In the second step, tubes were incubated at 42°C for 2 min after adding 4 
µl of 5 X First strand buffer, 2 µl of 0.1 M of DTT (Invitrogen, Life Technologies) 
and 1 µl of 10 mM dNTP to the reaction volume. Finally, in the third step, SuperScript 
II RT (1 µl) was added, and tubes were incubated at 42°C for 50 min followed by 70°C 
for 15. After completion of the third step, tubes were stored at -20°C until needed for 
PCR. 
 
2.15.3 Gene amplification 
Amplification of genes was carried out using real-time polymerase chain reaction Bio-
Rad MJ Mini personal Thermal cycler (Bio-Rad Laboratories, UK). The reaction 
mixture (10.5 µl) for PCR was prepared in 8 well PCR tube strips by adding the 
following components: 
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1 Quantifast SYBR green PCR mix 4.5 µl 
2  Forward primers 1 µl 
3 Reverse primers 1 µl 
4 c-DNA 3 µl 
5 RNase free water 1 µl 
 
(Forward and reverse primers are listed in Table 1 and 2) 
After preparation of the reaction mixture, PCR condition was set as follows: 
• Initial denaturation at 95°C for 5 min 
• A 40 cycle of cDNA amplification. 
• Final denaturation at 95°C for 30 Sec 
• Annealing temperature at 58°C for 30 sec 
• Final extension at 72°C for 30 sec (SYBR Green fluorescence was read after 
each cycle for amplification curve). 
Genes studied for the expression and the primer used are listed in table 1. All the genes 
were normalised to β-actin (Actb) expression and analysed using the ΔΔCt method. 
 
2.16 Statistical Analysis  
The experimental data were analysed using GraphPad Prism (Version 3). Acute in 
vitro insulin secretion studies for test peptides with 8 technical replicates and acute 
and long-term in vivo studies with 6 and 8 biological replictaes respectively, were 
performed. Values were expressed as mean ± SEM for a given number of replicates 
(n). Data were compared using unpaired Students t-test (non-parametric), with two-
tailed P values and 95% confidence interval) and one-way ANOVA followed by 
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student Newman-Keuls post hoc test.  Using the trapezoidal rule with baseline 
subtraction, the area under curve was calculated from data obtained. Group of datasets 
were considered to be significantly different if P<0.05.
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Table 1: List of the primers and their sequence for gene expression studies in islets 
 
Sr 
no 
Gene Common name Forward Primer sequence Reverse Primer sequence 
1 Ins1 Mus musculus insulin 1  AAG CTG GTG GGC ATC CAG TA 
 
GAC AAA AGC CTG GGT GGG TT 
2 Slc2α2  Glucose transporter 2 GAA GAA GAG TGG TTC GGC CC CGC ACA CCG AGG AAG GAA TC 
3 
 
Gck Glucokinase, Transcript variant 1 AGG CCC TGA CAG GAG ACA TC 
 
GCC TCT AGA CGG ACT CAG CA 
 
4 Abcc8 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 8 
TGA AGC GCA TCC ACA CAC TC 
 
 
ATC TTC TGT CCT GGG GCG AT 
 
5 Kcnj11 
 
Potassium inwardly-rectifying channel, 
subfamily J, member 11 (Transcript 
variant 1) 
TGG GTT GGG GGC TCA GTA AG 
 
 
ACC TCT AGG CTG GTA TGC CC 
 
6 Cacna1c Calcium channel,voltage-dependent, L-
type, alpha 1C subunit 
ACA TGC TTT TCA CCG GCC TC 
 
GCT CCC AAT GAC GAT GAG GAA G 
 
7 Glp1r Glucagon-1 like peptide receptor GCT GAG GGT CTC TGG CTA CA GGG ACA GGA GCT GTT CCT CA 
 
8 Gipr Gastric inhibitory polypeptide receptor TGC CCC GAC TAC CGA CTA AG 
 
GCC TTC AAC CTG TTC CTC CG 
9 Pdx1 Pancreatic and duodenal homeobox 1 CCT AGG CGT CGC ACA AGA AG 
 
TCG CTT GGC ATC AGA AGC AG 
 
10  Gcg Proglucagon gene GCC ACC AGG GAC TTC ATC AAC 
 
CAA GTG ACT GGC ACG AGA TGT  
 
11 Stat1 Signal transducer and activator of 
transcription 1, isoform 1 
CAT CCC GCA GAG AGA ACG C GGT GCA GGT TCG GGA TTC AA 
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Table 2: List of the primers and their sequence for gene expression studies in skeletal muscle tissue. 
 
Sr 
no 
Gene Common name Forward Primer sequence Reverse Primer sequence 
1 Irs1 Insulin receptors substrate AGG ACC TCA CGT CTT CCT CTT 
 
TTC CGG TGT CAC AGT GCT TTC 
2 Insr Insulin receptor GCA GGA AAT GGC TCC TGG AC GGG GTC CAA TGA TAA TTT TGG CAA T 
3 Ptb1 Protein phosphatase 1B TCG CCT GCG CAT TTG TAC TC TGA GTT TTC CAG TGC CCC AAA 
 
4 Pdk1 3-phosphoinositide dependent 
protein kinase 1 
TGG GTC CAG TGG ATA AGC GAA 
 
 
CCG GTA ATT ACA TCG TGT GGA CAA 
 
5 Pik3Ca Phosphatidylinositol 3-Kinase, 
catalytic, alpha polypeptide 
ACA GAG ACA GAG CAC GAT CCA TCC ACG TGC TGT GAG GTT TC 
 
6 Akt1 Protein kinase B alpha GCC GCC TGA TCA AGT TCT CC CAG CGC ATC CGA GAA ACA AAA C 
7 Slc2α4 Glucose transporter 4 (Glut4) ACT AGA TCC CGG AGA GCC TGG  
 
TGG AAA CCC GAC GGC ATC TT 
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Figures 2.1 HPLC Separation of iodinated bovine insulin 
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Iodinated 125I - bovine insulin was purified from the reaction mixture by reversed-phase 
HPLC, operated at a flow rate of 1 ml/min. All fractions were collected using an 
automated fraction collector. Radioactivity of each fraction was determined by running 5 
µl sample from each on Wizard™ 1470 automatic gamma counter (Perkin Elmer, USA), 
gamma counter. Fractions collected between 5-7 min (Peak A) contain unbound Sodium 
iodide (Na125I), and hence it was disposed off. Whereas the fraction between 21-26 min 
(Peak B) contained iodinated insulin which was selected to perform antibody binding test.  
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Figure 2.2 Standard curve for glucose analysis by GOD-PAP reagent 
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Standard curve of glucose was prepared over a concentration range of 0-60 mmol/lit. O.D. 
was measured at 505 nm. 
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Figure 2.3 A typical standard curve for cAMP assay 
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A standard curve of stock solution (provided in kit) was prepared over a concentration 
range of 240-3.75 pmol/ml. O.D. was measured at 450 and 540 nm. 
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Figures 2.4 BRIN-BD11 Cells (A) and Islet cells (B) growing in culture 
A) 
 
 
 
B) 
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Figure 2.5 Reversed-phase HPLC 
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Figure 2.6 Dual-energy X-ray Absorptiometry (DXA) PIXImus densitometer 
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Figure 2.7 Fluorescent microscope (Olympus System Microscope BX51, Olympus 
instruments, UK). 
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Chapter 3 
 
Insulinotropic, glucose-lowering and beta-cell anti-apoptotic 
actions of temporin and esculentin peptides from skin 
secretions of frogs belonging to family of Ranidae 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
88 
 
3.1 Summary  
The present Chapter evaluated whether temporin and esculentin-1 peptides, identified in 
skin secretion of frog Rana temporaria and Rana esculenta, respectively, could represent 
a template for the design of new types of drugs for use in T2DM therapy. Temporin A, 
temporin F, and temporin G, and Esculentin-1a (1-21).NH2,  esculentin-1b(1-18).NH2, 
and esculentin-1a(1-14).NH2 evoked concentration-dependent stimulation of insulin 
release from BRIN-BD11 rat clonal β-cells, 1.1B4 human-derived pancreatic β-cells and 
isolated mouse islets with no cytotoxicity at concentrations up to 3 μM. In contrast, 
temporin B, C, E, and analog [D-Lys14, D-Ser17] esculentin-1a (1-21).NH2 (esculentin (1-
21)-1c) were less potent and, temporin H, K and esculentin-1a(9-21) were inactive. The 
data indicate that cationicity, hydrophobicity, and the angle subtended by the charged 
residues in the temporin, and helicity in the esculentin-1 peptides are important 
determinants for in vitro insulinotropic activity. The mechanism of insulinotropic action 
of esculentin-1 peptides involved membrane depolarization and an increase in 
intracellular Ca2+ concentrations, whereas temporin peptides had no effect on these 
parameters. Temporin A, temporin F, esculentin-1a (1-21) NH2 and esculentin (1-21)-1c 
(1 µM) protected BRIN-BD11 cells against cytokine-induced apoptosis to a similar extent 
as GLP-1 (1 µM). In contrast, the protective effects of esculentin-1b (1-18).NH2 and 
esculentin-1a (1-14).NH2 were comparably less, whereas temporin G failed to show any 
effect. Temporin A, temporin F and esculentin (1-21)-1c (1 µM) also augmented 
proliferation of the cells to a similar extent as GLP-1. In contrast proliferative effect of 
esculentin-1a (1-21)NH2 was less significant, while temporin G, esculentin-1b (1-
18).NH2, and esculentin-1a (1-14).NH2 failed to show any positive effects. Intraperitoneal 
injection of either temporin G or esculentin (1-21)-1c together with an intraperitoneal 
glucose load (18 mmol/kg bw) in NIH Swiss mice improved glucose tolerance with a 
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concomitant increase in insulin secretion. Whereas temporin A, temporin F, esculentin-
1a (1-21).NH2, esculentin-1b (1-18).NH2 and esculentin-1a (1-14)  administration was 
without significant effect on plasma glucose levels. 
 
3.2 Introduction 
 The global rise in the prevalence of Type 2 diabetes mellitus (T2DM) has mandated a 
search for new therapeutic options for treating patients with the disease (Ríos et al., 2015). 
After the discovery of insulin therapy, scientists have shown immense interest in 
exploring peptides with antidiabetic properties from natural sources. Many frog-skin 
peptides that were first identified on the basis of their ability to inhibit the growth of 
bacteria and regulate cytokine production have subsequently been shown to evoke insulin 
release from clonal β-cells in vitro and lower blood glucose concentrations in mouse 
models of T2DM (Conlon et al., 2014a. 2018).  
Temporin and esculentin-1 peptides were identified in frogs belonging to the extensive 
family Ranidae of both Eurasian and N. American (Conlon et al., 2009, Xu & Lai, 2015). 
The genes encoding a family of such peptides were identified in a cDNA library from the 
skin of the European common frog Rana temporaria (Simmaco et al., 1996) and Rana 
esculenta (Simmaco et al., 1994). Temporins are small (8 - 17 amino acid residues), C-
terminally α-amidated peptides, while esculentin-1 peptide is relatively large size, 
containing a cystine-bridged, cyclic domain rendering them difficult to synthesize. These 
peptides are best known for their ability to inhibit the growth of the microorganism (Ponti 
et al., 1999, Mangoni et al., 2016). The N-terminal fragments of the esculentin-1 peptide, 
esculentin-1b (1-18) (Mangoni et al., 2003, Marcellini et al., 2009, Maisetta et al., 2009, 
Luca et al., 2014) and esculentin-1a (1-21) (Luca et al., 2014, Mangoni et al., 2015) also 
retain the full antimicrobial activity of the intact peptides and showed reduced cytotoxic 
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activity against eukaryotic cells. The certain members of the temporin family have been 
shown to display chemoattractive (Chen et al., 2004, Di Grazia et al., 2014) anti-
inflammatory (Capparelli 2009), and vasorelaxant and antitumour activity (Kim et al., 
2000). Recent studies have shown that the truncated forms of the esculentin-1 peptide and 
the C-terminally α-amidated esculentin-1a (1-21).NH2  play a significant role in 
promoting wound healing and in treating Pseudomonas aeruginosa infections in patients 
with cystic fibrosis (Cappiello et al., 2016) and keratitis (Kolar et al., 2015, Casciaro et 
al., 2017) as well as clinical mastitis caused by bacteria in dairy cows (Islas-Rodrìguez et 
al., 2009). The therapeutic effects of esculentin-1a (1-21).NH2  were augmented by 
incorporation of D-amino acids at positions 11th and 14th position and the resulting 
analogue, termed Esc(1-21)-1c), showed greater stability in serum, reduced cytotoxicity 
towards mammalian cells, increased activity against the biofilm form of P. aeruginosa, 
and increased ability to promote migration of lung epithelial cells  (Di Grazia et al., 2015, 
Loffredo et al., 2017). 
Preliminary studies have shown that temporins from Rana ornativentris and Lithobates 
virgatipes and Lithobates catesbeianus (Abdel-Wahab et al., 2007, Mechkarska et al., 
2011) and, esculentin 1a and esculentin 1b peptides isolated from Rana saharica 
(Marenah et al., 2006), demonstrated insulinotropic activity in glucose-responsive rat 
clonal β-cells BRIN-BD11. The present study aimed to investigate the insulin-releasing 
ability of a series of temporins and synthetic N-terminal fragments of esculentin-1a and -
1b peptides in vitro using established rat and human clonal β-cell lines and freshly 
prepared mouse pancreatic islets. Effects of these peptides on glucose tolerance and 
insulin release in vivo also were investigated in overnight fasted lean mice (NIH Swiss 
mice).  It has recently been shown that the frog skin-derived peptide PGLa-AM1 also 
protects against cytokine-induced DNA damage as well as promotes β-cell proliferation 
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(Owolabi et al., 2017). Consequently, the effects of the temporin and esculentin-1 
peptides on these parameters were also investigated using BRIN-BD11 cells. 
 
3.3 Materials and Methods 
3.3.1 Reagents 
All reagents used in this study are listed in Chapter 2, Section 2.1. 
 
3.3.2 Peptides 
The purity and identity of peptides were confirmed by reversed-phase HPLC (Chapter 2, 
Section 2.2.1.1) and MALDI-TOF mass spectrometry (Chapter 2, Section 2.2.2) 
respectively. The primary structures, calculated isoelectric points (pI), and Grand 
Average of Hydropathy (GRAVY), calculated using the hydrophobicity scale of Kyte and 
Doolittle. The secondary structures of esculentin-1 peptides were predicted using the  
AGADIR program. 
 
3.3.3 Acute in vitro insulin release studies using BRIN-BD11 and 1.1B4 cells 
The culturing of rat clonal pancreatic β-cells (BRIN-BD11) and human-derived 
pancreatic β-cells (1.1B4) is described in detail in Chapter 2, Section 2.3.1. The acute 
insulin-releasing effects of temporin and esculentin-1 peptides (3 x 10-6 - 10-12 M; n = 8) 
were performed by incubating with cells for 20 min at 37°C using KRB buffer 
supplemented with 5.6 mM glucose. The procedure for measuring acute releasing effects 
of peptides is described in Chapter 2 Section 2.4.1.1. Control incubations were carried 
out by incubating cells with human GLP-1 (10 nM) and alanine (10 mM). After 
incubation, the cell supernatant was collected for measuring insulin (Chapter 2, Section 
2.4.4) and LDH concentration (Chapter 2, Section 2.5). 
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3.3.4 Cytotoxicity assay  
The cytotoxic effects of peptides (3 x 10-6 - 10-12 M; n = 4) on BRIN-BD11 cells were 
measured using a CytoTox 96 non-radioactive cytotoxicity assay kit, as previously 
described in Chapter 2, Section 2.5. 
 
3.3.5 Insulin release studies using isolated mouse islets 
The procedure for pancreatic islets isolation from an adult, male National Institutes of 
Health (NIH) Swiss mice (Harlan Ltd, Bicester, UK) is outlined in Chapter 2 Section 
2.4.2.1. After isolation, islets were cultured for 48 hr under the same conditions as used 
for BRIN-BD11 and 1.1B4 cells. The experimental procedure for measuring the acute 
effects of peptides on the rate of insulin release has been described in Chapter 2, Section 
2.4.2.2. After incubating islets with peptides (10-8 and 10-6 M) made in KRB buffer 
supplemented with 16.7 mM glucose, for 1 hr at 37°C, the supernatant was removed and 
measured for insulin by radioimmunoassay as outlined in Chapter 2, Section 2.4.4. The 
islet cells were then subjected to acid ethanol treatment for measuring total insulin content 
as previously described in Chapter 2, Section 2.4.2.4. GLP-1 (10 nM) and alanine (10 
mM) were used as a positive control in the experiment. 
 
3.3.6 Effect of temporin and esculentin-1 peptides on membrane potential and 
intracellular calcium ([Ca2+]i) concentrations 
Effects of the temporin and esculentin-1-derived peptides (1 µM) on membrane potential 
and intracellular Ca2+ concentrations in BRIN-BD11 cells were investigated using 
membrane potential and intracellular Ca2+assay kits (Molecular Devices, Sunnyvale, CA, 
USA). The experimental procedure is described in detail in Chapter 2, Section 2.6 and 
2.7. BRIN-BD11 cells were incubated with peptides (10-6 M) at 37C in 5.6 mM glucose 
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for 5 min, and information was acquired using a Flex Station scanning fluorimeter 
(Molecular Devices).  Control incubation: 5.6 mM glucose only, Positive control for 
membrane potential: 5.6 mM glucose plus 30 mM KCl and Positive control for 
intracellular calcium: 5.6 mM glucose plus 10 mM alanine were also carried out. 
 
3.3.7 Effects of the temporin and esculentin-1 peptides on cytokine-induced 
apoptosis in BRIN-BD11 cells 
The protective effects of temporin and esculentin-1 peptides against cytokine-induced 
DNA damage was investigated by exposing BRIN-BD11 cells (seeded at a density of 5 x 
104 cells per well) for 18 hr at 37°C to cytokine mixture (200 U/ml tumour-necrosis 
factor-a, 20 U/ml interferon-g, and 100 U/ml interleukin-1b) in the presence and absence 
of peptides (10-6 M). GLP-1 (10-6 M) was used as a positive control. The experimental 
procedure is outlined in Chapter 2, Section 2.10. Cells were washed with phosphate-
buffered saline (PBS) and fixed immediately using 4 % paraformaldehyde. After fixation, 
cells were permeabilised by treatment with 0.1 M sodium citrate buffer, pH 6.0 at 94°C 
for 20 min and then incubated with TUNEL reaction mixture1 hr at 37°C.  After 
incubation, cells were washed again with PBS and slides were viewed using a fluorescent 
microscope with 488 nm filter (Olympus System Microscope, model BX51; Southend-
on-Sea, UK). 
 
3.3.8 Effects of the temporin and esculentin-1 peptides on proliferation in BRIN-
BD11 cells 
The positive effect of temporin and esculentin-1 peptides on β-cell proliferation was 
investigated by using Ki-67 primary antibody (Abcam, Cambridge, UK). BRIN-BD11 
cells were incubated with 1 µM of test peptide for 18 hr at 37°C as previously described 
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in Chapter 2, Section 2.10. GLP-1 (10-6 M) was used as a positive control. After 
immediate fixing and permeabilization, cells were subjected to treatment with rabbit anti-
Ki-67 primary antibody and subsequently with Alexa Fluor 594 secondary antibody, 
which stains proliferating cells in red. Approximately 150 cells per replicate were 
analysed. 
 
3.3.9 Acute in vivo insulin release studies 
All animal experiments were carried out by the UK Animals (Scientific Procedures) Act 
1986 and EU Directive 2010/63EU for animal experiments and approved by Ulster 
University Animal Ethics Review Committee. All necessary precaution steps were taken 
to protect the animal from any potential suffering. Healthy adult (8 weeks old) NIH Swiss 
mice (Harlan Ltd, Bicester, UK), were housed separately and maintained in an air-
conditioned room (22 ± 2°C) with a 12-h light: 12- h dark cycle. The procedure for 
investigating acute in vivo effects of the peptide on glucose and insulin concentration is 
described in Chapter 2, Section 2.13.2. Overnight fasted were injected intraperitoneally 
with glucose alone (18 mmol/kg bw) or together with the test peptide (75 nmol/ bw). 
GLP-1 (25 nmol/kg bw) was used as positive control.  Blood samples were collected by 
tail bleeding, before and after peptide injection at time point 15, 30 and 60 min. Blood 
glucose was measured using an Ascencia Contour Blood Glucose Meter and plasma 
insulin by radioimmunoassay (Chapter 2, Section 2.13.5).  
 
3.3.10 Statistical Analysis 
Experimental data were analysed using GraphPad PRISM (Version 3). Results were 
expressed as means ± SEM and data compared using unpaired Student's t-test 
(nonparametric, with two-tailed P values and 95% conﬁdence interval) and one-way 
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ANOVA with Bonferroni post-hoc test wherever applicable. Group of datasets were 
considered to be significantly different if P<0.05.  
 
3.4 Results 
3.4.1 Peptides 
Temporin and esculentin-1petides were supplied in pure form (>95%) by Prof Michael 
Conlon. The purity peptides were confirmed using reverse phase HPLC (Figure 3.1-3.4). 
The molecular weight of peptides confirmed by MALDI- TOF (Figure 3.5-3.8). The 
primary structures of the peptides investigated in this study, their molecular charge at pH 
7, Grand Average of Hydropathy (GRAVY), calculated using the hydrophobicity scale 
of Kyte and Doolittle, and predicted secondary structures of esculentin-1, determined 
using AGADIR program, are shown in Table 3.3 and 3.4.  
 
3.4.2 Effects of temporin and esculentin-1 peptides on insulin release from BRIN 
BD11 and 1.1B4 cells 
As expected, alanine (10 mM) and GLP-1 (10 nM) produced a significant (P<0.001) 
increase (approximately 2.5 - 7 folds) in the rate of insulin release on incubation with 
BRIN-BD11 cells compared with the rate in the presence of glucose alone. The insulin-
releasing effects of temporin and esculentin-1a peptides are summarised in Table 3.5 & 
3.6 respectively. The experimental data shows that, among temporin peptides, temporin 
A, F, and G were the most potent with a threshold concentration of 0.1 nM and produced 
>2-fold increase in the rate of insulin release at a concentration of 3 µM (Figure 3.9). A 
similar increase in the rate of insulin release was also produced by esculentin-1a (1-
21).NH2, esculentin-1a (1-14).NH2 and esculentin-1b (1-18).NH2 at 3 µM concentration 
on incubation with BRIN-BD11 cells. The stimulatory effects of these active esculentin-
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1a peptides were observed up to 1 nM concentration (Figure 3.11). There was no 
statistical difference in the responses produced by analogue esculentin (1-21)-1c and the 
other active esculentin-1a peptides at 3 µM concentration, however, the stimulatory 
response was observed up to 10 nM concentration. Neither temporin nor esculentin-1 
peptides produced a significant increase in the rate of release of the cytosolic enzyme 
LDH from BRIN-BD11 cells, at concentrations up to and including 3 µM (Figure 3.10 & 
3.12), suggesting that integrity of plasma membrane is intact. In the presence of DMSO 
(100%), significant increase (P<0.001) in LDH release was observed. 
The insulin-releasing effects of active temporin and esculentin-1 peptides were also 
reflected in a glucose-responsive 1.1B4 cell line (Figure 3.13 & 3.14). Temporin G on 
incubation with 1.1B4 cells produced a significant (P<0.05) increase in the rate of insulin 
release at concentrations ≥ 0.1 nM. On the other hand, the threshold concentration for 
temporin A and F was 1 nM.  The response produced by temporin G at 3 µM 
concentration was comparable to that produced by 10 nM GLP-1. Esculentin-1a (1-
21).NH2, esculentin-1a(1-14).NH2 and esculentin-1b (1-18).NH2 demonstrated increase 
in the rate of insulin release up 0.1 nM concentration. Whereas, the threshold 
concentration of analogue esculentin (1-21)-1C was 10-fold less compared to other active 
esculentin-1a peptides. Similar to temporin G, the response produced by 3 μM esculentin-
1a (1-21).NH2 was comparable to that produced by 10 nM GLP-1. 
 
3.4.3 Effects of temporin and esculentin-1 peptides on insulin release from isolated 
mouse islets 
Incubation of active temporins (temporins A, F & G) and esculentin-1 [esculentin-1a (1-
21).NH2, Esc(1-21)-1c, esculentin-1b (1-18).NH2 & esculentin-1a (1-14).NH2] peptides 
(10 nM and 1 µM) peptides with isolated islets from NIH Swiss mice produced a 
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significant (P<0.05 - P<0.001) and dose-dependent increase in the rate of insulin release 
compared with the rate in the presence of 16.7 mM glucose alone (Figure 3.15 & 3.16). 
However, the magnitude of increase in insulin release by active temporin and esculentin-
1 peptides was less than that demonstrated by the same concentration of GLP-1.  
 
3.4.4 Effects of temporin and esculentin-1 peptides on membrane depolarization and 
intracellular calcium ([Ca2+]i) in BRIN-BD11 cells 
Incubation of cells with insulin secretagogues, 30 mM KCl and alanine (10 mM) 
produced an immediate and sustained increase in membrane potential (Figure 3.17 & 
3.19) and intracellular calcium respectively (Figure 3.18 & 3.20). In contrast, 1 µM of 
active temporin peptides (temporin A, F & G) which were added 20 sec after start of data 
acquisition at a rate of ~62 μl/sec, produced no significant effects on membrane 
depolarization (Figure 3.17) and [Ca2+]i (Figure 3.18) compared with 5.6 mM glucose 
only. On the other hand, 1 µM of esculentin-1a (1-21).NH2, esculentin-1b (1-18).NH2 and 
esculentin-1a (1-14).NH2 produced significant increases in both membrane potential 
(Figure 3.19) and [Ca2+]i  (Figure 3.20) compared with control (5.6 mM glucose alone). 
However, in case of analogue esculentin (1-21)-1c, on incubation with cells did not lead 
to a significant increase in both membrane potential and [Ca2+]i compared to control. 
 
3.4.5 Effects of temporin and esculentin-1 peptides on cytokine-induced apoptosis 
and proliferation in BRIN-BD11 cells  
As shown in Figure 3.21, treatment of BRIN-BD11 cells with 1 µM concentration of 
temporin A and F, and GLP-1 alone, had no significant effect on the number of cells 
displaying DNA damage. In agreement, the number of apoptotic cells increased 
significantly (P<0.001) by 3-fold on incubation with proinflammatory cytokines mixture. 
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However, when the BRIN-BD11 cells co-incubated with temporin A and the cytokine 
mixture, the number of apoptotic cells was reduced significantly (P<0.01) by 37%. The 
corresponding value for temporin F was 42% (P<0.001). The degree of protection 
provided by temporin A and temporin F were comparable to that provided by the same 
concentration of concentration of GLP-1 (40%; P <0.01). On the other hand, temporin G 
failed to provide any protection to cell against cytokine mixture. In similar fashion, 
treatment of BRIN-BD11 cells with temporin A and temporin F (1 µM) resulted 
significant (P<0.01, P<0.001) increased in proliferating cells by 49% and 80% 
respectively, which were comparable to that produced by 1 µM GLP-1 (65 % increase; 
P<0.01). In temporin G treated cells, no significant effects on cell proliferation was 
observed (Figure 3.22). 
As shown in Figure 3.23, no adverse effects were observed in BRIN-BD11 cells treated 
with active esculentin-1 peptides. The number of cells exhibiting DNA damage was 
comparable to control.  However, all active esculentin-1 peptides have shown to protect 
BRIN-BD11 cells against cytokine-induced DNA damage. The degree of protection 
provided by esculentin-1a (1-21).NH2  and esculentin (1-21)-1c were comparable to that 
provided by the same concentration of GLP-1 (39%; P<0.01).  Esculentin-1b (1-18).NH2 
and esculentin-1a (1-14).NH2, also protected cells against cytokines but the effect was 
comparatively less than GLP-1. Similarly, incubation of cells with esculentin-1a (1-
21).NH2  and esculentin (1-21)-1c peptides resulted in significant (P<0.01) increase in the 
number of the proliferating cells (Figure 3.24). The increase produced by esculentin (1-
21)-1c was comparable to that produced by the same concentration of GLP-1. In the case 
of esculentin-1b (1-18).NH2 and esculentin-1a (1-14).NH2, no effects on proliferating 
cells were observed. 
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3.4.6 Effects of temporin and esculentin-1 peptides on glucose tolerance and insulin 
concentrations in mice  
No adverse effects were observed in the animals following intraperitoneal injection of the 
temporin and esculentin-1 peptides. Blood glucose concentrations in lean NIH Swiss mice 
receiving glucose plus temporin G (75 nmol/kg bw) or esculentin (1-21)-1c (75 nmol/kg 
bw) were significantly (P<0.05, P<0.01) lower at 15 min and 30 min after injection 
compared with animals receiving glucose only (Figure 3.25A & 3.27A). Similarly, the 
overall response of blood glucose (area under the curve) over 60 min was significantly 
(P<0.05) decreased after administration of the temporin G or esculentin (1-21)-1c (Figure 
3.25 B & 3.27B). These glucose-lowering effects of peptides were associated with a 
significant increase in plasma insulin concentration. Plasma insulin concentrations were 
significantly (P<0.05) higher at 15 min after glucose administration in animals receiving 
temporin G or esculentin (1-21)-1c compared with animals receiving glucose only (Figure 
3.25 C & 3.27C) and the integrated response i.e. total amount of insulin released over 60 
min was significantly greater  (P<0.05) (Figure 3.25 D & 3.27D). In contrast, no 
significant effects on blood glucose were observed at any time point after co-injection of 
temporin A, temporin F, esculentin-1a (1-21), esculentin-1b (1-18).NH2 and esculentin-
1a (1-14) with glucose compared to injection of glucose only (Figure 3.26 & 3.28). 
 
3.5 Discussion 
This study has identified temporins (Temporin A, B, F and G) and peptides derived from 
the N-terminal domain of the host-defence peptides esculentin-1a and -1b [esculentin-1a 
(1-21).NH2, esculentin-1b (1-18).NH2 and esculentin-1a (1-14).NH2] that stimulated the 
release of insulin from rodent and human clonal β-cells and isolated mouse islets at low 
concentrations without apparent toxicity.  
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Although the factors that influence the antimicrobial and cytotoxic activities of small 
peptides are reasonably well understood (Conlon et al., 2007a, Grieco et al., 2011, 
Mojsoska &, Jenssen 2015, Ramesh et al., 2016), the structural determinants of insulin-
releasing activity are largely unknown. Among temporin peptides, temporin A and G with 
a calculated pI of 10.06 and temporin F with a calculated pI of 8.86 were the most potent 
with a threshold concentration of 10-9 M (Table 3.5).  On the other hand, temporin B 
peptide also produced a significant increase in the rate of insulin release at 10-9 M but the 
maximum effects of the peptide was appreciably less than that of temporin A, F, and G. 
The significant, albeit weak  insulin-releasing activity of anionic peptides, temporin C 
and E with a threshold concentration of 10-7 M, demonstrates that a net positive charge at 
physiological pH is not a mandatory requirement. Similarly, cationicity is not the only 
parameter influencing this activity as temporin H and K with a calculated pI of 8.86 
lacked insulin-releasing actions at concentrations up to and including 3 x 10-6 M. This 
suggests that peptide hydrophobicity is also an important determinant of activity as these 
peptides were appreciably more hydrophilic than the other temporins. Despite having the 
same isoelectric point and similar hydrophobicities, temporin B peptide displayed 
reduced insulinotropic activity compared with temporin F.  In a cationic, amphipathic α-
helical peptide, the polar angle (Ф) subtended by the positively charged amino acids is an 
important determinant of antimicrobial and hemolytic activity (Dathe et al., 2004). In the 
case of temporin-1DRa analogues, increasing the polar angle to 180o by appropriate 
substitutions by L-lysine produced inactive components (Conlon et al., 2007a). As shown 
in Fig. 3.29, the angle subtended by the positive charge on the α-amino group of the N-
terminal residue and the positive charge on the ε-amino group of the lysine residue is 180o 
for temporin B and 120o for temporin F. This could be the reason for the reduced insulin-
releasing activity of temporin B compared with temporin F. 
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The present study has provided evidence that the degree of helicity is of particular 
importance is determining the insulin-releasing activity of the esculentin-1 peptides. 
Consistent with secondary structure predictions using the AGADIR algorithm (Kyte, & 
Doolittle, 1982) (Table 3.4), circular dichroism (Grazia et al., 2015) and NMR (Ghosh et 
al., 2016) studies have shown that esculentin-1a (1-21).NH2 possess a random coil 
structure in aqueous solution but adopts a predominantly α-helical conformation in the 
environment of lysophosphatidylcholine and lipopolysaccharide micelles. A similar 
investigation of the preferred conformation of esculentin-1b (1-18).NH2 has demonstrated 
that the N-terminal domain of this peptide (Phe3 -Leu11) adopts a stable α-helical 
structure in the membrane-mimetic solvent 50% trifluoroethanol-water while the more 
hydrophobic C-terminal portion is unstructured (Manzo et al., 2012). The presence of 
helix-destabilizing D-amino acid residues in esculentin (1-21)-1c means that the α-helical 
domain is confined to the N-terminal region of the peptide (Muller et al., 2005). While 
the cationicity and hydrophobicity of the diastereomer are the same as the native peptide, 
this reduction in helicity results in a decrease in the in vitro insulinotropic activity. 
Similarly, the molecular charge of esculentin-1a (1-14).NH2 and esculentin-1a (9-21) are 
the same, and their hydrophobicities are very similar, but the AGADIR programme 
predicts that the former peptide has the propensity to adopt a stable α-helical 
conformation whereas the latter is unstructured in solution. In consequence, esculentin-
1a (1-14).NH2 is equipotent and equally effective as esculentin-1a (1-21).NH2 in 
stimulating insulin release whereas esculentin-1a (9-21) is inactive (Table 3.6). 
Insulin secretion from pancreatic beta cells is regulated by the KATP channel-dependent 
and KATP channel-independent pathway (Henquin, 2000, 2004). In the former pathway, 
ATP molecule generated from glucose metabolism depolarize the cell by blocking the 
ATP-sensitive potassium channel. As a result, calcium ion influx through the opening of 
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voltage-dependent channels, which induce the beta cell to release insulin. Previous 
studies have reported that naturally occurring frog skin-derived peptides such as 
alyteserin-2a (Ojo et al. 2013b), tigerinin-1R (Ojo et al. 2011), and CPF-6 (Srinivasan et 
al. 2013) stimulate insulin release by depolarising membrane of BRIN-BD11 cells with 
a significant increase in intracellular Ca2+, suggesting that these peptides operate via the 
KATP channel-dependent pathway. In common with these peptides, incubation of BRIN-
BD11 cells with esculentin-1 peptides resulted in a significant increase in membrane 
potential and intracellular calcium. In contrast, hymenochirin 1B (Owolabi et al., 2015), 
phylloseptin-L2 (Abdel-Wahab et al., 2008b) pseudin-2 (Abdel-Wahab et al., 2008a) 
peptide did not affect these parameters when incubated with BRIN-BD11 cells under the 
same condition. Consistent with these, incubation of temporin A, F and G with BRIN-
BD11 cells did not have any effects on either membrane depolarization or intracellular 
calcium suggesting that the insulinotropic action of peptides is mediated via a calcium-
independent pathway.  
The progression of type 2 diabetes is linked to the loss of beta cell mass as well as beta 
cell function, which may contribute to impaired insulin secretion (Cantley & Ashcroft, 
2015, Arden, 2018). In this regard, we further investigated the proliferative and anti-
apoptotic effects of active temporin and esculentin-1 peptides. Consistent with previous 
reports (Yabe et al., 2011, Lee et al., 2014), GLP-1 protected the beta cell against 
cytokines induced apoptosis as well as significantly improved proliferation of beta cells. 
The present study has shown that the proliferative activity of temporin A and temporin F, 
and esculentin (1-21)-1c was comparable to that of GLP-1. Furthermore, these peptides, 
including esculentin-1a (1-21) were equally effective as GLP-1 in protecting the beta cell 
against cytokines induced apoptosis. On the other hand, temporin G, esculentin-1a (1-14) 
and esculentin-1b (1-18) peptides failed to show any positive effect of beta cell 
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proliferation. However, the latter two peptides showed weakly, but significant protective 
effects against cytokines induced beta-cell apoptosis cells. 
After demonstrating positive effects on insulin release in BRIN-BD11, 1.1B4 and primary 
islet cells, active temporin and esculentin-1 peptides were further investigated for their 
effects on glucose tolerance in lean mice. Temporin A, temporin F, esculentin-1a (1-21), 
esculentin (1-14) and esculentin (1-18) despite their high insulinotropic potency in vitro, 
failed to lower blood glucose when administered interpretationally to overnight fasted 
mice. The reason for the loss of activity could be rapid degradation or clearance of these 
peptides from the circulation. Therefore, it is necessary to design long-acting analogues 
if these peptides are to find application as incretins in T2DM therapy. The D-amino acid 
substituted analogue esculentin (1-21)-1c, although a less potent insulin secretagogue in 
vitro, has been shown to possess increased stability in serum (Grazia et al., 2015). 
Administration of this peptide to mice under the same conditions significantly improved 
glucose tolerance and increased circulating insulin concentrations. Analogues of the frog 
skin-derived peptide esculentin-2Cha (1-30) containing D-amino acids have also been 
designed that exhibit increased resistance to degradation by serum peptidases and 
consequently show improved glucose-lowering properties in insulin-resistant high fat fed 
mice compared with the unsubstituted peptide (Vasu et al., 2017). It is well established 
that individuals with T2DM are more prone to microbial infections than healthy subjects 
(Muller et al., 2005). Esculentin (1-21)-1c displays potent broad-spectrum antimicrobial 
activity (Grazia et al., 2015, Loffredo et al., 2017) so that regular injections of the peptide 
as a part of a therapeutic strategy may have a prophylactic effect on preventing infection 
as well as promoting glucose homeostasis in these patients. Temporin G (75 nmol/kg bw) 
also significantly stimulated insulin release and lowered blood glucose concentrations in 
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vivo when administered to mice, however, the effects were less than that produced by 
GLP-1 (25 nmol/kg bw). 
In conclusion, the study has shown the insulinotropic activity of temporin and esculentin-
1 peptides and its analogue esculentin (1-21)-1c as well as their positive effects on beta 
cell proliferation and survival. These peptides could represent a template for the design 
of new types of drugs for use in T2DM therapy. Further studies are warranted to develop 
longer-acting forms of peptides for assessment in appropriate animal models of T2DM, 
such as the insulin-resistant, glucose-intolerant, high fat fed mouse. 
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Table 3.1 Amino acid sequence of temporin and esculentin-1 peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No 
Peptide Sequence 
 
1 
 
Temporin A 
 
 
FLPLIGRVLSGIL-NH2 
 
2 
 
Temporin B 
 
 
LLPIVGNLLKSLL-NH2 
 
3 
 
Temporin C 
 
 
LLPILGNLLNGL-NH2 
 
4 
 
Temporin E 
 
 
VLPIIGNLLLNS-NH2 
 
5 
 
Temporin F 
 
 
FLPLIGKVLSGIL-NH2 
 
6 
 
Temporin G 
 
 
FFPVIGRILNGIL-NH2 
 
7 
 
Temporin H 
 
 
LSPNLLKSLL-NH2 
 
8 
 
Temporin K 
 
 
LLPNLLKSLL-NH2 
 
9 
 
Esculentin-1a (1-21) 
 
 
GlFSKLAGKKlKNLLlSGLKG-NH2   
 
10 
 
Esculentin (1-21)-1C 
 
 
GIFSKLAGKKlKNLLlSGLKG-NH2   
 
11 
 
Esculentin-1a (1-14) 
 
 
GlFSKLAGKKlKNL 
 
 
12 
 
Esculentin-1a (9-21) 
 
 
KKlKNLLlSGLKG 
 
 
13 
 
Esculentin-1b (1-18) 
 
 
GlFSKLAGKKLKNLLlSG-NH2 
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Table 3.2 Reverse phase HPLC, retention time and MALDI-TO MS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No 
Peptide Molecular 
weight Da 
(Theoretical) 
Molecular 
weight Da 
(Experimental) 
Retention 
time (min) 
 
1 
 
Temporin A 
 
 
1397 
 
1397.4 
 
28.4 
 
2 
 
Temporin B 
 
 
1392 
 
1392.7 
 
28.2 
 
3 
 
Temporin C 
 
 
1362 
 
1362.2 
 
27.5 
 
4 
 
Temporin E 
 
 
1378 
 
1377.9 
 
27.1 
 
5 
 
Temporin F 
 
 
1369 
 
1368.9 
 
28.7 
 
6 
 
Temporin G 
 
 
1458 
 
1458.1 
 
27.3 
 
7 
 
Temporin H 
 
 
1113 
 
1113.2 
 
25.1 
 
8 
 
Temporin K 
 
 
1123 
 
1122.7 
 
28.7 
 
9 
 
Esculentin-1a (1-21) 
 
 
2184 
 
2183.3 
 
26.4 
 
10 
 
Esculentin (1-21)-1C 
 
 
2184 
 
2184.1 
 
26.3 
 
11 
 
Esculentin-1a (1-14) 
 
 
1516 
 
1516.2 
 
26.8 
 
12 
 
Esculentin-1a (9-21) 
 
 
1411 
 
1412 
 
26.2 
 
13 
 
Esculentin-1b (1-18) 
 
 
1886 
 
1886.1 
 
26.6 
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Table 3.3 Primary structure and physicochemical properties of the temporin 
peptides used in this study 
 
Peptide           Primary structure     Calc. pI         GRAVY 
 
Temporin A        FLPLIGRVLSGIL.NH2     10.06     1.81 
 
Temporin B        LLPIVGNLLKSLL.NH2     8.86      1.64  
 
Temporin C        LLPILGNLLNGLL.NH2     5.28      1.67 
  
Temporin E        VLPIIGNLLLNSL.NH2     5.28      1.55 
 
Temporin F        FLPLIGKVLSGIL.NH2     8.86      1.85  
 
Temporin G        FFPVIGRILNGIL.NH2     10.06     1.58 
 
Temporin H        LSP***NLLKSLL.NH2     8.86      0.84  
 
Temporin K        LLP***NLLKSLL.NH2     8.86      1.30 
 
 
Calc.pI refers to calculated isoelectric point and GRAVY represents Grand Average of 
Hydropathy determined using the hydrophobicity scales of Kyte and Doolittle. 
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Table 3.4 Primary structure and physicochemical properties of the esculentin-1 
peptides used in this study 
  
Peptide         Primary structure        Charge  GRAVY Helical              
                                                        Domain             
 
Esc-1a(1-21)       GIFSKLAGKKIKNLLISGLKGa       +6    0.34    5-14 
 
Esc-1a(1-21-1C   GIFSKLAGKKIKNlLIsGLKGa     +6      0.34    ND 
 
Esc-1a(1-14)     GIFSKLAGKKIKNLa           +4    0.04    5-11 
  
Esc-1a(9-21)     KKIKNLLISGLKG             +4   -0.02 Nonhelical                     
                                                      
Esc-1b(1-18)     GIFSKLAGKKLKNLLISGa          +5     0.38    5-14 
 
              
 
a denotes C-terminal α-amidation. Charge refers to the net charge at pH 7.0 and GRAVY 
represents Grand Average of Hydropathy determined using the hydrophobicity scales of 
Kyte and Doolittle.  Secondary structure (extent of the helical domain) was predicted 
using the AGADIR algorithm. ND not determined. 
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Table 3.5 Effects of temporin peptides on the rate of insulin release from BRIN-
BD11 and 1.1B4 clonal β-cells 
 
                BRIN-BD11                                                  1.1B4 
 
Peptide Threshold  
Conc.(M) 
Insulin release at 3 µM 
Conc.  
ng/106 cells/20min 
Threshold  
Conc.(M) 
Insulin release at 3 µM 
Conc.  
ng/106 cells/20min 
 
None 
 
 
NA 
 
0.73 ± 0.08  
 
 
NA 
 
0.09 ± 0.01 
 
 
Temporin A 
 
 
10-9 
 
 
1.92 ± 0.20*** 
 
10-9* 
 
 
0.18 ± 0.01 
 
Temporin B 
 
 
10-9 
 
 
1.25 ± 0.07*** 
 
10-8* 
 
 
ND 
 
Temporin C 
 
 
10-7 
 
 
1.11 ± 0.12** 
 
10-7* 
 
 
ND 
 
Temporin E 
 
 
10-7 
 
 
1.10 ± 0.08** 
 
10-7* 
 
 
ND 
 
 
Temporin F 
 
 
10-9 
 
 
1.85 ± 0.20*** 
 
10-9** 
 
 
0.17 ± 0.01  
 
Temporin G 
 
 
10-9 
 
 
1.73 ± 0.17*** 
 
10-10* 
 
 
0.21 ± 0.01 
 
Temporin H 
 
 
NA 
 
No effect 
 
ND 
 
ND 
 
Temporin K 
 
 
NA 
 
No effect 
 
ND 
 
ND 
 
 
Threshold concentration refers to the minimum concentration of peptide producing a 
significant increase in the rate of insulin release compared with the rate in the presence 
of glucose only. Max, effect refers to the rate of insulin release in the presence of 3 µM 
peptide. NA: not applicable; ND: not determined. *P<0.05, **P<0.01, ***P<0.001 vs 5.6 
mM glucose alone. 
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Table 3.6 Effects of the esculentin-1 peptides on the rate of insulin release from 
BRIN-BD11 and 1.1B4 clonal β-cells 
 
                       BRIN-BD11                                  1.1B4 
 
Peptide Threshold  
Conc.  (M) 
Insulin release at 3 
µM Conc  
ng/106 cells/20min  
Threshold  
Conc. (M) 
Insulin release at 3 
µM Conc  
ng/106 cells/20min  
 
None 
 
NA 
 
    1.29 ± 0.08  
 
NA 
 
0.04 ± 0.01 
 
Esculentin-1a(1-21)a 
 
 
10-9* 
 
 
2.53 ± 0.05*** 
 
10-10* 
 
 
0.07 ± 0.01*** 
 
       Esculentin (1-
21)- 1C 
 
 
10-8* 
 
 
2.63 ± 0.12*** 
 
10-9* 
 
0.07 ± 0.01*** 
 
Esculentin-1a (1-14)a
 
 
 
10-9* 
 
 
2.67 ± 0.03*** 
 
10-10* 
 
0.07 ± 0.01*** 
 
Esculentin-1a (9-21) 
 
NA 
 
 
1.29 ± 0.08 
 
ND 
 
ND 
 
Esculentin-1b (1-18)a 
 
 
10-9** 
 
 
2.81 ± 0.08*** 
 
10-9** 
 
 
0.07 ± 0.01*** 
 
 
Threshold concentration refers to the minimum concentration of peptide producing a 
significant increase in the rate of insulin release compared with the rate in the presence 
of glucose only. Max. effect refers to the rate of insulin release in the presence of 3 µM 
peptide. NA: not applicable; ND: not determined. *P<0.05, **P<0.01, ***P<0.001 vs 5.6 
mM glucose alone. 
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Figure 3.1 Representative reverse-phase HPLC profile of temporin peptides 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
 
112 
 
Figure 3.2 Representative reverse-phase HPLC profile of temporin peptides 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 3.3 Representative reverse-phase HPLC profile of esculentin-1 peptides 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 3.4 Representative reverse-phase HPLC profile of esculentin-1 peptides 
 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 3.5 Representative MALDI-TOF spectra of temporin peptides 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 3.6 Representative MALDI-TOF spectra of temporin peptides 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 3.7 Representative MALDI-TOF spectra of esculentin-1 peptides 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 3.8 Representative MALDI-TOF spectra of esculentin-1 peptides 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 3.9 Effects of temporin peptides on insulin release from BRIN-BD11 rat 
clonal β-cells. 
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Effects of A) Temporin A, B) Temporin F and C) Temporin G on insulin release from 
BRIN-BD11 rat clonal β-cells. Values are mean ± SEM for n = 8. *P<0.05, **P<0.01, 
and ***P<0.001 compared to 5.6 mM glucose alone.  
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Figure 3.10 Effects of temporin peptides on LDH release from BRIN-BD11 rat 
clonal β-cells  
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Effects of A) Temporin A, B) Temporin F, and C) Temporin G on LDH release from 
BRIN-BD11 rat clonal β-cells. DMSO (100%) was used as positive control. Values 
are Mean ± SEM with n=4 for LDH. 
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Figure 3.11 Effects of esculentin-1 peptides on insulin release from BRIN-BD11 
rat clonal β-cells 
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Effects of A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C, C) Esculentin-1a (1-14) 
and D) Esculentin-1b (1-18) on insulin release from BRIN-BD11 rat clonal β-cells. 
Values are mean ± SEM for n = 8. *P<0.05, **P<0.01, and ***P<0.001 compared to 
5.6 mM glucose alone.  
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Figure 3.12 Effects of esculentin-1 peptides on LDH release from BRIN-BD11 
rat clonal β-cells 
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Effects of A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C, C) Esculentin-1a (1-14) 
and D) Esculentin-1b (1-18) on LDH release from BRIN-BD11 rat clonal β-cells. 
DMSO (100%) was used as positive control. Values are Mean ± SEM with n=4 for 
LDH. 
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Figure 3.13 Effects of temporin peptides on insulin release from 1.1B4 human 
clonal β-cells 
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Effects of A) Temporin A, B) Temporin F, and C) Temporin G on insulin release from 
1.1B4 human clonal β-cells. Values are mean ± SEM for n = 8. **P<0.01 and 
***P<0.001 compared to 5.6 mM glucose alone.  
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Figure 3.14 Effects of esculentin-1 peptides on insulin release from 1.1B4 
human clonal β-cells 
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Effects of A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C, C) Esculentin-1a (1-14) 
and D) Esculentin-1b (1-18) on insulin release from 1.1B4 human clonal β-cells. 
Values are mean ± SEM for n = 8. *P<0.05, **P<0.01, and ***P<0.001 compared to 
5.6 mM glucose alone.  
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Figure 3.15 Effects of temporin peptides on insulin release from release from 
isolated mouse islets 
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Effects of A) Temporin A, B) Temporin F, and C) Temporin G on insulin release from 
isolated mouse islets. Values are mean ± SEM for n = 8. *P<0.05, **P<0.01, and 
***P<0.001 compared to 5.6 mM glucose alone.  
126 
 
Figure 3.16 Effects of esculentin-1 peptides on insulin release from release from 
isolated mouse islets 
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Effects of A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C , C) Esculentin-1a (1-14) 
and D) Esculentin-1b (1-18) on insulin release from isolated mouse islets. Values are 
mean ± SEM for n = 8. *P<0.05, **P<0.01 and ***P<0.001 compared to 5.6 mM 
glucose alone.  
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Figure 3.17 Effects of temporin peptides on membrane potential in BRIN-BD11 
cells expressed as a line graph (A, C, E) and area under the curve (B, D, F) 
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Effects of Temporin A, Temporin F and Temporin G on membrane potential in BRIN-
BD11 cells expressed as relative fluorescence units, RFU as a function of time (A, C, 
E) and the integrated response (area under the curve) (B, D, F) for respective peptide. 
Peptides were added 20 sec after start of data acquisition at a rate of ~62 μl/sec. Values 
are mean ± SEM (n = 6).  ***P<0.001 compared with 5.6 mM glucose alone. 
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Figure 3.18 Effects of temporin peptides on intracellular calcium in BRIN-BD11 
cells (A, C, E) and area under the curve (B, D, F) 
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Effects of Temporin A, Temporin F and Temporin G on intracellular calcium in BRIN-
BD11 cells expressed as relative fluorescence units, RFU as a function of time (A, C, 
E) and the integrated response (area under the curve) (B, D, F) for respective peptide. 
Peptides were added 20 sec after start of data acquisition at a rate of ~62 μl/sec. Values 
are mean ± SEM (n = 6).  ***P<0.001 compared with 5.6 mM glucose alone. 
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Figure 3.19 Effects of esculentin-1 peptides on membrane potential in BRIN-
BD11 cells expressed as a line graph (A, C, E, G) and area under the curve (B, D, 
F, H) 
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Effects of Esculentin-1a (1-21), Esculentin (1-21)-1C, Esculentin-1a (1-14) and 
Esculentin-1b (1-18) on membrane potential in BRIN-BD11 cells expressed as relative 
fluorescence units, RFU as a function of time (A, C, E, G) and the integrated response 
(area under the curve) (B, D, F, H) for respective peptide. Peptides were added 20 sec 
after start of data acquisition at a rate of ~62 μl/sec. Values are mean ± SEM (n = 6). 
*P<0.05, **P<0.01 and ***P<0.001 compared with 5.6 mM glucose alone. 
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Figure 3.20 Effects of esculentin-1 peptides on intracellular Ca2+ in BRIN-BD11 
cells expressed as line graph (A, C, E, G) and area under the curve (B, D, F, H) 
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Effects of Esculentin-1a (1-21), Esculentin (1-21)-1C, Esculentin-1a (1-14) and 
Esculentin-1b (1-18) on intracellular calcium in BRIN-BD11 cells expressed as 
relative fluorescence units, RFU as a function of time (A, C, E, G) and the integrated 
response (area under the curve) (B, D, F, H) for respective peptide. Peptides were 
added 20 sec after start of data acquisition at a rate of ~62 μl/sec. Values are mean ± 
SEM (n = 6).  *P<0.05 and ***P<0.001 compared with 5.6 mM glucose alone. 
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Figure 3.21 Effect of temporin peptides on cytokine-induced apoptosis in BRIN-
BD11 cells 
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Effects of 1 µM A) Temporin A, B) Temporin F and C) Temporin G on apoptosis in 
BRIN-BD11 cells compared with 1 µM GLP-1. Values are mean ± SEM for n=3. 
**P<0.01 and ***P<0.001 compared with incubation in culture medium alone, 
ΔΔP<0.01 and ΔΔΔP<0.001 compared with incubation in the cytokine-containing 
medium.  
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Figure 3.22 Effect of temporin peptides on proliferation in BRIN-BD11 cells 
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Effects of 1 µM A) Temporin A, B) Temporin F and C) Temporin G on proliferation 
in BRIN-BD11 cells compared with 1 µM GLP-1. Values are mean ± SEM Values are 
mean ± SEM for n=3. **P<0.01, ***P<0.001 compared with incubation in culture 
medium alone, ΔΔΔP<0.001 compared to GLP-1 treated cells. 
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Figure 3.23 Effect of esculentin-1 peptides on cytokine-induced apoptosis in 
BRIN-BD11 cells 
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Effects of 1 µM A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C, C) Esculentin-1a 
(1-14) and D) Esculentin-1b (1-18) on apoptosis in BRIN-BD11 cells compared with 
1 µM GLP-1. Values are mean ± SEM for n=3. **P<0.01, ***P<0.001 compared with 
incubation in culture medium alone, ΔP<0.05, ΔΔP<0.01 compared with incubation in 
cytokine-containing medium.  
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Figure 3.24 Effect of esculentin-1 peptides on proliferation in BRIN-BD11 cells 
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Effects of 1 µM A) Esculentin-1a (1-21), B) Esculentin (1-21)-1C, C) Esculentin-1a 
(1-14) and D) Esculentin-1b (1-18) on proliferation in BRIN-BD11 cells compared 
with 1 µM GLP-1. Values are mean ± SEM Values are mean ± SEM for n=3. **P<0.01 
compared with incubation in culture medium alone, ΔΔP<0.01 and ΔΔΔP<0.001 
compared to GLP-1 treated cells. 
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Figure 3.25 Effects of temporin G on glucose tolerance and insulin concentrations 
in mice 
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Effects of intraperitoneal administration of Temporin G Peptide (75 nmol/kg bw) and 
GLP-1 (25 nmol/kg bw) on blood glucose (panels A and B) and plasma insulin (panels 
C and D) concentrations in lean mice after co-injection of glucose (18 mmol/ kg bw). 
Values are mean ± SEM for n = 6). *P<0.05, **P<0.01 and ***P<0.001 compared 
with glucose alone, ΔP<0.05 compared with the effect of GLP-1. 
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Figure 3.26 Effects of temporin A and temporin F on glucose tolerance in mice 
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Effects of intraperitoneal administration of Temporin A, Temporin F (75 nmol/kg bw) 
and GLP-1 (25 nmol/kg bw) on blood glucose (panels A and B) in lean mice after co-
injection of glucose (18 mmol/ kg bw). Values are mean ± SEM for n = 6). ***P<0.001 
compared with glucose alone, ΔP<0.05 and ΔΔP<0.01 compared with the effect of 
GLP-1. 
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Figure 3.27 Effects of esculentin (1-21)-1C on glucose tolerance and insulin 
concentrations in mice 
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Effects of intraperitoneal administration of esculentin (1-21)-1C peptide (75 nmol/kg 
bw) and GLP-1 (25 nmol/kg bw) on blood glucose (panels A and B) and plasma insulin 
(panels C and D) concentrations in lean mice after co-injection of glucose (18 mmol/ 
kg bw). Values are mean ± SEM for n = 6. *P<0.05, **P<0.01 and ***P<0.001 
compared with glucose alone. 
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Figure 3.28 Effects of esculentin-1a (1-21), esculentin-1a (1-14) and esculentin-
1b (1-18) on glucose tolerance in mice 
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Effects of intraperitoneal administration of esculentin-1a (1-21), esculentin-1a (1-14) 
and esculentin-1b (1-18) peptide (75 nmol/kg bw) and GLP-1 (25 nmol/kg bw) on 
blood glucose (panels A & B) concentrations in lean mice after co-injection of glucose 
(18 mmol/ kg bw). Values are mean ± SEM for n = 6. ***P<0.001 compared with 
glucose alone, ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the effect of GLP-1. 
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Figure 3.29 A Schiffer-Edmundson helical wheel projection of the temporin B 
and temporin F structures 
 
 
 
The arrows illustrate the angle (Ф) subtended by the positive charge on the α-amino 
group of the N-terminal residue and the positive charge on the ε-amino group of the 
lysine residue. 
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Chapter 4 
 
In vitro and in vivo antidiabetic effects of Frenatin 2D 
peptide and its synthetic analogues 
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4.1 Summary  
Four naturally occurring frenatin peptides [frenatin 2.1S 
(GLVGTLLGHIGKAILG.NH2), frenatin 2.2S (GLVGTLLGHIGKAILS.NH2) and 
frenatin 2.3S (GLVGTLLGHIGKAILG.COOH) from Sphaenorhynchus lacteus and 
frenatin 2D (DLLGTLGNLPLPFI.NH2) from Discoglossus sardus] were tested for 
insulin-releasing effects from BRIN-BD11 rat clonal β-cells cells. Frenatin 2D was 
the most promising and effective in releasing insulin in a concentration-dependent 
manner without displaying cytotoxicity. The strategy to replace each amino acid 
residue in frenatin 2D by a bulky, hydrophobic tryptophan (W) did not lead to the 
design of analogues with increased insulinotropic activity, but the [D1W] and [G7W] 
analogues were as potent and effective as the native peptide. Also, deletion of the C-
terminal α-amide group did not affect the activity. Frenatin 2D and its synthetic 
analogues [D1W] and [G7W] also stimulated insulin release from 1.1B4 human-
derived clonal β-cells and isolated mouse islets. The insulinotropic activity of these 
peptides was not associated with membrane depolarization or an increase in 
intracellular [Ca2+]. Frenatin 2D and its synthetic analogues [(D1W and (G7W)] 
maintained their activities in the presence of verapamil, diazoxide and 4,4-
diisothiocyanostilbene-2,2-disulfonic acid (DIDS). Incubation of frenatin 2D and its 
synthetic analogues [(D1W and (G7W)] (1μM) with BRIN-BD11 cells produced a 
modest, but significant, increase in cAMP production. Stimulation of insulin release 
was abolished in protein kinase A-downregulated cells but maintained in protein 
kinase C-downregulated cells. Frenatin 2D and its synthetic analogues [(D1W and 
(G7W)] (1μM) also stimulated proliferation of BRIN-BD11 cells and provided 
significant protection to the cells against cytokine-induced apoptosis. Furthermore, 
[G7W] frenatin 2D, significantly suppressed appetite in overnight fasted mice (18 hr). 
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Acute in vivo administration of frenatin 2D and its synthetic analogues [(D1W and 
(G7W)] also improved glucose tolerance concomitant with increased circulating 
insulin concentrations in mice. However, [D1W] frenatin 2D was most effective, and 
hence it was chosen for further studies. We then assessed long-term treatment (28 
days) of [D1W] frenatin 2D (75 nmol/kg bw) analogue in genetically obese-diabetic 
mice (db/db), in comparison to native peptide frenatin 2D (75 nmol/kg bw) and 
exenatide (25 nmol/kg bw). Blood glucose, HbA1c, glycaemic response to 
intraperitoneal glucose challenge and insulin sensitivity were improved significantly 
in all treated groups. Plasma insulin level remained unchanged in [D1W] frenatin 2D 
treatment but improved significantly in frenatin 2D and exenatide-treated groups. 
Liver and kidney functions were improved in all treated groups. Plasma triglycerides 
and low-density lipoprotein level were decreased with both frenatin 2D and [D1W] 
frenatin 2D treatment, but not to the same extent as in exenatide treatment. Amylase 
activity was unaltered by frenatin 2D and [D1W] frenatin 2D treatment. However, it 
was increased significantly by exenatide treatment group. Frenatin 2D and [D1W] 
frenatin 2D treatment exhibited a beneficial effect on islet morphology by preventing 
a loss of large and medium-size islet in db/db mice. Furthermore, all peptides tested 
exerted a positive effects on expression of genes involved in glucose homeostasis both 
in muscle and islets. Taken together, these data suggest that frenatin 2D peptides exert 
beneficial metabolic effects in genetically obese-diabetic mice (db/db). 
 
4.2 Introduction 
 
The dramatic global increase in the incidence of T2DM in the past decade has 
necessitated the search for new naturally occurring therapeutic agents that regulate 
glucose concentrations and prevent the complications associated with the disease. The 
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discovery of exendin-4 in the venom of a reptile, the Gila monster Heloderma 
suspectum (Eng et al., 1992) highlights the importance of non-mammalian sources in 
the search for new antidiabetic peptides. Exendin-4 is an agonist at the glucagon-like 
peptide-1 (GLP-1) receptor (GLP1R) that stimulates glucose-dependent insulin 
release and improves pancreatic β-cell function (Fehse et al., 2005). Exendin-4 is more 
potent and longer-acting in vivo than GLP-1 and is used in routine clinical practice in 
T2DM therapy (Bunck et al., 2011). The skin secretions of many frog species contain 
bioactive peptides that play an important contributory role in protecting the host from 
invasion by a pathogenic microorganism in the environment and ingestion by 
predators (Raaymakers et al., 2017). These peptides are multifunctional and may 
possess antimicrobial, antifungal, antiviral, anticancer and immunomodulatory 
activities (reviewed in (Conlon et al., 2014a, Xu & Lai et al., 2015)]. Additionally, 
several host defence peptides that were first identified on the basis of their 
antimicrobial properties have been shown to stimulate insulin release from clonal β-
cells and isolated pancreatic islets and improve glucose tolerance following 
intraperitoneal administration in mice and so represent agents with therapeutic 
potential for treatment of patients with T2DM [reviewed in (Conlon et al., 2018)].  
The frenatins are a family of structurally related small peptides that were first 
identified in skin secretions of the Australian treefrog Litoria infrafrenata (reclassified 
as Nyctimystes infrafrenatus) (Pelodryadidae) (Raftery et al., 1996) Subsequently, 
frenatin 2D [DLLGTLGNLPLPFI.NH2] was isolated from skin secretions of the 
Tyrrhenian painted frog Discoglossus sardus (Alytidae) (Conlon et al., 2013) and 
frenatin 2.1S [GLVGTLLGHIGKAILG.NH2], frenatin 2.2S 
[GLVGTLLGHIGKAILS.NH2] and frenatin 2.3S [GLVGTLLGHIGKAILG] from 
the Orinoco lime frog Sphaenorhynchus lacteus (Hylidae) (Conlon et al., 2014b).  
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Frenatin 2D lacked antimicrobial activity but stimulated the production of the 
proinflammatory cytokines TNF-α, and IL-1β by mouse peritoneal macrophages 
suggesting that the peptide may act on macrophages in frog skin to produce a cytokine-
mediated stimulation of the adaptive immune system in response to invasion by 
microorganisms (Conlon et al., 2013). In contrast, frenatin 2.1S and 2.2S show potent 
antimicrobial activity against Gram-negative bacteria and are cytotoxic to non-small 
cell lung adenocarcinoma A549 cells (Conlon et al., 2014b). Frenatin 2.1S also 
stimulates the production of pro-inflammatory cytokines by mouse peritoneal 
macrophages and downregulates production of the anti-inflammatory cytokine IL-10 
by lipopolysaccharide-stimulated cells. A single injection of frenatin 2.1S (100 μg) in 
BALB/c mice enhances the activation state and homing capacity of Th1 type 
lymphocytes (Pantic et al., 2015) and led to a marked increase in the number and 
tumoricidal capacity of activated peritoneal natural killer (NK) cells (Pantic et al., 
2017a) in the peritoneal cavity suggesting that the peptide should be regarded as a 
candidate for antitumor immunotherapy. Activity against yellow fever virus has also 
been reported for the frenatin 2 peptides present in S. lacteus skin secretions (Muñoz-
Camargo et al., 2016). 
Certain frog skin peptides, such as esculentin-2cha (1-30) from Chiricahua leopard 
frog Lithobates chiricahuensis (Vasu et al., 2017), tigerinin-1R from Haplobatrachus 
rugulosus (Ojo et al., 2015b), CPF-SE1 from Silurana epitropicalis (Srinivasan et al., 
2015), Magainin related peptides from Xenopus amieti (Ojo et al., 2015a) have shown 
to improve glycaemic control, glucose tolerance, insulin sensitivity and pancreatic 
beta cell function in animal model of T2DM. The present study aimed to investigate 
the therapeutic potential of frenatin 2D, 2.1S. 2.2S, and 2.3S (Table 4.1 for the 
structure of peptides) for development into agents for the treatment of patients with 
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T2DM. Their ability to stimulate insulin release in vitro was evaluated using BRIN-
BD11 rat clonal β-cells (McClenaghan et al., 1996), 1.1 B4 human clonal β-cells 
(McCluskey et al., 2011) and isolated mouse islets. Their ability to lower blood 
glucose concentration and stimulate insulin release in vivo was determined in 
overnight-fasted, male NIH Swiss TO mice.  Also, the effects of frenatin 2D on β- cell 
proliferation and its ability to inhibit cytokine-induced apoptosis was studied in BRIN-
BD11 cells. The antidiabetic effects of frenatin 2D peptides were also studied in db/db 
mice, in comparison to the established antidiabetic agent, exenatide. 
 
4.3 Materials and Methods 
4.3.1 Reagents 
All the chemical reagents used in the experiments were of analytical grade and listed 
in Chapter 2, Section 2.1. Synthetic frenatin peptides were purchased from SynPeptide 
(China) and GL Biochem Ltd (Shanghai, China). Cytotoxicity Assay kit (Catalogue 
number: G1780) was supplied by Promega (Southampton, UK).  Intracellular calcium 
assay kit (Catalogue number: R8041) and membrane potential assay kit (Catalogue 
number: R8042) were purchased from Molecular Device (Berkshire, UK). Apoptosis 
and proliferation experiments were performed using IN SITU Cell Death Fluorescein 
kit (Sigma-Aldrich, Catalogue number: 11684795910) and Rabbit polyclonal to Ki67 
(Abcam, Catalogue number: ab15580) respectively. Masterclear Cap Strips and real-
time PCR TubeStrips (Catalogue number: 0030132890) purchased from Mason 
Technology Ltd (Dublin, Ireland). 
 
4.3.2 Peptide synthesis and purification 
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Frenatin 2D and its tryptophan-containing analogues, as well as non-amidated frenatin 
2D and its tryptophan-containing analogues (listed in Table 4.1), were supplied in 
crude form by SynPeptide Ltd (Shanghai, China).  Frenatin 2.1S, 2.2S, and 2.3S were 
supplied in crude form by GL Biochem Ltd (Shanghai, China). The peptides were 
purified to near homogeneity (>98 % purity) by reversed-phase HPLC as previously 
described in Chapter 2, Section 2.2.1.1. The identity of all peptides was confirmed by 
MALDI-TOF mass spectrometry (Chapter 2, Section 2.2.2) using a Voyager DE-PRO 
instrument (Applied Biosystems, Foster City, USA). 
 
4.3.3 Insulin release studies using clonal beta cells  
The culture of BRIN-BD11 rat clonal β-cells and 1.1B4 human-derived pancreatic β-
cells and the method for measuring the effects of peptides on the release of insulin has 
been described in Chapter 2, Section 2.3.1 and 2.4.1.1, respectively. Incubations with 
the frenatin peptides (3 x 10-6 - 10-12 M; n = 8) were carried out for 20 min at 37°C in 
Krebs-Ringer bicarbonate (KRB) buffer, pH 7.4 supplemented with 5.6 mM glucose. 
Control incubations were carried out in the presence of GLP-1 (10 nM), exendin-4 (10 
nM) and alanine (10 mM). After incubation, aliquots of cell supernatant were removed 
for measurement of insulin by radioimmunoassay as outlined in Chapter 2, Section 
2.4.4. In order to determine cytotoxicity, the effects of the frenatin peptides (10-12 M - 
3 x 10-6 M; n = 4) on the rate of lactate dehydrogenase (LDH) release from BRIN-
BD11 cells were measured using a CytoTox 96 non-radioactive cytotoxicity assay kit 
(Promega, Southampton, UK) according to the manufacturer’s instructions Chapter 2, 
Section 2.5.  
In the second series of experiments designed to investigate mechanisms of action, 
incubations of BRIN-BD11 cells with frenatin 2D and its analogues (1 µM) were 
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carried out in the presence of known modulators of insulin release (Chapter 2, Section 
2.4.1.2): the K+ channel activator diazoxide (300 µM), the L-type voltage-dependent 
Ca2+ channel blocker verapamil (50 μM), depolarizing stimulus KCl (30 mM) and a 
and chloride channel blocker 4,4-diisothiocyanostilbene-2,2-disulfonic acid (0.66 
mM). To determine the role of extracellular calcium in mediating the insulinotropic 
activity of the peptide, cells were pre-incubated in calcium-free KRB buffer (pH 7.4) 
supplemented with 1.1 mM glucose and 1 mM EGTA for 1 hr at 37°C (Chapter 2, 
Section 2.4.1.3). After pre-incubation, cells were incubated for 20 min at 37°C with 
frenatin 2D (1 µM) in calcium-free KRB buffer containing 5.6 mM glucose. 
 
4.3.4 Insulin release studies using isolated mouse islets 
The preparation of isolated pancreatic islets from an adult, male National Institutes of 
Health NIH Swiss mice (Harlan Ltd, Bicester, UK) and the procedure for determining 
the effects of peptides on the rate of insulin release have been described in Chapter 2, 
Section 2.4.2.2.  The islets were incubated for 1 hr at 37°C with synthetic peptides (10-
8 and 10-6 M) in KRB buffer supplemented with 16.7 mM glucose. Supernatants were 
removed for determination of insulin by radioimmunoassay (Chapter 2, Section 2.4.4). 
The islet cells were retrieved and extracted with acid-ethanol to determine total insulin 
content as previously described in Chapter 2, Section 2.4.2.4. 
 
4.3.5 Effects of peptides on membrane potential and intracellular Ca2+ 
concentrations 
Changes in membrane potential and intracellular Ca2+ concentrations in response to 
incubation with either frenatin 2D or its analogue (1 µM) were determined 
fluorimetrically with monolayers of BRIN-BD11 cells using a FLIPR Membrane 
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Potential Assay Kit and a FLIPR Calcium 5 Assay Kit (Molecular Devices, Sunnyvale, 
CA, USA) according to the manufacturer’s recommended protocols as described in 
Chapter 2, Section 2.6 and 2.7. Cells were incubated in 5.6 mM glucose with peptide 
at 37C for 5 min and data were acquired using a Flex Station scanning fluorimeter 
with integrated fluid transfer workstation (Molecular Devices).  Control incubations 
with 5.6 mM glucose alone, 5.6 mM glucose plus 30 mM KCl, and 5.6 mM glucose 
plus 10 mM alanine) were also carried out.  
 
4.3.6 Effects of peptides on cyclic AMP production 
The procedure for determining the effects of frenatin 2D and its analogues (1 µM) on 
the production of cAMP by BRIN-BD11 cells has been described in Chapter 2, Section 
2.8. Incubations were carried out for 20 min in KRB buffer supplemented with 5.6 
mM glucose and the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine 
(IBMX; 200µM). cAMP concentrations in the cell lysate were measured using a 
Parameter kit (R & D Systems, Abingdon, UK) following the manufacturer’s 
recommended protocol. Control incubations in the presence of 5.6 mM glucose alone 
and GLP-1 (10 nM) were also carried out. 
 
4.3.7 Effects of down-regulation of the PKA and PKC pathways on insulin release 
In order to investigate further the mechanism of insulinotropic action of frenatin 2D 
and its analogues, BRIN-BD11 cells were incubated for 18 hr at 37°C in an atmosphere 
of 5 % CO2 and 95 % air with 25 µM forskolin (Sigma-Aldrich, UK) to downregulate 
the PKA pathway or with 10 nM phorbol 12-myristate 13-acetate (PMA; Sigma-
Aldrich, UK) to downregulate the PKC pathway or with 25 µM forskolin plus 10 nM 
PMA to downregulate both pathways. Details of the experimental procedure have been 
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described in Chapter 2, Section 2.9. Cells were preincubated for 40 min at 37°C with 
KRB buffer, pH 7.4 supplemented with 1.1 mM glucose and 0.1 % bovine serum 
albumin followed by a 20 min incubation with (a) either frenatin 2D or its analogue (1 
µM), (b) GLP-1 (10 nM) and (c) CCK-8 (10 nM) in KRB buffer supplemented with 
5. 6 mM glucose. Control incubations with forskolin alone (25 µM), PMA (10 nM) 
alone and forskolin (25 µM) + PMA (10 nM) alone were also carried out. Aliquots of 
the cell supernatants were removed for measurement of insulin by radioimmunoassay 
(Chapter 2, Section Section 2.4.4).  
 
4.3.8 Effects of the peptides on cytokine-induced apoptosis and proliferation  
The ability of frenatin 2D and its analogues to protect against cytokine-induced DNA 
damage was analysed by incubating BRIN-BD11 cells, seeded at a density of 5 x 104 
cells per well, for 18 hr at 37°C with a cytokine mixture  (200 U/ml tumour-necrosis 
factor-a, 20 U/ml interferon-γ and 100 U/ml interleukin-1β), in the presence and 
absence of either frenatin 2D (1 µM)  or its analogues (1 µM) or GLP-1 (1 µM).  The 
details of the experimental procedure have been described in Chapter 2, Section 2.10.  
To study effects on β-cell proliferation, BRIN-BD11 cells were incubated with either 
frenatin 2D (1 µM) or its analogues (1 µM) or GLP-1 (1 µM) for 18 hr at 37°C as 
described in Chapter 2, Section 2.10. 
 
4.3.9 Assessments of plasma degradation of the frenatin 2D peptide. 
The metabolic stability of frenatin 2D was evaluated by incubating peptide with 
murine plasma. The experimental procedure is described in Section 2.12. 
 
4.3.10 Effects of peptides on glucose uptake in C2C12 cells 
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The procedure for determining the effects of peptides on the glucose uptake in C2C12 
cells is described in Chapter 2, Section 2.11. 
 
4.3.11 Acute in vivo effects of peptides on food intake 
After i.p injection of saline and test peptide, food intake was measured in overnight 
(21 hr) fasted mice as described in Chapter 2, Section 2.13.4.   
 
4.3.12 Acute in vivo insulin release studies 
All animal experiments were carried out by the UK Animals (Scientific Procedures) 
Act 1986 and EU Directive 2010/63EU for animal experiments and approved by 
Ulster University Animal Ethics Review Committee. All necessary steps were taken 
to prevent any potential animal suffering. Eight-week-old male NIH Swiss TO mice 
(Harlan Ltd, Bicester, UK), were housed separately and maintained in an air-
conditioned room (22 ± 2 °C) with a 12-hr light: 12-hr dark cycle. The procedure for 
determining the effects of intraperitoneal administration glucose alone (18 mmol/kg 
bw) and in combination with frenatin 2D or its analogues (75 nmol/kg bw) or GLP-1 
(25 nmol/kg bw) has been described in Chapter 2, Section 2.13.2. Blood samples were 
collected and measured for glucose concentrations using an Ascencia Contour Blood 
Glucose Meter and plasma insulin by radioimmunoassay (Chapter 2, Section 2.13.5). 
In another set of experiments, in overnight (21 hr) fasted mice, food intake was 
measured after i.p injection of saline and test peptides as described in Chapter 2, 
Section 2.13.4.   
 
4.3.13 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D in db/db mice 
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Before the initiation of treatment with peptides, db/db mice were injected twice daily 
with saline (0.9 % w/v) for 3 days to adapt mice to handling and injection stress.  
During this period mice were monitored for body weight, energy intake, glucose and 
insulin. Mice (db/db) received twice daily i.p. injections of either saline (0.9 % w/v) 
or frenatin 2D (75 nmol/kg bw) or [D1W] frenatin 2D (75 nmol/kg bw) or exenatide 
(25 nmol/kg bw) for 28 consecutive days. Every 72 hr during the study, body weight, 
energy intake, non-fasted blood glucose and plasma insulin were assessed. After the 
end of treatment period, terminal studies were performed which included 
measurement of the HbA1c (Chapter 2, Section 2.13.9), glucose tolerance test using 
an intraperitoneal or oral glucose load (Chapter 2, Section 2.13.2), and insulin 
sensitivity (Section 2.13.3). Fasting (18 hr) blood was collected and measured for 
insulin and glucose to determine insulin resistance using homeostatic model 
assessment (HOMA) formula: HOMA-IR = fasting glucose (mmol/l) x fasting insulin 
(mU/l)/22.5. After collecting terminal blood, animals were subjected to DEXA scan 
(PIXImus densitometer, USA) (Chapter 2, Section 2.13.8) to measure body fat 
composition and bone mineral content/density. Dissected tissues from animals were 
processed for histology studies (Chapter 2, Section 2.14), hormonal content (Chapter 
2, Section 2.13.11) and expression of key genes involved in glucose homeostasis 
(Chapter 2, Section 2.15). Islets were isolated from the pancreas (Chapter 2, Section 
2.4.2.1) and examined for insulin secretory response to glucose and established insulin 
secretagogues as described in Chapter 2, Section 2.4.2.3. 
 
4.3.14 Biochemical tests  
Plasma was retrieved from blood and used for various biochemical tests. The 
procedures for measuring blood/plasma glucose and plasma insulin are described in 
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Chapter 2, Section 2.13.5. Additional tests included lipid profile, liver and kidney 
function test and amylase activity (Chapter 2, Section 2.13.12). 
 
4.3.15 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on islet morphology 
The pancreatic tissues were embedded in paraffin wax after processing on tissue 
processor. Using microtome, sections of 7 µM thickness were made and placed on a 
slide. Sections were allowed to dry overnight on a hotplate and then stained for insulin 
and glucagon as described in Chapter 2, Section 2.14.1.  
 
4.3.16 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on gene expression 
RNA was extracted from skeletal muscle tissue and islet cells (Chapter 2, Section 
2.15.1), and examined for the expression of genes involved in glucose homeostasis 
(Chapter 2, Section 2.15.2 and 2.15.3). 
 
4.3.17 Statistical Analysis 
Experimental data analysed using GraphPad PRISM (Version 3) were expressed as 
means ± SEM and data were compared using the unpaired student t-test 
(nonparametric, with two-tailed P values and 95% conﬁdence interval) and one-way 
ANOVA with Bonferroni post-hoc test. Group of datasets were considered to be 
significantly different if P<0.05. 
 
4.4 Results 
4.4.1 Characterization of peptides 
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The purity of all frenatin peptides was confirmed using reverse phase HPLC (Figure 
4.1-4.5). The molecular weight of peptides confirmed by MALDI- TOF (Figure 4.6-
4.10) was closely related to the theoretical molecular weight (Table 4.2). 
 
4.4.2 Effects of frenatin peptides on insulin release from BRIN BD11 rat clonal 
β-cells 
The rate of insulin release from BRIN-BD11 cells in the presence of 5.6 mM glucose 
alone was 1.01 ± 0.04 ng/106 cells/20 min. Incubation with the established insulin 
secretagogue alanine (10 mM) increased insulin release to 5.42 ± 0.30 ng/106 cells/20 
min and to 3.08 ± 0.10 ng/106 cells/20 min with GLP-1 (10 nM). The effects of 
increasing concentrations of frenatin 2D, 2.1S, 2.2S and 2.3S are shown in Figure 
4.11(A-D). Frenatin 2D was the most potent peptide with a threshold concentration 
(the concentration producing a significant increase in the rate of insulin release 
compared with the rate in the presence of 5.6 mM glucose alone) of 0.1 nM and the 
greater stimulator of insulin release (a 2.3-fold increase at 3 µM). At concentrations 
up to 3 µM, no significant increase in the rate of release of the cytosolic enzyme LDH 
from the BRIN-BD11 cells was observed for any of the frenatin peptides indicating 
that the integrity of plasma membrane remained intact (Figure 4.12). 
   Substitution of the Thr5, Asn8, Pro10, and Ile14 residues in frenatin 2D by Trp (W) 
and interchange of Pro12 and Phe13 led to the loss of insulinotropic activity. [L2W], 
[L3W], [G4W], [L6W], [L9W] and [L11W] analogue displayed weak insulin-
releasing activity (Table 4.3), but the [D1W] and [G7W] analogues were as potent and 
effective as the native peptide (Figure 4.13A-C). The insulinotropic activity of frenatin 
2D and its [D1W] and [G7W] analogues were unaffected by the removal of the 
amidated group and was equally effective to their amidated counterpart (Table 4.3). 
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4.4.3 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on insulin release from 1.1B4 human clonal β-cells and 
isolated mouse islets 
The stimulatory effect of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release was replicated in the glucose-responsive 
1.1B4 human-derived cell line at both 5.6 mM and 16.7 mM glucose. The native 
peptide and analogues produced a significant (P<0.05) increase in insulin release at a 
0.1 nM in the presence of 5.6 mM glucose (Figure 4.15A-C) and 1 nM in the presence 
of 16.7 mM glucose (Figure 4.16A-C), with an approximate 2-fold increase at 3 µM 
concentration. The magnitude of the response to 3 µM frenatin 2D was less than the 
response to 10 nM GLP-1. Incubation of frenatin 2D with isolated mouse islets also 
produced a significant increase of insulin release at 10 nM (P<0.05) and at 1 µM 
(P<0.01) compared with the rate in the presence of 16.7 mM glucose only (Figure 
4.17). Similar stimulatory effects were observed with islets incubated with either 
[D1W] or [G7W] frenatin 2D.  Again, the magnitudes of insulin responses of frenatin 
2D peptides were significantly less than the responses to GLP-1 at the same 
concentration. 
 
4.4.4 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on membrane depolarization and intracellular calcium 
([Ca2+]i) 
Incubation of BRIN-BD11 cells with 30 mM KCl produced an immediate and 
sustained increase in membrane potential. In contrast, incubation with frenatin 2D 
peptides (1 µM) had no significant effect on membrane depolarization (Figure 4.18).  
Similarly, incubation of BRIN-BD11 cells with 10 mM alanine produced an 
155 
 
immediate and sustained increase in [Ca2+]i, whereas incubation with frenatin 2D 
peptides (1 µM) had no significant effect on this parameter (Figure 4.19).  
 
4.4.5 Effects of established modulators of insulin release and chloride channel 
blocker on the insulinotropic activity of frenatin 2D and its synthetic analogues 
([D1W] frenatin 2D and [G7W] frenatin 2D) 
The effects of known insulin release modulators, Ca2+ free buffer and chloride channel 
blocker on the insulinotropic activity of frenatin 2D peptides are shown in Figure 4.20, 
4.21 and 4.22 respectively.  The ability of the peptides to stimulate insulin release from 
BRIN-BD11 cells was unaffected in the presence of diazoxide (300 µM), the K+ 
channel activator, verapamil (50 μM), the L-type voltage-dependent and Ca2+ channels 
blocker (Figure 4.20), Ca2+ free buffer (Figure 4.21) and 4,4-diisothiocyanostilbene-
2,2-disulfonic acid (0.66 mM), the chloride channel blocker (Figure 4.22). The 
depolarizing stimulus 30 mM KCl produced a marked (3-fold) increase in insulin 
release, and the rate was significantly (P<0.01) augmented when the 30 mM KCl 
solution was supplemented with frenatin 2D peptides (1 µM). In the presence of IBMX 
(200 µM) frenatin 2D peptides produced a minor but still significant (P<0.05) increase 
in insulin release. 
 
4.4.6 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on cyclic AMP in BRIN-BD11 rat clonal β-cells  
Incubation of BRIN-BD11 cells with GLP-1 (10 nM) in the presence of IBMX resulted 
in a 215% increase (P<0.001) in cAMP compared with cells incubated with 5.6 mM 
glucose plus IBMX alone. Incubation with frenatin 2D peptides (1 µM) produced a 
smaller but still significant (P<0.01) increase in cAMP, which was associated with 
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enhanced in insulin release, suggesting an involvement of the PKA pathway (Figure 
4.23A-B). In the second series of experiments, the insulinotropic activity of frenatin 
2D peptides was examined after down-regulation of the PKA and PKC pathways by 
overnight culture of BRIN-BD11 cells with forskolin and PMA respectively (Figure 
4.24A-C). When the activators were not present, the rates of insulin release produced 
by frenatin 2D peptides, GLP-1, and CCK-8 were significantly (P<0.001) greater than 
that produced by 5.6 mM glucose alone. The insulin stimulatory activities of frenatin 
2D peptides and GLP-1, but not CCK-8, were significantly reduced when the PKA 
pathway was down-regulated with 25µM forskolin. In contrast, down-regulation of 
the PKC pathway with 10 nM PMA was without significant effect on the stimulatory 
activity of frenatin 2D and GLP-1, but the effect of CCK-8 was abolished.  Down-
regulation of both the PKA and PKC pathways by preincubation with forskolin plus 
PMA abolished the stimulatory responses of all peptides tested.  
 
4.4.7 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on proliferation and cytokine-induced apoptosis in BRIN-
BD11 β-cells   
Incubation of BRIN-BD11 cells with frenatin 2D peptides (1 µM) or with GLP-1 (1 
µM) did not affect the number of cells exhibiting DNA damage, as measured by 
TUNEL assay. Incubation of the cells with a mixture of proinflammatory cytokines 
resulted in a 272% increase (P<0.001) in the number of cells displaying apoptosis. The 
number of the apoptotic cells was reduced by 48% (P<0.001) when the BRIN-BD11 
cells were co-incubated with GLP-1 (1µM) and the cytokine mixture. A comparable 
(38%-42%, P<0.05) reduction in the number of apoptotic cells was observed when the 
cells were co-incubated with frenatin 2D peptides (1µM) and the cytokine mixture 
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(Figure 4.25A-C). Incubation of BRIN-BD11 cells with frenatin 2D, [D1W] frenatin 
2D and [G7W] frenatin 2D (1 µM) significantly (P<0.05) increased proliferation by 
18%, 21% and 17% respectively, compared with incubations in the presence of culture 
medium alone (Figure 4.26). This degree of proliferative stimulation was less than that 
provided by incubation with 1 µM GLP-1 (48% increase). 
 
4.4.8 Stability of frenatin 2D in murine plasma 
Metabolic stability of frenatin 2D was evaluated by incubating peptide with murine 
plasma. HPLC profile reveals that frenatin 2D was resistant to the proteolytic enzyme 
in plasma for at least 4 hrs. The identity of the frenatin 2D peptide in the collected 
fraction was further confirmed by MALDI-TOF MS (Figure 4.27-4.28) 
 
4.4.9 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on glucose uptake in C2C12 cells 
As shown in Figure 4.29-4.30, insulin (1 µM) stimulated a significant increase 
(P<0.05) in glucose uptake in C2C12 cells. On the other hand, treatment of frenatin 
2D peptides (1 µM) showed no positive effect on glucose uptake. However, a modest 
increase in glucose uptake was observed in the presence of insulin, but not significant. 
 
4.4.10 Acute effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 
2D and [G7W] frenatin 2D) on food intake in mice 
As shown in Figure 4.31, GLP-1 significantly (P<0.05) suppressed appetite from 60 
min up to 180 min post-injection in mice. Administration of frenatin 2D did not affect 
food intake. However, a noticeable decrease in food intake was observed in [D1W] 
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frenatin 2D injected mice. [G7W] frenatin 2D, significantly (P<0.05) inhibited food 
intake from 120 min up to 180 min post-injection. 
 
4.4.11 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on glucose tolerance and insulin concentrations in mice  
Blood glucose concentrations in lean male NIH swiss TO mice receiving 
intraperitoneal glucose plus frenatin 2D (75 nmol/kg bw) or [G7W] frenatin 2D (75 
nmol/kg bw) were significantly (P<0.05) lower at 15 min and 30 min after 
administration compared with animals receiving glucose only (Figure 4.32A). [D1W] 
frenatin 2D (75 nmol/kg bw) displayed a significant reduction in glucose at 30 and 60 
min. The integrated responses of blood glucose (area under the curve) after frenatin 
2D or [G7W] frenatin 2D or [D1W] frenatin 2D were significantly (P<0.05, P<0.01) 
less after administration of vehicle only (Figure 4.32B).  Plasma insulin concentrations 
were significantly (P<0.001) higher at 15 min after glucose administration in animals 
receiving frenatin 2D peptides (Figure 4.32C) and the integrated response (total 
amount of insulin released over 60 min) was significantly (P<0.05, P<0.01) greater 
compared with animals receiving glucose alone (Figure 4.32D). However, the 
magnitude of the effects on blood glucose concentrations and insulin release produced 
by administration of 75 nmol/kg bw of [D1W] frenatin 2D peptide was comparable to 
the effects produced by administration of 25 nmol/kg bw of GLP-1 (Figure 4.32A-D). 
 
4.4.12 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and 
[G7W] frenatin 2D) on glucose tolerance, 2 hrs and 4 hrs after peptide 
administration in mice  
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In another set of experiments overnight fasted male NIH swiss TO mice were injected 
with either saline or peptides [frenatin 2D, [D1W] frenatin 2D, [G7W] frenatin 2D (all 
at 75 nmol/kg bw) and GLP-1 (25 nmol/kg bw)] two or four hr prior to glucose 
administration (18 mmol/kg bw) (Figure 4.33 & 4.34). Frenatin 2D peptide 
significantly decreases blood glucose at 15 min, when administered 2 hr prior to 
glucose challenge. Under the same experimental conditions [D1W] frenatin 2D 
decreased blood glucose at 15 and 30 min. The integrated responses of blood glucose 
in mice receiving either frenatin 2D or [D1W] frenatin 2D (area under the curve) were 
comparable to mice receiving GLP-1.  [G7W] frenatin 2D, however, failed to produce 
a beneficial effect on blood glucose (Figure 4.33A-B). Only [D1W] frenatin 2D, 
exhibited a glucose-lowering effect (P<0.05) when administered 4 hr prior to glucose 
challenge (Figure 4.34A-B). 
 
4.4.13  Effects of different doses of frenatin 2D and its synthetic analogues [D1W] 
frenatin 2D on glucose tolerance in mice  
Mice administered with frenatin 2D at 50 nmol/kg body weight did not produce any 
significant changes in plasma glucose concentrations compared with mice 
administered with glucose alone (Figure 4.35 A, B). In contrast, [D1W] frenatin 2D 
produced a smaller but significant (P<0.05) decrease in plasma glucose concentration 
(Figure 4.35 C, D). However, at 25 nmol/kg body weight,  [D1W] frenatin 2D did not 
show any effects on plasma glucose concentration.  Mice when administered with 
either 75 nmol/kg body weight or 150 nmol/kg body weight of frenatin 2D or [D1W] 
frenatin 2D,  produced comparable glucose-lowering effects. No statistical difference 
in glucose concentrations were observed between the groups treated with 75 and 150 
nmol/kg body weight of either frenatin 2D or [D1W] frenatin 2D.    
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4.4.14 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on body weight, energy intake, fluid intake, non-
fasting blood glucose and plasma insulin in db/db mice 
All db/db mice exhibited significant (P<0.001) increase in body weight, energy intake, 
water, non-fasting blood glucose and plasma insulin compared to lean controls (Figure 
4.36 and 4.37).  Twice daily intraperitoneal administration of frenatin 2D and [D1W] 
frenatin 2D for 28 days had no effects on body weight and energy intake in db/db mice 
(Figure 4.36A-D). As expected, energy intake was significantly (P<0.001) decreased 
with exenatide treatment, however, no difference in body weight was observed 
compared to db/db controls. In db/db mice, blood glucose concentration was 
significantly (P<0.05) decreased by both frenatin 2D and [D1W] frenatin 2D, but not 
to the same extent as exenatide (Figure 4.37A, B). Frenatin 2D and exenatide but not 
[D1W] frenatin 2D significantly (P<0.05, P<0.001) increased overall plasma insulin 
compared to db/db controls (Figure 4.37D). As shown in Figure 4.36E, significant 
(P<0.05, P<0.01) decrease in fluid intake was observed from 24th days onwards, in 
both frenatin 2D and [D1W] frenatin 2D treatment group compared to db/db control. 
However, no statistical difference was observed in the overall fluid intake (Figure 
4.36F). With exenatide treatment, fluid intake was decreased significantly (P<0.001) 
by 42% compared to db/db control. 
 
4.4.15 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on glycated haemoglobin (HbA1c) in db/db mice 
Glycated haemoglobin (HbA1c) level reflects the average blood glucose level to a 
period of 2-3 month. As expected, all db/db mice, exhibited significantly higher 
HbA1c level (P<0.05 - P<0.001) than the lean control. As shown in Figure 4.38, twice 
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daily injection of frenatin 2D and [D1W] frenatin 2D resulted significant (P<0.05) 
decrease in blood HbA1c level by 34% and 27% respectively compared to db/db 
control.  Treatment with exenatide induced 52% decrease in HbA1c level.  
 
4.4.16 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on glucose tolerance in db/db mice following 
intraperitoneal and oral glucose load 
As expected, saline-treated db/db mice exhibited impaired glucose tolerance after a 
glucose load (18 mmol/kg bw), resulting in a higher area under the glucose curve 
compared to lean littermates. After 28 days of treatment, intraperitoneal glucose 
tolerance was significantly (P<0.05) improved in both frenatin 2D and [D1W] frenatin 
2D treated mice (Figure 4.39A-D). Blood glucose concentration was significantly (P 
<0.05) lowered at 15 min in both frenatin 2D and [D1W] frenatin 2D treated mice 
compared to saline-treated db/db mice (Figure 4.39A). This improvement was 
associated with significant (P<0.05) increase in insulin response (93% to 95% 
increase, P<0.05, Figure 4.39D). However, the magnitude of the decrease in blood 
glucose and an increase in insulin response in both frenatin 2D and [D1W] frenatin 
2D treated db/db mice were less than exenatide-treated db/db mice. 
In another set of experiments, the glycaemic response to an oral glucose load (OGTT) 
was investigated (Figure 4.40A-D). In [D1W] frenatin 2D treated group, blood glucose 
was significantly (P<0.05) less at 15 and 30 min compared to db/db control group 
(Figure 4.40A). This was associated with significant (P<0.05) increase in insulin 
release at 30 min (Figure 4.40C). However, no statistical difference was observed in 
overall insulin response (Figure 4.40D). Frenatin 2D treated mice showed a tendency 
to lower blood glucose and improve insulin level, but no significant difference was 
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observed compared to db/db control. On the other hand, blood glucose and insulin 
after oral glucose challenge were significantly (P<0.05) improved in exenatide-treated 
mice. 
 
4.4.17 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on insulin sensitivity in db/db mice 
Following 28 days treatment, a significant (P<0.05, Figure 4.41A-B) improvement in 
the hypoglycaemic effect of insulin was observed in both frenatin 2D and [D1W] 
frenatin 2D treated mice compared to saline-treated db/db mice. The alleviation of 
insulin resistance was further confirmed by HOMA-IR calculations derived using 
fasted blood glucose and plasma insulin concentrations. Both frenatin 2D and [D1W] 
frenatin 2D exhibited lower HOMA-IR index although it was not significant compared 
to db/db control. In exenatide-treated mice, the HOMA-IR index was reduced by 53% 
(P<0.05, Figure 4.41C).  
 
4.4.18 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on bone mineral density, bone mineral content and 
fat composition in db/db mice 
Figure 4.42A-G shows the results of a DEXA scan of the various groups of mice. At 
the end of treatment period, bone mineral density (BMD), bone mineral content 
(BMC), bone area, lean body mass, body fat and body fat (expressed a percentage of 
total body mass) were similar in all db/db groups. In comparison to lean control, lean 
body mass was decreased (P<0.001) significantly in frenatin 2D and [D1W] frenatin 
2D treatment group. Whereas, body fat in [D1W] frenatin 2D treatment group was 
found similar to lean control.  
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4.4.19 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on pancreatic weight and insulin content 
All db/db mice exhibited similar pancreatic weights (Figure 4.43A). However, when 
compared to lean mice, we observed a significant (P<0.05, P<0.01) increase in 
pancreatic weight in exenatide and frenatin 2D treated db/db mice. The pancreatic 
insulin content in saline-treated db/db mice was significantly (P<0.01) decreased by 
68% compared to lean control (Figure 4.43B). The exenatide and frenatin 2D treated 
group showed significant (P<0.05, P<0.01) increase in pancreatic insulin content 
compared to db/db control. On the other hand, [D1W] frenatin 2D treated group had 
had similar pancreatic insulin content as db/db control.  
 
4.4.20 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on insulin secretory responses of islets of db/db mice 
At the end of the treatment period, insulin secretory responses of islets isolated from 
treated and untreated mice were examined. As expected, islets from saline-treated 
db/db mice displayed impaired insulin secretory response to glucose (1.4 mM, 5.6 
mM, 16.7 mM) and known modulators of insulin release including alanine, GIP, GLP-
1, KCl and arginine (Figure 4.43C, D). Under the same experimental conditions, islets 
from frenatin 2D treated mice demonstrated significant improvements in insulin 
release (Figure 4.43C), but not to the same extent as that observed following 
exenatide-treatment db/db mice. On the other hand, islets from [D1W] frenatin 2D 
treated db/db mice, displayed marginal improvement in insulin secretory response 
(Figure 4.43D).  
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4.4.21 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on lipid profile in db/db mice 
Plasma lipid levels were examined in all experimental groups after 28 days treatment 
period. As shown in Figure 4.44A, C, cholesterol and high-density lipoprotein (HDL) 
were unaffected by peptide treatments in db/db mice. However, triglycerides and low-
density lipoprotein (LDL) were decreased by both frenatin 2D and [D1W] frenatin 2D 
treatment, but not to the same extent as in exenatide-treated mice (Figure 4.44B, D). 
 
4.4.22 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on liver and kidney functions in db/db mice 
The biomarkers for a liver function such as ALT, AST and ALP levels were examined 
after the end of treatment period. As shown in Figure 4.45A-C, these liver parameters 
were significantly (P<0.001) increased by 76%, 246% and 105% respectively in 
saline-treated db/db mice compared to lean control. In the exenatide treatment group, 
these elevated parameters were decreased markedly (P<0.05 - P<0.001) by 1.2 – 2.0 
folds. Interestingly, we observed a similar decrease in these parameters in both frenatin 
2D and [D1W] frenatin 2D treatment group. Also, elevated creatinine level in db/db 
was reduced significantly (P<0.05, P<0.01) by frenatin 2D and [D1W] frenatin 2D 
treatment, but not to the same as exenatide (Figure 4.45D).  
 
4.4.23 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on plasma amylase concentration in db/db mice 
As shown in figure 4.46, amylase activity was unaltered in both frenatin 2D and 
[D1W] frenatin 2D treated db/db mice. However, in exenatide treatment, significant 
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(P<0.001) increase in amylase activity was observed compared to db/db and lean 
control. 
 
4.4.24 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on islet number, islet area, beta cell areas, alpha cell 
area and islet size distribution 
At the end of the treatment period, effects of peptides on islet morphology were 
evaluated. (Figure 4.47A-F). Figure 4.47A presents images of pancreatic islets of lean 
control and both untreated and treated db/db mice, showing alpha cells in red and beta 
cells in green. The number of islets per mm2 was significantly (P<0.05, P<0.01) 
decreased in all db/db mice compared to lean controls. However, within db/db groups, 
no significant difference in islet number was observed (Figure 4.47 B). Lean control, 
db/db control, frenatin 2D and [D1W] frenatin 2D treatment groups exhibited no 
significant differences in islet area. Exenatide-treated group displayed significantly 
(P<0.05) increased islet area compared to db/db control (Figure 4.47C). As expected, 
the beta cell area was decreased (P<0.05) and alpha cell area was increased (P<0.01) 
in db/db controls compared to lean littermates. Frenatin 2D and [D1W] frenatin 2D 
induced no significant changes in beta cell area (Figure 4.47D). A noticeable decrease 
in the alpha cell was observed compared to db/db controls, this was not significant 
(Figure 4.47E). On the other hand, exenatide treatment significantly improved overall 
islet morphology, showing positive effects on islet, beta cell, and alpha cell area 
comparable to lean controls. The number of large and medium-size islet were 
increased (P<0.05 - P<0.001) and small size islet were decreased (P<0.05, P<0.01) in 
all treatment groups compared to db/db controls (Figure 4.47F). 
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4.4.25 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on gene expression in skeletal muscle 
Effects of frenatin 2D and [D1W] frenatin 2D on the expression of skeletal muscle 
insulin signalling genes were examined after the treatment period (Figure 4.48A-G). 
We observed elevated mRNA expression of glucose transporter 4 (Slc2a4), insulin 
receptor (Insr), insulin receptor substrate 1 (Irs1), phosphatidylinositol 3-kinase, 
catalytic, alpha polypeptide (Pik3ca), protein kinase B alpha (Akt1) and protein 
phosphatase 1B (Ptb1) genes in untreated db/db mice compared to the lean controls 
(Figure 4.48A-C & E-G). The expression of these genes was downregulated by both 
frenatin 2D and [D1W] frenatin 2D treatment. Interestingly, effects produced by the 
frenatin 2D peptides were not different from exenatide treatment. No statistical 
differences in expression of 3-phosphoinositide-dependent protein kinase 1 (Pdk1) 
gene were observed in the various groups of mice (Figure 4.48D).  
 
4.4.26 Effects of twice daily administration of frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on gene expression in islets 
In db/db mice, expression of islet genes involved in insulin secretion including Mus 
musculus insulin 1 (Ins1), ATP-binding cassette, sub-family C (CFTR/MRP), member 
8 (Abcc8), potassium inwardly-rectifying channel, subfamily J, member 11 (Transcript 
variant 1) (Kcnj11), glucose transporter 2 (Slc2a2), calcium channel, voltage-
dependent, L type, alpha 1C subunit (Cacna1c) and glucokinase, transcript variant 1 
(Gck) were investigated following 28 days treatment (Figure 4.49A-F). In saline-
treated db/db mice, expression of these genes was significantly (P<0.001)  
downregulated compared to lean littermate mice. Frenatin 2D prevented down-
regulation of these genes (P<0.01, P<0.001), but not to the same extent as observed in 
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exenatide-treated db/db mice. On the other hand, [D1W] frenatin 2D countered 
downregulation of Ins1, Abcc8, Slc2a2  and Gck genes in db/db treated mice. 
Downregulation of mRNA expression of gastric inhibitory polypeptide receptor 
(Gipr), glucagon-1 like peptide receptor (Glp1r), glucagon (Gcg) and pancreatic islets 
of homeobox 1 (Pdx1) genes in db/db mice was countered (P<0.05 - P<0.001) by 
exenatide and frenatin 2D treatments (Figure 4.50A-D). Signal transducer and 
activator of transcription 1 (Stat1) that were significantly upregulated in db/db mice 
were less highly expressed after treatment with exenatide and frenatin 2D (Figure 
4.50E). [D1W] frenatin 2D treatment had no significant effects on Gipr, Glp1r, Gcg, 
Pdx1 and Stat1 genes’ expressions.  
 
4.5 Discussion 
The bioactive peptides in frog skin secretions with antimicrobial activity are regarded 
as an essential component in the animal’s system of host-defence. The initial 
enthusiasm of the discovery that these peptides to kill antibiotic-resistant 
microorganisms that had become resistant to conventional antibiotics has dwindled 
thus no frog skin peptide is currently in clinical practice as an antimicrobial agent. 
More promising potential clinical applications of amphibian host-defence peptides 
might lie in their use as immunomodulatory agents (Pantic et al., 2017b), promoters 
of wound healing [reviewed in (Mangoni et al., 2016)] and as templates for the design 
of drugs to treat patients with T2DM (Conlon et al., 2018).   
The present study has shown that naturally occurring frenatin peptides (frenatin 2D 
from Discoglossus sardus and frenatin 2.1S, 2.2S & 2.3S from Sphaenorhynchus 
lacteus) demonstrate dose-dependent insulin-releasing activity from clonal β-cells 
(BRIN-BD11 cells) at concentrations that are not cytotoxic to the cells.  Frenatin 2D 
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was the most potent peptide producing a significant increase in insulin release from 
BRIN-BD11 cells at a concentration of 100 pM with an impressive 2.3-fold increase 
at a concentration of 3 µM. The stimulatory effects of frenatin 2D were also replicated 
in human 1.1B4 cells as well as isolated mouse islet cells. Consequently, frenatin 2D 
was chosen for further studies aimed at designing analogues with increased 
insulinotropic activity and to elucidate the mechanism of action of the frenatins.  
The relative antimicrobial and cytotoxic activities of naturally occurring peptides are 
determined by complex interactions between molecular charge, conformation, 
hydrophobicity and, in the case of α-helical peptides, amphipathicity (Mojsoska & 
Jenssen, 2015). Studies with a wide range of such peptides have shown that increasing 
cationicity, while maintaining amphipathicity, generally by substitution of appropriate 
neutral or acidic amino acids by L-lysine, results in increased antimicrobial activity 
by promoting interaction with the negatively charged cell membrane of prokaryotes 
(Kumar et al., 2018).  In the present study, each amino acid in frenatin 2D was replaced 
by a bulky, hydrophobic tryptophan (W) residue in an attempt to promote interaction 
with the zwitterionic plasma membrane of BRIN-BD11 cells. The strategy did not lead 
to the design of an analogue with increased insulinotropic activity, but the study 
demonstrated that the frenatin 2D molecule was very sensitive to changes in amino 
acid composition. Replacement of Thr5, Asn8, Pro10, and Ile14 by Trp (W) led to the 
loss of insulinotropic activity at concentrations up to and including 3 µM. 
Substitutions at Leu2, Leu3, Gly4, Leu6, Leu9, Leu11, Phe12 and Phe13 also led to marked 
decreases in insulinotropic activity (Table 4.3). In contrast, replacements at Asp1 and 
Gly7 and deletion of the C-terminal α-amide group did not affect activity. The 
stimulatory effects of [D1W], [G7W] analogues was also replicated in human 1.1B4 
cells and isolated moue islet cells. 
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Insulin release from pancreatic β-cells is regulated by KATP channel-dependent and 
KATP channel-independent pathways (Henquin, 2000, 2004). In the former pathway, 
an increase in intracellular ATP generated from glucose metabolism results in closure 
of ATP-sensitive potassium channels, activation of chloride channels and an influx of 
Ca2+ through the opening of voltage-dependent Ca2+ channels, leading to exocytosis. 
The insulinotropic frog skin peptides CPF-SE1 (Srinivasan et al., 2013), tigerinin-1R 
(Ojo et al., 2016), and PGLa-AM1 (Owolabi et al., 2017) depolarise BRIN-BD11 cells 
and increase [Ca2+]i suggesting that they operate via the KATP channel-dependent 
pathway.  In contrast, pseudin-2 (Abdel-Wahab et al., 2008a), hymenochirin 1B 
(Owolabi et al., 2016), and temporins A, F, and G (chapter 6) stimulate insulin release 
without significant effects on membrane depolarization or [Ca2+]i.  Similar to the 
second group of peptides, incubation of BRIN-BD11 cells with either frenatin 2D or 
its analogues ([D1W] and [G7W] frenatin 2D) did not affect membrane potential or 
[Ca2+]i suggesting an involvement of the KATP channel-independent pathway. 
Consistent with this hypothesis, the insulinotropic activity of frenatin 2D peptide and 
its analogues was preserved in calcium-free medium and in the presence of diazoxide, 
an agent that inhibits the secretion of insulin by opening ATP-sensitive potassium 
channels in β-cells, and verapamil, an agent that inhibits insulin release by blocking 
voltage-dependent Ca2+ channels. Although less well studied, activation of the 
chloride channel in pancreatic beta cells causes comparatively modest membrane 
depolarization and to release of insulin (Kinard et al., 2001). The insulin-releasing 
activity of peptide was unaffected even after blocking chloride channel by using DIDS. 
In KATP channel-independent pathway, activation of adenylate cyclase by an agonist 
such as GLP-1 results in the generation of cAMP which in turn activates PKA to 
promote insulin release (Green et al., 2004a, 2005). Incubation of BRIN-BD11 cells 
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with either frenatin 2D or its analogues produced a modest but significant increase of 
cAMP.  Consistent with this observation, the stimulatory effect of frenatin 2D and its 
analogues on insulin release was abolished in PKA-downregulated BRIN-BD11 cells, 
whereas in PKC downregulated cells the stimulatory effect of peptides was unaffected. 
It is suggested, therefore, that the insulin-releasing activity of frenatin 2D in these cells 
is mediated predominantly, if not exclusively, by the KATP channel-independent 
pathway. 
The progression of T2DM is associated with a decrease in the ability of the pancreatic 
β-cell to release insulin due to a decline in β-cell number and function. It has also been 
shown also that the GLP-1 stimulates proliferation of β-cells and protect the cells 
against apoptosis stimulated by cytokines, glucose and fatty acids (Cornu et al., 2009, 
Lee et al., 2014). Overnight incubation of BRIN-BD11 cells with either frenatin 2D 
or its analogue, also stimulated β-cell proliferation but the effect was significantly less 
than the effects of an equimolar concentration of GLP-1. Similarly, frenatin 2D 
provided significant protection of cells against cytokine-induced apoptosis and, in this 
case, the effect was comparable to that provided by GLP-1.  
The frenatin 2D peptide was also active in vivo when administered to mice together 
with a glucose load, resulting in lower blood glucose and higher circulating insulin 
concentrations. Also, both analogues ([D1W] and [G7W] frenatin 2D) improved 
glucose tolerance by increasing insulin release following intraperitoneal 
administration with glucose in normal NIH TO mice. Moreover, we observed that 
glucose lowering effect of [D1W] frenatin 2D was sustained when administered 4 hr 
before glucose load, suggesting enhanced peptide stability. On the other hand, frenatin 
2D and [G7W] frenatin 2D failed to retain its activity when pre-administered in vivo. 
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Glucose tolerance tests conducted with coadministration of different doses of peptide 
revealed that doses of frenatin 2D or [G7W] frenatin 2D peptide below 75 nmol/kg 
body, failed to retain its glucose-lowering effects. In contrast, the [D1W] frenatin 2D 
analogue induced a modest decrease in blood glucose level. When tested at a higher 
dose of 150 nmol/kg, no additional glucose lowering effect was observed with frenatin 
2D and [D1W] frenatin 2D peptide. Hence, the peptide dose of 75 nmol/kg bw was 
selected for further studies. 
Based on these findings, we further investigated long-term (28 days) effects of twice 
daily administration of frenatin 2D and [D1W] frenatin 2D, in comparison with 
antidiabetic agent exenatide, in genetically obese-diabetic mice (db/db). In line with 
previous reports (Wang et al., 2002, Breyer et al., 2005), db/db mice used for the 
present study displayed hyperglycaemia, hyperinsulinemia, insulin resistance, 
hyperlipidaemia and impaired blood glucose control.  
With the progress of the study, a steady decrease of plasma insulin and an increase in 
blood glucose level were observed in db/db mice receiving saline only. These 
observations in db/db mice are in line with previous reports and indicate a degenerative 
form of diabetes (Coleman, 1978, Dalbøge et al., 2013). In frenatin 2D treated db/db 
mice, progressive loss of insulin was delayed significantly. Blood glucose in both 
frenatin 2D and [D1W] Frenatin 2D treated db/db mice was delayed significantly. The 
intraperitoneal glucose tolerance and blood HbA1c level were also improved 
significantly. These beneficial effects of frenatin 2D and [D1W] Frenatin 2D peptide 
were independent of any changes in body weight or fat content of db/db mice. In 
agreement with acute in vivo feeding studies, no effect of the frenatin 2D and [D1W] 
frenatin 2D peptide was observed on energy intake. Both, frenatin 2D and [D1W] 
frenatin 2D also exhibited a tendency to improve glycaemic response to an oral 
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glucose load. Furthermore, a decrease in water intake was observed in both frenatin 
2D and [D1W] frenatin 2D treated db/db mice from day 24 onwards, which correlates 
with improved glycaemic control. However, the magnitude of the beneficial effects of 
frenatin 2D and [D1W] frenatin 2D on blood glucose, insulin, glucose tolerance, 
HbA1c and water intake were less impressive than exenatide. With exenatide 
treatment, we observed a decrease in energy intake, which corresponds well to the 
previous studies (Gedulin et al., 2005, Schlögl et al., 2015), but body weight remained 
unaltered.  
The hypoglycemic action of exogenous insulin was significantly improved in both 
frenatin 2D and [D1W] frenatin 2D treated db/db mice, which correlated with 
improved HOMA-IR index. To further evaluate the mechanisms by which the peptides 
improved insulin resistance, mRNA expression of insulin signalling genes was 
studied. We observed elevated expression of Glut4, Insr, Irs1, Akt1, Pik3ca and Ptb1 
in saline-treated db/db mice compared to their littermates. These observations are in 
harmony with previous studies where an increase in the activity of PI 3-kinase and 
Akt/PKB were observed in the liver and kidney of db/db mice (Feliers et al., 2001).  
Similarly, an increase in the activity of proximal insulin signalling cascade was 
observed in the animal model of liver cirrhosis, (Jessen et al., 2006). In L6 myotubules 
after chronic exposure to glucose or insulin, an increase in GLUT4 activity was also 
observed (Huang et al., 2001). In both frenatin 2D and [D1W] frenatin 2D treatment 
mice, expression of SlC2a4, Insr, Irs1, Akt1, Pik3ca and Ptb1 genes were 
downregulated. Interestingly, the magnitude of these effects was comparable to 
exenatide treatment.  
 In agreement with other studies (Son et al., 2015, Lee et al., 2014), lipid metabolism 
was impaired in db/db mice. Elevated plasma triglycerides and LDL levels of db/db 
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mice were reversed by frenatin 2D and [D1W] frenatin 2D treatment, but the effect 
was significantly less than the exenatide. Plasma cholesterol and HDL remain 
unaffected in all peptide-treated mice. The db/db mice are also used as a model of non-
alcoholic fatty liver disease (NAFLD), which is characterised by elevated liver 
enzymes such as ALT, AST and ALP (Biden et al., 2014, Parikh et al., 2014, Lau et 
al., 2016). In agreement, these liver biomarkers were significantly elevated in control 
db/db mice and decreased significantly by both frenatin 2D and [D1W] frenatin 2D 
treatment. The creatinine level in db/db mice was also lowered by these peptides, 
indicating that liver and kidney function were improved by peptide treatment. 
Furthermore, amylase activity was unaffected by frenatin 2D and [D1W] frenatin 2D 
treatment. These observations suggest that frenatin 2D peptides could be safe for the 
treatment of diabetes. Importantly, no adverse effects were observed in treated db/db 
mice which correlated well with in vitro toxicity studies. Nevertheless, we did observe 
an increase in amylase activity in exenatide-treated mice. In several clinical studies, 
enhanced amylase activity has been observed in type 2 diabetes and linked to possible 
incidence of pancreatitis (Nauck, 2013).  
In harmony with others (Ishida et al., 2004, Do et al., 2014), islets from saline-treated 
db/db mice showed impaired insulin secretory responses to glucose and known insulin 
secretagogues. In the present study, frenatin 2D treatment significantly improved 
insulin secretory responses of db/db mouse islets. This was associated with a 
significant increase in pancreatic insulin content, suggesting the beneficial effects of 
the peptide on pancreatic beta cell function. However, the beneficial effects of [D1W] 
frenatin 2D treatment on islet insulin secretory response and pancreatic insulin content 
was not to the same as the native peptide. As expected, insulin secretory defect was 
reversed and the pancreatic insulin content was significantly increased in exenatide-
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treated mice. The beneficial effects of peptides on the pancreatic beta cell was further 
evaluated by gene expression studies and immunohistochemical analysis. The positive 
effects of frenatin 2D on beta cell function corresponded with an improved expression 
of insulin secretory genes (Ins1, Pdx1, Glp1R, Gipr, Abcc8, Kcnj11, Gck, Cacna1c, 
SlC2a2 and Gcg). In addition, upregulation of apoptosis Stat1 gene was prevented by 
frenatin 2D treatment. Although frenatin 2D and [D1W] frenatin 2D treatment did not 
alter islet area/beta cell area, a noticeable decrease in alpha cell area was observed. 
Furthermore, a substantial decrease in large and medium-size islets and an increase in 
small size islets of db/db mice were prevented by all peptide treatments. Overall the 
beneficial effects of frenatin 2D and [D1W] frenatin 2D on islet architecture were 
similar but not as prominent as with exenatide.  
In conclusion, the present Chapter has demonstrated the antidiabetic potential of 
frenatin 2D peptides. In db/db mice, frenatin 2D treatment significantly delayed the 
demise of beta cell function and insulin concentration, improved glycemic control and 
enhanced insulin sensitivity. The abnormal expression of the genes involved in 
glucose homeostasis in muscle and islets of db/db mice were reversed by frenatin 2D 
treatment. However, [D1W] frenatin 2D was not as effective as frenatin 2D in db/db 
mice.  
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Table 4.1 Amino acid sequence of frenatin peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No 
Peptide Sequence 
 
1 
 
Frenatin 2D 
 
DLLGTLGNLPLPFI.NH2 
 
2 
 
Frenatin 2.1S 
 
GLVGTLLGHIGKAILG.NH2 
 
3 
 
Frenatin 2.2S 
 
GLVGTLLGHIGKAILS.NH2 
 
4 
 
Frenatin 2.3S 
 
GLVGTLLGHIGKAILG.COOH 
 
5 
 
[D1W] Frenatin 2D 
 
WLLGTLGNLPLPFI.NH2 
 
6 
 
[L2W] Frenatin 2D 
 
DWLGTLGNLPLPFI.NH2 
 
7 
 
[L3W] Frenatin 2D 
 
DLWGTLGNLPLPFI.NH2 
 
8 
 
[G4W] Frenatin 2D 
 
DLLWTLGNLPLPFI.NH2 
 
9 
 
[T5W] Frenatin 2D 
 
DLLGWLGNLPLPFI.NH2 
 
10 
 
[L6W] Frenatin 2D 
 
DLLGTWGNLPLPFI.NH2 
 
11 
 
[G7W] Frenatin 2D 
 
DLLGTLWNLPLPFI.NH2 
 
12 
 
[N8W] Frenatin 2D 
 
DLLGTLGWLPLPFI.NH2 
 
13 
 
[L9W] Frenatin 2D 
 
DLLGTLGNWPLPFI.NH2 
 
14 
 
[P10W] Frenatin2D 
 
DLLGTLGNLWLPFI.NH2 
 
15 
 
[L11W] Frenatin 2D 
 
DLLGTLGNLPWPFI.NH2 
 
16 
 
[P12W] Frenatin 2D 
 
DLLGTLGNLPLWFI.NH2 
 
17 
 
[F13W] Frenatin 2D 
 
DLLGTLGNLPLPWI.NH2 
 
18 
 
[I14W] Frenatin 2D 
 
DLLGTLGNLPLPFW.NH2 
 
19 
 
Frenatin 2D  (Non-amidated) 
 
DLLGTLGNLPLPFI 
 
20 
 
[D1W] Frenatin 2D  (Non-amidated) 
 
WLLGTLGNLPLPFI 
 
21 
 
[G7W] Frenatin 2D  (Non-amidated) 
 
DLLGTLWNLPLPFI 
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Table 4.2 Reverse phase HPLC, retention time and molecular weight 
 
 
Purity and molecular mass of peptides were confirmed using RP-HPLC and MALDI-
TOF respectively. The retention time was verified using ChromQuest software. 
 
 
Sr. 
No 
Peptide Molecular 
weight Da 
(Theoretical) 
Molecular 
weight Da 
(Experimental) 
Retention 
time (min) 
 
1 
 
Frenatin 2D 
 
1481.78  
 
1481.90 
 
25 
 
2 
 
Frenatin 2.1S 
 
1518.89 
 
1517.03 
 
30 
 
3 
 
Frenatin 2.2S 
 
1571.92 
 
1572.54 
 
33 
 
4 
 
Frenatin 2.3S 
 
1519.88 
 
1519.91 
 
31 
 
5 
 
[D1W] Frenatin 2D 
 
1552.9 
 
1552.65 
 
26 
 
6 
 
[L2W] Frenatin 2D 
 
1554.83 
 
1554.65 
 
25 
 
7 
 
[L3W] Frenatin 2D 
 
1554.83 
 
1555.64 
 
26 
 
8 
 
[G4W] Frenatin 2D 
 
1610.93 
 
1611.83 
 
26 
 
9 
 
[T5W] Frenatin 2D 
 
1566.68 
 
1567.55 
 
28 
 
10 
 
[L6W] Frenatin 2D 
 
1554.83 
 
1555.09 
 
25 
 
11 
 
[G7W] Frenatin 2D 
 
1610.93 
 
1611.11 
 
26 
 
12 
 
[N8W] Frenatin 2D 
 
1553.88 
 
1553.48 
 
26 
 
13 
 
[L9W] Frenatin 2D 
 
1554.83 
 
1554.83 
 
26 
 
14 
 
[P10W] Frenatin2D 
 
1570.87 
 
1571.62 
 
26 
 
15 
 
[L11W] Frenatin 2D 
 
1554.83 
 
1555.75 
 
25 
 
16 
 
[P12W] Frenatin 2D 
 
1570.87 
 
1571.61 
 
26 
 
17 
 
[F13W] Frenatin 2D 
 
1520.81 
 
1521.04 
 
25 
 
18 
 
[I14W] Frenatin 2D 
 
1554.83 
 
1555.47 
 
27 
 
19 
 
Frenatin 2D  (Non-amidated) 
 
1482.78 
 
1483.06 
 
25 
 
20 
 
[D1W] Frenatin 2D  (Non-amidated) 
 
1553.9 
 
1554.7 
 
26 
 
21 
 
[G7W] Frenatin 2D  (Non-amidated) 
 
1611.94 
 
1611.72 
 
27 
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Table 4.3 Effects of analogues and non-amidated frenatin 2D peptide on insulin 
release from BRIN-BD11 rat clonal β-cells 
Conditions 
Threshold 
Concentration (nM) 
 Insulin release at 3 µM 
(ng/106 cells/20 min) 
5.6 mM Glucose 
 
 1.01 ± 0.04 
Frenatin 2D 0.1  2.30 ± 0.03 *** 
[D1W] Frenatin 2D 0.1  2.61 ± 0.25 *** 
[L2W] Frenatin 2D 10  1.81 ± 0.11 *** 
[L3W] Frenatin 2D 3000  1.21 ± 0.04 ** 
[G4W] Frenatin 2D 3000  1.26 ± 0.07 ** 
[T5W] Frenatin 2D >3000  1.17 ± 0.15 
[L6W] Frenatin 2D 1000  1.59 ± 0.05 *** 
[G7W] Frenatin 2D 0.1  2.57 ± 0.12 *** 
[N8W] Frenatin 2D >3000  1.09 ± 0.04 
[L9W] Frenatin 2D 100  1.63 ± 0.01 *** 
[P10W] Frenatin 2D >3000  1.10 ± 0.06 
[L11W] Frenatin 2D 100  1.30 ± 0.02 *** 
[P12W] Frenatin 2D 1000  1.30 ± 0.05 *** 
[F13W] Frenatin 2D 3000  1.44 ± 0.02 *** 
[114W] Frenatin 2D >3000  1.10 ± 0.04 
Frenatin 2D non-amidated 0.1  2.14 ± 0.12*** 
[D1W] Non-amidated 0.1  2.00 ± 0.24*** 
[G7W] Non-amidated 0.1  2.01 ± 0.11*** 
[P12F, F13P] Frenatin 2D >3000  1.00 ± 0.03 
 
Values are mean ± SEM for n = 8. **P<0.01 and ***P<0.001 compared to 5.6 mM 
glucose alone.  
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Figure 4.1 Representative reverse-phase HPLC profile of frenatin peptides. 
 
 
  
C-8 analytical column was used to obtain profile using a gradient from 0 to 100 % acetonitrile over 28 min for frenatin 2D and gradient from 0 
to 40% of acetonitrile over 10 minutes, to 60% over 20 minutes and from 60% to 100% over 5 minutes for frenatin 2.1S, 2.2S and 2.3S 
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Figure 4.2 Representative reverse-phase HPLC profile of frenatin 2D peptides 
 
 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 4.3 Representative reverse-phase HPLC profile of frenatin 2D peptides 
 
 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 4.4 Representative reverse-phase HPLC profile of frenatin 2D peptides 
 
 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 4.5 Representative reverse-phase HPLC profile of frenatin 2D peptides 
 
 
 
C-8 analytical column was used to obtain a profile using a gradient from 0 to 100 % acetonitrile over 28 min. 
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Figure 4.6 Representative MALDI-TOF spectra of frenatin peptides 
 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 4.7 Representative MALDI-TOF spectra of frenatin 2D peptides 
 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
185 
 
Figure 4.8 Representative MALDI-TOF spectra of frenatin 2D peptides 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 4.9 Representative MALDI-TOF spectra of frenatin 2D peptides 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 4.10 Representative MALDI-TOF spectra of frenatin 2D peptides 
 
 
 
 
Matrix α-cyano cinnamic acid (1.5 µl) was mixed with purified peptide (1.5 µl) and left to dry on the MALDI plate. After drying, MALDI plate 
was applied to Voyager DE Bio spectrometry workstation. The mass-to-charge ratio versus peak intensity was recorded. 
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Figure 4.11 Effects of frenatin peptides on insulin release from BRIN-BD11 rat 
clonal β-cells  
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Effects of (A) frenatin 2D, (B) frenatin 2.1S, (C) frenatin 2.2S and (D) frenatin 2.3S 
on insulin release from BRIN-BD11 rat clonal β-cells. Values are mean ± SEM for n 
= 8. *P < 0.05, **P<0.01, and ***P<0.001 compared to 5.6 mM glucose alone.  
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Figure 4.12 Effects of frenatin peptides on LDH release from BRIN-BD11 rat 
clonal β-cells  
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Values are Mean ± SEM with n=4 for LDH. DMSO (100%) was used as positive 
control. ***P<0.001 compared to 5.6 mM glucose alone. 
0
100
200
300
***
Glucose (5.6 mM)
DMSO (100%)
Glucose (5.6 mM) + Alanine (10 mM)
Glucose (5.6 mM) + GLP-1 (10
-8
M)
Glucose (5.6 mM) + Frenatin-2.1S
3 X 10-6 10-6 3 x 10-7 10-7 3 x 10-8 10-8 3 x 10-9 10-9 3 x 10-10 10-10 3 x 10-11 10-11 3 x 10-12 10-12
B)
Peptide concentration (M)
C
el
lu
la
r 
LD
H
 R
el
ea
se
(%
 o
f 
co
nt
ro
l)
190 
 
Figure 4.13 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from BRIN-BD11 rat clonal β-cells 
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Comparison of the effects of A) Frenatin 2D, B) [D1W] frenatin 2D, and C) [G7W] 
frenatin 2D on insulin release from BRIN-BD11 rat clonal β-cells. Values are mean ± 
SEM for n = 8. *P<0.05, **P<0.01, and ***P<0.001 compared to 5.6 mM glucose 
alone.  
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Figure 4.14 Effects of [D1W] frenatin 2D and [G7W] frenatin 2D on LDH release 
from BRIN-BD11 rat clonal β-cells  
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Values are Mean ± SEM with n=4 for LDH. 
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Figure 4.15 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from 1.1B4 human clonal β-cells 
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Effects of A) Frenatin 2D, B) [D1W] frenatin 2D, and C) [G7W] frenatin 2D on insulin 
release from 1.1B4 human clonal β-cells. Values are mean ± SEM for n = 8. *P<0.05, 
**P<0.01 and ***P<0.001 compared to 5.6 mM glucose alone.  
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Figure 4.16 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from 1.1B4 human clonal β-cells 
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Effects of A) Frenatin 2D, B) [D1W] Frenatin 2D, and C) [G7W] Frenatin 2D on 
insulin release from 1.1B4 human clonal β-cells. Values are mean ± SEM for n = 8. 
*P<0.05, **P<0.01 and ***P<0.001 compared to 16.7 mM glucose alone.  
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Figure 4.17 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from isolated mouse islets 
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Effects of frenatin 2D, [D1W] and [G7W] Frenatin 2D on insulin release from isolated 
mouse islets. Values are Mean ± SEM (n=4). *P<0.05, **P<0.01 and ***P<0.001 
compared to 16.7 mM glucose. 
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Figure 4.18 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on membrane potential in BRIN-BD11 rat clonal β-cells 
expressed as line graph (A, C, E) and area under the curve (B, D, F)  
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Effects of frenatin 2D (A), [D1W] frenatin 2D (C), [G7W] frenatin 2D (E) on 
membrane potential in BRIN-BD11 cells expressed as relative fluorescence units, 
RFU as a function of time and (B), (D) and (F) the integrated response (area under the 
curve) for respective peptide. Peptides were added 20 sec after start of data acquisition 
at a rate of ~62 μl/sec. Values are mean ± SEM (n = 6).  ***P < 0.001 compared with 
5.6 mM glucose alone. 
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Figure 4.19 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on intracellular calcium in BRIN-BD11 rat clonal β-cells 
expressed as line graph (A, C, E) and area under the curve (B, D, F)  
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Effects of frenatin 2D (A), [D1W] frenatin 2D (C), [G7W] frenatin 2D (E) on 
intracellular calcium ion concentration [Ca2+]i in BRIN-BD11 cells expressed as 
relative fluorescence units, RFU as a function of time and (B), (D) and (F) the 
integrated response (area under the curve) for respective peptide. Peptides were added 
20 sec after start of data acquisition at a rate of ~62 μl/sec. Values are mean ± SEM 
for n = 6.  ***P<0.001 compared with 5.6 mM glucose alone. 
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Figure 4.20 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from BRIN-BD11 rat clonal β-cells in 
the presence of known modulators of insulin release 
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Values are Mean ± SEM (n=8). *P<0.05, ***P<0.001 compared to 5.6 mM glucose 
alone. +++P<0.001 compared to 5.6 mM glucose in the presence of the peptide. 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to respective incubation in the absence of 
the peptide. 
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Figure 4.21 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on insulin release from BRIN-BD11 rat clonal β-cells in 
the presence or absence of extracellular calcium  
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Values are Mean ± SEM (n=8). *P<0.05, **P<0.01, ***P<0.001 compared to 5.6 mM 
glucose alone. ++P<0.01 compared to 5.6 mM glucose in the presence of the peptide. 
ΔΔΔP<0.001 compared to respective incubation in the absence of the peptide.  
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Figure 4.22 Effects of frenatin 2D on insulin release in the presence of chloride 
channel blocker DIDS from BRIN-BD11 rat clonal β-cells   
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Values are mean ± SEM (n=8). **P<0.01, ***P<0.001 compared to 5.6 mM glucose 
alone. +P<0.05 compared to 5.6 mM glucose in the presence of the peptide. ΔΔP<0.01, 
ΔΔΔP<0.001 compared to respective incubation in the absence of the peptide. 
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Figure 4.23 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on cyclic AMP in BRIN-BD11 rat clonal β-cells   
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Effects of frenatin 2D peptides on A) cAMP production and B) Insulin release in 
BRIN-BD11 cells. Values are Mean ± SEM with n=3 for cAMP and n=4 for insulin 
release. *P<0.05, **P<0.01, ***P<0.001 compared to 5.6mM glucose alone. ΔP<0.05, 
ΔΔP<0.01, ΔΔΔP<0.001 compared to 5.6mM glucose + IBMX. 
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Figure 4.24 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on down‑regulation of the PKA and PKC pathways in 
BRIN-BD11 rat clonal β-cells   
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Values are mean ± SEM for n = 8. ***P<0.001 compared with 5.6 mM glucose, 
ΔΔΔP<0.001, ΔP<0.05 compared to standard culture conditions, +++P<0.001, ++P<0.01, 
+P<0.05 compared to culture with PMA, φφφP<0.001, φφP<0.01, φP<0.05 compared 
with culture with forskolin. 
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Figure 4.25 Effect of frenatin 2D and its synthetic analogues ([D1W] frenatin 
2D and [G7W] frenatin 2D) on cytokine-induced apoptosis in BRIN-BD11 rat 
clonal β-cells  
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Effects of 1 µM A) frenatin 2D, B) [D1W] and C) [G7W] frenatin 2D on apoptosis in 
BRIN-BD11 cells compared with 1 µM GLP-1. Values are mean ± SEM for n=3. 
**P<0.01, ***P<0.001 compared with incubation in culture medium alone, ΔP<0.05, 
ΔΔP<0.01 and ΔΔΔP<0.001 compared with incubation in cytokine-containing medium.  
203 
 
Figure 4.26 Effect of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D 
and [G7W] frenatin 2D) on proliferation in BRIN-BD11 rat clonal β-cells 
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Effects of 1 µM Frenatin 2D and [D1W], [G7W] analogues on proliferation in BRIN-
BD11 cells compared with 1 µM GLP-1. Values are mean ± SEM Values are mean ± 
SEM for n=3. *P<0.05, **P<0.01, ***P<0.001 compared with incubation in culture 
medium alone, ΔΔΔP<0.001   compared to GLP-1 treated cells. 
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Figure 4.27 HPLC profile of Plasma degradation of frenatin 2D at 0 hrs (A) and 
4 hrs (B) 
 
A) 
 
 
B) 
 
 
HPLC profile of frenatin 2D following incubation with Swiss lean mice plasma for 0 
and 4 hrs. The fraction was separated with a C8 column using a gradient from 0 to 
40% acetonitrile from 0 to 10 min, to 60% over 30 min.  
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Figure 4.28 MALDI-TOF spectra of plasma degradation of frenatin 2D fraction 
collected at 4 hrs 
 
 
 
Peptide samples (1.5 μl) were mixed with matrix α-cyanocinnamic acid (1.5 μl) on a 
100 well MALDI plate and left to dry. After complete drying, samples were applied 
to a Voyager DE Biospectrometry workstation. The mass-to-charge ratio (m/z) versus 
peak intensity was recorded.  
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Figure 4.29 Effect of insulin on glucose uptake in differentiated C2C12 cells 
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Glucose uptake was expressed as % of control (glucose). Apigenin was used as 
negative control for glucose uptake. Values are Mean ± SEM with n=3. *P<0.05 
compared with glucose alone. 
 
 
 
 
 
 
 
 
 
 
 
 
207 
 
Figure 4.30 Effect of frenatin 2D and its synthetic analogues ([D1W] frenatin 
2D and [G7W] frenatin 2D) on glucose uptake in differentiated C2C12 cells 
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Glucose uptake was expressed as % of control (glucose). Apigenin was used as 
negative control for glucose uptake. Values are Mean ± SEM with n=3. *P<0.05, 
**P<0.01 compared with glucose alone. 
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Figure 4.31 Acute effect of frenatin 2D and its synthetic analogues ([D1W] 
frenatin 2D and [G7W] frenatin 2D) on cumulative food intake in 21 hr fasted 
lean NIH Swiss TO mice 
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Cumulative food intake was measured before at 0 min and after i.p. injection of saline 
vehicle (0.9% w/v NaCl) or GLP-1 (25 nmol/kg bw) or test peptides (75 nmol/kg bw) 
at time point 30, 60, 90, 120, 150, 180 min in overnight (21 hr) fasted mice. Values 
represent mean ± SEM (n=8). *P<0.05 compared to saline control.
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Figure 4.32 Effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and [G7W] frenatin 2D) on glucose tolerance and 
insulin concentrations in mice 
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A comparison of the effects of intraperitoneal administration of frenatin 2D peptides (75 nmol/kg body weight) and GLP-1 (25 nmol/kg body 
weight) on blood glucose (panels A and B) and plasma insulin (panels C and D) concentrations in lean mice after co-injection of glucose (18 
mmol/ kg body weight). Values are mean ± SEM (n = 6). *P<0.05, **P<0.01 and ***P<0.001 compared with glucose alone.  
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Figure 4.33 Effects of 2 hours pre-treatment with frenatin 2D and its synthetic 
analogues ([D1W] frenatin 2D and [G7W] frenatin 2D) on blood glucose levels 
expressed as line graph (A) and area under the curve (B) in lean NIH Swiss TO 
mice 
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Blood glucose was measured before and after intraperitoneal injection of glucose (18 
mmol/kg bw, control) in lean NIH Swiss TO mice treated with saline or GLP-1 (25 
nmol/kg bw) or frenatin 2D peptides (75 nmol/kg bw) 2 hr prior to experiment. Values 
are mean ± SEM (n=6). *P<0.05 compared to control. 
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Figure 4.34 Effects of 4 hours pre-treatment with frenatin 2D and its synthetic 
analogues ([D1W] frenatin 2D and [G7W] frenatin 2D) on blood glucose levels 
expressed as line graph (A) and area under the curve (B) in lean NIH Swiss TO 
mice 
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Blood glucose was measured before and after intraperitoneal injection of glucose (18 
mmol/kg bw, control) in lean NIH Swiss TO mice treated with saline or GLP-1 (25 
nmol/kg bw) or frenatin 2D peptides (75 nmol/kg bw) 4 hr prior to experiment. Values 
are mean ± SEM (n=6). *P<0.05 compared to control. 
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Figure 4.35 Acute effects of frenatin 2D and its synthetic analogues ([D1W] frenatin 2D and [G7W] frenatin 2D) on blood glucose levels 
expressed as line graph (A, C) and area under the curve (B, D) in lean NIH Swiss TO mice 
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Blood glucose was measured before and after intraperitoneal administration of glucose (18 mmol) or in combination with frenatin 2D (50/75/150 
nmol/kg body weight) or [D1W] Frenatin 2D (25/50/75/150 nmol/kg body weight) in NIH Swiss TO mice. Values are mean ± SEM (n=6). *P<0.05, 
**P<0.01 compared to glucose alone mice.
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Figure 4.36 Effects of 28-day treatment with frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on body weight (A, B), energy intake (C, D) and 
water Intake (E, F) in db/db mice 
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Body weight, energy intake and water intake were measured 3 days prior to, and every 
72 hours during treatment with saline or exenatide (25 nmol/kg bw) or peptide (75 
nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice and ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001compared to 
control db/db mice.
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Figure 4.37 Effects of 28-day treatment with frenatin 2D and its synthetic analogue [D1W] frenatin 2D on non-fasting blood glucose (A, 
B) and plasma insulin (C, D) in db/db mice  
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Parameters were measured 3 days prior to, and every 72 hours during treatment (indicated with black bar) with saline or exenatide (25 nmol/kg 
bw) or peptide (75 nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 compared to lean mice and 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to control db/db mice. 
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Figure 4.38 Effects of frenatin 2D and its synthetic analogue [D1W] frenatin 2D 
on HbA1c in db/db mice 
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HbA1c level was measured after long term treatment with twice-daily injections of 
either saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) for 28 days. 
Values are mean ± SEM for 4 mice. ***P<0.001, **P<0.01, *P<0.05 compared with 
lean mice and ΔP<0.05, ΔΔP<0.01compare with db/db control mice. 
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Figure 4.39 Long-term effects of frenatin 2D and its synthetic analogue [D1W] 
frenatin 2D on plasma glucose (A, B) and insulin (C, D) concentrations following 
intraperitoneal glucose administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after 
intraperitoneal administration of glucose (18 mmol/kg bw) to db/db mice pre-treated 
with twice-daily injections of either saline or exenatide (25 nmol/kg bw) or peptide 
(75 nmol/kg bw) for 28 days. Values are mean ± SEM for 8 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice and ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001compared to 
control db/db mice. 
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Figure 4.40 Long-term effects of frenatin 2D and its synthetic analogue [D1W] 
frenatin 2D on plasma glucose (A, B) and insulin (C, D) concentrations following 
oral glucose administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after oral 
administration of glucose (18 mmol/kg bw) to db/db mice pre-treated with twice-daily 
injections of either saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) 
for 28 days. Values are mean ± SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 
compared to lean mice and ΔP<0.05, ΔΔP<0.01 compared to control db/db mice. 
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Figure 4.41 Long-term effects of frenatin 2D and its synthetic analogue [D1W] 
frenatin 2D on insulin sensitivity in db/db mice 
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Plasma glucose was measured prior to and after intraperitoneal injection of insulin (50 
U/kg bw) in db/db mice pre-treated with twice-daily injections of either saline or 
exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) for 28 days. Values are mean 
± SEM for 8 mice. ***P<0.001 compared with lean mice and ΔP<0.05, ΔΔP<0.01 
compare with db/db control mice. 
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Figure 4.42 Effects of frenatin 2D and its synthetic analogue [D1W] frenatin 2D 
on body composition in db/db mice 
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Effects of frenatin 2D and [D1W] frenatin 2D on body composition in lean and db/db 
mice. Animals were injected with either saline or peptide (25/75 nmol/kg bw) for 28 
days. The figure shows (A) representative DEXA scans, (B) bone mineral density, (C) 
bone mineral content, (D) bone area. (E) lean body mass, (F) body fat and (G) body 
fat expressed a percentage of total body mass. Values are mean ± SEM for 8 mice. 
*P<0.05, **P<0.01, ***P<0.001 compared with saline-treated lean mice. 
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Figure 4.43 Effects of frenatin 2D and its synthetic analogue [D1W] frenatin 2D 
on pancreatic weight (A), total insulin content (B), and insulin secretory response 
of isolated islets (C&D) from lean, and db/db mice treated 
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Mice were treated with saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg 
bw) for 28 days prior to the experiment. Values are mean ± SEM with n=4. *P<0.05, 
**P<0.01, ***P<0.001 compared with the response of islets isolated from each group 
of mice at 16.7 mM glucose; ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the 
response of islets isolated from lean mice (saline treated) to each secretagogue or 
glucose concentration. 
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Figure 4.44 Effects of long-term treatment with frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on total cholesterol (A), Triglycerides (B), HDL (C) 
and LDL (D) in db/db mice 
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Plasma sample was collected after 28 days treatment with either saline (control) or 
exenatide or peptide. Values are mean ± SEM for 6 mice. *P<0.05, *P<0.05, 
***P<0.001 compared to lean mice. ΔP<0.05, ΔΔP<0.01 compared to db/db control 
mice. 
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Figure 4.45 Effects of long-term treatment with frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on plasma AST (A) ALT (B) ALP (C) and creatinine 
(D) levels in db/db mice 
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Following 28 days injection with either saline (control) or exenatide or peptide, a 
plasma sample was collected and measured for ALT, AST, ALP and creatinine levels.  
Values are mean ± SEM for 6 mice. **P<0.01, ***P<0.001 compared to lean control. 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 4.46 Effects of long-term treatment with frenatin 2D and its synthetic 
analogue [D1W] frenatin 2D on amylase activity in diabetic mice (db/db) 
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Following 28 days injection with either saline (control) or exenatide or peptide, a 
plasma sample was collected and measured for amylase activity. Values are mean ± 
SEM for n=6 mice. ***P<0.001 compared to lean control. ΔΔΔP<0.001 compared to 
db/db control. 
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Figure 4.47 Effects of frenatin 2D & its synthetic analogue [D1W] frenatin 2D 
treatment on islet morphology in db/db mice 
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Representative images (A) showing insulin (green) and glucagon (red) 
immunoreactivity from lean, db/db control, frenatin 2D and [D1W] frenatin 2D treated 
mice. B, C, D, E and F shows islet number, islet area, beta cell area, alpha cell area 
and islet size distribution respectively. Values are mean ± SEM for 6 mice (~80 islets 
per group). *P<0.05, **P<0.01 compared to normal saline control. ΔP<0.05, ΔΔP<0.01, 
ΔΔΔP<0.001 compared to db/db control. 
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Figure 4.48 Effects of frenatin 2D & its synthetic analogue [D1W] frenatin 2D 
treatment on expression of genes involved in insulin action in skeletal muscle 
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3µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4. *P<0.05, **P<0.01, ***P<0.001 compared to 
normal control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 4.49 Effects of frenatin 2D and its synthetic analogue [D1W] Frenatin 2D 
treatment on expression of genes involved in insulin secretion from mouse islets 
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3µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4. *P<0.05, **P<0.01, ***P<0.001 compared to 
normal control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 4.50 Effects of frenatin 2D and its synthetic analogue [D1W] frenatin 2D 
treatment on expression of genes involved in insulin secretion (A-C), beta cell 
proliferation (D) and beta cell apoptosis (E) in mouse islets 
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3µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4.  *P<0.05, **P<0.01, ***P<0.001 compared 
to normal control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control mice. 
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Chapter 5 
 
In vitro and in vivo antidiabetic effects of a 
structurally modified analogue of peptide glycine 
leucine amide-AM1 (PGLa-AM1) isolated from frog 
Xenopus amieti 
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5.1 Summary  
 
The present Chapter investigated the antidiabetic potential of [A14K] PGLa-AM1 
(GMASKAGSVLGKVKKVALKAAL.NH2), an analogue of native PGLa-AM1 
(GMASKAGSVLGKVAKVALKAAL.NH2) with increased cationicity. Like the 
native peptide, [A14K] PGLa-AM1 displayed dose-dependent stimulatory nontoxic 
effects on insulin release from BRIN-BD11 as well as from human-derived pancreatic 
1.1B4 beta cells. [A14K] PGLa-AM1 also provided protection against cytokine-
induced apoptosis and stimulated proliferation in BRIN-BD11 cells. Twice daily 
administration of [A14K] PGLa-AM1 (75 nmol/kg bw) or exenatide (25 nmol/kg bw) 
to db/db mice for 28 days, markedly delayed gradual decline of insulin and improved 
HbA1c, hyperglycaemia, glucose tolerance and insulin sensitivity. In contrast, native 
PGLa-AM1 (75 nmol/kg bw) produced no significant changes in these parameters. 
Energy intake and fluid intake were unaffected in PGLa-AM1 and [A14K] PGLa-
AM1 but decreased significantly by exenatide. Elevated levels of triglycerides and 
LDL were reversed by [A14K] PGLa-AM1 and exenatide but not by PGLa-AM1. The 
cholesterol level was decreased significantly by [A14K] PGLa-AM1. Plasma AST, 
ALT, ALP and creatinine were decreased markedly by [A14K] PGLa-AM1 and 
exenatide.  Except for ALP, these biomarkers were also significantly decreased by 
PGLa-AM1. Amylase activity was elevated in all treatment groups. Pancreatic insulin 
was significantly increased by [A14K] PGLa-AM1and exenatide. No significant 
changes were observed in the islet, beta cell and alpha cell area in the treated groups 
except for exenatide. However, the loss of large and medium-size islet in db/db mice 
was significantly countered in all peptide treated groups. Islets isolated from peptide-
treated db/db mice showed improved insulin secretory responses to glucose and 
known insulin modulators. In un-treated db/db mice, the expression of insulin 
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signalling genes was upregulated, and that of insulin secretory genes was down-
regulated. These changes were reversed by [A14K] PGLa-AM1 and exenatide 
treatment. In transgenic GluCre-ROSA26EYFP mice, receiving [A14K] PGLa-AM1, 
the numbers of Ins+/GFP+ cells, GFP+ cells and Ins+/Glu+ were increased significantly, 
indicating that the analogue could have positive effects on transdifferentiation of 
glucagon-expressing alpha to insulin-expressing beta cells.   
 
5.2 Introduction 
The granular glands present in the frog skin has proven to contain biologically active 
peptides having a wide range of pharmacological activities that may have medicinal 
importance (Conlon, 2017). These peptides play an important role in host defence 
against pathogenic microorganisms such as bacteria, fungi, protozoa and viruses.  
Hence, they were called host defence peptides and classified based on antimicrobial 
activities. Additionally, these peptides have displayed tumoricidal activity and 
cytokine-mediated immunomodulatory properties (Xu and Lai et al., 2015, Conlon et 
al., 2014a).  Interestingly, few peptides in frog skin secretions were structurally related 
to mammalian peptides such as cholecystokinin and tachykinins (Marenah et al., 
2004a).  
Many host defence peptides with multifunctional activities have also shown insulin-
releasing activity in vitro using rat clonal pancreatic beta cell line (BRIN-BD11 cell 
line), human-derived pancreatic beta cells (1.1B4 cell line) and mouse pancreatic 
islets, without affecting the architecture of plasma membrane (Conlon et al., 2017).  
Additionally, these peptides have been shown to improve glycemic response both in 
lean and high fat-induced insulin resistance diabetic mice when administered together 
with glucose (Srinivasan et al., 2015, Owolabi et al., 2016, Vasu et al., 2017). 
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Furthermore, some of these peptides stimulated the release of GLP-1, an incretin 
peptide which plays an essential role in maintaining pancreatic beta cell mass and 
function, from GLUTag murine enteroendocrine cell line (Ojo et al., 2013a).  
Based on structure-activity analysis of frog skin insulinotropic peptides, previous 
studies have revealed the key determinants that influence the insulin-releasing activity 
of frog skin peptides (Abdel Wahab et al., 2008a, Ojo et al., 2013b, Srinivasan et al., 
2016). Analogues containing lysine (K) or tryptophan (W) substitution have shown 
greater insulinotropic potency than the parent peptide. Synthetic analogues of the 
brevinine 2-related -peptide (B2RP) (Abdel Wahab et al., 2010), tigerinin-1R 
(Srinivasan et al., 2016), hymenochirin–1B (Owolabi et al., 2016), esculentin-2Cha 
(Vasu et al., 2017) exhibited potent insulinotropic activity both in vitro and in vivo. 
Peptide glycine-leucine-amide (PGLa) is well-known for its broad-spectrum 
antibacterial and antifungal activities (Gibson et al., 1986). It was first isolated from 
skin secretions of the South African frog Xenopus laevis (Glattard et al., 2016). PGLa-
AM1 (GMASKAGSVLGKVAKVALKAAL.NH2) is a paralogue of PGLa, found in 
skin secretions of the octoploid frog Xenopus amieti (Conlon et al., 2010). It 
demonstrated a dose-dependent release of GLP-1 and insulin from GLUTag and 
BRIN-BD11 cells respectively, without compromising architecture of plasma 
membrane (Ojo et al., 2013a, Owolabi et al., 2017). In the recent study, the synthetic 
analogue [A14K] PGLa-AM1, generated by substituting alanine at position 14 by 
lysine in the parent peptide, produced the stronger insulin secretory response from 
BRIN-BD11 cells and mouse islets (Abdel-Wahab et al., 2010, Manzo et al., 2015, 
Owolabi et al., 2017). Furthermore, acute administration of [A14K] PGLa-AM1 (75 
nmol/ kg bw) both in lean and high fat-fed mice, resulted in a significant increase of 
plasma insulin and improved blood glucose.   
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Based on these promising preliminary results, the insulinotropic activity of [A14K] 
PGLa-AM1 was further investigated in 1.1B4 human-derived pancreatic β-cells. 
Additionally, the beneficial effects of [A14K] PGLa-AM1 on beta cell proliferation 
and its ability to protect cytokine-induced DNA damage was examined in BRIN-BD11 
cells. Furthermore, longer-term in vivo antidiabetic effects of [A14K] PGLa-AM1 
were examined in genetically obese-diabetic mice (db/db), in comparison to its parent 
peptide (PGLa-AM1) and an antidiabetic agent, exenatide. An additional in vivo study 
was performed using transgenic GluCre-ROSA26EYFP mice, to investigate beneficial 
effects of [A14K] PGLa-AM1 on transdifferentiation of glucagon-producing alpha 
cells to insulin-producing beta cells. These in vivo studies were carried out in parallel 
with the evaluation of frenatin 2D as presented in Chapter 4. 
 
5.3 Materials and Methods 
5.3.1 Reagents 
All the reagents used in the experiments were of analytical grade and listed in Chapter 
2, Section 2.1. Synthetic peptide (PGLa-AM1 and [A14K] PGLa-AM1) used in this 
Chapter were supplied by SynPeptide (China). CytoTox 96 Non-Radioactive 
Cytotoxicity Assay kit (Catalogue number: G1780) purchased from Promega 
(Southampton, UK).  FLIPR Calcium Assay Kit (Catalogue number: R8041) and 
Membrane potential blue (Catalogue number: R8042) were purchased from Molecular 
Devices (Berkshire, UK). Apoptosis and proliferation experiments were performed 
using IN SITU Cell Death Fluorescein kit (Sigma-Aldrich, Catalogue number: 
11684795910) and Rabbit polyclonal to Ki67 (Abcam, Catalogue number: ab15580) 
respectively. Masterclear Cap Strips and real-time PCR TubeStrips (Catalogue 
number: 0030132890) purchased from Mason Technology Ltd (Dublin, Ireland). 
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5.3.2 Peptide synthesis and purification 
Synthetic peptide [A14K] PGLa-AM1 was puriﬁed to near homogeneity (>98% 
purity) by reverse phase HPLC using a Vydac (C-18) column as described in Chapter 
2, Section 2.2.1.1. The molecular mass of the collected peak was characterised using 
MALDI-TOF MS (Chapter 2, Section 2.2.2). Peptide PGLa-AM1 used in this Chapter 
was supplied in pure form by SynPeptide (China).  (See Figure 5.1 for peptides 
structure) 
 
5.3.3 Effects of [A14K] PGLa-AM1 on insulin release from BRIN-BD11 and 
1.1B4 cells 
The dose-dependent insulin secretory studies of peptide [A14K] PGLa-AM1 was 
performed using BRIN-BD11 (passage 15-30) and 1.1B4 cells (passage 25-28).  The 
procedure for studying the insulin-releasing activity of peptide has been described in 
Chapter 2, Section 2.4.1.1. [A14K] PGLa-AM1 (3x10-6 - 10-12 M, n=8) was incubated 
for 20 min at 37 °C using Krebs-Ringer bicarbonate (KRB) buffer supplemented with 
5.6 mM glucose. After incubation, the cell supernatant was aliquoted and stored at -
20 °C for insulin radioimmunoassay as outlined in Chapter 2, Section 2.4.4. 
 
5.3.4 Cytotoxicity studies 
LDH release from [A14K] PGLa-AM1 treated cells was determined using CytoTox 
96 non-radioactive cytotoxicity assay kit, as described in Chapter 2, Section 2.5. 
 
5.3.5 Effects of [A14K] PGLa-AM1 on apoptosis and proliferation in BRIN-BD11 
cells 
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The ability of [A14K] PGLa-AM1 to protect against cytokine-induced DNA damage 
was investigated in BRIN-BD11 cells. Cells were seeded at a density of 5 x104 cells 
per well in 12 well plate and exposed to a cytokine mixture  (200 U/ml tumour-necrosis 
factor-α, 20 U/ml interferon-γ and 100 U/ml interleukin-1β), in the presence or 
absence of [A14K] PGLa-AM1 (10-6 M) for 18 hr at 37 °C. GLP-1 (10-6 M) was used 
as a positive control in the experiment. The detailed procedure is described in Chapter 
2, Section 2.10. 
The positive effect of [A14K] PGLa-AM1 (10-6 M) or GLP-1 (10-6 M) on the 
proliferation of BRIN-BD11 cells is described in Chapter 2, Section 2.10. After fixing 
of BRIN-BD11 cells using 0.1 M sodium citrate buffer (pH 6.0) and treatment with 
300 µl of 1.1% BSA, cells were stained with rabbit anti-Ki-67 primary antibody and 
subsequently with Alexa Fluor 594 secondary antibody (Abcam. Cambridge, UK).  
 
5.3.6 Effects of the peptide on glucose uptake in C2C12 cells 
The procedure for determining the effects of peptides on the glucose uptake in C2C12 
cells is described in Chapter 2, Section 2.11. 
 
5.3.7 Acute in vivo effects of the peptide on food intake 
Food intake was measured in overnight (21 hr) fasted mice after i.p injection of saline 
and test peptides as described in Chapter 2, Section 2.13.4.   
 
5.3.8 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-AM1 
in db/db mice 
Twice daily i.p. injections of saline (control) or peptide (75 nmol/kg bw) or Exenatide 
4 (75 nmol/kg bw) were administered for 28 days in db/db male mice. The various 
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control groups were the same mice as reported in chapter 4. Before the start of the 
treatment, all mice were injected twice daily with saline for 3 days and body weight, 
energy intake and blood glucose were observed. After initiation of treatment at every 
3 days interval body weight, energy intake, non-fasted blood glucose and plasma 
insulin were assessed. Glucose in blood and plasma were measured by Ascencia 
counter blood glucose meter (Bayer, UK) and GOD-PAP reagent, respectively 
(Chapter 2, Section 2.13.5). Plasma insulin was measured by radioimmunoassay, as 
outlined in Chapter 2, Section 2.13.5. At the end of treatment, terminal studies were 
performed to measure HbA1c (Chapter 2, Section 2.13.9), glycaemic response to an 
intraperitoneal and oral glucose load (Chapter 2, Section 2.13.2) and insulin sensitivity 
test (Section 2.13.3). Fasting (18 hr) blood glucose and plasma were measured and 
used to assess insulin resistance using homeostatic model assessment (HOMA) 
formula: HOMA-IR = fasting glucose (mmol/l) x fasting insulin (mU/l)/22.5. After 
collecting terminal blood, animals were sacrificed, and terminal analysis was 
performed which include measurement of body fat composition and bone mineral 
density using DEXA scanning (PIXImus densitometer, USA) (Chapter 2, Section 
2.13.8). Terminal plasma was used for lipid profile, assessment of liver and kidney 
function and amylase activity (Chapter 2, Section 2.13.12). Tissues dissected from 
sacrificed animals were processed for immunohistochemistry (Chapter 2, Section 
2.14), measurement of pancreatic insulin (Chapter 2, Section 2.13.11) and expression 
of key genes involved in glucose haemostasis (Chapter 2, Section 2.15). Islets were 
isolated from the pancreas (Chapter 2, Section 2.4.2.1) and used to evaluate insulin 
secretory responses to established insulin secretagogues as described in Chapter 2, 
Section 2.4.2.3. 
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5.3.9 Biochemical analysis 
Pancreatic tissues were homogenised in acid ethanol to measure insulin content by 
radioimmunoassay as described in Chapter 2, Section 2.13.11. The HbA1c level in 
saline and peptide-treated mice was measured using A1cNow+ kits (PTS diagnostics, 
IN, USA) (Chapter 2, Section 2.13.9). Effect of peptide treatment on renal and liver 
function test was performed by measuring creatinine, alanine transaminase (ALT), 
aspartate transaminase (AST), alkaline phosphatase (ALP) level (Chapter 2, Section 
2.13.12). 
 
5.3.10 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on islet morphology 
Pancreatic tissue was excised from saline and peptide-treated mice and fixed in 4% 
paraformaldehyde. Tissue was processed in an automated tissue processor (Leica 
TP1020, Leica Microsystems, Nussloch, Germany) as outlined in Chapter 2, Section 
2.14. After processing, tissues were embedded in paraffin and sectioned (7 μm 
thickness) using microtome. Sections were placed on a slide and stained for insulin 
and glucagon as described in Chapter 2, Section 2.14.1.  
 
5.3.11 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on gene expression 
Tissues dissected from saline and peptide treated db/db mice were used to study the 
expression of key genes involved in glucose homeostasis. Islet cells were isolated from 
pancreatic tissue by collagenase digestion methods (Chapter 2, Section 2.4.2.1) on the 
same day after culling of mice and stored at -70 °C to study the expression of insulin 
secretory genes. RNA was extracted from muscle tissue and islet cells using TriPure 
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reagent as outlined in Chapter 2, Section 2.15.1, followed by synthesis of cDNA 
(Chapter 2, Section 2.15.2). Genes involved in glucose homeostasis were examined 
using SYBR Green real-time PCR (Chapter 2, Section 2.15.3). 
 
5.3.12 Effects of twice daily administration of [A14K] PGLa-AM1 in GluCre-
ROSA26EYFP mice  
Streptozotocin pre-treated GluCre-ROSA26EYFP mice received twice daily 
intraperitoneal injections of saline or test peptide (75 nmol/kg bw) for 11 days 
(Chapter 2 Section 2.13.1.3). Every 3 days interval non-fasting blood glucose, body 
weight, food intake and water intake were measured. Blood samples were collected 
prior to strep treatment, before initiation of peptide treatment and after peptide 
treatment, and analysed for insulin concentration using RIA (Chapter 2, Section 
2.13.6). Animals were sacrificed, and pancreatic tissues were excised and processed 
for histological staining as described in Chapter 2, Section 2.14 and 2.14.1.  
 
5.3.13 Statistical Analysis 
Experimental data were analysed using GraphPad PRISM (Version 3). Results were 
expressed as means ± SEM and data compared using unpaired student's t-test 
(nonparametric, with two-tailed P values and 95% conﬁdence interval) and one-way 
ANOVA with Bonferroni post-hoc test wherever applicable. Group of datasets were 
considered to be significantly different if P<0.05.  
 
5.4 Results  
5.4.1 Purification and characterisation of [A14K] PGLa-AM1 
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[A14K] PGLa-AM1 was purified and characterised by reverse-phase HPLC and 
MALDI-TOF respectively, as described in Chapter 2, Section 2.2.1.1 and Section 
2.2.2 (Figure 5.2). 
 
5.4.2 Effects of [A14K] PGLa-AM1 on insulin release from BRIN-BD11 and 
1.1B4 cells 
The insulin-releasing activity of [A14K] PGLa-AM1 was investigated in glucose-
responsive BRIN-BD11 and 1.1B4 cell line. As shown in Figure 5.3A, [A14K] PGLa-
AM1 (3 x 10-6 M – 10-12 M) treated BRIN-BD11 cells exhibited a significant dose-
dependent insulin release (P<0.05) up to a concentration of 30 pM.  The stimulatory 
response observed at 3 µM was 3.6-fold greater than basal (0.74 ng/106 cells/20 min). 
[A14K] PGLa-AM1 at concentrations up to and including 3 µM, did not affect the 
release of LDH from the cells indicating that the integrity of the plasma membrane 
was not compromised (Figure 5.3B). As shown in Figure 5.4 A, B incubation of 1.1B4 
cells with [A14K] PGLa-AM1 in 5.6 mM and 16.7 glucose evoked approximately 2.5-
fold increase in insulin response at 3 µM. The peptide exhibited a significant (P<0.05) 
increase in the rate of insulin release at concentrations ≥ 30 pM.  
 
5.4.3 Effects of [A14K] PGLa-AM1 on apoptosis and proliferation in BRIN-BD11 
cells 
[A14K] PGLa-AM1 (1 µM) treated BRIN-BD11 cells were subject to TUNEL assay 
and rabbit anti-Ki-67 primary antibody to evaluate the effects on beta cells apoptosis 
and proliferation. GLP-1(1 µM) used as positive control in the experiment. As shown 
in Figure 5.5A, neither [A14K] PGLa-AM1 nor GLP-1 alone had any effects on 
apoptosis. On the other hand, in cytokine-treated BRIN-BD11 cells, the number of 
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cells undergoing apoptosis was increased 3.7-fold. When the BRIN-BD11 cells were 
incubated with [A14K] PGLa-AM1 and the cytokine mixture, the number of the 
apoptotic cells reduced significantly (P<0.001) by 49%. The degree of protection 
provided by [A14K] PGLa-AM1 was comparable to that provided by GLP-1 (48 % 
reduction). As shown in the Figure 5.5B, [A14K] PGLa-AM1 (1 µM) treatment for 18 
hrs significantly (P<0.001) increased proliferation (42% increase) of BRIN-BD11, 
that was comparable to that produced by 1 µM GLP-1 (43 % increase). On the other 
hand, the proliferation of cytokine-treated BRIN-BD11 cells decreased significantly 
(P<0.01) by 30%. 
 
 
5.4.4 Effects of [A14K] PGLa-AM1 on glucose uptake in C2C12 cells 
 
As shown in Figure 5.6, [A14K] PGLa-AM1 (1 µM) treatment had no significant 
effect on glucose uptake. However, in the presence of insulin, peptide showed a 
noticeable increase in glucose uptake. In the presence of negative control (Apigenin 
50µM), glucose uptake was significantly decreased by 30% (P<0.05).  
 
5.4.5 Acute effects of [A14K] PGLa-AM1 peptides on food intake in mice 
As shown in Figure 5.7, GLP-1 significantly (P<0.05) decreased food intake from 60 
min up to 180 min post-injection in mice. [A14K] PGLa-AM1 showed no effect on 
food intake.  
 
5.4.6 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-AM1 
on body weight, energy intake, non-fasting blood glucose and plasma insulin in 
db/db mice 
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Effects of twice daily administration of PGLa-AM (75 nmol/kg bw) and [A14K] 
PGLa-AM1 (75 nmol/kg bw) on body weight, energy intake, water intake, non-fasting 
blood glucose and plasma insulin were investigated in diabetic male mice (db/db, 
BKS.Cg-+Leprdb/+Leprdb/OlaHsd). As discussed in Chapter 4, Exenatide was used 
as positive control (25 nmol/kg bw). As expected, these parameters were significantly 
increased (P<0.001) in all db/db mice compared to their littermates (Figure 5.8 & 5.9). 
After 28 days of treatment, no significant change in body weight, energy intake and 
fluid intake was observed in PGLa-AM1 and [A14K] PGLa-AM1 treated groups in 
comparison to db/db control group (Figure 5.8A-F). Elevated blood glucose and 
decreased plasma insulin in saline-treated db/db mice was reversed by treatment with 
exenatide and [A14K] PGLa-AM1 (Figure 5.9A-D). Whereas in PGLa-AM1 treated 
db/db mice, these parameters were not significantly different from saline-treated db/db 
mice. 
 
5.4.7 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-AM1 
on Glycated haemoglobin (HbA1c) in db/db mice 
Treatment with 25 nmol/kg bw exenatide and 75 nmol/kg bw [A14K] PGLa-AM 
resulted in significant decrease in HbA1c by 48% (P<0.05) and 30% (P<0.01) 
respectively compared to saline-treated db/db mice. On the other hand, there was no 
significant decrease in blood HbA1c level in PGLa-AM1 treated db/db mice (Figure 
5.10). 
 
5.4.8 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-AM1 
on glucose tolerance in db/db mice following intraperitoneal and oral glucose load 
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Following intraperitoneal glucose load (18 mmol/kg bw), a signiﬁcant reduction 
(P<0.01, P<0.001) in individual glucose was observed at all time point (15, 30 and 60 
min) in exenatide and [A14K] PGLa-AM1 treated groups compared to saline-treated 
db/db mice (Figure 5.11A). This resulted in a decrease (P<0.05, P<0.001) in an overall 
glycaemic excursion in these mice (Figure 5.11B). Correspondingly, insulin 
concentration was significantly (P<0.05 - P<0.001) increased at all time points with 
exenatide, and at 15 and 30 min after [A14K] PGLa-AM1 (Figure 5.11C). The overall 
insulin concentration was also increased (P<0.05, P<0.001) significantly in these mice 
compared to db/db controls (Figure 5.11D). PGLa-AM1 treated group also showed a 
tendency to improve blood glucose and insulin concentration.  
In another set of experiments, the glycaemic response to an oral glucose challenge was 
investigated in treated and untreated mice (Figure 5.12A-D). Post oral glucose 
administration, blood glucose concentrations were significantly (P<0.01, P<0.001) 
decreased at all time points in [A14K] PGLa-AM1 treated group compared to db/db 
control mice. In the exenatide-treated group, blood glucose was decreased at 15 and 
30 min resulting in significant (P<0.01, P<0.001) reduction in overall blood glucose 
AUC values compared to db/db control mice (Figure 5.12A, B). Similarly, plasma 
insulin concentrations were increased (P<0.05, P<0.01) at 15 and 60 min in exenatide 
and [A14K] PGLa-AM1 treated groups respectively (Figure 5.12C). Furthermore, the 
overall insulin concentration was increased (P<0.05, P<0.01) signiﬁcantly in these 
groups (Figure 5.12D). The PGLa-AM1 treated group showed a similar pattern of 
glucose and insulin response to those observed after intraperitoneal glucose load. 
 
5.4.9 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-AM1 
on insulin sensitivity in db/db mice 
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Following intraperitoneal administration of insulin (50 U/kg bw), circulating blood 
glucose levels were substantially decreased in [A14K] PGLa-AM1 and exenatide-
treated db/db mice compared to saline-treated db/db mice (Figure 5.13A, B). There 
was no significant decrease in blood glucose in PGLa-AM1 treated db/db mice.  The 
improvement in insulin sensitivity in [A14K] PGLa-AM1 treated mice was further 
confirmed by HOMA-IR calculation. [A14K] PGLa-AM1 and exenatide decreased 
(P<0.05, P<0.01) HOMA-IR by 45% and 54% respectively compared to db/db 
controls (Figure 5.13C). Whereas in PGLa-AM1 treated mice, there was no significant 
decrease in HOMA-IR index.  
 
5.4.10 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on bone mineral density, bone mineral content and fat composition in db/db 
mice 
Figure 5.14 illustrates a DEXA scan of all groups of mice (lean control, db/db control, 
Exenatide, PGLa-AM1 and [A14K] PGLa-AM1 treated group). After 28 days of 
treatment, no significant changes in bone mineral density (BMD), bone mineral 
content (BMC), bone area, body fat and body fat (expressed a percentage of total body 
mass) were observed in the db/db mouse groups. Interestingly, lean body mass was 
significantly less than lean control in both  PGLa-AM1 and [A14K] PGLa-AM1 
treated groups (Figure 5.14E). 
 
5.4.11 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on pancreatic weight and insulin content 
As shown in Figure 5.15A, pancreatic weight remained unchanged in all treatment 
groups compared to db/db control mice. However, in comparison to lean control, the 
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pancreatic weight was significantly (P<0.05, P<0.01) higher. Exenatide and [A14K] 
PGLa-AM1 treatment resulted significant (P<0.05, P<0.01) increase in pancreatic 
insulin content compared to db/db controls (Figure 5.15B). Whereas in PGLa-AM1 
treated group pancreatic insulin content remained unchanged. 
 
5.4.12 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on insulin secretory responses of islets in db/db mice 
As expected, islets from saline-treated db/db mice exhibited impaired insulin secretory 
response to exogenous glucose (1.4 mM, 5.6 mM, 16.7 mM) and insulin secretagogues 
(like alanine, GIP, GLP-1, KCl and arginine) compared to lean control. Treatment 
with exenatide and [A14K] PGLa-AM1 resulted in significant improvements in 
insulin secretory responses compared to untreated db/db control (Figure 5.15C). Under 
the same experimental conditions, islets from  PGLa-AM1 treated mice also showed 
improved insulin secretory responses, but not to the same extent as [A14K] PGLa-
AM1 (Figure 5.15D). 
 
5.4.13 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on lipid profile in db/db mice 
Treatment with exenatide and [A14K] PGLa-AM1 significantly (P<0.05, P<0.01) 
lowered triglycerides and LDL level compared with db/db control (Figure 5.16B, D). 
Whereas, in a PGLa-AM1 treated group no significant change was observed. 
Interestingly, significant (P<0.05) reduction in cholesterol was observed in [A14K] 
PGLa-AM1 treated mice compared with saline-treated db/db mice and lean controls 
(Figure 5.16A). HDL was similar in all groups of mice (Figure 5.16C). 
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5.4.14 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on liver and kidney function in db/db mice 
Plasma aspartate transaminase (AST), alanine transaminase (ALT), alkaline 
phosphatase (ALP) and creatinine were increased (P<0.001) in saline-treated db/db 
mice (Figure 5.17). Exenatide and [A14K] PGLa-AM1 significantly decreased AST 
(1.5-2.0-fold, P<0.001), ALT (1.3-1.9-fold, P<0.05, P<0.001) ALP (1-1.25-fold, 
P<0.05, P<0.001) and creatinine (1.3-1.9-fold, P<0.001) compared to control db/db 
mice. These biomarkers were significantly (P<0.05 - P<0.001) decreased with  PGLa-
AM1 except ALP.  
 
5.4.15 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on plasma amylase concentration in db/db mice 
Amylase activity was significantly (P<0.01, P<0.001) increased in peptide treated 
groups compared with saline-treated db/db mice and lean controls (Figure 5.18).  
 
5.4.16 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on islet number, islet area, beta cell areas, alpha cell area and islet size 
distribution 
Figure 5.19A, represent images of pancreatic islets, showing alpha cells in red and 
beta cells in green. The number of islets (per mm2 of the pancreas) was significantly 
(P<0.05, P<0.01) decreased in all db/db mice. In all peptide treated db/db groups, there 
was no significant difference in the number of islets (Figure 5.19B). Lean control, 
db/db control, PGLa-AM1 and [A14K] PGLa-AM1treated groups showed no 
differences in islet area (Figure 5.19C).  On the other hand, islet area was significantly 
(P<0.05) increased after exenatide treatment. Beta cell area was decreased (P<0.05) 
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and alpha cell area was increased ( P<0.01)  in db/db mice compared to their 
littermates  (Figure 5.19D,E). Except for exenatide, no significant improvement in 
beta cell and the alpha area was observed in peptide treated db/db mice. Interestingly, 
in all treated groups, the number of large (>25,000 µm2) and medium (10,000-25,000 
µm2) size islet were increased (P<0.05 - P<0.001) and the number of small size 
(<10,000 µm2) islet was decreased (P<0.01) compared to db/db control (Figure 5.19F). 
 
5.4.17 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on gene expression in skeletal muscle 
Insulin signalling genes were significantly (P<0.05 - P<0.001) upregulated in db/db 
mice. The increased expression of Slc2a4 gene in db/db mice was reversed by 
exenatide and [A14K] PGLa-AM1 (Figure 5.20A). Similarly, upregulated Insr, Irs1, 
Pik3ca, Akt1 and Ptb1 genes were reversed (Figure 5.20B-C & 5.20E-G). No 
significant changes in the expression of Irs1, Pik3ca and Ptb1 were observed after 
PGLa-AM1 treatment. However, the enhanced expression of Slc2a4, Insr and Akt1 
genes was countered. In all groups, no significant differences in the expression of Pdk1 
gene were observed (Figure 5.20D).  
 
5.4.18 Effects of twice daily administration of PGLa-AM1 and [A14K] PGLa-
AM1 on gene expression in islets 
Expression of genes involved in insulin secretion including Ins1, Abcc8, Kcnj11, 
Slc2a2, Cacna1c and Gck were investigated after 4 week treatment of db/db mice 
(Figure 5.21A-F). These genes were significantly (P<0.001) downregulated in saline-
treated db/db mice compared with lean mice. In PGLa-AM1 and [A14K] PGLa-AM1 
treated mice, expression of diabetes downregulated Ins1, Abcc8, Kcnj11, Slc2a2 and 
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Gck genes were significantly (P<0.01, P<0.001) upregulated. However, mRNA 
expression of Cacna1c remained downregulated in PGLa-AM1 and [A14K] PGLa-
AM1 treated mice. All genes were significantly (P<0.001) upregulated in the 
exenatide-treated group.  
Diabetes-induced down-regulation of Gipr, Glp1r, Gcg and Pdx1 genes were reversed 
(P<0.05 - P<0.001) by treatment with exenatide, PGLa-AM1 and [A14K] PGLa-AM1 
(Figure 5.22A-D). The upregulation of Stat1 gene was reversed by exenatide and 
[A14K] PGLa-AM1. However, expression of Stat1 gene was comparable to db/db 
controls in PGLa-AM1 treated mice (Figure 5.22E). 
 
5.4.19 Effects of twice daily administration of [A14K] PGLa-AM1 on body weight 
change, food intake and water intake in GluCre-ROSA26EYFP mice 
Following streptozotocin (STZ) treatment, a significant increase (P<0.01, P<0.001) in 
water intake and energy intake was observed in GluCre mice compared to the lean 
controls (5.23C,D). A decrease in body weight was also observed (5.23A). In [A14K] 
PGLa-AM1 (75 nmol/kg bw) treated group, no significant changes were observed 
compared to STZ mice.  
 
5.4.20 Effects of twice daily administration of [A14K] PGLa-AM1 on blood 
glucose and plasma insulin in GluCre-ROSA26EYFP mice  
Treatment with streptozotocin (STZ) resulted in significant (P<0.001) increase in 
blood glucose compared to lean controls (5.24A). Following 11 days of treatment, 
significant (P<0.001) decrease in plasma insulin concentrations were observed in STZ 
control mice (Figure 5.24B). This was associated with significant (P<0.001) increase 
in blood glucose. [A14K] PGLa-AM1 treatment at the close showed a tendency to 
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improve blood glucose and plasma insulin, but no statistical significance was observed 
compared to STZ controls. 
 
5.4.21 Effects of twice daily administration of [A14K] PGLa-AM1 on pancreatic 
insulin content in GluCre-ROSA26EYFP mice  
Insulin content in all regions of the pancreas was significantly (P<0.05, P<0.01, 
P<0.001) decreased in GluCre mice following streptozotocin (STZ) treatment 
compared to untreated controls (Figure 5.25). Administration of [A14K] PGLa-AM1 
significantly (P<0.05, P<0.01) improved insulin content, particularly in the tail region 
of pancreas compared to STZ controls. 
 
5.4.22 Effects of twice daily administration of [A14K] PGLa-AM1 on islet 
number, islet area, beta cell areas, alpha cell area and islet size distribution in 
GluCre-ROSA26EYFP mice 
At the end of the treatment period, pancreatic islet morphology was evaluated in all 
groups.  Figure 5.26A represents images of pancreatic islets, showing alpha cell in 
green and beta cell in red colour. As shown in Figure 5.26B, no statistical significances 
were observed in the number of islets per mm2 in the whole pancreas. However, in the 
pancreatic head region, the number of islets per mm2 was significantly (P<0.01) 
decreased in both STZ and peptide-treated groups compared to lean controls. 
Interestingly, in the tail region, the opposite pattern was observed. In STZ controls, 
islet area was significantly decreased (P<0.01, P<0.001) in the whole pancreas 
specifically in the tail region which was reversed by peptide treatment (Figure 5.26C). 
Insulin-expressing beta cells were markedly reduced (P<0.001) by STZ treatment 
particularly in the tail region compared to lean controls (Figure 5.26D). However, in 
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peptide-treated mice, beta cell area was significantly increased in both head (1.6-fold, 
P<0.05) and tail regions (1.7-fold, P<0.01) of the pancreas compared to STZ control. 
Glucagon expressing alpha cells were substantially increased by STZ treatment, 
particularly in the head region of pancreas compared to lean controls (Figure 5.26E). 
However, in peptide treated groups no significant differences were noticed compared 
to STZ control. Islet size distribution was also significantly altered by streptozotocin 
treatment (Figure 5.26F). The number of smaller size islet were significantly increased 
in the whole pancreas, whereas large and medium-size islet were reduced particularly 
in the pancreatic tail region in saline-treated STZ mice compared to lean control group. 
The peptide-treated groups exhibited 20% (P<0.05) decrease in smaller sized islets 
and 49% (P<0.05) and 65% (P<0.001) increase in medium and large-sized islets 
compared to STZ control. 
 
5.4.23 Effects of twice daily administration of [A14K] PGLA-AM1 on pancreatic 
islets in GluCre-ROSA26EYFP mice 
The immunofluorescent staining revealed that GFP was significantly expressed in 
glucagon-producing alpha cells in all mice groups (Figure 5.27A). The number GFP 
positive cells expressing insulin (Ins+/GFP+) was significantly (P<0.05, P<0.001) 
increased in streptozotocin-treated mice compared to lean controls (Figure 5.27B). 
However, in [A14K] PGLa-AM1 treated mice, the number of Ins+/GFP+ cells was 
increased (P<0.05) compared to STZ controls. Interestingly, in [A14K] PGLa-AM1 
treated mice, the percentage of cells expressing only GFP was significantly increased 
in the head region of the pancreas (Figure 5.27D). However, in the whole pancreas, 
no significant difference was observed. On the other hand, the number of cells co-
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expressing both insulin and glucagon was increased (P<0.05) significantly in the 
whole pancreas compared to both lean and STZ control mice (5.27E). 
 
5.5 Discussion 
Type 2 diabetes is one of the severe health problems in modern society (World Health 
Organization, 2016). In the last few decades, the exponential growth in the diabetes 
population has triggered the search for alternative treatment options that can achieve 
good glycaemic control and prevent the complications associated with the disease. The 
discovery of Exendin-4 from the venom of the Gila monster lizard, which showed 
glucose-dependent insulin release and improved pancreatic beta cell function (Fehse 
et al., 2005; Bunk et al., 2011), has intensified the search for the potential antidiabetic 
peptides from animal sources.  
Bioactive peptides found in skin secretions of frogs, whose primary function is to 
protect the host from microorganisms, has also shown anti-tumour and 
immunomodulatory activities (Jackway et al., 2011, Conlon et al., 2014a, Xu et al., 
2015). Interestingly, some of these peptides have been shown to stimulate insulin 
release from rat clonal pancreatic beta cell line (BRIN-BD11) and primary islet cells 
in a dose-dependent manner without affecting the integrity of plasma membrane 
(Conlon et al., 2017). Additionally, these peptides have been shown to improve blood 
glucose and plasma insulin concentration when administered together with glucose in 
lean and high-fat fed mice. PGLa-AM1 is one such peptide isolated from Xenopus 
amieti, its [A14K] analogue, synthesised by substituting alanine at position 14 by 
lysine, displayed appreciably greater insulinotropic activity than the parent peptide. 
The [A14K] analogue significantly increased membrane potential and intracellular 
calcium, but no direct effect on KATP channels was observed. Additionally, [A14K] 
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produced a significant increase in cellular cAMP and its insulin-releasing activity was 
abolished in protein kinase A downregulated cells. Furthermore, the [A14K] analogue 
exhibited improved glycaemic response both in lean and high-fat diet mice following 
intraperitoneal administration with glucose (Owolabi et al., 2017).  Based on these 
evidences, the [A14K] PGLa-AM1 analogue was selected for further studies.  
Reassuringly, this analogue displayed potent insulinotropic activity both in BRIN-
BD11 and 1.1B4 cells without affecting the architecture of plasma membrane up to 3 
µM concentrations. This observation is line with previous studies where analogues 
carrying lysine substitution have displayed potent insulinotropic activity, with no 
cytotoxic action (Abdel-Wahab et al., 2008b, Ojo et al., 2013b, Owolabi et al., 2015). 
The detrimental effects of proinflammatory cytokines in islet dysfunction are well 
documented (Morris et al., 2015). When tested in BRIN-BD11 cells, [A14K] PGLa-
AM1 displayed beta-cell proliferative activity comparable to that of GLP-1 and was 
also equally effective in protecting the cells against cytokine-induced apoptosis. 
Similarly, Esculentin (1-21)1c, Temporin A and Temporin F peptides have also shown 
these positive effects (Musale et al., 2018a, b). However further studies are required 
to delineate the mechanism by which these peptides exhibit proliferative and 
protective effects.  Taken together these results provided a strong base to study long-
term in vivo effects of [A14K] PGLa-AM1 in an animal model of diabetes.  
In the present study, the antidiabetic potential of [A14K] PGLa-AM1 was examined 
in db/db mouse model of obesity-diabetes in comparison with native peptide PGLa-
AM1 and a well-known antidiabetic agent, exenatide. The db/db mouse is leptin 
receptor-deficient, having characteristics similar to human type 2 diabetes. Hence, it 
is widely used to study diseases pathogenesis and development of therapeutic agents 
for type 2 diabetes (Bogdanov et al., 2014, Cat et al., 2018, Simon and Taylor, 2001, 
251 
 
Kim et al., 2008). In general, db/db mice are hyperinsulinemia, with age plasma 
insulin level decreases and eventually, db/db mice develop insulinopia, which 
resembles late stage of T2DM (Fujiwara et al., 1991, Dalbøge et al., 2013). Consistent 
with this observation, in saline-treated db/db mice plasma insulin level was gradually 
decreased to the level close to their littermates. Interestingly, in [A14K] PGLa-AM1 
treatment mice, a gradual decrease in plasma insulin was markedly delayed. This 
observation points towards a beneficial effect of analogue on pancreatic beta cell 
function. In agreement with previous studies (Wang et al., 2002, Park et al., 2007), 
exenatide, which was used as positive control in the study attenuated the age-related 
decline of insulin in db/db mice. The increase of blood glucose in db/db mice was 
suppressed by treatment with [A14K] PGLa-AM1 and exenatide. The native peptide 
PGLa-AM1, however, failed to produce the same effect as analogue.    
Glycated haemoglobin (HbA1c) reflects the average blood glucose levels up to 3-
month period (American Diabetes Association, 2011). In the recent study, esculentin-
2CHa and its analogue have shown to improve blood HbA1c in insulin resistance high-
fat fed mice (Vasu et al., 2017). In the present study, the HbA1c was significantly 
decreased in [A14K] PGLa-AM1 and exenatide-treated group compared to saline-
treated db/db mice. However, in PGLa-AM1 treated mice, no significant change in 
blood HbA1c was observed. This finding suggests, [A14K] PGLa-AM1 improves 
glucose concentration in db/db mice, along with exenatide. 
At the end of the chronic treatment period, the glycaemic response was significantly 
improved in [A14K] PGLa-AM1 and exenatide-treated groups compared to db/db 
controls. This include improvement of insulin sensitivity and lowered HOMA-IR 
index. Body weight and fat content were not affected, ruling out the possibility that 
improvement in insulin sensitivity was simply due to the reduction of adipose tissue 
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in these mice. However, in PGLa-AM1 treated mice, no significant change in glucose 
tolerance and insulin sensitivity were noticed.  Also, no significant changes in energy 
intake were observed in PGLa-AM1 and [A14K] PGLa-AM1 treated mice, which 
correlated with results of acute in vivo feeding studies. In agreement with others 
(Gedulin et al., 2005, Schlögl et al., 2013), energy intake was reduced significantly by 
exenatide treatment. However, body weight was unaffected. Bone mineral density/ 
content and lean body mass were similar in all groups of db/db mice. 
We observed elevated mRNA expression of insulin signalling gene in db/db mice. As 
shown in Figure 5.18, of mRNA expression of Slc2a2, Insr, Irs1, Akt1, Pik3ca and 
Ptb1 was upregulated significantly compared with littermates. Such observation could 
be due to a defect in GLUT4 translocation. A study conducted by Jassen et al., 2006 
also observed an increase in the activity of proximal insulin signalling cascade, in the 
animal model of liver cirrhosis. In fact, insulin resistance in liver cirrhosis patient is 
well documented (Moscatiello et al., 2007, Garcia-Compean et al., 2009, Goral & 
Kucukoner, 2010) An increase in GLUT4 activity was observed in L6 myotubules on 
chronic exposure to glucose and inulin (Huang et al., 2001). Interestingly, in [A14K] 
PGLa-AM1 and exenatide treatment groups, the expression of these genes was 
reversed. Therefore, it is essential to explore the factors responsible for these changes 
to understand the mechanism of insulin resistance.  
It is evident that hyperlipidaemia is a major risk factor in the progression of diabetes 
(Zang et al., 2008, Chen et al., 2015). In type 2 diabetes patients with non-alcoholic 
fatty liver diseases (NAFLD), triglycerides (TG), total cholesterol (TC), Low-density 
lipoprotein (LDL) are increased significantly, whereas high-density lipoprotein (HDL) 
is decreased (Biden et al., 2014, Parikh et al., 2014). Biden et al., 2014, reported 
adverse effects of hyperlipidaemia on glucose homeostasis. Therefore, controlling the 
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level of TG, TC, LDL and HDL levels could have a positive effect on glucose 
homeostasis. Several other synthetic analogues of amphibian host defence peptides 
have shown to improved blood lipid profile in high fat fed mice (Srinivasan et al., 
2015, Ojo et al., 2015c, Owolabi et al.,2016). In the present study, plasma TG and 
LDL level were decreased significantly in [A14K] PGLa-AM1 and exenatide-treated 
mice. Also, in the PGLa-AM1 treated group, these parameters were decreased but not 
significantly. Interestingly, TC was decreased significantly only in [A14K] PGLa-
AM1 treated db/db mice, indicating that peptide could have a role in the prevention of 
cardiovascular events associated with type 2 diabetes. Plasma HDL level remained 
unaffected in all db/db mice compared to their littermates.  
In diabetes, the normal function of the liver is compromised by the accumulation of 
lipid, which induces hypertrophic changes in hepatocytes, as indicated by the elevated 
level of ALT, AST and ALP (Son et al.,2015). In the present study, elevated liver 
enzymes of control db/db mice were reversed by [A14K] PGLa-AM1 and exenatide 
treatment. Interestingly, the positive effect of these peptides on the lipid profile in 
db/db mice was corroborated with improved liver function test. Except for ALP, other 
liver parameters were also reduced significantly in PGLa-AM1 treated mice. 
Furthermore, the creatinine level was markedly decreased in all treatment groups. 
These observations suggest that native peptide and its synthetic analogue have positive 
effects on liver and kidney function, and therefore could be safely used for the 
treatment. 
Serum amylase is a commonly used biomarker of acute pancreatitis (Pieper-Bigelow 
et al., 1990). In the present study, an increase in amylase activity was observed in all 
peptide-treated mice, suggesting the potential risk of pancreatitis. In several studies, 
incretin-based drugs have been linked to pancreatitis and pancreatic cancer (Filippatos 
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et al., 2014, Egan et al., 2014). However, the study by Steinberg et al., 2017,  reports 
that elevated amylase activity in liraglutide-treated patients was not related to the 
development of acute pancreatitis. 
Impaired insulin secretion is one of the significant hallmarks of type 2 diabetes (Kahn 
et al., 2006). In agreement with others (Do et al., 2014), islet isolated from db/db mice 
exhibited impaired insulin release in response to the different concentration of 
exogenous glucose and insulin secretagogues. However, in [A14K] PGLa-AM1 and 
exenatide-treated group, insulin secretion was improved significantly. On the other 
hand, PGLa-AM1 also showed a tendency to enhance insulin secretory response but 
failed to produces the same effect as its analogue. Furthermore, pancreatic insulin 
content was significantly higher in [A14K] PGLa-AM1 and exenatide but not in 
PGLa-AM1 treated group compared to saline-treated db/db mice.  
To further evaluate the positive effects of peptides on pancreatic beta cell function, 
gene expression was studied. Consistent with other studies (Wang & Thurmond, 2012, 
Poitout, 2013, Shimoda et al., 2011), in db/db mice insulin secretory genes including 
Ins1, Pdx1, Glp1r, Gipr, Abcc8, Kcnj11, Gck, Cacna1c and Gcg were significantly 
downregulated, and the gene for apoptosis Stat1 was significantly upregulated 
compared to lean littermates. These diabetes-induced changes were attenuated by 
[A14K] and exenatide treatment. The parent peptide also showed a tendency to 
improve the expression of these genes except for Stat1 gene. Immunohistochemical 
analysis of pancreatic sections revealed that all peptides prevented a substantial 
decline of the large and medium-size islet in db/db mice. In PGLa-M1 treated group 
no significant changes in the islet area, beta-cell area and alpha-cell area were 
observed compared to saline treatment db/db mice. However, [A14K] PGLa-AM1 
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treatment showed a tendency to improve this islet morphology. As expected, islet 
morphology was significantly enhanced in the exenatide-treated group.  
An additional study was performed using the transgenic mouse bearing the transgenes 
GluCre (tamoxifen inducible tagger) and ROSA26-YFP (reporter), to investigate the 
effects of [A14K] PGLa-AM1 on transdifferentiation of glucagon-expressing alpha 
cells to insulin-expressing beta cells.  Alpha cells whose primary function is to produce 
glucagon hormone have also shown the ability to transdifferentiate into insulin-
producing beta cells under conditions of extreme beta cell loss (Thorel et al., 2010). 
In agreement with this, in our study, we observed a significant increase in the number 
of beta cells which were transdifferentiated from alpha cells (i.e. Ins+ GFP+) as well as 
cells expressing both insulin and glucagon (i.e. Ins+ Glu+) were increased in 
streptozotocin-treated mice compared to lean control. However, in peptide-treated 
mice, these cells were increased significantly compared to STZ control mice. 
Furthermore, peptide treatment resulted in significant increases of islet area and beta 
cell area compared to STZ control. Additionally, large and medium-sized islets 
increased, and smaller sized islet decreased significantly in the peptide-treated mice. 
Taken together, these results indicate that the [A14K] PGLa-AM1 could have an 
important role in the regeneration of beta cells by transdifferentiation of alpha to beta 
cells. 
In conclusion, the present study has demonstrated the insulinotropic activity of 
[A14K] PGLa-AM1 in BRIN-BD11 and 1.1B4 cells. Furthermore, [A14K] PGLa-
AM1 triggered proliferation and protected BRIN-BD11 cells against cytokine-induced 
apoptosis. The in vivo studies suggest that [A14K] PGLa-AM1 was more impressive 
than parent peptide PGLa-AM1, showing positive effects on the HbA1c, glycaemic 
responses, insulin secretion, hyperlipidaemia and insulin resistance in db/db mice. 
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Liver and kidney function was significantly improved in all treatment groups. [A14K] 
PGLa-AM1 treatment attenuated diabetes-induced expression of islet genes in db/db 
mice. Importantly, analogue has the potential to delay the progression of diabetes. 
Furthermore, data from the GluCre study suggest that [A14K] PGLa-AM1 could have 
an important role in the transdifferentiation of glucagon-expressing alpha cells to 
insulin-expressing beta cells. These observations are encouraging for the development 
of frog skin peptide analogues for the treatment of type 2 diabetes. 
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Figure 5.1 Schematic diagrams of the amino acid sequence of A) PGLa-AM1 and 
B) [A14K] PGLA-AM1 
A) 
 
 
B) 
 
 
G=Glycine (Gly), M= Mthionine (Met), A= Alanine (Ala), S= Serine (Ser), K= 
Lysine (Lys). V= Valine (Val), L=Leucine (Leu). 
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Figure 5.2 Representation of Reverse-Phase HPLC (A) and MALDI-TOF 
profile (B) of [A14K] PGLA-AM1 
A) 
 
 
B) 
 
Purity and molecular mass of peptide were confirmed using RP-HPLC and MALDI-
TOF respectively. The retention time was verified using ChromQuest software. 
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Figure 5.3 Dose-dependent effects of [A14K] PGLa-AM1 on Insulin (A) and LDH 
(B) release from BRIN-BD11 cells. 
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Values are Mean ± SEM with n=8 for insulin release and n=4 for LDH. Alanine (10 
mM) and Exenatide-4 (10-8 M) were used as positive control for insulin secretion 
studies. DMSO (100%) was used as positive control for LDH assay. *P<0.05, 
**P<0.01, ***P<0.001 compared to 5.6mM glucose alone. 
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Figure 5.4 Dose-dependent effects of [A14K] PGLa-AM1 on Insulin release from 
1.1B4 cells in (A) 5.6 and (B)16.7 mM glucose 
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Values are Mean ± SEM with n=8 for insulin release. Alanine (10 mM) and Exenatide-
4 (10-8 M) were used as positive control for insulin secretion studies. *P<0.05, 
**P<0.01, ***P<0.001 compared to 5.6 mM glucose (A) and *P<0.05, **P<0.01, 
***P<0.001 compared to 16.7 mM glucose (B). 
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Figure 5.5 Effects of [A14K] PGLa-AM1 on apoptosis (A) and cell proliferation 
(B) in BRIN-BD11 cells 
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(A) Comparison of the effects of [A14K] PGLa-AM1 (1 µM) and GLP-1 (1 µM) on 
protection against cytokine-induced apoptosis in BRIN-BD11 cells. **P<0.01, ***P 
< 0.001 compared to incubation in culture medium alone, ΔΔΔP < 0.001 compared to 
incubation in cytokine-containing medium. (B) Comparison of the effects of [A14K] 
PGLa-AM1 (1 µM) and GLP-1 (1 µM) on proliferation of BRIN-BD11 cells. 
**P<0.01, ***P < 0.001 compared to incubation in culture medium alone 
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Figure 5.6 Effects of [A14K] PGLa-AM1 on glucose uptake in differentiated 
C2C12 cells 
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Glucose uptake was expressed as % of control (glucose). Apigenin was used as 
negative control for glucose uptake. Values are mean ± SEM with n=3. *P<0.05 
compared with glucose alone. 
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Figure 5.7 Acute effects of [A14K] PGLa-AM1 peptide on cumulative food intake 
in 21 hr fasted lean NIH Swiss TO mice 
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Cumulative food intake was measured prior to and after after i.p. injection of saline 
vehicle (0.9% w/v NaCl) or GLP-1 (25 nmol/kg bw) or test peptides (75 nmol/kg bw) 
at time point 30, 60, 90, 120, 150, 180 min in overnight (21 hr) fasted mice. Values 
represent mean ± SEM (n=8). *P<0.05 compared to saline control. 
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Figure 5.8 Effects of 28-day treatment with PGLa-AM1 and [A14K] PGLa-AM1 
on body weight (A, B), energy intake (C, D) and water intake (E, F) in db/db mice 
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Body weight, energy intake and water intake were measured 3 days prior to, and every 
72 hours during treatment with saline or exenatide (25 nmol/kg bw) or peptide (75 
nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice and ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001compared to 
control db/db mice
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Figure 5.9 Effects of 28-day treatment with PGLa-AM1 and [A14K] PGLa-AM1 on non-fasting blood glucose (A, B) and plasma insulin 
(C, D) in db/db mice  
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Parameters were measured 3 days prior to, and every 72 hours during treatment (indicated with black bar) with saline or exenatide (25 nmol/kg 
bw) or peptide (75 nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 compared to lean mice and 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to control db/db mice
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Figure 5.10 Long-term effects of PGLa-AM1 and [A14K] PGLa-AM1 on HbA1c 
in db/db mice 
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HbA1c level was measured after long term treatment with twice-daily injections of 
either saline or peptide (75nmol/kg bw) for 28 days. Values are Mean ± SEM for 4 
mice. *P<0.05, **P<0.01, ***P<0.001 compared with lean mice and ΔP<0.05, 
ΔΔP<0.01 compare with db/db control mice. 
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Figure 5.11 Long-term effects of PGLa-AM1 and [A14K] PGLa-AM1 on plasma 
glucose (A, B) and insulin (C, D) concentrations following intraperitoneal glucose 
administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after 
intraperitoneal administration of glucose (18 mmol/kg bw) to db/db fed mice pre-
treated with twice-daily injections of either saline or peptide (75nmol/kg bw) for 28 
days. Values are Mean ± SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 compared 
to lean mice and ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001compared to control db/db mice. 
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Figure 5.12 Long-term effects of PGLa-AM1 and [A14K] PGLa-AM1 on plasma 
glucose (A, B) and insulin (C, D) concentrations following oral glucose 
administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after oral 
administration of glucose (18 mmol/kg bw) to db/db mice pre-treated with twice-daily 
injections of either saline or peptide (75nmol/kg bw) for 28 days. Values are Mean ± 
SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 compared to lean mice and ΔP<0.05, 
ΔΔP<0.01, ΔΔΔP<0.001compared to control db/db mice. 
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Figure 5.13 Long-term effects of PGLa-AM1 and [A14K] PGLa-AM1 on insulin 
sensitivity in db/db mice 
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Plasma glucose were measured prior to and after intraperitoneal injection of insulin 
(50 U/kg bw) in db/db mice pre-treated with twice-daily injections of either saline or 
peptide (75nmol/kg bw) for 28 days. Values are Mean ± SEM for 8 mice. ***P<0.001 
compared with to lean mice and ΔΔP<0.05, ΔΔP<0.01 compare with db/db control mice. 
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Figure 5.14 Effects of PGLa-AM1 and [A14K] PGLa-AM1 on body composition 
in db/db mice 
A)  
 
0.00
0.01
0.02
0.03
0.04
0.05
0.06
Lean (Saline)
db/db Control (Saline)
B)
Exenatide (25 nmol/kg bw)
PGLa-AM1 (75 nmol/kg bw)
*** *** ***
[A14K] PGLa-AM1 (75 nmol/kg bw)
***
B
o
n
e 
m
in
er
al
d
en
si
ty
(B
M
D
, g
/c
m
3 )
0.0
0.1
0.2
0.3
0.4
0.5
Lean (Saline)
db/db Control (Saline)
C)
PGLa-AM1 (75 nmol/kg bw)
Exenatide (25 nmol/kg bw)
*** *** ***
[A14K] PGLa-AM1 (75 nmol/kg bw)
***
B
o
n
e 
m
in
er
al
co
n
te
n
t
(B
M
C
, g
/c
m
3
)
0.0
2.5
5.0
7.5
10.0
Lean (Saline)
db/db Control (Saline)
D)
Exenatide (25 nmol/kg bw)
PGLa-AM1 (75 nmol/kg bw)
** * **
***
[A14K] PGLa-AM1 (75 nmol/kg bw)
B
o
n
e 
ar
ea
 (c
m
2 )
0
10
20
30
Lean (Saline)
db/db Control (Saline)
E)
Exenatide (25 nmol/kg bw)
PGLa-AM1 (75 nmol/kg bw)
*
[A14K] PGLa-AM1 (75 nmol/kg bw)
*
L
ea
n
 b
o
d
y 
m
as
s 
(g
)
0
5
10
15
20
Lean (Saline)
db/db Control (Saline)
**
F)
Exenatide (25 nmol/kg bw)
PGLa-AM1 (75 nmol/kg bw)
**
**
[A14K] PGLa-AM1 (75 nmol/kg bw)
*
B
o
d
y 
fa
t (
g
)
0
10
20
30
40
50
Lean (Saline)
db/db Control (Saline)
G)
Exenatide (25 nmol/kg bw)
PGLa-AM1 (75 nmol/kg bw)
**
** ***
[A14K] PGLa-AM1 (75 nmol/kg bw)
**
B
o
d
y 
fa
t
(%
 o
f t
o
ta
l b
o
d
y
m
as
s)
 
Effects of PGLa-AM1 and [A14K] PGLa-AM1 on body composition in lean and db/db 
mice. Animals were injected with either saline or peptide (75 nmol/kg body weight 
per day) for 28 days. The figure shows (A) representative DEXA scans, (B) bone 
mineral density, (C) bone mineral content, (D) bone area. (E) lean body mass, (F) body 
fat and (G) body fat expressed and percentage of total body mass. Values are means ± 
SEM for 8 mice. *P<0.05, **P<0.01, ***P<0.001 compared with saline-treated lean 
mice. 
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Figure 5.15 Effects of PGLa-AM1 and [A14K] PGLa-AM1 on pancreatic weight 
(A), total insulin content (B), and insulin secretory response of isolated islets 
(C&D) from lean and db/db mice to glucose and insulin secretagogues
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Mice were treated with saline or peptide (75nmol/kg bw) for 28 days prior to 
experiment. Values are means ± SEM with n=4. *P<0.05, **P<0.01, ***P<0.001 
compared with the response of islets isolated from each group of mice at 16.7mM 
glucose; ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the response of islets isolated 
from lean mice (saline treated) to each secretagogue or glucose concentration. 
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Figure 5.16 Effects of long-term treatment with PGLa-AM1 and [A14K] PGLa-
AM1 on total cholesterol (A), triglycerides (B), HDL (C) and LDL (D) in db/db 
mice 
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Plasma sample was collected after 28 days treatment with either saline (control) or 
peptide. Values are Mean ± SEM for 6 mice. *P<0.05, ***P<0.001 compared to lean 
mice. ΔP<0.05, ΔΔP<0.01 compared to db/db control mice. 
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Figure 5.17 Effects of long-term treatment with PGLa-AM1 and [A14K] PGLa-
AM1 on plasma AST (A) ALT (B) ALP (C) and creatinine (D) levels  in db/db 
mice 
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Following 28 days injection with either saline (control) or peptide, plasma sample was 
collected and measured for ALT, AST, ALP and creatinine levels.  Values are Mean 
± SEM for 6 mice. **P<0.01, ***P<0.001 compared to lean control. ΔP<0.05, 
ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
 
 
 
 
 
 
 
274 
 
Figure 5.18 Effects of long-term treatment with PGLa-AM1 and [A14K] PGLa-
AM1 on amylase activity in diabetic mice (db/db) 
0
500
1000
1500
2000
Lean (Saline)
db/db Control (Saline)
PGLa-AM1 (75 nmol/kg bw)
Exenatide (25 nmol/kg bw)
[A14K] PGLa-AM1 (75 nmol/kg bw)
*** ***
 

A
m
yl
as
e 
ac
ti
vi
ty
(U
/l)
 
 
Plasma samples were collected after 28 days injection of [A14K] PGLa-AM1 and 
amylase activity was measured. Values are Mean ± SEM for n=6 mice. ***P<0.001 
compared to lean control, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 5.19 Effects of PGLa-AM1 & [A14K] PGLa-AM1 treatment on islet 
morphology in db/db mice 
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Representative islets (A) showing insulin (green) and glucagon (red) 
immunoreactivity from lean, db/db control, Exenatide, PGLa-AM1 and [A14K] 
PGLa-AM1 treated mice. B, C, D, E, and F shows islet number, islet area, beta cell 
area, alpha cell area and islet size distribution respectively. Mean ± SEM for 6 mice 
(~80 islets per group). *P<0.05, **P<0.01 compared to normal saline control, 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 5.20 Effects of PGLa-AM1 & [A14K] PGLa-AM1 treatment on expression 
of genes involved in insulin action in skeletal muscle 
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3µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4. *P<0.05, **P<0.01, ***P<0.001 compared to 
normal control, ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 5.21 Effects of PGLa-AM1 and [A14K] PGLa-AM1 treatment on 
expression of genes involved in insulin secretion from islets 
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3 µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4.  *P<0.05, **P<0.01, ***P<0.001 compared 
to normal control, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control mice. 
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Figure 5.22 Effects of PGLa-AM1 and [A14K] PGLa-AM1 treatment on 
expression of genes involved in insulin secretion (A- C), beta cell proliferation (D) 
and beta cell apoptosis (E) in islets 
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3 µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4.  *P<0.05, **P<0.01, ***P<0.001 compared 
to normal control, ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control mice. 
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Figure 5.23 Effects of twice daily administration of [A14K] PGLa-AM1 on body 
weight change (A and B), food intake (C) and water intake (D) in GluCre-
ROSA26EYFP mice  
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Streptozotocin (50mg/kg bw) induced diabetic mice were grouped prior to the peptide 
treatment. Body weight (A & B), food intake (C), water intake (D) were measured 3 
days prior to, and every 72 hours during treatment with saline or [A14K] PGLa-AM1 
(75 nmol/kg bw) for 11 days. Values are mean ±SEM for 5 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice. 
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Figure 5.24 Effects of twice daily administration of [A14K] PGLa-AM1 on blood 
glucose (A) and plasma insulin (B) in GluCre-ROSA26EYFP  
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Blood glucose (A) and plasma insulin (B) were measured before and after 
streptozotocin, and after 11 days treatment with saline or [A14K] PGLa-AM1 (75 
nmol/kg bw). Values are mean ±SEM for 5 mice. ***P<0.001 compared to lean mice. 
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Figure 5.25 Effects of twice daily administration of [A1K] PGLa-AM1 on 
pancreatic insulin content in GluCre-ROSA26EYFP mice 
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Pancreatic insulin content was measured after 11 days treatment with saline or [A14K] 
PGLa-AM1(75 nmol/kg bw). Values are mean ±SEM for 5 mice *P<0.05, **P<0.01, 
***P<0.001 compared to normal saline control, ΔP<0.05, ΔΔP<0.01 compared to 
streptozotocin control. 
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Figure 5.26 Effects of [A14K] PGLa-AM1 treatment on islet morphology in 
GluCre-ROSA26EYFP mice 
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Representative islets (A) showing insulin (red) and glucagon (green) 
immunoreactivity from lean, streptozotocin and [A14K]-PGLa-AM1 treated mice. B, 
C, D, E, and F shows islet number, islet area, beta cell area, alpha cell area and islet 
size distribution respectively. Mean ± SEM for 5 mice (~50 Islets per group). *P<0.05, 
**P<0.01, ***P<0.001 compared to normal lean control, ΔP<0.05, ΔΔP<0.01 
compared to streptozotocin control. 
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Figure 5.27 Effect of [A14K] PGLa-AM1 on pancreatic Islets in GluCre-
ROSA26EYFP mice 
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Quantification Of A) Glucagon-GFP positive cells, B), Insulin-GFP positive cells C) 
Glucagon positive cells and D) GFP positive cells per total islets (~50 Islets per group). 
*P<0.05, **P<0.01, **P<0.001 compared to normal saline control, ΔP<0.05, 
ΔΔΔP<0.001 compared to streptozotocin control. 
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Chapter 6 
 
 
In vitro and in vivo antidiabetic effects of [Lys4] 
substituted analogue of CPF-AM1 from Xenopus 
amieti 
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6.1 Summary  
We studied the pharmacological properties of [S4K] CPF-AM1 analogue, synthesised 
by substituting serine at position 4 by lysine in parent peptide CPF-AM1 isolated from 
frog Xenopus amieti. [S4K] CPF-AM1 exhibited dose-dependent insulin release in 
BRIN-BD11 and 1.1B4 cells without affecting the integrity of the plasma membrane. 
[S4K] CPF-AM1 also provided protection against cytokine-induced DNA damage, as 
well as stimulated proliferation of BRIN-BD11 cells. Chronic effects of [S4K] CPF-
AM1 in db/db mice were studied in comparison with its parent peptide and antidiabetic 
agent exenatide. [S4K] CPF-AM1 treatment significantly delayed the progressive 
decline of insulin in db/db mice. This was associated with significant improvement in 
glycaemic control, HbA1c, glycaemic response to intraperitoneal glucose challenge 
and insulin sensitivity. However, these effects were less pronounced than with 
exenatide. The parent CPF-AM1 (75 nmol/kg bw) treatment also significantly 
improved glycaemic control and insulin sensitivity. Body weight remained unchanged 
in all peptide-treated groups, whereas energy intake and water intakes were decreased 
considerably by exenatide treatment. Biomarkers of liver and kidney function were 
improved significantly in all treated groups, indicating the non-toxic nature of the 
peptides. The triglyceride levels were significantly decreased in the CPF-AM1 treated 
group. In all peptide-treated groups, amylase activity was increased. Bone mineral 
density/content, body fat mass was not affected by peptide treatment. Islets from all 
treated groups displayed improved insulin secretory responses to glucose and insulin 
secretagogues. Pancreatic insulin was significantly increased in [S4K] CPF-AM1 and 
exenatide but not in CPF-AM1 treated group. Except for exenatide, no significant 
changes were observed in the islet, beta cell and alpha cell area. However, the loss of 
large and medium-size islets was significantly prevented by all peptide treatment. The 
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insulin signalling genes were upregulated, and secretory genes were downregulated 
by exenatide and [S4K] CPF-AM1. In [S4K] CPF-AM1 treated transgenic mice, the 
number of Ins+/GFP+ cells, GFP+ cells and Ins+/Glu+ were increased significantly, 
indicating that peptide has a significant role in the conversion of glucagon-expressing 
alpha to insulin-expressing beta cells. 
 
6.2 Introduction 
Type 2 diabetes is becoming one of the significant health challenges particularly in 
developing countries, due to increasingly sedentary lifestyles, urbanisation and obesity 
(Hu, 2011, Animaw & Seyoum, 2017). Currently available antidiabetic drugs fail to 
achieve long-term glycaemic control and secondary complications associated with 
diabetes (Parkes et al., 2013, Kahn et al., 2014). Hence, there is a constant need to 
develop alternative therapies that can overcome these challenges. The discovery of 
exendin-4 from the venom of the Gila monster lizard (Heloderma suspectum), which 
share similar properties with GLP-1 (Conlon et al., 2006, Parkes et al., 2013), has 
intensified the search for the antidiabetic peptide from an animal source.  
Skin secretion of frog has proven to contain a rich source of peptides with therapeutic 
potential (Conlon et al., 2014a, Xu and Lai, 2015). Isolation and characterisation of 
these peptides have become a useful strategy to identify their therapeutic potential. 
Peptides, particularly from Pipidae, Hylidae, Ranidae family, which were isolated 
based on its antimicrobial activity, have subsequently been shown to demonstrated 
anti-viral, anti-cancer and immunomodulatory activity (Conlon et al., 2014). In our 
lab, some of these peptides [e.g. brevinin-2-related peptide, tigerinin-1R, 
hymenochirin 1B, esculentin-2Cha (1-30)] have shown to stimulate insulin release in 
vitro in BRIN-BD11 cell and mouse pancreatic islet cells, as well as improved 
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glycaemic response both in lean and high fat fed mice (Abdel-Wahab et al., 2010, Ojo 
et al., 2011, Owolabi et al., 2015, Vasu et al., 2017).  
In a recent study, Conlon et al., 2012a designed alyteserin-2a-derived cationic 
analogue containing D-lysin substitution at position 7 and 11, which resulted in a 
superior antimicrobial potency than the parent peptide. Interestingly, the analogue 
showed lower haemolytic activity, suggesting that such modification of peptide could 
be safe for treatment. Similarly, hymenochirin-1B derived analogues carrying D-lysin 
or L-lysin substitution showed potent anti-tumour activity with lower haemolytic 
activity (Attoub et al., 2013a). Based on this knowledge, synthetic analogues of frog 
skin insulinotropic peptides including brevinin-2-related peptide, tigerinin-1R, 
hymenochirin 1B, esculentin-2Cha (1-30) with enhanced cationicity were designed 
which exhibited potent insulinotropic activity in vitro and also improved blood 
glucose by upregulating expression of crucial genes involved in glucose homeostasis 
in an animal model of type 2 diabetes (Abdel-Wahab et al., 2010, Ojo et al., 2016, 
Owolabi et al., 2016, Vasu et al., 2017).   
A previous study has reported broad-spectrum antimicrobial activity of CPF-AM1 
(GLGSVLGKALKIGANLL.NH2), derived from skin secretion of frog Xenopus 
amieti (Conlon et al., 2010, 2012b).   CPF-AM1 is orthologous to Caerulein precursor 
fragment (CPF) and caerulein precursor fragment (CPF) related peptides which have 
shown insulin-releasing activity in BRIN-BD11 cells with no cytotoxic effects 
(Srinivasan e al., 2013). In recent studies, like CPF and CPF related peptides, CPF-
AM1 also exhibited concentration-dependent insulin-releasing activity in BRIN-
BD11 cells (Ojo et al., 2012). Additionally, CPF-AM1 induced the release of GLP-1 
in a dose dependent-manner from GLUtag cells (Ojo et al., 2013a).  Furthermore, its 
L-lysine substituted analogue (GLGKVLGKALKIGANLL.NH2) which was 
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synthesised by substituting serine at 4th position by lysine displayed superior insulin-
releasing activity than parent peptide in BRIN-BD11 cells and improved glycaemic 
responses both in lean and high-fat diet induced diabetic mice in response to glucose 
challenge (unpublished data). 
Based on these promising results, in the present study the insulin-releasing activity of 
[S4K] CPF-AM1 was verified in BRIN-BD11 cells and 1.1B4 cells.  Also, the effects 
of the analogue on proliferation and apoptosis were investigated. We then examined 
the effects of twice-daily administration of [S4K] CPF-AM1 (75 nmol/kg bw) for 28 
days on glycemic control, insulin level, islet morphology and expression of key genes 
in muscles and islets involved in glucose homeostasis in genetically obese-diabetic 
mice (db/db) in comparison with native peptide CPF-AM1 (75 nmol/kg bw) and 
antidiabetic agent exenatide (25 nmol/kg bw). An additional study was also 
performed, to investigate beneficial effects of [S4K] CPF-AM1 on reprogramming of 
alpha to beta cells using GluCre-ROSA26EYFP mice. 
 
6.3 Materials and Methods 
 
6.3.1 Reagents 
In this Chapter, all the reagents used for the experiments were of analytical grade listed 
in Chapter 2, Section 2.1. Membrane potential (Catalogue number: R8042) and 
Intracellular calcium assay kit (Catalogue number: R8041) were purchased from 
Molecular Devices (Berkshire, UK). IN SITU Cell Death Fluorescein kit (Catalogue 
number: 11684795910) were purchased from Sigma-Aldrich and Rabbit polyclonal to 
Ki67 (Catalogue number: ab15580) from Abcam for apoptosis and proliferation 
experiment, respectively. [S4K] CPF-AM1 was supplied in crude form by GL 
Biochem Ltd (Shanghai, China) and native peptide CPF-AM1 was purchased in pure 
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form by SynPeptide (China). LightCycler 480 Sybr Green (Catalogue number: 
04707516001) was purchased from Roche Diagnostics Limited, UK. Masterclear Cap 
Strips and real-time PCR TubeStrips for gene expression studies (Catalogue number: 
0030132890) were supplied by Mason Technology Ltd (Dublin, Ireland).  
 
6.3.2 Peptide synthesis and purification 
Using Reverse phase HPLC, crude peptide [S4K] CPF-AM1 was puriﬁed to near 
homogeneity (>98% purity) using a Vydac (C-18) column as described in Chapter 2, 
Section 2.2.1.1. The molecular mass of the collected peak was confirmed by MALDI-
TOF MS (Chapter 2, Section 2.2.2). Parent peptide CPF-AM1 used in this Chapter 
was supplied in pure form by SynPeptide (China) (See Figure 6.1 for peptides 
structure). 
 
6.3.3 Effects of [S4K] CPF-AM1 on insulin release from BRIN-BD11 and 1.1B4 
cells 
Insulinotropic activity of [S4K] CPF-AM1 (3x10 -6 - 10 -12 M, n=8) was verified in 
BRIN-BD11 (passage 15-30) and 1.1B4 cells (passage 25-28). The experimental 
procedure outlined in Chapter 2, Section 2.4.1.1. After 20 min incubation with 
different dilutions of peptide made in 5.6 mM glucose Krebs-Ringer bicarbonate 
(KRB) buffer, the supernatants were aliquoted and measured for insulin using 
radioimmunoassay as outlined in Chapter 2, Section 2.4.4. 
 
6.3.4 Cell viability assay 
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Lactate dehydrogenase (LDH) assay was performed to determine the cytotoxic effect 
of the peptide, using a CytoTox 96 non-radioactive cytotoxicity assay kit (Promega), 
as described in Chapter 2, Section 2.5. 
  
6.3.5 Effects of [S4K] CPF-AM1 on apoptosis and proliferation in BRIN-BD11 
cells 
The protective effects of [S4K] CPF-AM1 against cytokine-induced DNA damage 
was studied in BRIN-BD11 cells, as outlined in Chapter 2, Section 2.10. Cells were 
incubated with [S4K] CPF-AM1 or GLP-1 (10-6M) for 18 hr at 37°C in the presence 
or absence of cytokine mixture (200 U/ml tumour-necrosis factor-α, 20 U/ml 
interferon-γ and 100 U/ml interleukin-1β). After incubation, cells were fixed and 
permeabilised using 4 % paraformaldehyde and 0.1 M sodium citrate buffer (pH 6.0) 
respectively and subsequently stained using TUNEL reaction mixture. The 
proliferative effect of [S4K] CPF-AM1 (10-6 M) was investigate in BRIN-BD11 cells 
using anti-Ki-67 primary antibody (Chapter 2, Section 2.10). GLP-1 (10-6 M) was used 
as a positive control in the experiment. 
 
6.3.6 Effects of the peptides on glucose uptake in C2C12 cells 
The procedure for determining the effects of peptides on the glucose uptake in C2C12 
cells is described in Chapter 2, Section 2.11. 
 
6.3.7 Acute in vivo effect of the peptide on food intake 
In overnight (21 hr) fasted mice, food intake was measured after i.p injection of saline 
and test peptides as described in Chapter 2, Section 2.13.4.   
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6.3.8 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 in 
db/db mice 
Before initiation of treatment all mice were injected twice daily with saline for 3 days 
to adapt mice to handling and injection stress. Genetically obese-diabetic mice (db/db) 
were administered for 28 days with a twice-daily dose of exenatide 4 (25 nmol/kg bw) 
or CPF-AM1 (75 nmol/kg bw) or [S4K] CPF-AM1(75 nmol/kg bw). Various 
parameters like body weight, food intake, water intake, blood glucose and plasma 
insulin were monitored at 3 day intervals. After 28 days treatment period 
intraperitoneal and oral glucose tolerance test (Chapter 2, Section 2.13.2), HbA1c test 
(Chapter 2, Section 2.13.9) and insulin sensitivity (Chapter 2, Section 2.13.3) were 
performed. Insulin resistance was determined using the homeostatic model assessment 
(HOMA) formula: HOMA-IR = fasting glucose (mmol/l) x fasting insulin 
(mU/l)/22.5. 
After performing the above tests, mice were sacrificed by cervical dislocation and 
measured for body fat composition and bone mineral density using DEXA scanning 
(PIXImus densitometer, USA) (Chapter 2, Section 2.13.8). Islets were isolated from 
pancreases by collagenase digestion method (Chapter, Section 2.4.2.1) and 
investigated for insulin secretory responses (Chapter 2, Section 2.4.2.3) and 
expression of insulin secretory genes (Chapter 2, Section 2.15). Pancreatic tissues 
were processed for immunohistochemistry. Tissues including pancreases and skeletal 
muscle were snap frozen in liquid nitrogen and stored at -80 °C to perform further 
studies.  
 
6.3.9 Biochemical analysis 
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Blood glucose and plasma/pancreatic insulin content were measured as outlined in 
Chapter 2, section 2.13.5 and 2.13.11. Various biochemical test such as lipid profile 
test, liver and kidney function test and amylase activity (Chapter 2, Section 2.13.12) 
were performed. 
 
6.3.10 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
islet morphology 
After processing, pancreatic tissues were embedded in paraffin wax, and sections of 7 
µM thickness were made using microtome. Sections were placed on a slide and 
allowed to dry overnight on a hotplate.  Sections were then stained for insulin and 
glucagon as described in Chapter 2, Section 2.14.1.  
 
6.3.11 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
gene expression 
The expression of genes in muscles and islets involved in glucose homeostasis was 
investigated in db/db mice after chronic treatment with peptides. RNA was extracted 
from muscle tissue and islet cells using TriPure reagent (Chapter 2, Section 2.15.1).  
cDNA was synthesised from extracted RNA by following the procedure described in 
Chapter 2, Section 2.15.2. The reaction mix was prepared, and PCR condition was set 
as outlined in Chapter 2, Section 2.15.3. 
 
6.3.12 Effects of twice daily administration of [S4K] CPF-AM1 in GluCre-
ROSA26EYFP mice  
GluCre-ROSA26EYFP mice were treated with streptozotocin (STZ) and grouped as 
previously described in Chapter 2 Section 2.13.1.3. Grouped GluCre mice than 
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received twice daily intraperitoneal injections of saline or test peptide (75 nmol/kg 
bw) for 11 consecutive days. Parameters such as non-fasting blood glucose, body 
weight, food intake and water intake were monitored every 3 days interval during the 
treatment period. Additionally, blood samples were collected 3 times: prior to STZ 
treatment, before peptide treatment and after peptide treatment, and analysed for 
insulin concentration using RIA, as described previously in Chapter 2, Section 2.13.6. 
After the end of the treatment, animals were sacrificed by cervical dislocation, and 
pancreatic tissues were excised and processed for histological staining as described in 
Chapter 2, Section 2.14 and 2.14.1.  
 
6.3.13 Statistical Analysis 
Experimental data were analysed using GraphPad PRISM (Version 3). Results were 
expressed as means ± SEM and data compared using unpaired student's t-test 
(nonparametric, with two-tailed P values and 95% conﬁdence interval) and one-way 
ANOVA with Bonferroni post-hoc test wherever applicable. Group of datasets were 
considered to be significantly different if P<0.05.   
 
6.4 Results  
6.4.1 Purification and characterisation of [S4K] CPF-AM1 
[S4K] CPF-AM1 was purified and characterised by reverse-phase HPLC and MALDI-
TOF respectively, as described in Chapter 2, Section 2.2.1.1 and Section 2.2.2 (Figure 
6.2). 
 
6.4.2 Effects of [S4K] CPF-AM1 on insulin release from BRIN-BD11 and 1.1B4 
cells 
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The insulinotropic activity of analogue [S4K] CPF-AM1 was studied from 
concentration 3 µM to 1 pm in BRIN-BD11 cells and 1.1B4 cells. As shown in Figure 
6.3A, [S4K] CPF-AM1 treated BRIN-BD11 cells displayed dose-dependent insulin 
release with significant (P<0.05) stimulatory effects up to a concentration of 0.1 nM.  
At 3 µM, [S4K] CPF-AM1 produced approximately 2.6-fold increase in insulin 
release compared to the basal rate (0.98 ± 0.02 ng/106 cells/20 min). Leakage of the 
lactate dehydrogenase enzyme was not detected from peptide-treated BRIN-BD11 
cells (Figure 6.3B), suggesting that the integrity of the plasma membrane remained 
intact. As shown in Figure 6.4A, treatment of 1.1B4 cells with [S4K] CPF-AM1 (3 x 
10-6 M - 10-12 M) in 5.6 mM glucose produced dose-dependent insulin release with 
approximately 3-fold increase at 3 µM. The peptide demonstrated significant (P<0.05) 
insulin release up to concentrations of 0.1 nM. A similar stimulatory effect was 
observed when the 1.1B4 cells were incubated with peptide in 16.7 mM glucose 
(Figure 6.4B).  As expected, alanine and exenatide demonstrated maximum 
stimulatory response compared to basal rate both in BRIN-BD11 and 1.1B4 cells. 
 
6.4.3 Effects of [S4K] CPF-AM1 on apoptosis and proliferation in BRIN-BD11 
cells 
[S4K] CPF-AM1 (1 µM), treatment had no effects on apoptosis of BRIN-BD11 cells. 
On the other hand, in cytokine-treated BRIN-BD11 cells, the number of cells 
undergoing apoptosis was increased by 272%. When the BRIN-BD11 cells were co-
incubated with [S4K] CPF-AM1 and the cytokine mixture, the number of tunnel 
positive cells were reduced to 115%. This degree of protection was comparable to that 
provided by GLP-1 (1 µM) (Figure 6.5A).  As shown in Figure 6.5B, [S4K] CPF-AM1 
(1 µM) treatment for 18 hr resulted in a significant (P<0.001) increase in proliferation 
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(33% increase) of BRIN-BD11, that was comparable to that produced by 1 µM GLP-
1 (43% increase). BRIN-BD11 cells Co-cultured with cytokine cocktail resulted in a 
decrease in proliferation by 30% compared to control cultures (P<0.001).  
 
6.4.4 Effects of [S4K] CPF-AM1 peptides on glucose uptake in C2C12 cells 
 
[S4K] CPF-AM1 peptides (1 µM) had no significant effect on glucose uptake in 
C2C12 cells compared to control (Figure 6.6). However, in the presence of insulin, a 
noticeable increase in glucose uptake was observed. As expected, insulin (1 µM) 
showed a significant increase (P < 0.05) in glucose uptake in C2C12 cells compared 
to control. In the presence of negative control (Apigenin 50µM), glucose uptake was 
decreased significantly by 30% (P<0.05).  
 
6.4.5 Acute effect of [S4K] CPF-AM1 peptides on food intake in lean mice 
As expected, in overnight fasted lean mice, GLP-1 significantly (P<0.05) suppressed 
appetite from 60 min up to 180 min. [S4K] CPF-AM1 did not affect food intake 
(Figure 6.7). 
 
6.4.6 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
body weight, energy intake, fluid intake, non-fasting blood glucose and plasma 
insulin in db/db mice  
As excepted, body weight, energy intake, fluid intake, non-fasting blood glucose and 
plasma insulin were significantly increased (P<0.001) in all groups of db/db mice 
(BKS.Cg-+Leprdb/+Leprdb/OlaHsd) mice compared to their littermates (Figure 6.8 
& 6.9). After 28 days of treatment, no significant differences in body weight were 
observed in all four db/db groups [db/db control, CPF-AM1 (75 nmol/kg bw), [S4K] 
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CPF-AM1 (75 nmol/kg bw), Exenatide (25 nmol/kg bw)] (Figure 6.8A, B). Also, 
energy intake and fluid intake in CPF-AM1 and [S4K] CPF-AM1 treated groups 
showed no difference compared to db/db controls. However, these parameters were 
decreased significantly (P<0.001) in the exenatide-treated group (Figure 6.8 C-F). As 
shown in Figure 6.9A-D, [S4K] CPF-AM1 significantly (P<0.05, P<0.01) lowered 
blood glucose and delayed the progressive decline of circulating insulin in db/db mice, 
but not to the same extent as exenatide. The native peptide lowered (P<0.05) blood 
glucose in db/db mice but failed to produce any positive effects on plasma insulin.  
 
6.4.7 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
Glycated haemoglobin (HbA1c) in db/db mice 
As shown in Figure 6.10, [S4K] CPF-AM1 and exenatide treatment significantly 
(P<0.05, P<0.01) decreased blood HbA1c by 29% and 52% respectively, compared to 
db/db controls. CPF-AM1 treatment also decreased blood HbA1c level in db/db mice, 
but not significantly. 
 
6.4.8 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
glucose tolerance in db/db mice following intraperitoneal and oral glucose load 
[S4K] CPF-AM1 and exenatide-treated db/db mice exhibited significant improvement 
in glycaemic response following intraperitoneal glucose load (18 mmol/kg bw) 
(Figure 6.11A, B). The blood glucose was significantly (P <0.05 - P<0.001) lowered 
at 15, 30 and 60 min in [S4K] CPF-AM1 and exenatide-treated mice compared to 
db/db control. The integrated blood glucose response was also significantly (P<0.01, 
P<0.001) less than db/db controls. Correspondingly, significantly (P<0.01, P<0.001) 
increased insulin response was observed at 15 min in [S4K] CPF-AM1 and exenatide-
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treated db/db mice after glucose load. The overall AUC insulin was increased 
significantly (P <0.05, P<0.001) in these mice compared to saline-treated db/db mice. 
CPF-AM1 treated group, also exhibited lowered (P<0.05, P<0.01) blood glucose at 15 
and 30 min (see table below), but no significant difference in overall AUC glucose 
and insulin were observed compared to db/db controls (Figure 6.11C, D). 
In another set of experiments, both [S4K] CPF-AM1 and CPF-AM1 treated db/db 
mice showed a tendency to lower blood glucose and improve insulin response 
following an oral glucose load. However, a significant difference in overall AUC 
glucose and insulin compared to db/db controls was not observed. AUC blood glucose 
and insulin were significantly (P<0.01) improved in exenatide-treated mice after oral 
glucose challenge (Figure 6.12A-D). 
 
6.4.9 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
insulin sensitivity in db/db mice 
As shown in Figure 6.13A-B, CPF-AM1, [S4K] CPF-AM1 and exenatide treatment 
significantly improved insulin sensitivity in db/db mice. After intraperitoneal 
administration of insulin (50 U/kg bw), a decrease in blood glucose level was observed 
in all peptide treated groups compared to db/db control. When the data presented in 
the form of the area under the curve, the overall blood glucose level in CPF-AM1, 
[S4K] CPF-AM1 and the exenatide treatment group were reduced significantly 
(P<0.05, P<0.01) by 23%, 25% and 40% respectively, compared to db/db controls. 
This observation was further supported by HOMA-IR calculations, revealing 
improved insulin resistance in [S4K] CPF-AM1 and the exenatide-treated mice 
compared to db/db control.  Whereas in CPF-AM1 treated group a noticeable decrease 
in HOMA-IR index was observed (Figure 6.13C). 
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6.4.10 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
bone mineral density, bone mineral content and fat composition in db/db mice 
Figure 6.14 illustrates a DEXA scan of all groups of mice. After 28 days of treatment, 
no significant differences were found in bone mineral density (BMD), bone mineral 
content (BMC), body fat and body fat (expressed a percentage of total body mass) in 
any of the db/db groups. Interestingly, the bone area in CPF-AM1 treated mice was 
similar to lean controls.   
  
6.4.11 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
pancreatic weight and insulin content 
After 28 days of treatment, no significant changes in pancreatic weight were observed 
in peptide treated db/db mice compared to db/db controls (Figure 6.15A). In 
comparison to lean mice, the pancreatic weights of [S4K] CPF-AM1 and exenatide-
treated groups were significantly (P<0.05, P<0.01) higher. Both [S4K] CPF-AM1 and 
exenatide-treated groups also considerably increased (1.7-2.4-fold, P<0.05, P<0.01) 
pancreatic insulin compared to db/db controls. In CPF-AM1 treated group, pancreatic 
insulin remained unaltered Figure 6.15B). 
 
6.4.12 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
insulin secretory response of islet in db/db mice 
Islets from treated and untreated mice were examined for insulin secretory responses 
to glucose (1.4 mM, 5.6 mM, 16.7 mM) and other established insulin secretagogues 
(Figure 6.15C & D). Islets from db/db mice exhibited impaired insulin secretory 
responses, were reversed by treatment with exenatide and [S4K] CPF-AM1. Less 
pronounced effects were observed with CPF-AM1.  
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6.4.13 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
lipid profile in db/db mice 
Plasma TC (total cholesterol), triglycerides, LDL (low-density lipoprotein) and HDL 
(high-density lipoprotein) levels were analysed after the treatment period (Figure 
6.16).  As shown in figure (Figure 6.16A, C), cholesterol and high-density lipoprotein 
(HDL) were not significantly different in all mice groups. In db/db mice elevated 
triglycerides and LDL levels were reversed (P<0.05, P<0.01) by exenatide treatment 
(Figure 6.16B, D). Treatment with [S4K] CPF-AM1 significantly lowered triglyceride 
but not LDL compared to db/db controls. CPF-AM1 treatment showed a tendency to 
reduce triglyceride and LDL in db/db mice. 
 
6.4.14 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
liver and kidney function in db/db mice 
As shown in Figure 6.17A-C, the basal levels of ALT, AST and ALP were 
significantly (P<0.001) elevated in saline-treated db/db mice by 76%, 246% and 105% 
respectively compared to their littermates. Treatment with exenatide, CPF-AM1 and 
[S4K] CPF-AM1 significantly (P<0.05, P<0.001) lowered these biochemical 
parameters compared to db/db controls. Interestingly, both CPF-AM1 and [S4K] CPF-
AM1 was equally effective as exenatide in lowering ALT and ALP level. Additionally, 
all peptide treatment resulted significant (P<0.05, P<0.01) reduction in creatinine 
compared to db/db controls (Figure 6.17D). 
 
6.4.15 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
plasma amylase concentration in db/db mice 
300 
 
All db/db mice subjected to peptide treatment displayed significantly (P<0.05 - 
P<0.001) increased amylase activity relative to db/db mice and lean controls (Figure 
6.18).  
 
6.4.16 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
islet number, islet area, beta cell areas, alpha cell area and islet size distribution 
Following 28 days, islet morphology was examined in both treated and untreated mice. 
Figure 6.19A represents images of pancreatic islets of mice, showing alpha cells in red 
and beta cells in green. In all db/db mice, no significant differences in a number of 
islets per mm2 were observed (Figure 6.19B). Lean control, db/db control and CPF-
AM1 treated groups showed no differences in islet area. [S4K] CPF-AM1 treated 
group showed a tendency to improve islet area, but no statistical difference was 
observed compared to db/db controls (Figure 6.19C). In contrast, islet area was 
significantly (P<0.05) increased in the exenatide-treated group. In the db/db control 
group, pancreatic beta cell population were decreased, and alpha cell population were 
increased significantly compared to their littermates (Figure 6.19D-E). Both CPF-
AM1 and [S4K] CPF-AM1 treatment had no effects on beta cell and alpha cell area. 
Exenatide treatment significantly increased (P<0.05) beta cell area and decreased 
(P<0.01) alpha cell area compared to db/db controls. In all peptide treated groups, the 
number of large and medium-size islets were increased (P<0.01, P<0.001) and small 
size islets were decreased (P<0.01) significantly compared to db/db controls (Figure 
6.19F). 
 
6.4.17 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
gene expression in skeletal muscle 
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After the treatment period, the expression of insulin signalling genes in skeletal muscle 
tissue of treated and untreated mice was examined. (Figure 6.20). Muscles from db/db 
mice showed significant (P<0.05 - P<0.001) increase in mRNA expression of Slc2a4, 
Insr, Irs1, Pik3ca, Akt1 and Ptb1 genes compared to lean littermates (Figure 6.20A-C 
& 6.20E-G). Expression of these genes was reversed in [S4K] CPF-AM1 and 
exenatide-treated mice. After CPF-AM1, the expression of these genes was 
diminished but the effect was not to the same extent as analogue. No significant 
differences in expression of Pdk1 gene were observed in any of the groups (Figure 
6.20D).  
 
6.4.18 Effects of twice daily administration of CPF-AM1 and [S4K] CPF-AM1 on 
gene expression in islets 
Expression of essential genes involved in the insulin secretion including Ins1, Abcc8, 
Kcnj11, Slc2a2, Cacna1c as well as Gck were investigated in the islet cells isolated 
from pancreatic tissue from treated and untreated mice (Figure 6.21A-F). In saline-
treated db/db mice, expression of these genes was significantly (P<0.001) 
downregulated, which was reversed by treatment with exenatide and [S4K] CPF-
AM1. The native peptide CPF-AM1 also upregulated these genes, except for Kcnj11.  
Exenatide and [S4K] CPF-AM1 treatment also prevented downregulation of Gipr, 
Glp1r, Gcg and Pdx1 genes in the islets of db/db mice (Figure 6.22A-D). Stat1 gene 
which was significantly upregulated in db/db mice was reversed by treatment with 
exenatide and [S4K] CPF-AM1. CPF-AM1 treatment had no effects on these genes, 
except for Glp1r and Gcg which was upregulated (P<0.05) compared with db/db 
controls (Figure 6.22E). 
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6.4.19 Effects of twice daily administration of [S4K] CPF-AM1 on body weight 
change, food intake and water intake in GluCre-ROSA26EYFP mice 
Treatment with streptozotocin (STZ) resulted in a significant (P<0.01) decrease in 
body weight and an increase (P<0.01, P<0.001) in water intake and energy intake in 
GluCre mice compared to the lean controls (Figure 6.23A-C). [S4K] CPF-AM1 had 
no significant effects on body weight, water intake and energy intake in GluCre mice.  
 
6.4.20 Effects of twice daily administration of [S4K] CPF-AM1 on blood glucose 
and plasma insulin in GluCre-ROSA26EYFP mice  
Blood glucose was significantly (P<0.001) increased in streptozotocin (STZ) control 
mice compared to lean controls (Figure 6.24A). This was associated with significant 
(P<0.001) decrease in plasma insulin (Figure 6.24B). [S4K] CPF-AM1 treatment 
showed a tendency to improve blood glucose and plasma insulin, but no statistical 
significance was observed compared to compared to STZ controls. 
 
6.4.21 Effects of twice daily administration of [S4K] CPF-AM1 on pancreatic 
insulin content in GluCre-ROSA26EYFP mice  
As expected, treatment with streptozotocin (STZ) resulted in a significant (P<0.01, 
P<0.001) decrease of insulin content in all regions of the pancreas in GluCre mice 
compared to untreated controls (Figure 6.25). [S4K] CPF-AM1, significantly (P<0.05, 
P<0.01) improved insulin content, particularly in the tail region of pancreas compared 
to STZ controls. 
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6.4.22 Effects of twice daily administration of [S4K] CPF-AM1 on islet number, 
islet area, beta cell area, alpha cell area and islet size distribution in GluCre-
ROSA26EYFP mice  
Pancreatic islet morphology was evaluated after the treatment period.  Figure 6.26A 
represents images of pancreatic islets, showing alpha cells in green and beta cells in 
red colour. As shown in Figure 6.26B, no significant changes in the number of islets 
per mm2 were observed in the whole pancreas. However, in [S4K] CPF-AM1 treated 
mice, the number of islets per mm2 was significantly (P<0.01) increased in the 
pancreatic head region. In the tail region, the opposite pattern was observed. A 
noticeable increase in islet area was seen in the whole pancreas, particularly in the tail 
region, of peptide-treated mice compared to STZ controls (Figure 6.26C). As 
expected, a significant (P<0.001) beta cell loss was observed in STZ control mice, 
particularly in the tail region of the pancreas which was prevented (P<0.001) by the 
[S4K] CPF-AM1 treatment (Figure 6.26D). Also, a noticeable decrease in alpha cell 
area was observed in the head region of the pancreas of peptide-treated mice (Figure 
6.26E).  The islet size distribution was altered by streptozotocin treatment.  The 
number of smaller size islets were significantly increased in the whole pancreas in 
STZ controls compared to lean controls. Additionally, large and medium-size islet 
were reduced particularly in the pancreatic tail region. The peptide treatment resulted 
in significant (P<0.05) increase in the number of large size islets in the whole pancreas 
and significant (P<0.05) increase in medium size islets particularly in the tail region 
of pancreas compared to STZ controls (Figure 6.26F). 
 
6.4.23 Effect of [S4K] CPF-AM1 on pancreatic islets in GluCre-ROSA26EYFP 
mice 
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The immunofluorescent staining of pancreatic section confirmed that in all mice 
groups GFP was significantly expressed in glucagon expressing alpha cells (Figure 
6.27A). The number GFP positive cells expressing insulin were significantly (P<0.05, 
P<0.001) increased in STZ controls compared to lean controls. In [S4K] CPF-AM1 
treated mice, Ins+/GFP+ cells were increased significantly (65%, P<0.05) compared to 
STZ controls (Figure 6.27B). Interestingly, the percentage of cells expressing only 
GFP as well as cells co-expressing both insulin and glucagon (bihormonal cells) were 
increased (P<0.05 - P<0.001) significantly in the peptide-treated mice compared to 
both STZ and lean controls (Figure 6.27D, E).  
 
6.5 Discussion 
The pharmaceutical industry has shown immense interest in peptide drug development 
after the discovery of insulin therapy. To date, more than 60 peptide drugs are 
approved for clinical use, and over 150 are currently evaluated in human clinical 
studies (Lau and Dunn, 2018). The major obstacles faced by peptide drug candidates 
are 1) rapid degradation by a proteolytic enzyme, 2) toxicity, and 3) rapid clearance 
from circulation (Green et al., 2004b, Fosgerau & Hoffmann, 2014). As a result, 
researchers have begun to use peptide chemistry techniques to develop peptide 
analogues by substituting amino acid or by modifying C or N terminal or by covalently 
linking fatty acid moiety to enhance pharmaceutical properties of peptides (Heard et 
al., 2013, Conlon et al., 2007a). Using similar approaches several host defence 
peptides with antidiabetic properties were transformed to analogues, which 
demonstrated potent in vitro and in vivo antidiabetic activities (Abdel-Wahab et al., 
2008a, Srinivasan et al., 2015).  
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Previous studies conducted in our laboratory have shown the insulin-releasing activity 
of Caerulein-precursor fragment (CPF-AM1) peptide isolated from frog skin secretion 
of Xenopus amieti. Additionally, CPF-AM1 has been shown to induce the release of 
GLP-1 from GLUtag cells (Ojo et al., 2012, 2013a). The [S4K] analogue of CPF-
AM1, which was synthesised by substituting serine (S) at 4th position by lysine, 
displayed appreciably greater insulinotropic activity in rat clonal BRIN-BD11 cells 
than native peptide, as well as, improved glycaemic response both in lean and high-
fat diet induced diabetic mice in response to glucose challenge (Unpublished data).  
Based on these promising results, [S4K] CPF-AM1 analogue was selected for further 
studies. Reassuringly, in the present study [S4K] CPF-AM1 analogue displayed potent 
insulinotropic activity in BRIN-BD11, as well as, in 1.1B4 pancreatic β-cells without 
affecting the architecture of the plasma membrane. The improved insulinotropic 
activity of [S4K] CPF-AM1 analogue is in harmony with previous studies, where 
analogues of PGLa-AM1, hymenochirine-1B with lysine substitution displayed potent 
insulinotropic activity (Owolabi et al., 2016, 2017). The role of cytokines in beta cell 
dysfunction is well documented, which is characterised by impaired glucose-
stimulated insulin release (Donath et al., 2009, Vasu et al., 2014, Barlow et al., 2018). 
Interestingly, [S4K] CPF-AM1 analogue was effective in protecting BRIN-BD11 cells 
against cytokine-induced apoptosis. Additionally, analogue also displayed beta-cell 
proliferative activity comparable to that of GLP-1. A similar effect was also shown by 
peptide [A14K] PGLa-A1M, esculentin (1-21)1c, temporin A and temporin F 
(Owolabi et al., 2017, Musale et al., 2018).  Although, more detail studies are required 
to investigate the mechanism by which these peptides induce protective and 
proliferative effects. Based on these findings long-term in vivo studies was conducted 
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to evaluate the beneficial effects of [S4K] CPF-AM1 analogue in an animal model of 
type 2 diabetes.  
In T2DM, with time insulin biosynthesis and secretion decline progressively, which 
results in a decrease in insulin and an increase in glucose level (Butler et al., 2003). 
After initiation of treatment the progressive loss of non fasting insulin was delayed 
significantly in db/db mice receiving [S4K] CPF-AM1 treatment, suggesting positive 
effects of analogues on pancreatic beta cell function. When the results for insulin was 
presented in the form of the area under the curve, the insulin level was significantly 
higher than db/db controls. On the other hand, native peptide also showed a tendency 
to delay loss of insulin, but the effect was not to the same extent as analogue. The 
reason for the beneficial effects of analogue on plasma insulin over parent peptide 
could be due to the improved enzymatic stability. 
In T2DM, maintaining strict glycaemic control is one of the key factors to prevent 
microvascular complications (UK Prospective Diabetes Study (UKPDS) Group, 
1998). In the present study, [S4K] CPF-AM1 treatment significantly improved blood 
glycaemic control as well as decreased HbA1c in db/db mice. The reduction of blood 
glucose was correlated with improvement in polydipsia, which is commonly observed 
in the severe diabetic state (Zimmermann et al., 2012, Grosbellet et al., 2016). On the 
other hand, native peptide also significantly lowered blood glucose in db/db mice, 
however, an only a small decrease in HbA1c was observed. The improvement in blood 
glucose in CPF-AM1 and [S4K] CPF-AM1 treated groups was not associated with 
any change in body weight or energy intake. However, in the exenatide-treated group, 
energy intake was reduced significantly in db/db mice, which corresponds well to the 
previous studies (Gedulin et al., 2005, Schlögl et al., 2015). Body weight remained 
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unaffected suggesting that increased energy expenditure might explain the reason for 
no change in body weight.  
Genetically obese-diabetic mice (db/db) as early as 6 weeks of age show impaired 
glycaemic response to a glucose load, and this impairment deteriorates with age (Wang 
et al., 2002). There have been previous reports of several frog skin peptides and their 
analogues showing improved glucose tolerance in insulin resistance high-fat fed mice 
(Vasu et al., 2017, Ojo et al., 2015b, Owolabi et al., 2016, Srinivasan et al., 2015). In 
the present study, untreated db/db mice showed an impaired glycaemic response to 
both intraperitoneal and oral glucose load. After chronic treatment with [S4K] CPF-
AM1 for 28 days, the glycaemic response was improved substantially to 
intraperitoneal glucose challenge but failed to produce the same effect to oral glucose 
challenge. On the other hand, CPF- AM1 treated mice, under the same experimental 
condition, also showed a tendency to improve glycaemic response. Whereas, 
exenatide-treated db/db mice, displayed a positive effect on both intraperitoneal and 
oral glucose challenge. This improvement in glycaemic response correlated with 
improved insulin sensitivity in [S4K] CPF-AM1 and exenatide-treated group, which 
was further confirmed by HOMA-IR calculation.  
It is evident that hyperlipidaemia, exacerbate insulin resistance in type 2 diabetes 
(Kraegen et al., 2001). Hyperlipidaemia is one of the significant factors in the 
development of diabetic nephropathy (Yang et al., 2017), therefore, improving lipid 
metabolism may have beneficial effects in a diabetes patient. In agreement with others 
(Son et al., 2015, Kim et al., 2013), impaired lipid metabolism was observed in db/db 
mice. Plasma triglycerides and LDL levels were elevated significantly in db/db control 
compared to their littermates. In the present study, [S4K] CPF-AM1 treatment showed 
a tendency to restore elevated triglycerides and LDL levels; however, there was no 
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significant difference compared to db/db controls. Interestingly, triglycerides were 
significantly decreased with CPF-AM1 treatment, which was comparable to 
exenatide. This observation is in agreement with previous studies where CPF-SE1 
peptide which is orthologues to CPF-AM1 have been shown to reduce triglycerides 
levels in high fat fed mice (Srinivasan et al., 2015). Plasma HDL level remained 
unaffected in all db/db mice and was comparable to lean littermates. However, a small 
decrease in cholesterol level was observed in both [S4K] CPF-AM1 and CPF-AM1 
treatment, but this was not significant. The improvement in plasma lipids could be the 
reason for improved insulin sensitivity in CPF-AM1 treated db/db mice. Bone mineral 
density/ content, lean body mass and body fat were unaffected by all peptide treatment 
in db/db mice. 
In clinical practice, liver parameters such as ALT, AST and ALP levels are tested to 
monitor the progression of diseases and toxicity of drugs. T2D patient suffering from 
liver dysfunction have elevated levels ALT, AST and ALP (Bora et al., 2016). 
According to the results of the present study, these liver parameters were significantly 
decreased in both [S4K] CPF-AM1 and CPF-AM1 treated db/db mice. The magnitude 
of these effects was comparable to exenatide treatment. The creatinine in db/db mice 
was also attenuated by [S4K] CPF-AM1 and CPF-AM1. These observations show that 
liver and kidney function were improved by peptide treatment suggesting that peptides 
could be safe for the treatment of type 2 diabetes. A significant increase in amylase 
activity was observed in all peptide treated db/db mice compared to db/db controls, 
suggesting a potential issue with pancreatitis. This has previously been reported for 
GLP-1 mimetics, but it is not considered to be clinically significance (Nauck, 2013).  
Insulin resistance in type 2 diabetes has been proposed due to impairment of insulin 
signalling in the muscle tissue (Björnholm et al., 1997, Goodyear et al., 1995, 
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Defronzo and Tripathi, 2009). In the present study, an increase in mRNA expression 
of insulin signalling genes was observed in the muscles of db/db mice. The expression 
of GLU4, Insr, Irs1, Akt1, Pik3ca and Ptb1 was upregulated significantly compared to 
lean controls. These observations are in harmony with previous findings, where an 
increase in the activity of proximal insulin signalling cascade was observed in the 
animal model of liver cirrhosis, (Jessen et al., 2006). Similarly, an increase in the 
activity of PI 3-kinase and Akt/PKB was observed in the liver and kidney of db/db 
mice (Feliers et al., 2001). The increase in insulin signalling activity could be to 
compensate GLUT4 translocation defect from intracellular membrane to cell surface, 
which is observed in diabetes (Huang et al., 2002, DeFronzo & Tripathy, 2009). 
Interestingly, in [S4K] CPF-AM1 and exenatide treatment, expression of these genes 
was reversed in db/db mice. A similar finding was also observed in a native peptide-
treated group. However, the effect was comparatively less than analogue.  
In the present study, immunohistochemical analysis of pancreatic tissue revealed that 
the number of islets per mm2 was unaffected by the treatment and was comparable to 
db/db controls. However, a substantial decline in a large and medium-size islet in 
db/db mice were prevented by all peptide treatments. The loss of islets and beta cell 
area and an increase in alpha cell area in db/db mice were attenuated by [S4K] CPF-
AM1 treatment, but not significantly. This observation correlated with an increase in 
pancreatic insulin content and improved insulin secretory response to glucose and 
insulin secretagogues after [S4K] CPF-AM1 treatment. On the other hand, the native 
peptide also displayed these beneficial effects but not to the same extent as the 
analogue. To further evaluate the positive effects of both [S4K] CPF-AM1 and CPF-
AM1 on pancreatic beta cell function, gene expression studies were performed. In 
db/db mice insulin secretory genes Ins1, Pdx1, Glp1r, Gipr, Abcc8, Kcnj11, Gck, 
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Cacna1c and Gcg were significantly downregulated, and the apoptosis gene Stat1 was 
significantly upregulated compared to littermates. The high blood glucose and lipid 
levels could be the reason for these changes in gene expression in db/db mice (Piro et 
al., 2002, Wang & Thurmond, 2012, Poitout, 2013, Shimoda et al., 2011). In [S4K] 
CPF-AM1 treatment, upregulation of insulin secretory genes and downregulation of 
apoptosis gene could explain its beneficial effect on beta cell function. On the other 
hand, parent peptide also showed a tendency to improve the expression of these genes, 
but the effect was not to the same extent as the analogue. 
An additional study was performed using the transgenic mouse (GluCre-
ROSA26EYFP mice) bearing the transgenes GluCre (tamoxifen inducible tagger) and 
ROSA26-YFP (reporter), to investigate chronic effects (11 days) of [S4K] CPF-AM1 
on reprogramming of alpha to beta cells. Immunohistochemical analysis of pancreatic 
section revealed that the number of beta cells which were transdifferentiated from 
alpha cells (Ins+/GFP+ cells), as well as cells co-expressing both insulin and glucagon 
(Ins+/Glu+), were increased significantly in STZ group compared to lean control, 
indicating that glucagon expressing alpha cells started expressing insulin. These 
observations are consistent with the previous study, where transdifferentiate of 
glucagon-producing alpha cells into insulin-producing beta cells were observed under 
conditions of extreme beta cell loss (Thorel et al., 2010). [S4K] CPF-AM1 treatment, 
substantially increased the number of Ins+ /GFP+ and Ins+/Glu+ cells compared to both 
lean and STZ control. This observation correlates with increased beta cell area and 
insulin content in [S4K] CPF-AM treated mice. Also, cells expressing only GFP was 
increased significantly. Furthermore, an increase in large size islets in peptide-treated 
mice also shows the sign of beta cell regeneration. Taken together, these results 
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indicate that [S4K] CPF-AM1 treatment could influence the conversion of the 
glucagon-expressing alpha cell to insulin-producing beta cells. 
In conclusion, L -lysine substituted analogue of CPF-AM1 showed superior beneficial 
metabolic effects in db/db mice than the parent peptide. [S4K] CPF-AM1 treatment 
improved circulating plasma insulin concentration, glucose haemostasis, glucose 
tolerance, insulin resistance, insulin secretory response and liver and kidney function, 
in db/db mice. Also, the expression of genes involved in insulin secretion and insulin 
signalling were enhanced. Data from the GluCre study suggested that [S4K] CPF-
AM1 treatment could also influence the transdifferentiation of alpha to beta cells. 
These observations encourage further investigation to identify the specific receptor 
through which [S4K] CPF-AM1 exerts its beneficial effects. 
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Figure 6.1 Schematic diagrams of the amino acid sequence of A) CPF-AM1 and 
B] [S4K]-CPF-AM1 
A) CPF-AM1 
     
 
B) [S4K] CPF-AM1 
 
 
 
I=Isoleucin (Ile), K=Lysine (Lys), L=Leucine (Leu), N= Asparagine (Asn), 
V=Valine (Val), G=Glycine (Gly), A=Alanine (Ala). 
 
 
313 
 
Figure 6.2 Representation of reverse-phase HPLC profile (A) and MALDI-TOF 
spectra (B) of [S4K] CPFA-M1 
A) 
 
 
B) 
 
Purity and molecular mass of peptide were confirmed using RP-HPLC and MALDI-
TOF respectively. The retention time was verified using ChromQuest software.  
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Figure 6.3 Dose-dependent effects of [S4K] CPF-AM1 on insulin release from 
BRIN-BD11 cells 
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Values are mean ± SEM with n=8 for insulin release and n=4 for LDH. Alanine (10 
mM) and Exenatide (10-8 M) were used as positive control for insulin secretion studies. 
DMSO (100%) was used as positive control for LDH assay. *P<0.05, **P<0.01, 
***P<0.001 compared to 5.6 mM glucose alone. 
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Figure 6.4 Dose-dependent effects of [S4K] CPF-AM1 on insulin release from 
1.1B4 cells in (A) 5.6 and (B) 16.7 mM glucose 
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Values are mean ± SEM with n=8 for insulin release. Alanine (10 Mm) and Exenatide 
(10-8 M) were used as positive control for insulin secretion studies. *P<0.05, 
**P<0.01, ***P<0.001 compared to 5.6 mM glucose (A) and *P<0.05, ***P<0.001 
compared to 16.7 mM glucose (B). 
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Figure 6.5 Effects of [S4K] CPF-AM1 on apoptosis (A) and cell proliferation (B) 
in BRIN-BD11 cells 
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Comparison of the effects of [S4K] CPF-AM1 (1 µM) and GLP-1 (1 µM) on 
protection against cytokine-induced apoptosis in BRIN-BD11 cells. *P<0.05, 
***P<0.001 compared to incubation in culture medium alone. ΔΔΔP<0.001 compared 
to incubation in cytokine-containing medium. (B) Ccomparison of the effects of [S4K] 
CPF-AM1 (1 µM) and GLP-1 (1 µM) on proliferation of BRIN-BD11 cells. **P<0.01, 
***P<0.001 compared to incubation in culture medium alone 
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Figure 6.6 Effect of [S4K] CPF-AM1 on glucose uptake in differentiated C2C12 
cells 
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Glucose uptake was expressed as % of control (glucose). Apigenin was used as 
negative control for glucose uptake. Values are mean ± SEM with n=3. *P<0.05 
compared with glucose alone. 
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Figure 6.7 Effect of peptide [S4K] CPF-AM1 on food intake in intake in 21 hr 
fasted lean NIH Swiss TO mice 
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Cumulative food intake was measured prior to and after after i.p. injection of saline 
vehicle (0.9% w/v NaCl) or GLP-1 (25 nmol/kg bw) or test peptides (75 nmol/kg bw) 
at time point 30, 60, 90, 120, 150, 180 min in overnight (21 hr) fasted mice. Values 
represent mean ± SEM (n=8). *P<0.05 compared to saline control. 
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Figure 6.8 Effects of 28-day treatment with CPF-AM1 and [S4K] CPF-AM1 on 
body weight (A, B), energy intake (C, D) and water Intake (E, F) in db/db mice 
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Body weight, energy intake and water intake were measured 3 days prior to, and every 
72 hours during treatment with saline or exenatide (25 nmol/kg bw) or peptide (75 
nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice and ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001compared to 
control db/db mice
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Figure 6.9 Effects of 28-day treatment with CPF-AM1 and [S4K] CPF-AM1 on non-fasting blood glucose (A, B) and plasma insulin (C, 
D) in db/db mice  
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Parameters were measured 3 days prior to, and every 72 hours during treatment (indicated with black bar) with saline or exenatide (25 nmol/kg 
bw) or peptide (75 nmol/kg bw) for 28 days. Values are mean ±SEM for 8 mice. *P<0.05, **P<0.01 ***P<0.001 compared to lean mice and 
ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to control db/db mice. 
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Figure 6.10 Effects of CPF-AM1 and [S4K] CPF-AM1 on HbA1c in db/db mice 
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HbA1c level was measured after long term treatment with twice-daily injections of 
either saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) for 28 days. 
Values are mean ± SEM for 4 mice. *P<0.05, ***P<0.001 compared with lean mice 
and ΔP<0.05, ΔΔP<0.01compare with db/db control mice. 
 
 
 
 
 
 
 
 
 
 
 
322 
 
Figure 6.11 Long-term effects of CPF-AM1 and [S4K] CPF-AM1 on plasma 
glucose (A, B) and insulin (C, D) concentrations following intraperitoneal glucose 
administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after 
intraperitoneal administration of glucose (18 mmol/kg bw) to db/db mice pre-treated 
with twice-daily injections of either with saline or exenatide (25 nmol/kg bw) or 
peptide (75 nmol/kg bw) for 28 days. Values are mean ± SEM for 8 mice. *P<0.05, 
**P<0.01, ***P<0.001 compared with lean mice (normal, saline). ΔP<0.05, ΔΔP<0.01, 
ΔΔΔP<0.001 compared to db/db control mice. 
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Figure 6.12 Long-term effects of CPF-AM1 and [S4K] CPF-AM1 on plasma 
glucose (A, B) and insulin (C, D) concentrations following oral glucose 
administration to db/db mice 
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Plasma glucose and insulin concentrations were measured prior to and after oral 
administration of glucose (18 mmol/kg bw) to db/db mice pre-treated with twice-daily 
injections of either saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) 
for 28 days. Values are Mean ± SEM for 8 mice. *P<0.05, **P<0.01, ***P<0.001 
compared with lean mice (normal, saline). ΔΔP<0.01 compared to db/db control. 
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Figure 6.13 Long-term effects of CPF-AM1 and [S4K] CPF-AM1 on insulin 
sensitivity in db/db mice 
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Plasma glucose were measured prior to and after intraperitoneal injection of insulin 
(50 U/kg bw) in db/db mice pre-treated with twice-daily injections of either saline or 
exenatide (25 nmol/kg bw) or peptide (75 nmol/kg bw) for 28 days. Values are mean 
± SEM for 8 mice. ***P<0.001 compared with to lean mice and ΔP<0.05, ΔΔP<0.01 
compare with db/db control mice. 
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Figure 6.14 Effects of CPF-AM1 and [S4K] CPF-AM1 on body composition in 
db/db mice. 
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Effects of CPF-AM1 and [S4K] CPF-AM1 on body composition in lean and db/db 
mice. Animals were injected with either saline or exenatide (25 nmol/kg bw) or 
peptide (75 nmol/kg bw) for 28 days. The figure shows (A) representative DEXA 
scans, (B) bone mineral density, (C) bone mineral content, (D) bone area. (E) lean 
body mass, (F) body fat and (G) body fat expressed a percentage of total body mass. 
Values are means ± SEM for 8 mice. *P<0.05, **P<0.01, ***P<0.001 compared with 
saline-treated lean mice. 
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Figure 6.15 Effects of [S4K] CPF-AM1 on pancreatic weight (A), total insulin 
content (B), and insulin secretory response of isolated islets (C&D) from lean, 
and db/db mice treated 
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Mice were treated with saline or exenatide (25 nmol/kg bw) or peptide (75 nmol/kg 
bw) for 28 days prior to experiment. Values are means ± SEM with n=4. *P<0.05, 
**P<0.01, ***P<0.001 compared with the response of islets isolated from each group 
of mice at 16.7 mM glucose. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared with the 
response of islets isolated from lean mice (saline treated) to each secretagogue or 
glucose concentration. 
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Figure 6.16 Effects of long-term treatment with CPF-AM1 and [S4K] CPF-AM1 
on total cholesterol (A), Triglycerides (B), HDL (C) and LDL (D) in db/db mice 
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Plasma sample was collected after 28 days treatment with either saline or exenatide 
(25 nmol/kg bw) or peptide (75 nmol/kg bw). Values are mean ± SEM for 6 mice. 
*P<0.05, ***P<0.001 compared to lean mice. ΔP<0.05, ΔΔP<0.01 compared to db/db 
control mice. 
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Figure 6.17 Effects of long-term treatment with CPF-AM1 and [S4K] CPF-AM1 
on plasma AST (A) ALT (B) ALP (C) and creatinine (D) levels in db/db mice 
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Following 28 days injection with either saline or exenatide (25 nmol/kg bw) or peptide 
(75 nmol/kg bw), plasma sample was collected and measured for ALT, AST, ALP and 
creatinine levels. Values are mean ± SEM for 6 mice. **P<0.01, ***P<0.001 
compared to lean control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 6.18 Effects of long-term treatment with [S4K] CPF-AM1 on amylase 
activity in db/db mice. 
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Following 28 days injection with either saline (control) or exenatide or peptide, plasma 
sample was collected, and amylase activity was measured. Values are mean ± SEM 
for n=6 mice. *P<0.05, ***P<0.001 compared to normal control, ΔΔP<0.01, 
ΔΔΔP<0.001 compared to db/db control. 
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Figure 6.19 Effects of CPF-AM1 & [S4K] CPF-AM1 treatment on islet 
morphology in db/db mice. 
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Representative image (A) showing insulin (green) and glucagon (red) 
immunoreactivity from lean, db/db control, CPF-AM1 and [S4K] CPF-AM1 treated 
mice. B, C, D, E and F shows islet number, islet area, beta cell area, alpha cell area, 
and islet size distribution respectively. Mean ± SEM for 6 mice (~80 islets per group). 
*P<0.05, **P<0.01 compared to normal saline control, ΔΔP<0.05, ΔΔP<0.01, 
ΔΔΔP<0.001 compared to db/db control. 
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Figure 6.20 Effects of CPF-AM1 & [S4K] CPF-AM1 treatment on expression of 
genes involved in insulin action in skeletal muscle 
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3 µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4. *P<0.05, **P<0.01, ***P<0.001 compared to 
normal control. ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control. 
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Figure 6.21 Effects of [S4K] CPF-AM1 treatment on expression of genes involved 
in insulin secretion from islets 
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3 µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4.  *P<0.05, **P<0.01, ***P<0.001 compared 
to normal control, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control mice. 
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Figure 6.22 Effects of [S4K] CPF-AM1 treatment on expression of genes involved 
in insulin secretion (A- C), beta cell proliferation (D) and beta cell apoptosis (E) 
in islets 
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3 µg of mRNA was used for cDNA synthesis. Expression values were normalised to 
Actb. Values are mean ± SEM for n=4.  *P<0.05, **P<0.01, ***P<0.001 compared 
to normal control, ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to db/db control mice. 
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Figure 6.23 Effects of twice daily administration of [S4K] CPF-AM1 on body 
weight change (A and B), food intake (C) and water intake (D) in GluCre-
ROSA26EYFP mice   
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Streptozotocin (50mg/kg bw) induced diabetic mice were grouped prior to the peptide 
treatment. Body weight (A & B), food intake (C), water intake (D) were measured 3 
days prior to, and every 72 hours during treatment with saline or [S4K] CPF-AM1 (75 
nmol/kg bw) for 11 days. Values are mean ±SEM for 5 mice. *P<0.05, **P<0.01 
***P<0.001 compared to lean mice. 
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Figure 6.24 Effects of twice daily administration of [S4K] CPF-AM1 on blood 
glucose (A) and plasma insulin (B) in GluCre-ROSA26EYFP mice  
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Blood glucose (A) and plasma insulin (B) were measured before and after 
streptozotocin, and after 11 days treatment with saline or [S4K] CPF-AM1(75 nmol/kg 
bw). Values are mean ±SEM for 5 mice. ***P<0.001 compared to lean mice. 
 
 
 
 
 
336 
 
Figure 6.25 Effects of twice daily administration of [S4K] CPF-AM1 on 
pancreatic insulin content in GluCre-ROSA26EYFP mice 
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Pancreatic insulin content was measured after 11 days treatment with saline or [S4K] 
CPF-AM1(75 nmol/kg bw). Values are mean ±SEM for 5 mice **P<0.01, ***P<0.001 
compared to normal saline control, ΔP<0.05, ΔΔP<0.01 compared to streptozotocin 
control. 
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Figure 6.26 Effects of [S4K] CPF-AM1 treatment on islet morphology in GluCre-
ROSA26EYFP mice 
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Representative islets (A) showing insulin (red) and glucagon (green) 
immunoreactivity from lean, streptozotocin and [S4K] PGLa-AM1 treated mice. B, C, 
D, E, and F shows islet number, islet area, beta cell area, alpha cell area, and islet size 
distribution respectively. Mean ± SEM for 5 mice (~50 Islets per group). *P<0.05, 
**P<0.01, ***P<0.001 compared to normal saline control, ΔP<0.05, ΔΔP<0.01, 
ΔΔΔP<0.001 compared to streptozotocin control. 
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Figure 6.27 Effect of [S4K] PGLa-AM1 on pancreatic Islets in GluCre-
ROSA26EYFP mice 
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Quantification Of A) Glucagon-GFP positive cells, B) Insulin-GFP positive cells, C) 
Glucagon positive cells, D) GFP positive cells per total islets and E) Insulin-Glucagon 
positive cells (~50 Islets per group). *P<0.05, **P<0.01, **P<0.001 compared to 
normal saline control, ΔP<0.05, ΔΔP<0.01, ΔΔΔP<0.001 compared to streptozotocin 
control. 
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7.1 Type 2 diabetes- The growing epidemic 
Type 2 diabetes, which is a complex metabolic disorder characterised by pancreatic 
beta cells dysfunction and insulin resistance, is currently one of the major healthcare 
problem globally. More prevalent in adults, type 2 diabetes is also seen in children and 
young adults due to an increasingly sedentary lifestyle (Basu et al., 2013). It accounts 
for 91% of the global diabetes population, out of which 80% resides particularly in 
developing nations like India and China. According to data published by the 
International Diabetes Federation (IDF), more than 400 million people were reported 
with type 2 diabetes in 2015. If no appropriate actions are taken, this figure is predicted 
to rise to 629 million by 2045.  
Type 2 diabetes can be controlled and managed by living a healthy lifestyle; however, 
due to the progressive nature of diseases, it becomes necessary to rely on antidiabetic 
drugs. Several antidiabetic drugs are in clinical use to tackle type 2 diabetes which 
include metformin, sulphonylureas, thiazolidinediones, acarbose, GLP-1 agonists, 
DPP-4 inhibitors, SGLT2 inhibitors and insulin. However, none of these drugs is 
successful in achieving long-term glycaemic control and preventing secondary 
complications associated with diabetes. Several studies have reported the close 
association of these drugs with hypoglycaemia, weight gain, inflammation of 
the pancreas, heart failure and hepatotoxicity (Bolen et al., 2007, Kelly et al., 2009, 
Ray et al., 2009, Tahrani et al., 2011). Moreover, these antidiabetics drugs are 
recommended in combination, which make patients more prone to the side effect 
associated with drugs. Also, the cost associated with treatment, which has reached 
USD 727 billion, is expected to rise due to increasing diabetes population. Hence 
required new alternative therapies that are cost-effective and can overcome the 
limitations of existing drugs. 
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7.2 Exploiting Natural antidiabetic agents 
7.2.1 Antidiabetic agents from plants 
Since ancient times native plants and their active ingredients have been used in 
Ayurvedic medicine for the treatment of wide range a of diseases including diabetes 
(Shakya, 2016). The main active ingredients found in the plants displaying antidiabetic 
activities are being used as lead molecules for the synthesis of new drugs. It is 
estimated that one in four currently prescribed drugs are developed from active 
ingredients of plants (Ye & Stanley, 2013). Antidiabetic drug metformin, developed 
from parent compound guanide found in the plant Galega officinalis, is currently in 
clinical use and recommended as the first line of drug for type 2 diabetes treatment 
(Koehn & Carter, 2003). 
More than 1200 plants have been reported with antidiabetic activities, and these plants 
majorly belong to the family of Fabaceae, Asteraceae & Lamiaceae (Marles and 
Farnsworth, 1995, Trojan-Rodrigues et al., 2012). Permender et al., 2010 presented 
an overview of the most effective antidiabetic activities of 54 plants of the Fabaceae 
family. Few examples of these plants are Abrus precatorius, Acacia arabica, Acacia 
catechu, Albizia lebbek, Arachis hypogaea and Bauhinia forficate. Cinnamomum 
tamala which belongs to the family of Lamiaceae demonstrated antidiabetic and 
antidyslipidemic effects in streptozotocin-induced diabetic rats (Bisht & Sisodia, 
2011). In 2013, Sidhu and Sharma from Punjab University (India), created a database 
of antidiabetic plants which belong to family Asteraceae, Euphorbiaceae, Fabaceae, 
Lamiaceae and Moraceae. Studies conducted in the Diabetes Research Laboratory at 
Ulster University have also revealed the antidiabetic activity of plants which include 
Medicago sativa (Gray & Flatt 1997), Agrimony eupatoria (Gray & Flatt 1998), 
Agaricus bisporus (Swanston-Flatt et al., 1989), Coriandrum sativum (Gray & Flatt 
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1999), Sambucus nigra (Gray et al., 2000) and Terminalis berllirica (Kasabri et al., 
2010) 
  
7.2.2 Antidiabetic agents from animals’ source 
Many animals’ species have developed specialised organs during evolution that 
produces venom to protect from predator and to capture prey (Casewell et al., 2013). 
These animal venoms are rich in biologically active molecules such as peptides and 
proteins. In the past, whole animal venom was used in Chinese traditional and Indian 
Ayurvedic medicine for the treatment of wide range of diseases which include arthritis, 
asthma, cancer, gastrointestinal alignment and rheumatism and pain (Ried, 2007, 
King, 2011). The advancement in bioanalytical technologies and progress in the area 
of genomics and transcriptomics have accelerated the development of the drugs from 
the animal venom. The presence of disulphide bonds in most of the venom-derived 
peptides provide stability and resistance to proteolytic enzyme thus making them 
unique biomolecules for the development of therapeutic agents. Several of these 
venoms derived peptides produce a response by binding with a receptor present on the 
mammalian cell surface.  
Both peptides and proteins found in the venom of animals such as snakes, scorpions, 
spiders, jellyfishes, anemones and cone snails are the most well-known and studied 
biomolecules. The majority of these molecules either act directly on the cardiovascular 
or nervous system of the prey and predators (Utkin et al., 2015). Captopril, an 
angiotensin-converting enzyme (ACE) inhibitor, isolated from Brazilian viper 
Bothrops jararaca, is the first venom-derived drug approved by FDA for treatment of 
cardiovascular diseases (Ferreira et al., 1970). Eptifibatide and tirofiban from Pygmy 
rattlesnake and Saw-scaled viper respectively are available for the treatment of acute 
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coronary syndromes. Exendin-4, a GLP-1 analogue, is the first venom bioactive 
molecule, approved for the metabolic treatment (Eng et al., 1990).  Exendin-4, isolated 
from the venom of Gila monster Heloderma suspectum, is available in the market by 
name Byetta from the treatment of type 2 diabetes. (Eng et al., 1992).  
Exendin-4 is 39 amino acid peptide which shares 53% structural homology with native 
GLP-1 (Furman, 2012). In comparison to native GLP-1, exendin-4 displayed longer 
in vivo half-life of around 160 min (20-30 fold higher) and potent (5500-fold greater) 
glucose lowering effects (Parkes et al., 2001; Young et al., 1999).  After the discovery 
of exendin-4, several other venom peptides have been identified with potent glucose-
lowering effects. Recently, new GLP-1 peptide analogues were identified in the 
venom and intestine of platypus and echidna, which were resistant to DPP-4 
degradation and displayed potent insulinotropic activities in cultured rodent islets 
(Tsend-Ayush et al., 2016). Safavi-Hemamiet al., 2015, found insulin analogue 
peptide in the venom of con snail (Conus geographus). Cone snail captures its prey by 
inducing hypoglycemic shock. C. geographus insulin (Con-Ins G1) was found similar 
to fish insulin and has shown to activate insulin signalling pathway by binding to the 
insulin receptor (Menting et al., 2016). Unlike human insulin, Con-Ins G1 lacks the 
region of B chain responsible for dimerisation. This makes Con-Ins G1 as an ideal 
candidate for the development of fast-acting insulin formulation for the treatment of 
diabetes.  
Delayed rectiﬁer KV channels and BK channels are important for repolarisation of 
beta cells following insulin secretion (Smith et al.,1990). Peptide hanatoxin (k-
theraphotoxin-Gr1a), found in the venom of the tarantula Grammostola rosea, has 
been shown to stimulate insulin release from mouse and human beta cells in a glucose-
dependent manner by blocking delayed rectiﬁer KV2.1 channel (Swartz & 
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MacKinnon, 1995). Guangxitoxin-1, another KV2.1 channel blocker, isolated from 
Chinese earth tiger tarantula, also demonstrated insulin release in a glucose-dependent 
manner by increasing intracellular calcium concentrations (Herrington et al., 2006). 
Iberiotoxin (bTx), found in the venom of red scorpion Buthus tamulus, enhanced 
insulin secretion in human beta cells by blocking BK channels (Galvez et al., 1990, 
Braun et al., 2008). 
Several studies have reported the presence of insulinotropic bioactive compounds in 
the snake venom (Toyama et al., 2000, 2005, Nogueira et al., 2005, Hernandez et al., 
2008, Nguyen et al., 2012). The venom of Crotalus adamanteus, Crotalus vegrandis, 
Bitisnas icornis, Pseudechis australis and Pseudechis butleri snakes were studied in 
our laboratory for insulin-releasing activity in BRIN-BD11 cells. In this study, 
insulinotropic compounds which belong to the family of phospholipases A2 (PLA2), 
serine proteinases and disintegrins were identified in snake venom (Moore et al., 
2015a, Moore et al., 2015). The discovery of drugs with therapeutic utility in the 
venoms of the snake, lizards, scorpion, cone snail and other animals has created 
curiosity to investigate amphibian skin secretions for antidiabetic peptides. 
 
7.3 Insulinotropic, glucose‑lowering, and beta‑cell anti‑apoptotic actions 
of temporin and Esculentin-1 peptides  
Temporin and esculentin-1 peptides were identified in frogs belonging to the extensive 
family Ranidae of both Eurasian and N. American (Conlon et al., 2009, Xu & Lai, 
2015). Temporins were obtained from Rana temporaria, and esculentin-1 from Rana 
esculenta [(Pelophylax lessonae (Pool frog) x Pelophylax ridibundus (marsh frog)].  
These peptides are well known for their antimicrobial activity (Ponti et al., 1999, 
Mangoni et al., 2016). Chapter 3, reports antidiabetic effects of these peptides. 
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Acute in vitro insulin release studies revealed that Temporin A, B and G exhibited 
potent insulin release studies in BRIN-BD11 cells with no cytotoxic effects. 
Esculentin-1a (1-21).NH2, esculentin-1b (1-18).NH2 and esculentin-1a (1-14).NH2 
which are N terminal derived peptides of esculentin-1a and -1b also exhibited similar 
effects. In addition, analogue [D-Lys14, D-Ser17] esculentin-1a (1-21).NH2 (Esc(1-21)-
1c) also produced insulinotropic activity. The insulin inducing ability of these peptides 
were also replicated in human clonal β-cells and isolated mouse islets. The study also 
revealed that that cationicity, hydrophobicity and angle subtended by charged residue 
are an important factor for the insulin-releasing activity of temporin peptides, whereas 
helicity plays a key role in the insulinotropic activity of the esculentin-1 peptide. 
Esculentin-1 peptides produced a significant increase in membrane potential and 
intracellular calcium concentration in BRIN-BD11 cells. On the other hand, temporins 
peptide had no significant effects on these parameters. This preliminary observation 
suggests that esculentin-1a could exhibit its effects by the KATP channel-dependent 
pathway and temporin peptides by the KATP channel-independent pathway.  
In T2DM, insulin concentration declines with age due to loss of beta cell mass and 
function (Cantley & Ashcroft, 2015, Arden, 2018). Therefore, treatment strategies 
towards restoring beta cell mass and beta cell function would be beneficial in tackling 
T2DM. Temporin A, temporin F, esculentin-1a (1-21) NH2 and esculentin (1-21)-1c 
but not temporin G (1 µM) protected BRIN-BD11 cells against cytokine-induced 
apoptosis as well as the augmented proliferation of cells. On the other hand, 
esculentin-1b (1-18).NH2 and esculentin-1a (1-14).NH2 also showed a tendency to 
protect beta cells against cytokine-induced apoptosis and enhanced proliferation of the 
cells. Further acute in vivo studies revealed that temporin G and esculentin (1-21)-1c 
improved glycemic response in lean mice after intraperitoneal injection with glucose. 
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On the other hand, temporin A, temporin F, esculentin-1a (1-21).NH2, esculentin-1b 
(1-18).NH2 and esculentin-1a (1-14) failed to improve glucose tolerance (See Table 
7.1 and 7.2: For the summary of acute in vitro and in vivo studies of temporin and 
esculentin-1a peptides). 
In conclusion, Chapter 3 highlighted the insulin-releasing activity of temporin and 
esculentin-1 peptides and analogue esculentin (1-21)-1c. Also, the study revealed 
positive effects of these peptides on beta cell proliferation and protection against 
cytokines induced DNA damage. These peptides can be used as a templet to develop 
long-acting analogues with improved antidiabetic activities. 
 
7.4 Insulinotropic activities of frenatin 2D and its synthetic analogues 
Amphibian skin peptides have been reported with a wide range of biological activities 
(Conlon et al., 2014, Xu & Lai et al., 2015). This include antimicrobial, antifungal, 
antiviral, anticancer and immunomodulatory activities. Interestingly, some of these 
peptides have shown to evoke insulin release from BRIN-BD11 cells and primary islet 
cells and improve glycaemic response both in lean and high fat fed mice following 
intraperitoneal administration (Conlon et al., 2018). The norepinephrine-stimulated 
skin secretions of Discoglossus sardus and Sphaenorhynchus lacteus were reported 
with a high concentration of peptides that showed structural similarity to frenatin 2 
peptides found in the Australian frog Litoria infrafrenata. Hence these peptides were 
named as frenatins. Frenatin 2D from Discoglossus sardus was the most potent of four 
naturally occurring frenatin peptides tested for insulin-releasing activity in BRIN-
BD11 cells. Frenatin 2D, evoked dose-dependent insulin release from rat clonal beta 
cells without producing cytotoxic effects. In this study, 14 analogues of frenatin 2D 
were designed by replacing each amino acid by hydrophobic tryptophan (W) residue. 
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This strategy did not lead to design analogues with potent insulinotropic activity. 
However, the insulinotropic action of frenatin 2D was unaffected by substitution at 
Asp1 and Gly7. Interestingly, the activity of peptide was retained after deletion of the 
C-terminal α-amide group. Furthermore, the insulinotropic activity of [D1W] and 
[G7W] was replicated in human-derived pancreatic beta cells (1.1B4 cells) and 
isolated mouse islet cells.  
Frenatin 2D peptides did not produce any significant change in membrane potential 
and intracellular calcium. In agreement with this, the insulin-releasing ability of 
peptides was not completely diminished in the presence of verapamil, diazoxide and 
DIDS as well as in the absence of extracellular calcium. The similar observation was 
reported with pseudin-2 and hymenochirin 1B (Abdel-Wahab et al., 2008, Owolabi et 
al.,2016). However, frenatin 2D peptides produced a significant increase in cAMP. In 
line with this, the stimulatory effects of frenatin 2D peptides were abolished in PKA-
downregulated BRIN-BD11. These data indicate that frenatin 2D peptides may exhibit 
its action by the KATP channel-independent pathway. The role of GLP-1 in beta cell 
survival and proliferation is well documented (Cornu et al., 2009, Lee et al., 2014). 
Interestingly, frenatin 2D protected beta cells against cytokine-induced apoptosis as 
well as improved proliferation of BRIN-BD11 cells. Furthermore, acute in vivo 
glucose tolerance studies revealed that [D1W] Frenatin 2D was effective than other 
frenatin 2D peptides (See Table 7.3: For the summary of acute in vitro studies, and 
Table 7.4: For the summary of acute in vivo studies).  
Based on these results, we further investigated the long-term metabolic effects of 
[D1W] and parent peptide frenatin 2D in diabetic mice (db/db mice). In all treatment 
groups, blood glucose concentration was significantly decreased. This was associated 
with improved blood HbA1C and glucose tolerance. Furthermore, the overexpression 
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of insulin signalling genes in db/db mice was reversed by peptide treatment which 
could explain the augmentation of insulin sensitivity. Antidiabetic drugs lowering 
body fat and energy intake would be beneficial in preventing the occurrence of type 2 
diabetes. Unfortunately, frenatin 2D and [D1W] frenatin 2D had no significant effects 
on body fat and energy intake.  
In frenatin 2D and exenatide-treated mice, the improvement in glycaemic control was 
associated with augmentation of plasma insulin. The genes involved in insulin 
secretion were markedly increased, which might explain augmentation of beta cell 
function, secretion and pancreatic insulin content in these mice (Li et al., 2005, Bae et 
al., 2010). On the other hand, in [D1W] frenatin 2D treated mice, these changes were 
not equally effective as parent peptide. Except for exenatide, no significant changes in 
beta and alpha cells population were observed. However, loss of large and medium-
size islets was significantly prevented in all treated mice. With both frenatin 2D and 
[D1W] frenatin 2D treatment, no significant changes in lipid profile were observed. 
The biomarkers for liver and kidney function were improved significantly. 
Furthermore, amylase activity remained unaffected suggesting that peptide does not 
exert any toxic effects on the pancreas (See Table 7.5: For the summary of long-term 
in vivo studies).   
In conclusion, Chapter 4 highlighted the antidiabetic effects of frenatin 2D peptides 
both in vitro and in vivo. The amino acids substitution in frenatin 2D did not produce 
analogue with greater insulinotropic potency, suggesting that the peptide is sensitive 
to any change in its primary structure.  
 
7.5 Antidiabetic effects of a structurally modified analogue of peptide glycine 
leucine amide-AM1 (PGLa-AM1) 
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PGLa-AM is a 22 amino acids peptide, which was initially isolated from Xenopus 
amieti based on antimicrobial activity, interestingly have also shown to induce insulin 
release from BRIN-BD11 cells (Conlon et al., 2010, Owolabi et al., 2017). 
Additionally, peptide also stimulated the dose-dependent release of GLP-1 from 
GLUTag cell line (Ojo et al., 2013). Several frog skin peptide analogues containing L 
lysine substitution showed substantially greater insulinotropic activity than the parent 
peptide (Abdel-Wahab et al., 2008, Owolabi et al., 2016). Its more cationic analogue, 
[A14K] showed greater insulin-releasing activity in BRIN-BD11 cells than the parent 
peptide. Interestingly, in primary islet cells, the insulinotropic activity of [A14K] was 
comparable to that of GLP-1 at 1µM concentration. Furthermore, a decrease in blood 
glucose and an increase in plasma insulin concentration was noticed in both lean and 
high fat fed mice when injected together with glucose (Owolabi et al., 2017). Based 
on these promising findings, [A14K] analogue was chosen to investigate its long-term 
metabolic effects. 
In agreement, [A14K] analogue exhibited greater insulinotropic activity in glucose-
responsive rat clonal pancreatic beta-cell line with no cytotoxic effects.  The insulin-
releasing activity of analogue was also replicated in the human-derived pancreatic beta 
cell line (1.1B4 cells), at 5.6 and 16.7 mM glucose concentration. This suggests that 
analogue not only exhibit insulinotropic activity at physiological glucose level but also 
retain its activity at a higher glucose level. Moreover, analogue was equally effective 
as GLP-1, in protecting BRIN-BD11 cells against cytokine-induced apoptosis. An 
increase in beta cell proliferation was also observed. Further studies of the expression 
of protein kinase B (PKB), which plays a key role in beta-cell growth and survival, 
will help to delineate the mechanism by which the analogue produced protective and 
proliferative effects (Li et al., 2005).   
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Based on these results, a long-term (28 days) study was conducted in db/db mice to 
investigate antidiabetic effects of [A14K] PGLa-AM1 in comparison with its parent 
peptide PGLa-AM1 and FDA approved antidiabetic agent exenatide. In db/db mice, a 
gradual decline in plasma insulin was significantly delayed by [A14K] PGLa-AM1 
and exenatide treatments. This was associated with improved expression of insulin 
secretory genes in these mice. For example, a Pdx-1 gene which is an important 
transcription factor for insulin gene was increased in these mice (Kimura et al., 2014). 
The expression of GLUT2 and glucokinase genes were also elevated, which could 
explain the increase in pancreatic insulin content and the augmentation of glucose-
stimulated insulin secretion in these mice (Li et al., 2005, Bae et al., 2010). On the 
other hand, PGLa-AM1 had little beneficial effects on plasma insulin and insulin 
content, but not significant.  
In db/db mice, an increase in blood glucose was countered by [A14K] PGLa-AM1 and 
exenatide treatment. This was corroborated with improved HbA1c in these mice. In 
the hyperglycemic state, expression of the GLP-1 receptor was significantly 
downregulated in beta cells (Kaneto and Matsuoka, 2013). Upregulation of this gene 
could also explain improved blood glucose in [A14K] PGLa-AM1 and exenatide-
treated mice. PGLa-AM1 also showed a tendency to improve blood glucose and 
HbA1c, but no statistical significance was observed. Glycaemic response to oral and 
intraperitoneal glucose challenge was significantly improved by treatment with 
[A14K] PGLa-AM1 and exenatide. Irrespective of any change in body weight, insulin 
sensitivity was significantly improved by [A14K] PGLa-AM1 and exenatide. This was 
corroborated with lower HOMA-IR index and improved insulin signalling genes in 
skeletal muscle of these mice.  
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The risk of cardiovascular diseases in type 2 diabetes patient can be reduced by 
improving lipid metabolism (Chehade et al., 2013). Elevated triglycerides and LDL in 
db/db mice were reversed by treatment with [A14K] PGLa-AM1 and exenatide. 
Interestingly, cholesterol level in db/db mice was decreased only by [A14K] PGLa-
AM1 treatment. Liver and kidney functions were significantly improved by all peptide 
treatments. However, the increase in amylase activity was observed in all treated mice. 
Except for islet size distribution, no significant changes in islet morphology were 
observed in both PGLa-AM1 and [A14K] PGLa-AM1 treated mice. The large and 
medium islets were increased in these mice. As expected, islet morphology was 
significantly improved by treatment with exenatide (See Table 7.6: For the summary 
of long-term in vivo studies). In transgenic mice (GluCre-ROSA26EYFP mice), the 
number of Ins+/GFP+ and Ins+/Glu+ cells were increased by [A14K] PGLa-AM1 
treatment. In line with this, the increase in the beta cell area and, large and medium-
size islet were observed, indicating that [A14K] PGLa-AM1 could have an important 
role in transdifferentiation of alpha to beta cells. 
In conclusion, Chapter 5 reported the beneficial effects of [A14K] PGLa-AM1 on 
plasma insulin, blood HbA1c, glucose tolerance, lipid profile and insulin resistance. 
In vivo studies in transgenic mice showed that [A14K] PGLa-AM1 has an important 
role in the generation of new beta cells from glucagon-producing alpha cells. These 
results are encouraging to further develop frog skin peptide analogues for the treatment 
of T2DM. 
 
7.6 Therapeutic potential of [Lys4] substituted analogue of CPF-AM1 
Several frog skin host defence peptide with insulin releasing activity were transformed 
to analogues showing superior antidiabetic activity both in vitro and in vivo (Ojo et 
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al., 2013, Srinivasan et al., 2015, Owolabi et al., 2015, Vasu et al., 2017). CPF-AM1 
peptide found in the skin secretion of frog Xenopus amieti demonstrated 
concentration-dependent insulinotropic activity in rat clonal pancreatic beta cells 
(BRIN-BD11 cells). Additionally, peptide also showed to induce GLP-1 release from 
GLUTag cell line. Its more cationic [S4K] analogue, developed by substitution of L 
lysine at position 4, displayed potent insulinotropic activity than the parent peptide. 
Furthermore, analogue also showed the ability to decrease blood glucose and improve 
plasma insulin concentration in lean and high fat fed mice when injected together with 
glucose.  
In agreement, [S4K] analogue displayed potent insulin-releasing activity in BRIN-
BD11 cells. Its insulinotropic activity was also replicated in human-derived pancreatic 
beta cells (1.1B4 cells). Interestingly, [S4K] analogue when co-incubated with 
cytokine mixture, the number of tunnel positive cells were decreased significantly. 
Additionally, analogue improved beta-cell proliferative activity similar to that of 
glucagon-like peptide-1 (GLP-1). Based on these results and previous studies, [S4K] 
analogue was selected for long-term studies in db/db and GluCre-ROSA26EYFP 
mice. 
In T2DM, with the time, plasma insulin level decline due to beta cell loss (Buttler et 
al., 2003). Therefore, antidiabetic agent preventing beta cell loss would be beneficial. 
[S4K] CPF-AM1analogue and exenatide significantly delayed a gradual decline of 
plasma insulin levels in db/db mice. These findings correlated with improved 
pancreatic insulin content by [S4K] CPF-AM1 and exenatide treatment. CPF-AM1 
also showed a tendency to delay a gradual decline of plasma insulin levels, but no 
statistical significance was observed compared to db/db controls.  
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The onset of secondary complications in type 2 diabetes can be prevented by 
maintaining strict glycaemic control (UK Prospective Diabetes Study (UKPDS) 
Group, 1998). In all treated groups, blood glucose was significantly decreased. In both 
[S4K] CPF-AM1 and CPF-AM1 treated mice, a decrease in blood glucose was not 
associated with any significant change in either body weight or energy intake. Whereas 
in the exenatide-treated group, energy intake was reduced significantly. Blood HbA1c, 
which reflects average blood glucose levels up to a 3-month period, was lowered by 
[S4K] CPF-AM1 and exenatide treatment. CPF-AM1 also lowered blood HbA1c but 
not statistically significant compared to db/db controls. Treatment with [S4K] CPF-
AM1 and exenatide, significantly improved glycaemic response to intraperitoneal 
glucose challenge. This was associated with an improvement in insulin sensitivity in 
these mice. In agreement with this, elevated expression of insulin singling genes in 
db/db mice was reversed by [S4K] CPF-AM1 and exenatide treatment. On the other 
hand, in CPF-AM1 treatment, no significant changes in glucose tolerance and insulin 
sensitivity were observed.  
In db/db mice elevated triglycerides and LDL levels were decreased by [S4K] CPF-
AM1, but not significantly. Interestingly, the triglyceride level was significantly 
decreased by CPF-AM1, suggesting that peptide could also play an essential role in 
the prevention of cardiovascular diseases. Elevated liver and kidney biomarkers in 
db/db mice, were reversed in all treated groups indicating that peptides are safe for the 
treatment. In all peptide treated groups, increase in amylase activity was observed, 
suggesting a potential issue with pancreatitis. 
Islets from [S4K] CPF-AM1 treated mice showed improved insulin secretory 
response. These observations correlate with enhanced expression of insulin secretory 
genes. The expression of Glp1r, Gipr, Pdx1 and other secretory genes were 
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significantly upregulated. CPF-AM1 also showed a tendency to improve insulin 
secretory responses and expression of genes. No significant change was noticed in the 
islet area, beta-cell area and alpha cell area in both CPF-AM1 and [S4K] CPF-AM1 
treated groups. However, the loss of large and medium-size islet was prevented. As 
expected, insulin secretory responses, beta cell function and islet morphology were 
significantly improved by exenatide (See Table 7.7: For the summary of long-term in 
vivo studies). Furthermore, immunohistochemical analysis of pancreata from 
transgenic mice (GluCre-ROSA26EYFP mice) treated with [S4K] CPF-AM1 showed 
increase in Ins+/GFP+, Ins+/Glu+ and GFP+ cells. This result correlated with increased 
beta cell population, indicating that peptide could influence the conversion of alpha to 
beta cells. 
In conclusion, Chapter 6 reported that more cationic L -lysine substituted analogue of 
CPF-AM1 demonstrated potent antidiabetic activity than the parent peptide and could 
have an essential role in transdifferentiation of alpha to beta cells. These observations 
encourage further studies to find the specific receptor through which [S4K] CPF-AM1 
exerts its beneficial metabolic effects. 
 
7.7 Future studies 
This thesis demonstrated in vitro and in vivo antidiabetic potency of frog skin peptides 
and their synthetic analogue belonging to the family of Alytidae, Hylidae, Pipidae and 
Ranidae. Both, [A14K] PGLa-AM1 and [S4K] CPF-AM1 analogue exhibited positive 
effects on blood glucose and plasma insulin concentration in db/db mice. Also, the 
genes involved in insulin secretions and insulin signalling were significantly improved 
by the treatment. Positive effects of these peptide was also observed in 
transdifferentiation of glucagon producing alpha to insulin producing beta cells in 
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streptozotocin induced diabetic mice. Interestingly, [A14K] PGLa-AM1, significantly 
lowered cholesterol level in db/db mice. These promising data, will hopefully leds to 
further development these peptides into therapeutic agents. [D1W] frenatin 2D 
relatively showed weak antidiabetic activity in db/db mice compared to parent peptide. 
Further structure-activity relationship studies of frenatin 2D, as well as of temporin 
and esculentin-1 peptides are required to develop analogues with improved metabolic 
stability and insulinotropic activities. 
However, further studies are necessary to understand the precise mechanism of 
biological actions of these peptides. Understanding structural changes of these 
peptides upon interaction with membranes will help to improve the biological 
activities. The membrane interaction studies would be beneficial to identify the 
receptor through which peptides exert insulin-releasing activity followed by in vivo 
studies in receptor knockout mice. Studying the effects of the peptide on GLP-1 
release in vivo would be interesting. Investigation the expression of signalling protein 
[e.g. phospho-protein kinase B (PKB/AKT)] and transcription factor [phospho-
Forkhead box protein O1 (FOXO1) and pancreas duodenum homeobox-1 (PDX-1)] 
would help to delineate the mechanism through which peptide induce proliferation and 
protect the beta cell from cytokine-induced DNA damage. Additional studies to 
investigate the expression of insulin signalling genes in liver and adipose tissue would 
provide a better understanding of the biological action of these peptides. Esculentin-1 
peptides stimulated insulin release by KATP channel-dependent pathway. Further 
performing patch-clamp experiments will help to better understand the 
electrophysiological effects of the peptide on KATP and L-type calcium channels in 
beta cells. To examine the molecular mechanism through which peptide influence 
reprogramming of glucagon-expressing alpha to insulin-expressing beta cells. It would 
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be interesting to further investigate the effects of the peptide on the generation of new 
beta cells from non-beta cells using transgenic InsCre-ROSA26EYFP mice. The data 
in the present thesis and studies outlined above can form a strong base to develop frog 
skin peptides into antidiabetic agents. 
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Table 7.1 Summary of in vitro and acute in vivo results of temporin peptides 
 
 
 
Peptides 
Insulin release from BRIN-
BD11 cells 
Insulin release from 1.1 
B4 cells 
Insulin 
release from 
islet at 1 µM 
(% of total 
insulin 
content) 
 
LHD 
assay 
 
Intrace- 
llular 
calcium 
 
Membr- 
ane 
potential 
Effects on apoptosis 
in BRIN-BD11 
 
 
Effects on 
proliferation 
in BRIN-
BD11 
 
Acute effects of 
peptides on 
glucose tolerance 
in vivo 
 
% of basal 
insulin 
release at 3 
µM 
Threshold 
concent-
ration (nM) 
% of basal 
insulin 
release at 3 
µM 
 
Thresh- 
old 
concent-
ration 
(nM) 
Without 
cytokine 
With 
cytokine 
Plasma 
Glucose 
Plasma 
Insulin 
Temporin A 262.6 ± 27.81  10-9 
 
190.4 ± 10.98  10-9 
 
10.60 ± 0.43 NS NS NS NS   NS NS 
Temporin B 170.2 ± 10.16  10-9 
 
NT NT NT NS NT NT NT NT NT NT NT 
Temporin C 135.2 ± 7.284  10-7 
 
NT NT NT NS NT NT NT NT NT NT NT 
Temporin E 135.0 ± 4.173  10-7 NT NT NT NS NT NT NT NT NT NT NT 
Temporin F 251.9 ± 28.37  10-9 
 
176.1 ± 10.72  10-9 
 
12.64 ± 1.612  NS NS NS NS   NS NS 
Temporin G 235.8 ± 24.44  10-9 
 
219.1 ± 14.41  10-9 
 
12.24 ± 1.067  NS NS NS   NS   
Temporin H NS NA NT NA NT NT NT NT NT NT NT NT NT 
Temporin K NS NA NT NA NT NT NT NT NT NT NT NT NT 
 
 
NA: Not applicable, NS: No Significant, NT: Not tested, (   ) increase significantly, (   ) decrease significantly 
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Table 7.2 Summary of in vitro and acute in vivo results of esculentin-1 peptides 
 
 
 
 
Peptides 
Insulin release from 
BRIN-BD11 cells 
Insulin release from 1.1 B4 
cells 
Insulin 
release from 
islet at 1 µM 
(% of total 
insulin 
content) 
 
LDH 
assay 
 
Memb- 
rane 
potential 
 
Intracel- 
lular 
calcium 
 
Effects on apoptosis 
in BRIN-BD11 
 
 
Effects on 
proliferation 
BRIN-BD11 
 
Acute effects of 
peptides on 
glucose tolerance 
in vivo 
 
% of basal 
insulin 
release at 3 
µM 
Thres- 
hold 
concent-
ration 
(nM) 
% of basal 
insulin 
release at 3 
µM 
 
Threshold 
concent-
ration (nM) 
Without 
cytokine 
With 
cytokine 
Plasma 
Glucose 
Plasma 
Insulin 
Esculentin
-1a (1-21) 
196.0 ± 4.24 10-9 
 
224.2 ± 15.21  10-10 
 
12.76 ± 0.52 NS   NS   NS NS 
Esculentin
- 
(1-21)-1C 
189.7 ± 15.25 10-8 
 
175.2 ± 10.86  10-0 
 
13.79 ± 1.025 NS NS NS NS     
Esculentin
-1a(1-14) 
206.5 ± 2.380  10-9 
 
180.2 ± 23.02  10-10 
 
13.68 ± 0.63  NS   NS  NS NS NS 
Esculentin
-1a(9-21) 
NS NA NT NA NT NS NT NT NT NT NT NT NT 
Esculentin
-1b(1-18) 
218.0 ± 6.419  10-9 
 
176.2 ± 11.14  10-9 
 
13.51 ± 0.97 NS   NS  NS NS NS 
 
NA: Not applicable, NS: No Significant, NT: Not tested, (   ) increase significantly, (   ) decrease significantly 
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Table 7.3 Acute invitro studies of frenatin 2D, [D1W] frenatin 2D & [G7W] frenatin 
2D 
 
Tests 
Peptides 
Frenatin 2D [D1W] 
frenatin 2D 
[G7W] 
frenatin 2D 
Insulin release 
from BRIN-
BD11 cells  
%Basal insulin release 
at 3µM concentration 
227.3 ± 24.54 258.5 ± 24.95  254.2 ± 12.45 
Threshold 
concentration (nM) 
0.01 0.01 0.01 
Insulin release 
from 1.1B4 
cells 
% Basal insulin release 
at 3µM concentration 
215.7 ± 17.68  200.9 ± 12.04 164.6 ± 11.85  
Threshold 
concentration (nM) 
0.1 0.1 1 
Insulin release from islet at 1 µM (% of 
total insulin content) 
13.01 ± 0.52 15.62 ± 1.90 15.20 ± 1.13 
LDH assay NS NS NS 
Membrane potential NS NS NS 
Intracellular calcium NS NS NS 
 
Insulin release 
in presence of 
modulators 
Verapamil    
Diazoxide    
IBMX NS NS NS 
KCl    
Insulin release in the absence 
extracellular calcium 
   
Insulin release in presence of chloride 
channel blocker DIDS 
 NT NT 
cAMP production    
Insulin release 
in PKA and 
PKC 
downregulated 
cells 
 
PKA downregulated    
PKC downregulated  NS NS NS 
PKA & PKC 
downregulated 
NS NS NS 
Effects on 
apoptosis in 
BRIN-BD11 
Without cytokine NS NS NS 
With cytokine    
Effects on Proliferation in BRIN-BD11    
Glucose 
uptake in 
C2C12 cells 
Without insulin NS NS NS 
With insulin  NS NS NS 
 
NS: No Significant, NT: Not tested, (  ) increased significantly,  (  ) decreased 
significantly 
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Table 7.4 Acute in vivo studies of frenatin 2D [D1W] frenatin 2D & [G7W] frenatin 
2D 
 
 
Acute in vivo studies 
Peptides 
Frenatin 
2D 
[D1W] 
frenatin 2D 
[G7W] 
frenatin 2D 
Acute effect of peptide (75 nmol/kg/bw) on 
food intake 
NS NS  
 
Acute effect of peptide (75 
nmol/kg/bw) on glucose 
tolerance 
Glucose    
Insulin     
Persistent 
effect of 
peptide on 
glucose 
tolerance  
2 hr Glucose   NS 
4 hr Glucose NS  NT 
Acute effect of 
different dose 
of peptide on 
glucose 
tolerance 
150 
nmol/kg/bw 
Glucose     
50  
nmol/kg/bw 
Glucose  NS  NT 
25  
nmol/kg/bw 
Glucose NT NS NT 
 
 
NS: No Significant, NT: Not tested, (  ) increased significantly,  (  ) decreased 
significantly 
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Table 7.5 Metabolic effects of 28 days administration of frenatin 2D and [D1W] 
frenatin 2D in db/db mice 
 
 
Parameters 
Peptides 
Frenatin 2D [D1W] frenatin 2D Exenatide 
Non-fasting glucose    
Non-fasting insulin  NS                
Body weight NS NS NS 
Energy Intake NS NS  
Water Intake NS NS  
 
IPGTT 
Blood Glucose    
Plasma Insulin    
 
OGTT 
Blood Glucose NS NS  
Plasma Insulin NS NS  
Insulin sensitivity    
Blood HBA1c    
 
Lipid profile 
Cholesterol NS NS NS 
Triglycerides NS NS  
HDL NS NS NS 
LDL NS NS  
 
Liver and kidney 
function 
AST    
ALT    
ALP    
Creatinine    
Amylase activity NS NS  
Islet morphology Islet area NS NS  
Beta Cell area NS NS  
Alpha cell area NS NS  
 
NS: No Significant, NT: Not tested, (  ) increased significantly,  (  ) decreased 
significantly 
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Table 7.6 Metabolic effects of 28 days administration of PGLa-AM1 and [A14K] 
PGLa-AM1 in db/db mice 
 
 
Parameters 
Peptides 
PGLa-AM1 [A14K] PGLa-AM1 Exenatide 
Non-fasting glucose NS   
Non-fasting insulin NS                 
Body weight NS NS NS 
Energy Intake NS NS  
Water Intake NS NS  
 
IPGTT 
Blood Glucose NS   
Plasma Insulin NS   
 
OGTT 
Blood Glucose NS   
Plasma Insulin NS   
Insulin sensitivity NS   
Blood HBA1c NS   
 
Lipid profile 
Cholesterol NS  NS 
Triglycerides NS   
HDL NS NS NS 
LDL NS   
 
Liver and kidney 
function 
AST    
ALT    
ALP NS   
Creatinine    
Amylase activity    
Islet morphology Islet area NS NS  
Beta Cell area NS NS  
Alpha cell area NS NS  
 
NS: No Significant, NT: Not tested, (  ) increased significantly,  (  ) decreased 
significantly 
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Table 7.7 Metabolic effects of 28 days administration of CPF-AM1 and [S4K] CPF-
AM1 in db/db mice 
 
 
Parameters 
Peptides 
CPF-AM1 [S4K] CPF-AM1 Exenatide 
Non-fasting glucose    
Non-fasting insulin NS                 
Body weight NS NS NS 
Energy Intake NS NS  
Water Intake NS NS  
 
IPGTT 
Blood Glucose NS   
Plasma Insulin NS   
 
OGTT 
Blood Glucose NS NS  
Plasma Insulin NS NS  
Insulin sensitivity    
Blood HBA1c NS   
 
Lipid profile 
Cholesterol NS NS NS 
Triglycerides  NS  
HDL NS NS NS 
LDL NS NS  
 
Liver and kidney 
function 
AST    
ALT    
ALP    
Creatinine    
Amylase activity    
Islet morphology Islet area NS NS  
Beta Cell area NS NS  
Alpha cell area NS NS  
 
NS: No Significant, NT: Not tested, (  ) increased significantly,  (  ) decreased 
significantly 
 
 
364 
 
 
 
 
 
Chapter 8 
 
References 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
365 
 
Abdeen, G. and Le Roux, C. (2016) Mechanism underlying the weight loss and 
complications of Roux-en-Y gastric bypass. Review. Obesity Surgery, 26(2), 410-421 
Abdel-Wahab, Y.H., Marenah, L., Flatt, P.R. and Conlon, J.M. (2007) Insulin releasing 
properties of the temporin family of antimicrobial peptides. Protein and Peptide Letters, 
14(7), 702-707.  
Abdel-Wahab, Y.H., Marenah, L., Orr, D.F., Shaw, C. and Flatt, P.R. (2005) Isolation 
and structural characterisation of a novel 13-amino acid insulin-releasing peptide from 
the skin secretion of Agalychnis calcarifer. Biological Chemistry, 386(6), 581-587.  
Abdel-Wahab, Y.H., Power, G.J., Ng, M.T., Flatt, P.R. and Conlon, J.M. (2008a) 
Insulin-releasing properties of the frog skin peptide pseudin-2 and its [Lys18]-
substituted analogue. Biological Chemistry, 389(2), 143-148.  
Abdel-Wahab, Y.H., Power, G.J., Flatt, P.R., Woodhams, D.C., Rollins-Smith, L.A. and 
Conlon, J.M. (2008b) A peptide of the phylloseptin family from the skin of the frog 
Hylomantis lemur (Phyllomedusinae) with potent in vitro and in vivo insulin-releasing 
activity. Peptides, 29(12), 2136-2143.  
Abdel-Wahab, Y., Patterson, S., Flatt, P. and Conlon, J.M. (2010) Brevinin-2-related 
peptide and its [D4K] analogue stimulate insulin release in vitro and improve glucose 
tolerance in mice fed a high fat diet. Hormone and Metabolic Research, 42(09), 652-
656.  
Adriaenssens, A.E., Svendsen, B., Lam, B.Y., Yeo, G.S., Holst, J.J., Reimann, F. and 
Gribble, F.M. (2016) Transcriptomic profiling of pancreatic alpha, beta and delta cell 
populations identifies delta cells as a principal target for ghrelin in mouse islets. 
Diabetologia, 59(10), 2156-2165.  
Ahmed, A.M. (2002) History of diabetes mellitus. Saudi Medical Journal, 23(4), 373-
378.  
Akter, R., Cao, P., Noor, H., Ridgway, Z., Tu, L., Wang, H., Wong, A.G., Zhang, X., 
Abedini, A. and Schmidt, A.M. (2016) Islet amyloid polypeptide: structure, function, 
and pathophysiology. Journal of Diabetes Research, 2016  
American Diabetes Association. (2011) Executive summary: standards of medical care 
in diabetes--2011. Diabetes Care, 34 Suppl 1, S4-10.  
Amori, R.E., Lau, J. and Pittas, A.G. (2007) Efficacy and safety of incretin therapy in 
type 2 diabetes: systematic review and meta-analysis. Jama, 298(2), 194-206.  
Andrade, E. (2015) Amphibians: why preserve. Entomol.Ornithol.Herpetol, 5(1) 
Andralojc, K., Mercalli, A., Nowak, K., Albarello, L., Calcagno, R., Luzi, L., Bonifacio, 
E., Doglioni, C. and Piemonti, L. (2009) Ghrelin-producing epsilon cells in the 
developing and adult human pancreas. Diabetologia, 52(3), 486-493.  
366 
 
Animaw, W. and Seyoum, Y. (2017) Increasing prevalence of diabetes mellitus in a 
developing country and its related factors. PloS One, 12(11), e0187670.  
Arden, C. (2018) A role for glucagon-like peptide-1 in the regulation of β-cell 
autophagy. Peptides, 100, 85-93.  
Aschner, P., Kipnes, M.S., Lunceford, J.K., Sanchez, M., Mickel, C., Williams-Herman, 
D.E. and Sitagliptin Study 021 Group. (2006) Effect of the dipeptidyl peptidase-4 
inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. 
Diabetes Care, 29(12), 2632-2637.  
Atkinson, M.A. and Eisenbarth, G.S. (2001) Type 1 diabetes: new perspectives on 
disease pathogenesis and treatment. The Lancet, 358(9277), 221-229.  
Atkinson, B.J., Griesel, B.A., King, C.D., Josey, M.A. and Olson, A.L. (2013) Moderate 
GLUT4 overexpression improves insulin sensitivity and fasting triglyceridemia in high-
fat diet-fed transgenic mice. Diabetes, 62(7), 2249-2258.  
Atlas, D. (2017) International diabetes federation. IDF Diabetes Atlas, 8th edn: Brussels 
Belgium: International Diabetes Federation. 
Attoub, S., Arafat, H., Mechkarska, M. and Conlon, J.M. (2013a) Anti-tumor activities 
of the host-defense peptide hymenochirin-1B. Regulatory Peptides, 187, 51-56.  
Attoub, S., Mechkarska, M., Sonnevend, A., Radosavljevic, G., Jovanovic, I., Lukic, 
M.L. and Conlon, J.M. (2013b) Esculentin-2CHa: a host-defense peptide with 
differential cytotoxicity against bacteria, erythrocytes and tumor cells. Peptides, 39, 95-
102.  
Bae, J., Kim, T., Kim, M., Park, J. and Ahn, Y. (2010) Transcriptional regulation of 
glucose sensors in pancreatic β-Cells and liver: an update. Sensors, 10(5), 5031-5053.  
Balasubramanian, R., Robaye, B., Boeynaems, J. and Jacobson, K.A. (2014) 
Enhancement of glucose uptake in mouse skeletal muscle cells and adipocytes by P2Y6 
receptor agonists. PloS One, 9(12), e116203. 
Barlow, J., Solomon, T.P. and Affourtit, C. (2018) Pro-inflammatory cytokines 
attenuate glucose-stimulated insulin secretion from INS-1E insulinoma cells by 
restricting mitochondrial pyruvate oxidation capacity–Novel mechanistic insight from 
real-time analysis of oxidative phosphorylation. PloS One, 13(6), e0199505.  
Baron, A.D. (1998) Postprandial hyperglycaemia and α-glucosidase inhibitors. Diabetes 
Research and Clinical Practice, 40, S51-S55.  
Basu, S., Yoffe, P., Hills, N. and Lustig, R.H. (2013) The relationship of sugar to 
population-level diabetes prevalence: an econometric analysis of repeated cross-
sectional data. PloS One, 8(2), e57873.  
367 
 
Belaid, A., Aouni, M., Khelifa, R., Trabelsi, A., Jemmali, M. and Hani, K. (2002) In 
vitro antiviral activity of dermaseptins against herpes simplex virus type 1. Journal of 
Medical Virology, 66(2), 229-234.  
Belgi, A., Akhter Hossain, M., W Tregear, G. and D Wade, J. (2011) The chemical 
synthesis of insulin: from the past to the present. Immunology, Endocrine & Metabolic 
Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Immunology, 
Endocrine and Metabolic Agents), 11(1), 40-47. 
Bergaoui, I., Zairi, A., Tangy, F., Aouni, M., Selmi, B. and Hani, K. (2013) In vitro 
antiviral activity of dermaseptin S4 and derivatives from amphibian skin against herpes 
simplex virus type 2. Journal of Medical Virology, 85(2), 272-281.  
Berridge, M.J., Bootman, M.D. and Roderick, H.L. (2003) Calcium: calcium signalling: 
dynamics, homeostasis and remodelling. Nature Reviews Molecular Cell Biology, 4(7), 
517.  
Bettge, K., Kahle, M., Abd El Aziz, Mirna S, Meier, J.J. and Nauck, M.A. (2017) 
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical 
trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of 
published clinical trials. Diabetes, Obesity and Metabolism, 19(3), 336-347.  
Bhuiyan, M.B.A., Fant, M.E. and Dasgupta, A. (2003) Study on mechanism of action 
of Chinese medicine Chan Su: dose-dependent biphasic production of nitric oxide in 
trophoblastic BeWo cells. Clinica Chimica Acta, 330(1-2), 179-184.  
Biden, T.J., Boslem, E., Chu, K.Y. and Sue, N. (2014) Lipotoxic endoplasmic reticulum 
stress, β cell failure, and type 2 diabetes mellitus. Trends in Endocrinology & 
Metabolism, 25(8), 389-398.  
Bisht, S. and Sisodia, S.S. (2011) Assessment of antidiabetic potential of Cinnamomum 
tamala leaves extract in streptozotocin induced diabetic rats. Indian Journal of 
Pharmacology, 43(5), 582-585.  
Bjornholm, M., Kawano, Y., Lehtihet, M. and Zierath, J.R. (1997) Insulin receptor 
substrate-1 phosphorylation and phosphatidylinositol 3-kinase activity in skeletal 
muscle from NIDDM subjects after in vivo insulin stimulation. Diabetes, 46(3), 524-
527.  
Blind, E., Janssen, H., Dunder, K. and de Graeff, P.A. (2018) The European Medicines 
Agency's Approval of New Medicines for Type 2 Diabetes. Diabetes, Obesity and 
Metabolism 
Bogan, J.S. (2012) Regulation of glucose transporter translocation in health and 
diabetes. Annual Review of Biochemistry, 81, 507-532.  
Bogdanov, P., Corraliza, L., Villena, J.A., Carvalho, A.R., Garcia-Arumí, J., Ramos, D., 
Ruberte, J., Simó, R. and Hernández, C. (2014) The db/db mouse: a useful model for 
the study of diabetic retinal neurodegeneration. PLOS One, 9(5), e97302.  
368 
 
Bora, K., Borah, M., Chutia, H., Nath, C.K., Das, D. and Ruram, A.A. (2016) Presence 
of Concurrent Derangements of Liver Function Tests in Type 2 Diabetes and Their 
Relationship with Glycemic Status: A Retrospective Observational Study from 
Meghalaya. Journal of Laboratory Physicians, 8(1), 30-35.  
Boucher-Berry, C., Parton, E.A. and Alemzadeh, R. (2016) Excess weight gain during 
insulin pump therapy is associated with higher basal insulin doses. Journal of Diabetes 
& Metabolic Disorders, 15(1), 47.  
Bouskila, M., Hirshman, M.F., Jensen, J., Goodyear, L.J. and Sakamoto, K. (2008) 
Insulin promotes glycogen synthesis in the absence of GSK3 phosphorylation in skeletal 
muscle. American Journal of Physiology-Endocrinology and Metabolism, 294(1), E28-
E35.  
Braun, M., Ramracheya, R., Bengtsson, M., Zhang, Q., Karanauskaite, J., Partridge, C., 
Johnson, P.R. and Rorsman, P. (2008) Voltage-gated ion channels in human pancreatic 
beta-cells: electrophysiological characterization and role in insulin secretion. Diabetes, 
57(6), 1618-1628.  
Brereton, M.F., Vergari, E., Zhang, Q. and Clark, A. (2015) Alpha-, delta-and PP-cells: 
are they the architectural cornerstones of islet structure and co-ordination? Journal of 
Histochemistry & Cytochemistry, 63(8), 575-591.  
Breyer, M.D., Bottinger, E., Brosius, F.C.,3rd, Coffman, T.M., Harris, R.C., Heilig, 
C.W., Sharma, K. and AMDCC. (2005) Mouse models of diabetic nephropathy. Journal 
of the American Society of Nephrology: JASN, 16(1), 27-45.  
Briant, L., Salehi, A., Vergari, E., Zhang, Q. and Rorsman, P. (2016) Glucagon secretion 
from pancreatic α-cells. Upsala Journal of Medical Sciences, 121(2), 113-119.  
Broglio, F., Gottero, C., Benso, A., Prodam, F., Destefanis, S., Gauna, C., Maccario, 
M., Deghenghi, R., van der Lely, A. and Ghigo, E. (2003) Effects of ghrelin on the 
insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. 
The Journal of Clinical Endocrinology & Metabolism, 88(9), 4268-4272.  
Buchanan, T.A., Metzger, B.E., Freinkel, N. and Bergman, R.N. (1990) Insulin 
sensitivity and B-cell responsiveness to glucose during late pregnancy in lean and 
moderately obese women with normal glucose tolerance or mild gestational diabetes. 
American Journal of Obstetrics & Gynecology, 162(4), 1008-1014.  
Bunck, M.C., Corner, A., Eliasson, B., Heine, R.J., Shaginian, R.M., Taskinen, M.R., 
Smith, U., Yki-Jarvinen, H. and Diamant, M. (2011) Effects of exenatide on measures 
of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. 
Diabetes Care, 34(9), 2041-2047.  
Butler, A.E., Janson, J., Soeller, W.C. and Butler, P.C. (2003) Increased beta-cell 
apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 
369 
 
diabetes: evidence for role of islet amyloid formation rather than direct action of 
amyloid. Diabetes, 52(9), 2304-2314.  
Cantley, J. and Ashcroft, F.M. (2015) Q&A: insulin secretion and type 2 diabetes: why 
do β-cells fail? BMC Biology, 13(1), 33.  
Capparelli, R., Romanelli, A., Iannaccone, M., Nocerino, N., Ripa, R., Pensato, S., 
Pedone, C. and Iannelli, D. (2009) Synergistic antibacterial and anti-inflammatory 
activity of temporin A and modified temporin B in vivo. PLoS One, 4(9), e7191.  
Cappiello, F., Di Grazia, A., Segev-Zarko, L.A., Scali, S., Ferrera, L., Galietta, L., Pini, 
A., Shai, Y., Di, Y.P. and Mangoni, M.L. (2016) Esculentin-1a-Derived Peptides 
Promote Clearance of Pseudomonas aeruginosa Internalized in Bronchial Cells of 
Cystic Fibrosis Patients and Lung Cell Migration: Biochemical Properties and a 
Plausible Mode of Action. Antimicrobial Agents and Chemotherapy, 60(12), 7252-
7262.  
Casewell, N.R., Wüster, W., Vonk, F.J., Harrison, R.A. and Fry, B.G. (2013) Complex 
cocktails: the evolutionary novelty of venoms. Trends in Ecology & Evolution, 28(4), 
219-229.  
Cat, A.N.D., Callera, G.E., Friederich-Persson, M., Sanchez, A., Dulak-Lis, M.G., 
Tsiropoulou, S., Montezano, A.C., He, Y., Briones, A.M. and Jaisser, F. (2018) Vascular 
dysfunction in obese diabetic db/db mice involves the interplay between 
aldosterone/mineralocorticoid receptor and Rho kinase signaling. Scientific Reports, 
8(1), 2952.  
Cernea, S. and Dobreanu, M. (2013) Diabetes and beta cell function: from mechanisms 
to evaluation and clinical implications. Biochemia Medica: Biochemia Medica, 23(3), 
266-280.  
Chang, S., Choi, K., Jang, S. and Shin, H. (2003) Role of disulfide bonds in the structure 
and activity of human insulin. Molecules & Cells (Springer Science & Business Media 
BV), 16(3)  
Chang, T.W. and Goldberg, A.L. (1978) The metabolic fates of amino acids and the 
formation of glutamine in skeletal muscle. The Journal of Biological Chemistry, 
253(10), 3685-3693.  
Chehade, J.M., Gladysz, M. and Mooradian, A.D. (2013) Dyslipidemia in type 2 
diabetes: prevalence, pathophysiology, and management. Drugs, 73(4), 327-339.  
Chen, G., Li, L., Dai, F., Li, X., Xu, X. and Fan, J. (2015) Prevalence of and risk factors 
for type 2 diabetes mellitus in hyperlipidemia in China. Medical Science Monitor: 
International Medical Journal of Experimental and Clinical Research, 21, 2476.  
Chen, Q., Wade, D., Kurosaka, K., Wang, Z.Y., Oppenheim, J.J. and Yang, D. (2004) 
Temporin A and related frog antimicrobial peptides use formyl peptide receptor-like 1 
370 
 
as a receptor to chemoattract phagocytes. Journal of Immunology (Baltimore, Md.: 
1950), 173(4), 2652-2659.  
Chon, S. and Gautier, J. (2016) An update on the effect of incretin-based therapies on 
β-cell function and mass. Diabetes & Metabolism Journal, 40(2), 99-114.  
Chong, S., Ding, D., Byun, R., Comino, E., Bauman, A. and Jalaludin, B. (2017) 
Lifestyle changes after a diagnosis of type 2 diabetes. Diabetes Spectrum, 30(1), 43-50.  
Clarke, B.T. (1997) The natural history of amphibian skin secretions, their normal 
functioning and potential medical applications. Biological Reviews, 72(3), 365-379.  
Coleman, D.L. (1978) Obese and diabetes: two mutant genes causing diabetes-obesity 
syndromes in mice. Diabetologia, 14(3), 141-148.  
Conlon, J.M. (2008) Reflections on a systematic nomenclature for antimicrobial 
peptides from the skins of frogs of the family Ranidae. Peptides, 29(10), 1815-1819. 
Conlon, J.M., Al-Ghaferi, N., Abraham, B. and Leprince, J. (2007a) Strategies for 
transformation of naturally-occurring amphibian antimicrobial peptides into 
therapeutically valuable anti-infective agents. Methods, 42(4), 349-357.  
Conlon, J.M., Al-Ghaferi, N., Ahmed, E., Meetani, M.A., Leprince, J. and Nielsen, P.F. 
(2010) Orthologs of magainin, PGLa, procaerulein-derived, and proxenopsin-derived 
peptides from skin secretions of the octoploid frog Xenopus amieti (Pipidae). Peptides, 
31(6), 989-994.  
Conlon, J.M., Kolodziejek, J. and Nowotny, N. (2009) Antimicrobial peptides from the 
skins of North American frogs. Biochimica Et Biophysica Acta (BBA)-Biomembranes, 
1788(8), 1556-1563.  
Conlon, J.M. and Mechkarska, M. (2014) Host-defense peptides with therapeutic 
potential from skin secretions of frogs from the family pipidae. Pharmaceuticals, 7(1), 
58-77.  
Conlon, J.M., Mechkarska, M., Abdel-Wahab, Y.H. and Flatt, P.R. (2018) Peptides 
from frog skin with potential for development into agents for Type 2 diabetes therapy. 
Peptides, 100, 275-281.  
Conlon, J.M., Mechkarska, M., Arafat, K., Attoub, S. and Sonnevend, A. (2012a) 
Analogues of the frog skin peptide alyteserin‐2a with enhanced antimicrobial activities 
against Gram‐negative bacteria. Journal of Peptide Science, 18(4), 270-275.  
Conlon, J.M., Mechkarska, M. and King, J.D. (2012b) Host-defense peptides in skin 
secretions of African clawed frogs (Xenopodinae, Pipidae). General and Comparative 
Endocrinology, 176(3), 513-518.  
371 
 
Conlon, J.M., Mechkarska, M., Lukic, M.L. and Flatt, P.R. (2014a) Potential therapeutic 
applications of multifunctional host-defense peptides from frog skin as anti-cancer, anti-
viral, immunomodulatory, and anti-diabetic agents. Peptides, 57, 67-77.  
Conlon, J.M., Mechkarska, M., Pantic, J.M., Lukic, M.L., Coquet, L., Leprince, J., 
Nielsen, P.F. and Rinaldi, A.C. (2013) An immunomodulatory peptide related to 
frenatin 2 from skin secretions of the Tyrrhenian painted frog Discoglossus sardus 
(Alytidae). Peptides, 40, 65-71.  
Conlon, J.M., Mechkarska, M., Radosavljevic, G., Attoub, S., King, J.D., Lukic, M.L. 
and McClean, S. (2014b) A family of antimicrobial and immunomodulatory peptides 
related to the frenatins from skin secretions of the Orinoco lime frog Sphaenorhynchus 
lacteus (Hylidae). Peptides, 56, 132-140.  
Conlon, J.M., Patterson, S. and Flatt, P.R. (2006) Major contributions of comparative 
endocrinology to the development and exploitation of the incretin concept. Journal of 
Experimental Zoology Part A: Comparative Experimental Biology, 305(9), 781-786.  
Conlon, J.M. and Sonnevend, A. (2011) Clinical applications of amphibian 
antimicrobial peptides. J.Med.Sci, 4(2), 62-72.  
Conlon, J.M., Woodhams, D.C., Raza, H., Coquet, L., Leprince, J., Jouenne, T., Vaudry, 
H. and Rollins-Smith, L.A. (2007b) Peptides with differential cytolytic activity from 
skin secretions of the lemur leaf frog Hylomantis lemur (Hylidae: Phyllomedusinae). 
Toxicon, 50(4), 498-506.  
Cornu, M., Poussin, C., Yang, J., Widmann, C. and Thorens, B. (2008) Glucagon-like 
peptide-1 protects beta-cells against apoptosis by increasing the activity of an IGF-
2/IGF-1 receptor autocrine loop. Diabetes, 58(8):1816-25. 
Cruciani, R.A., Barker, J.L., Zasloff, M., Chen, H.C. and Colamonici, O. (1991) 
Antibiotic magainins exert cytolytic activity against transformed cell lines through 
channel formation. Proceedings of the National Academy of Sciences of the United 
States of America, 88(9), 3792-3796.  
Cuervo, J.H., Rodriguez, B. and Houghten, R.A. (1988) The Magainins: sequence 
factors relevant to increased antimicrobial activity and decreased hemolytic activity. 
Peptide Research, 1(2), 81-86.  
Cummings, D.E. and Cohen, R.V. (2016) Bariatric/Metabolic Surgery to Treat Type 2 
Diabetes in Patients with a BMI <35 kg/m2. Diabetes Care, 39(6), 924-933. 
Da Silva Xavier, G. (2018) The cells of the islets of langerhans. Journal of Clinical 
Medicine, 7(3), 54.  
Dalbøge, L.S., Almholt, D.L., Neerup, T.S., Vassiliadis, E., Vrang, N., Pedersen, L., 
Fosgerau, K. and Jelsing, J. (2013) Characterisation of age-dependent beta cell 
dynamics in the male db/db mice. PloS One, 8(12), e82813.  
372 
 
Dandona, P., Freedman, D.B., Foo, Y., Perkins, J., Katrak, A., Mikhailidis, D.P., 
Rosalki, S.B. and Beckett, A.G. (1984) Exocrine pancreatic function in diabetes 
mellitus. Journal of Clinical Pathology, 37(3), 302-306.  
Daneman, D. (2006) Type 1 diabetes. The Lancet, 367(9513), 847-858.  
Das, A.K. and Shah, S. (2011) History of diabetes: from ants to analogs. The Journal of 
the Association of Physicians of India, 59 Suppl, 6-7.  
Daskin, J.H. and Alford, R.A. (2012) Context-dependent symbioses and their potential 
roles in wildlife diseases. Proceedings.Biological Sciences, 279(1733), 1457-1465.  
Dathe, M., Wieprecht, T., Nikolenko, H., Handel, L., Maloy, W.L., MacDonald, D.L., 
Beyermann, M. and Bienert, M. (1997) Hydrophobicity, hydrophobic moment and angle 
subtended by charged residues modulate antibacterial and haemolytic activity of 
amphipathic helical peptides. FEBS Letters, 403(2), 208-212.  
Davidson, H.W. (2004) (Pro) Insulin processing. Cell Biochemistry and Biophysics, 
40(3), 143-157.  
De Meyts, P., Sajid, W., Palsgaard, J., Theede, A., Gauguin, L., Aladdin, H. and 
Whittaker, J. (2007) Insulin and IGF-I receptor structure and binding mechanism. In: 
Anon.Mechanisms of Insulin Action. Springer, 1-32.  
DeFronzo, R.A. (2004) Pathogenesis of type 2 diabetes mellitus. Medical Clinics, 88(4), 
787-835.  
DeFronzo, R., Fleming, G.A., Chen, K. and Bicsak, T.A. (2016) Metformin-associated 
lactic acidosis: current perspectives on causes and risk. Metabolism, 65(2), 20-29.  
DeFronzo, R.A. and Tripathy, D. (2009) Skeletal muscle insulin resistance is the 
primary defect in type 2 diabetes. Diabetes Care, 32 Suppl 2, S157-63.  
Di Grazia, A., Cappiello, F., Cohen, H., Casciaro, B., Luca, V., Pini, A., Di, Y.P., Shai, 
Y. and Mangoni, M.L. (2015) D-Amino acids incorporation in the frog skin-derived 
peptide esculentin-1a (1-21) NH 2 is beneficial for its multiple functions. Amino Acids, 
47(12), 2505-2519.  
Di Grazia, A., Luca, V., Segev-Zarko, L.A., Shai, Y. and Mangoni, M.L. (2014) 
Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular 
Staphylococcus aureus. Antimicrobial Agents and Chemotherapy, 58(5), 2520-2527.  
Dicker, D. (2011) DPP-4 inhibitors: impact on glycemic control and cardiovascular risk 
factors. Diabetes Care, 34 Suppl 2, S276-8.  
Dimitriadis, G., Mitrou, P., Lambadiari, V., Maratou, E. and Raptis, S.A. (2011) Insulin 
effects in muscle and adipose tissue. Diabetes Research and Clinical Practice, 93 Suppl 
1, S52-9.  
373 
 
Dixon, G., Nolan, J., McClenaghan, N., Flatt, P.R. and Newsholme, P. (2003) A 
comparative study of amino acid consumption by rat islet cells and the clonal beta-cell 
line BRIN-BD11 - the functional significance of L-alanine. The Journal of 
Endocrinology, 179(3), 447-454.  
Do, O.H., Low, J.T., Gaisano, H.Y. and Thorn, P. (2014) The secretory deficit in islets 
from db/db mice is mainly due to a loss of responding beta cells. Diabetologia, 57(7), 
1400-1409.  
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APPENDICES 
 
Materials: 
 
Sr No Materials Suppliers 
1 Sodium hydroxide (NaOH) BDH Chemicals Ltd 
2 Calcium chloride dihydrate (CaCl2.2H2O) BDH Chemicals Ltd 
3 D-glucose BDH Chemicals Ltd 
4 Disodium hydrogen orthophosphate (Na2HPO4) BDH Chemicals Ltd 
5 Dichloromethane  (CH2Cl2) BDH Chemicals Ltd 
6 Dimethyl sulphoxide (DMSO) BDH Chemicals Ltd 
7 Potassium  chloride (KCl) BDH Chemicals Ltd 
8 Sodium chloride (NaCl) BDH Chemicals Ltd 
9 Hydrochloric acid (HCl) BDH Chemicals Ltd 
10 Sodium bicarbonate  (NaHCO3) BDH Chemicals Ltd 
11 Magnesium sulphate (MgSO4) BDH Chemicals Ltd 
12 Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich (Poole, UK) 
13 Bovine serum albumin (BSA) Sigma-Aldrich (Poole, UK) 
14 Dextran T-70 Sigma-Aldrich (Poole, UK) 
15 Bovine insulin  Sigma-Aldrich (Poole, UK) 
16 Collagenase-V, Clostridium histolyticum Sigma-Aldrich (Poole, UK) 
17 Forskolin Sigma-Aldrich (Poole, UK) 
18 L-Alanine Sigma-Aldrich (Poole, UK) 
19 Trifluoroacetic acid (TFA) Sigma-Aldrich (Poole, UK) 
20 Diazoxide Sigma-Aldrich (Poole, UK) 
21 Verapamil Sigma-Aldrich (Poole, UK) 
22 Probenecid Sigma-Aldrich (Poole, UK) 
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23 Ethylene glycol-bis-N, N, N’, N’-tetraacetic acid 
(EGTA) 
Sigma-Aldrich (Poole, UK) 
24 Phorbol 12-myristate 13-acetate (PMA) Sigma-Aldrich (Poole, UK) 
25 Thimerosal Sigma-Aldrich (Poole, UK) 
26 Tolbutamide Sigma-Aldrich (Poole, UK) 
27 Trypan blue stain Sigma-Aldrich (Poole, UK) 
28 Activated charcoal Sigma-Aldrich (Poole, UK) 
29 HPLC grade acetonitrile  Sigma-Aldrich (Poole, UK) 
30 Trifluoroacetic acid (TFA) Sigma-Aldrich (Poole, UK) 
31 HPLC grade ethanol Sigma-Aldrich (Poole, UK) 
32 α-Cyano-4-hydroxycinnamic acid (CHCA) Sigma-Aldrich (Poole, UK) 
33 Roswell Park Memorial Institute medium (RPMI 
1640) tissue culture medium 
Gibco Life Technologies Ltd 
(Paisley, Strathclyde, UK) 
34 Hanks Buffered Saline Solution (HBSS) Gibco Life Technologies Ltd 
(Paisley, Strathclyde, UK) 
35 Trypsin/ Disodium ethylenediaminetetraacetate 
(EDTA) 
Gibco Life Technologies Ltd 
(Paisley, Strathclyde, UK) 
36 Foetal bovine serum (FBS) Gibco Life Technologies Ltd 
(Paisley, Strathclyde, UK) 
37 Penicillin and streptomycin Gibco Life Technologies Ltd 
(Paisley, Strathclyde, UK) 
38 FLIPR Calcium Assay Kit Molecular device 
39 FLIPR membrane potential blue Molecular device 
40 CytoTox 96® non-radioactive cytotoxicity kit  Promega (UK) 
41 Radiolabelled sodium iodide (Na125I) Perkin Elmer (UK) 
42 Rabbit polyclonal to Ki67 Abcam (Cambridge, UK) 
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43 Enzyme-linked immunosorbent assay (ELISA) 
kits for cAMP 
Millipore (Millipore, Watford, 
UK). 
44 In situ Cell Death Detection Kit  Roche Diagnostics (Burgess 
Hill, UK) 
45 Lipid profile: Triglyceride, total cholesterol and 
HDL kit 
Instrumentation Laboratory 
46 Amylase assay kit Instrumentation Laboratory 
47 Liver and Kidney function test Instrumentation Laboratory 
48 Cholecystokinin-8 (CCK-8) Sunnyvale (USA) 
49 Rat insulin Novo Industrial (Denmark) 
50 Synthetic Peptides SynPeptide (China) 
51 GLP-1, exenatide SynPeptide (China) 
52 Lipid profile: Triglyceride, total cholesterol and 
HDL kit 
Instrumentation Laboratory 
53 Glucose uptake Cell-Based assay kit. Cayman Chemicals, UK 
 
Purified water (18.2 MΩ-cm purity) used in the experiments was obtained from an 
Elga PURELAB Ultra system (Elga, Celbridge, Ireland). 
 
